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AGGRESSIVE (SHOTGUN) APPROACH 
TO THE NONOPERATIVE 
MANAGEMENT OF SEVERE 
PANCREATIC DUCT DISRUPTION
A. Abdo, N. Jani and S. C. Cunningham
Saint Agnes Hospital Center, Baltimore, MD
Pancreatic duct disruption may be challenging to manage, 
with diverse etiologies and sequelae in a heterogeneous 
population. Common etiologies include pancreatitis, iatro-
genic injury, and trauma, and common sequelae of pancreatic 
duct disruption include pseudocyst, pancreatic ascites, and 
fi stulae. Although general principles, such as pancreas rest 
and nutritional support are generally agreed upon, no univer-
sal consensus exists regarding which specifi c treatment strat-
egies are best and in which order. Some pancreatologists 
favor, for example, immediate NPO status vs oral diet as 
tolerated, octreotide vs no octreotide, endoscopic pancreatic 
duct stenting versus no stent. The more aggressive (ie, the 
former) of each of these treatment options is favored by the 
authors, who have found that a less aggressive approach 
using slower, stepwise initiation of progressively aggressive 
treatments simply delays resolution of pancreatic duct dis-
ruption. In our experience, strict and immediate NPO status 
with IV nutrition, immediate use of octreotide, aggressive 
image-guided percutaneous catheter drainage, and early 
endoscopic stenting of the pancreatic duct seem, anecdotally, 
in patients stratifi ed as having persistent, refractory, or oth-
erwise severe duct disruption, to have a high success rate in 
leading to the fast resolution of pancreatic duct disruption.
SURGICAL APPROACH IN PANCREATIC 
CANCER WITH PREOPERATIVE 3D-CT 
COMPUTER ASSISTED SURGERY 
PLANNING
Y. Abe, K. Takano and M. Shimazu
Department Of Surgery, Tokyo Medical University Hachioji 
Medical Center, Hachioji, Tokyo, Japan
Introduction: We suggest that neoadjuvant therapy in com-
bination with defi nitive R0 surgery could improve survival. 
We report the surgical approach in four cases of locally 
advanced pancreatic cancer with neoadjuvant chemoradio-
therapy and preoperative 3D-CT computer-assisted surgery 
planning (3D-CASP).
Materials and methods: We have four patients who had 
locally advanced pancreatic cancers that was found to have 
invaded the SMV and tumor abutment of the SMA or CHA. 
They were treated with radiation (2.0 Gyx25) and the com-
bination chemotherapy of S-1 plus gemcitabine (S-1: 40 mg/
m2/day day 1–14 and day 22–35, gemcitabine 400 mg/m2 iv, 
day 1, 8, 22 and 29). Five weeks later, a reduction of the 
tumor markers and no progressive disease were observed. 
3D-CASP were performed to determine resectability and 
plan operative strategy.
Results: All of four patients underwent surgery. 3D-CASP 
clarifi ed the anatomical relationships between tumor and 
vessels and enabled determination of the transection line. 
Frozen sections in dissection line were negative for cancer 
invasion so that R0 surgery were confi rmed in all cases. 
Appropriate vessel reconstructions were performed accord-
ing to plan by 3D-CASP. They are disease free (median 268 
days) and undergoing adjuvant chemotherapy except one 
case (died of gastrointestinal bleeding six months after 
surgery).
Conclusion: Although benefi t from surgery in the manage-
ment of locally advanced pancreatic adenocarcinoma remains 
controversial, we suggest such an approach be considered 
particularly following completion of neoadjuvant therapy 
without systemic progression. 3D-CASP was particularly 
helpful in patient with borderline resectable pancreatic 
cancer to reduce risk for a margin-positive resection.
LAPAROSCOPIC VS. OPEN LEFT 
LATERAL SECTIONECTOMY AND 
RIGHT HEPATECTOMY: A COST-
EFFECTIVENESS ANALYSIS FOR MINOR 
AND MAJOR HEPATECTOMY
M. Abu Hilal1, S. M. Syed2, R. Wiltshire1, F. DiFabio1, 
N. J. Pearce1 and J. N. Primrose1
1Southampton University Hospital Trust, Southampton, 
Hampshire, United Kingdom; 2Synergy Medical Healthcare 
Alliance, Saginaw, MI
Aims: Laparoscopic hepatectomy is progressively gaining 
popularity. However, data on the cost-effectiveness of the 
laparoscopic approach for minor and major hepatectomy 
compared to the open approach are still lacking.
Methods: A retrospective clinical and costs comparison 
analysis has been performed for patients undergoing laparo-
scopic right hepatectomy (LRH) and laparoscopic left lateral 
sectionectomy (LLLS) versus the open counterparts (ORH 
and OLLS). Data considered for the comparison analysis 
were: operative costs (surgical procedure, operative time, 
blood transfusions), postoperative costs (hospital stay, com-
plications’ management, readmissions) and overall costs.
Results: A total of 153 patients were included: 40 patients 
underwent LRH and 34 ORH; 60 patients underwent LLLS 
and 19 OLLS. For LRH the average operative, postoperative 
and overall costs were: £10591, £4928 and £15519; for ORH 
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the average operative, postoperative and overall costs were: 
£6638 (p < 0.0001), £10201 (p = 0.0004), and £16839 (p = 
0.35, t-test). Regarding LLLS, the average operative, post-
operative and overall costs were: £5597, £2546, and £8143; 
for OLLS the average operative, postoperative and overall 
costs were: £5470 (p = 0.78), £6220 (p < 0.0001), and 
£11690 (p = 0.0001, t-test).
Conclusions: Our data support the cost-effectiveness of 
laparoscopic minor and major hepatectomy. For LRH, intra-
operative costs were higher compared to the open approach; 
however the overall costs were not signifi cantly different. 
For LLS, cost analysis was clearly in favor of the laparo-
scopic approach. Extensive experience in liver surgery and 
laparoscopic technique is an essential condition to optimize 
costs.
EVALUATION OF THE HJORTSJO 
CROOK SIGN IN THE DELINEATION OF 
THE RIGHT POSTERIOR BILE DUCT 
ANATOMY IN MIDDLE EASTERN 
PATIENTS
H. M. Alghamdi1,2
1University Of Dammam, Alkhobar, Eastern Province, 
Saudi Arabia; 2King Fahad Hospital Of The University, 
Alkhobar, Eastern Province, Saudi Arabia
It is well recognized that most hilar bile ducts anatomical 
variations stem from different right posterior duct origin. 
Nakamura’s classifi es the supraportal right posterior duct 
into the most commonly type I (65%: in which the right 
posterior and anterior join to form a single right hepatic 
duct), type II (9.2:, the right posterior duct joins the confl u-
ence, forming trifurcation) the infraportal right posterior duct 
as type III (8.3%), type IV (15.8%, the right posterior duct 
joins the left hepatic duct) and the combination as type V 
2(1.7%). Hjortsjo fi rst reported the characteristic crook sign 
of the right posterior bile duct in cholangiography in 1951. 
This sign can be positive for the supraportal type. Recognition 
of this sign is helpful to achieve a safe liver resection and 
transplantation. The aim of the study is to evaluating the 
usefulness and frequent of the sign at ERCP and how helpful 
it is to delineate the right posterior duct confl uence pattern 
in middle eastern patients.
Material and methods: Prospective study involve recuret-
ing patient undergoing indicated ERCP from 1st of March 
2010 to 30th of May 2011, without a history of liver resection 
or biliary instrumentation.
Result and conclusion: 223 ERCP done in the study period. 
Only 86 were eligible to be included in the study. We found 
that Hjortsjo Crook signs positive in 39 patients (45%). Type 
1 29 (74%), type II: 2 (5%), type III: 1 (2.5%), type IV: 6 
(15%). Conclusion sign is not a commonly fi nd sign but if 
positive it’s strongly correlated to type I.
SINGLE CENTER EXPERIENCE WITH 
IRREVERSIBLE ELECTROPORATION 
FOR LIVER AND PANCREAS TUMOR 
ABLATION
N. S. Ali1, S. Cohn1,2 and V. Raofi 1,2
1Beaumont Health System, Royal Oak, MI; 
2Oakland University William Beaumont School Of 
Medicine, Royal Oak, MI
Introduction: Ablation of soft tissue tumors has become a 
vital part of oncology treatment algorithms, especially in the 
management of liver neoplasms. Bystander tissue injury is 
an ever-present concern (eg. biliary injury during HCC abla-
tion) with other types of ablation. Tumor ablation utilizing 
Irreversible electroporation (IRE) is achieved via micro-
second electrical pulses, instead of extreme heat, perma-
nently opening cell membranes leading to cell apoptosis. 
This approach potentially avoids vascular and biliary injury 
associated with heat-based ablations. We analyzed our expe-
rience with IRE in the ablation of soft-tissue tumors.
Methods: Retrospectively review of a prospectively-main-
tain database of patients who underwent IRE ablation of 
tumors from 2010 to present. Technique, complications, and 
clinical outcomes were assessed.
Results: 29 patients received IRE treatment to 35 lesions 
(liver 29, kidney 2, lung 2, and pancreas 2.) All lesions were 
chosen for IRE ablation due to proximity/involvement of 
vascular, biliary, or visceral (VBV) structures were ablated 
under ultrasound guidance, and liver and renal ablations 
were performed by laparoscopy. No patient experienced 
ablation-related VBV complications, although one patient 
suffered transient ascites and another has been found to have 
radiographic local recurrence (liver, adenocarcinoma) with 
mean follow-up of 9 months. Explant histologic assessment 
of two HCC lesions shows complete tumor destruction.
Conclusion: Our experience shows favorable treatment 
effect and short-term outcomes, most notably in lesions 
located in traditionally unablatable sites. This initial experi-
ence of IRE ablation of soft-tissue tumors is encouraging, 
prompting thoughtful application and investigation into IRE 
and its utility in oncology care.
LAPAROSCOPIC TRANSECTION OF THE 
THICK PANCREAS; A NON-STAPLER 
TECHNIQUE
A. Alseidi, F. Rocha and S. Helton
Virginia Mason Medical Center, Seattle, WA
Tricks of the trade: technical issue: Laparoscopic left pan-
createctomies have become a standard approach for both 
benign and malignant processes. The transected pancreas is 
often soft, since the disease is upstream, and too thick for the 
use of a reinforced stapler. Transection and hand-sewn 
closure has a high leak rate (28%, DISPACT trail) even when 
done open, likely higher in laparoscopy.
Management: The thick pancreas can be transected with 
energy (EnSeal(®) (Ethicon, Cincinnati, OH) and then the 
cut surface is sealed with surface radio frequency tissue 
sealer (lap EndoSH2.0) (Salient, Dover, OH).
Experience and results: Early results, both open and lapa-
roscopic are very promising. Laparoscopic transaction of the 
pancreas with this method is technically easy to perform. 
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Daily Amylase measurements (body fl uid) have revealed no 
leaks in our early series. We anticipate the fi nal percent leak, 
once target group achieved, to be signifi cantly less than 28% 
(published leak rate for hand-sewn closure).
EX-VIVO RIGHT TRISECTIONECTOMY 
WITH CAVAL RESECTION
F. A. Alvarez, J. I. Iniesta, E. Sieling, J. Pekolj and 
E. De Santibanes
General Surgery Service-HPB Surgery Section, Hospital 
Italiano De Buenos Aires, Ciudad Auta De Buenos Aires, 
Buenos Aires, Argentina
Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 
second most common primary liver tumor. Vascular invasion 
is a negative prognostic factor. Since complete resection 
offers the only chance for cure, an aggressive approach with 
extended resections in combination with complex vascular 
or biliary reconstructions is justifi ed.
Methods: We present a 54-year-old male with an abdominal 
mass found during a routine examination. The tumor marker 
CA 19–9 was elevated. A CT- scan revealed a liver tumor in 
the right lobe with compromise of the right portal vein, the 
right and middle hepatic veins and the inferior vena cava 
(ICV). Preoperative right portal vein embolization was per-
formed. Under venous extracorporeal circulation by cannula-
tion of the left femoral vein, the inferior mesenteric vein and 
the left axillary vein, total vascular exclusion was achieved 
and a right trisectionectomy with en-block resection of the 
retrohepatic IVC was performed. Caval reconstruction was 
accomplished using a gore-tex graft with reimplantation of 
the left hepatic vein. Biliary reconstruction was performed 
by an end-to-side hepaticoyeyunostomy.
Results: The patient developed a hem peritoneum that 
required relaparotomy and bilateral pleural effusion that was 
treated by chest tubes placement. The histo-pathological 
report informed ICC with negative lymph nodes and tumor-
free margins. Twenty two months later the patient is free of 
disease and in good condition.
Conclusions: The presented ex-vivo major hepatectomy 
performed with techniques of vascular exclusion and caval 
resection was feasible with satisfactory results. In patients 
with tumoral involvement of the IVC this surgical alternative 
offers the possibility to achieve complete tumor removal.
CONFOCAL MICROSCOPY IN 
COMBINATION WITH OBLIQUE 
INCIDENCE DIFFUSE REFLECTANCE 
SPECTROSCOPY FOR THE 
CONFIRMATION OF TUMOR FREE 
SURGICAL MARGINS IN PANCREATIC 
CANCER
A. Amini1, B. Banerjee1, A. Garcia-Uribe2,3, J. Zou2, 
L. Wang3, A. Rouse1, A. Gmitro1, T. Jie1, R. Gruessner1 and 
E. Ong1
1University Of Arizona, Tucson, AZ; 2Texas A&M 
University, College Station, TX; 3Washington University In 
St. Louis, St. Louis, MO
Introduction: The presence of a tumor positive resection 
margin is a strong independent risk factor for poor survival 
in patients with pancreatic cancer, as patients with no tumor 
cells (R0) have a better prognosis than those with tumor cells 
within 1 mm from the margin (R1). The ability to accurately 
diagnose R0 and R1 margins during surgery with frozen 
section is time consuming and inaccurate. We present the 
fi rst use of oblique incidence diffuse refl ectance spectros-
copy (OIDRS) with confocal microscopy (CM) to differ-
entiate between pancreatic adenocarcinoma and normal 
pancreatic tissue.
Methods: Freshly resected surgical specimens of pancreas 
in 14 patients were studied with OIDRS and CM and the 
results were compared to histology. OIDRS spectra were 
measured from the surface of the specimen, followed by the 
application of acridine orange dye and CM imaging of the 
same location.
Results: The fi gure shows representative OIDRS spectra, 
CM images, and histology from normal pancreas, pancreatic 
adenocarcinoma, and chronic pancreatitis. OIDRS and CM 
were able to instantly distinguish between normal and malig-
nant regions of the pancreas. These results were confi rmed 
by histology.
Conclusion: This early work suggests that OIDRS and 
CM may be useful in localizing the presence of cancer in 
the pancreas during surgery. OIDRS and CM provide 
both structural and functional information that may be useful 
in rapidly determining a safe margin at surgery. This tech-
nique will potentially enable more patients to have a tumor 
free margin at surgery and result in an improvement in 
survival.
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CONVERSION TO COMPLETE 
SURGICAL TREATMENT USING 
HEPATIC ARTERY INFUSIONAL 
CHEMOTHERAPY IN PATIENTS WITH 
UNRESECTABLE LIVER METASTASES 
FROM COLORECTAL CANCER
J. B. Ammori1, N. E. Kemeny2, Y. Fong2, A. Cercek2, 
R. P. Dematteo2, P. J. Allen2, P. B. Paty2, W. R. Jarnagin2 
and M. I. D’Angelica2
1University Hospitals Case Medical Center, Cleveland, 
OH; 2Memorial Sloan-Kettering Cancer Center, 
New York, NY
Purpose: This study analyzes the combination of HAI and 
systemic chemotherapy for treating unresectable CRLM, 
focusing on the conversion to complete resection and/or 
ablation (R/A) and long term outcomes.
Methods: All patients with initially unresectable CRLM 
treated with HAI and systemic chemotherapy from 2000–
2009 were included. Patients who responded suffi ciently to 
undergo complete R/A were compared to those who did not 
convert.
Results: 373 patients were included. 296 (79%) were previ-
ously treated with systemic chemotherapy. 115 (31%) were 
on a clinical protocol. 93 (25%) subsequently underwent 
complete R/A (conversion group). The percentage of patients 
submitted to complete R/A increased from 16% during 
2000–2003 to 30% during 2004–2009. Forty-three percent 
of chemotherapy-naïve patients eventually underwent com-
plete R/A, compared to 15% who were initially treated with 
systemic therapy (p < 0.001). Of the 115 protocol patients, 
46 (40%) underwent complete R/A, compared to 18% of off 
protocol patients (p < 0.001). Factors associated with conver-
sion on multivariate analysis were more recent treatment 
(2004–2009), no prior chemotherapy, and a clinical risk 
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score < 3. Overall survival was greater in the conversion 
group, with a median and predicted 5-year survival from the 
time of HAI pump placement of 54 months and 49%, com-
pared to 19 months and 6%, respectively (p < 0.001).
Conclusions: One-quarter of patients with unresectable 
CRLM responded suffi ciently to undergo complete R/A fol-
lowing HAI plus systemic chemotherapy. Conversion was 
more likely in patients who were chemotherapy-naïve (43%), 
had a clinical risk score < 3, and were treated in the more 
recent era. Survival in the conversion group was signifi cantly 
better.
ARE HEPATOCELLULAR CARCINOMA 
PATIENTS MORE LIKELY TO RECEIVE 
LIVER RESECTION IN REGIONS WITH 
LONGER TRANSPLANT WAIT-TIMES?
J. Anderson, K. Mekeel, D. C. Chang, M. Talamini and 
A. W. Hemming
University Of California, San Diego, San Diego, CA
Longer wait times for liver transplantation (LT) for patients 
with hepatocellular carcinoma (HCC) may increase waitlist 
dropout. In areas with longer LT wait times, liver resection 
(LR) offers an appropriate alternative in selected patients. 
This research examines odds of LR by region. Retrospective 
analysis of the US Nationwide Inpatient Sample database 
was performed from 1998–2008. Adult patients with HCC 
undergoing LT or LR were identifi ed. UNOS regions were 
ranked with lower rank number indicating shorter wait-time 
for patients with MELD scores of 19–24 and 25+, respec-
tively. Multivariate analysis found the odds ratio (OR) of LR 
versus LT comparing patients by region, controlling for age, 
race, gender, Charlson co-morbidity index, and teaching-
hospital status. Of 4516 patients, 1866 (40%) received LT 
and 2749 (60%) received LR. When regions were ranked by 
wait-times for MELD 19–24, the 3rd and 11th ranked regions 
had decreased OR of LR versus LT (Region 3: OR 0.4, p < 
0.001; Region 5: OR 0.4, p < 0.001), while the 10th ranked 
region had increased OR (Region 1: OR 2.2, p = 0.006) 
compared to the region with the shortest wait-time, Region 
10. According to regions ranked by wait-times for MELD 
25+, all regions except the 10th ranked region (Region 5) 
had increased OR compared to the region with the shortest 
wait-time, Region 3 (OR range from 1.8–5.8, p < 0.001), 
with the largest OR occurring in the 11th-ranked region 
(Region 1: OR 5.8, p < 0.001). In conclusion, regional varia-
tions in the practice of LT vs. LR are not completely explained 
by transplant wait times.
SURGICAL MANAGEMENT TRENDS FOR 
CHOLANGIOCARCINOMA IN THE 
UNITED STATES 1998–2009
J. Anderson, K. Mekeel, D. C. Chang, M. Talamini and 
A. W. Hemming
University Of California, San Diego, San Diego, CA
This research examines cholangiocarcinoma (CCA) surgical 
treatment patterns from 1998–2009. Retrospective analysis 
of the US Nationwide Inpatient Sample database was per-
formed from 1998–2009. CCA patients were identifi ed and 
categorized as inpatients at high-volume (HV) versus low-
volume (LV) hospitals, and at teaching versus non-teaching 
hospitals. Rates of surgical treatment were assessed over 
time. Analysis of differences between HV vs. LV hospitals, 
and teaching vs. nonteaching hospitals included multinomial 
and multivariate analyses to fi nd odds ratios (OR) of surgical 
treatment options. Liver resection (LR), pancreaticoduode-
nectomy, bile duct (BD) resection, and combined liver and 
BD resection were considered more aggressive therapy than 
BD stent or bypass. A total of 32,561 patients with CCA were 
identifi ed. The proportion of patients receiving surgery 
declined from 36% in 1998 to 30% in 2009. There was no 
increase in the proportion of LRs or combined liver and BD 
resection performed over time. Patients at HV or teaching 
hospitals were more likely to receive surgical treatment (OR 
1.3, p < 0.001; OR 1.4, p < 0.001), and moree surgery (OR 
2.0, p < 0.001; OR 2.3, p < 0.001). When comparing indi-
vidual procedures, patients at HV or teaching hospitals were 
more likely to receive combined BD and liver resection, liver 
resection, or bile duct resection, compared to each less-
aggressive procedure (OR 1.2–6.6, p < 0.05). Patients with 
CCA were more likely to receive aggressive surgical treat-
ment at HV or teaching hospitals. Although combined liver 
and BD resection has been advocated as standard manage-
ment for proximal CCA, the practice does not appear to have 
increased.
TREATMENT OF RECURRENT 
HEPATOCELLULAR CARCINOMA 
AFTER LIVER TRANSPLANTATION; 
ARE WE MAKING PROGRESS?
A. Annamalai, V. Menon, V. Puri, C. Bresee, B. Boland, 
A. S. Klein, J. Fair, S. D. Colquhoun and N. N. Nissen
Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Recurrence of hepatocellular carcinoma 
(HCC) after liver transplant (LT) remains an uncommon but 
vexing problem. Due to the heterogeneity of patients, treat-
ment guidelines are limited.
Methods: We reviewed our experience with recurrent HCC 
after LT, analyzing the treatments rendered, complication 
rates and outcomes.
Results: Between 2001 and 2011, 140 patients underwent 
LT for HCC at our center. Of these, 18 patients were diag-
nosed with recurrent HCC at a mean of 16 months post-LT 
(range 2–62). The pattern of initial disease recurrence was in 
lung (6), liver (4), peritoneum (3), bone (3) or diffuse (2). 
All patients underwent deliberate reduction of immunosup-
pression, and 10/18 were changed to a regimen of the mTOR 
inhibitor sirolimus instead of tacrolimus. Sorafenib was used 
in 9 patients diagnosed after 2008. Patients with oligometa-
static disease (n = 11) were treated with aggressive surgical 
and locoregional cytoreduction, and in these patients there 
were no complications attributable to immunosuppression. 
Hepatic artery chemoembolization in particular was well tol-
erated, with no hepatic complications. Compared to patients 
treated before 2008, more recently treated patients have a 
trend towards more aggressive cytoreduction, more use of 
sorafenib and sirolimus, and improved survival (fi gure). 
Three patients are alive at 25, 30 and 52 months 
post-recurrence.
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Conclusion: Recurrent HCC after LT has unique features, 
including an often oligometastatic pattern of recurrence, and 
the possibility of prolonged survival with an aggressive cyto-
reductive and immunomodulatory approach. Standard treat-
ments such as hepatic artery chemoembolization, liver 
resection and metastasectomy should not be withheld in 
these patients.
LOW BASELINE LEAN BODY MASS 
NEGATIVELY PREDICTS COMPLETION 
OF NEOADJUVANT THERAPY AMONG 
PATIENTS WITH RESECTABLE AND 
BORDERLINE RESECTABLE 
PANCREATIC CANCER
E. A. Asare, P. Knechtges, D. Green, Q. Ziang, 
T. C. Gamblin, K. Turaga, S. G. Pappas, K. K. Christians, 
E. J. Quebbeman, D. B. Evans and S. Tsai
Medical College Of Wisconsin, Milwaukee, WI
Background: Sarcopenia (lean muscle wasting) has been 
associated with increased rates of complications and 
decreased survival in surgical patients. We investigated the 
impact of lean body mass among patients who underwent 
neoadjuvant therapy and surgical resection for pancreatic 
cancer (PC).
Methods: Lean body mass was assessed in PC patients 
receiving neoadjuvant therapy by measuring total abdominal 
muscle area (TAMA) on CT scans using Tomovision 
SliceOmatic v4.3 software. The impact of low vs. high 
TAMA on completion of neoadjuvant therapy and surgical 
complications was assessed after controlling for clinicopath-
ological factors using multivariate modeling.
Results: Among 132 patients with resectable (61) or border-
line resectable (61) PC, median TAMA from pretreatment 
CT scans was 143.9 mm2/m2 and 97.7 mm2/m2 among men 
and women respectively. Low TAMA was present in 26 
(42%) of the 61 patients with resectable PC and 43 (69%) of 
61 patients with borderline resectable PC. Surgical resection 
was performed in 93 (70%) of the 132 patients and 7 (7%) 
of 93 developed major (Clavien grade > 3) post-operative 
complications. On multivariate logistic regression, low 
TAMA (OR 2.57, 95% CI 1.09–6.10, p = 0.03) was nega-
tively associated with successful completion of planned 
surgery. Low TAMA was independently associated with 
increased risk of any, but not major, postoperative complica-
tion (OR 2.01; p = 0.04, OR = 1.00, respectively).
Conclusions: Low lean body mass negatively predicts the 
completion of neoadjuvant therapy among PC patients. 
Dietary modifi cation and physical conditioning may reverse 
low lean body mass, and may be important adjuncts for high 
risk PC patients being treated on a neoadjuvant regimen.
EXPLORATION OF ENHANCING 
PANCREATIC CANCER TARGETED 
COMBINATION THERAPY THROUGH 
ANTIENDOTHELIAL EMAP II
N. Awasthi1, W. Ruan1, C. Zhang1, M. A. Schwarz2 and 
R. E. Schwarz1
1University Of Texas Southwestern Medical Center, Dallas, 
TX; 2University Of Texas Southwestern Medical Center, 
Dallas, TX
Combination treatment benefi ts of gemcitabine with suni-
tinib or sorafenib were evaluated with or without endothelial 
monocyte activating polypeptide II (EMAP) in pancreatic 
ductal adenocarcinoma (PDAC). Protein expression and cell 
proliferation were analyzed by Western blotting and WST-1 
assay. Survival experiments were performed in murine xeno-
grafts. Inhibition in PDAC cell (AsPC-1) proliferation by 
CLINICAL OUTCOMES OF ANAPLASTIC 
PANCREATIC CANCER
J. Arun, C. Clark, R. Graham and K. M. Reid-Lombardo
Mayo Clinic, Rochester, MN
Introduction: Anaplastic or undifferentiated pancreatic 
cancer comprises 2–7% of all pancreatic neoplasms. Previous 
case series have reported worse overall survival for anaplas-
tic pancreatic cancer compared to pancreatic ductal adeno-
carcinoma; however, the presence of osteoclastic giant cells 
(OSGCs) may predict improved survival.
Methods: We conducted a retrospective review of all 
patients with pathology-confi rmed anaplastic pancreatic 
cancer from 1987 to 2010 treated at Mayo Clinic. For 
resected patients, overall survival was compared with a 
cohort of patients with differentiated pancreatic adenocarci-
noma using Kaplan-Meier curves and log-rank test.
Results: Of 39 patients with anaplastic pancreatic cancer 
(22 males and 17 females), the average age was 63 years. 
Only two tumors were noted to have OSGCs (5%). Sixteen 
patients had metastases on presentation, 17 underwent surgi-
cal exploration, and 12 tumors were resected (31%). 
Perioperative morbidity was noted in 7 of 17 patients, and 1 
patient died within 30 days of operation. Median overall 
survival was 5.5 months. Resected patients had longer sur-
vival, 17 vs 4 months (p = 0.001). Overall survival was not 
signifi cantly different between anaplastic and differentiated 
pancreatic cancer, 17 months vs 20 months, respectively 
(p = 0.656). Patients with OSGC tumors survived 50 and 70 
months compared to a median of 16 months for patients 
without OSGCs (p = 0.024).
Conclusions: Anaplastic pancreatic cancer, when resect-
able, offers similar survival to differentiated pancreatic 
cancer. When present, OSGCs may portend a better survival 
compared to other types of anaplastic pancreatic cancer.
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in decreased formation of PF after DP. A randomized, pro-
spective trial may provide a defi nitive answer whether type 
of analgesia effects PF formation after open DP.
Table 1. Incidence of PF formation by type of analgesia 
used
ALL PCA PCEA P value
No of pt’s 153 72 81
Any Leak (%) 41 (27) 24 (30) 17 (21) 0.10
Clinically 
Signifi cant 
Leak (B, C; 
%)
14 (9) 8 (12) 6 (7) 0.58
RETROSPECTIVE COMPARISON OF 
MINIMALLY INVASIVE VERSUS OPEN 
PANCREATICODUODENECTOMY FOR 
PERIAMPULLARY NEOPLASMS
P. Q. Bao, P. Mazirka and K. T. Watkins
Stony Brook University Medical Center, Stony Brook, NY
Methods: Outcomes were compared between patients with 
preoperative diagnosis of periampullary neoplasm undergo-
ing elective minimally invasive pancreaticoduodenectomy 
(MIPD) or open resection (OPD) from November 2009 to 
July 2011.
Results: During this period, 28 MIPD and 28 OPD proce-
dures were performed. There were 4 conversions to open 
which were then included with the open group for analysis. 
Age, gender, and BMI distributions between groups were 
similar. Pancreatic adenocarcinoma and non-invasive IPMN 
were the most frequent malignant and benign neoplasms, 
respectively, though there were more cancers in the open 
group (91% vs 67%, p = 0.04). Comparing MIPD to OPD, 
median procedure time was greater [444 minutes (range 
340–628) vs 399 (190–621), p = 0.02]. For malignant pathol-
ogies, median lymph node harvest was less [15 (range 11–32) 
vs 20 (11–39), p = 0.01] while R0 resection rate was similar 
(75% vs 79%, p = 0.73). Complications were similar with 
respect to median length of stay [7.8 days (range 2–30) vs 
8.1 (5–100), p = 0.45], pancreatic fi stula rate of any grade 
(29% vs 34%, p = 0.68), delayed gastric emptying (16% vs 
12%, p = 0.71), and 30-day readmission rates (25% vs 25%). 
There tended to be fewer surgical site infections (17% vs 
41%, p = 0.05) and lower average daily oral morphine equiv-
alents given (31.6 ± 27.1 vs 50.7 ± 49.1, p = 0.23).
Conclusions: MIPD and OPD offer comparable approaches 
to periampullary tumor resection. Smaller but otherwise 
adequate lymph node yields need further study for clinical 
signifi cance if any. Similar to other procedures, the mini-
mally invasive approach appears to be associated with fewer 
wound complications and less pain.
gemcitabine (10 μM), sunitinib (10 μM) and EMAP (20 μM) 
was 45, 92 and 2 percent; combination of gemcitabine with 
sunitinib or EMAP had no signifi cant additive effects. In 
endothelial cells (HUVECs), gemcitabine, sunitinib and 
EMAP caused 95, 88 and 59 percent inhibition in prolifera-
tion, and combination of gemcitabine with sunitinib or 
EMAP had signifi cant additive effects. In WI-38 stromal 
fi broblasts, gemcitabine, sunitinib and EMAP caused 95, 87 
and 23 percent inhibition in proliferation, with no combina-
tion effects. Sorafenib inhibited proliferation of four different 
PDAC cells, HUVECs and WI-38 cells, while enhancing the 
inhibitory effects of gemcitabine in all these cells. Sunitinib 
and sorafenib induced apoptosis as observed by PARP-1 and 
caspase-3 cleavage. Median animal survival in controls, 
gemcitabine, gemcitabine+sunitinib, gemcitabine+EMAP 
and gemcitabine+sunitinib+EMAP was 19, 26, 37, 36 and 36 
days. In a separate experiment median survival in controls, 
gemcitabine, EMAP, sorafenib, gemcitabine+sorafenib, 
gemcitabine+EMAP, sorafenib+EMAP and gemcitabine+
sorafenib+EMAP was 22, 28, 24, 22, 29, 32, 24 and 35 days. 
Gemcitabine response was improved by antiangiogenic and 
antiendothelial agents in vivo, however differential inhibi-
tory effects on various cell lines were observed in vitro. 
These results demonstrate the potential of combining multi-
targeting agents with standard gemcitabine therapy for 
PDAC.
IS THE TYPE OF POST-OPERATIVE PAIN 
CONTROL RELATED TO PANCREATIC 
FISTULA FORMATION AFTER OPEN 
DISTAL PANCREATECTOMY?
H. H. Bach IV, E. Pappano, E. Bock, M. Shoup and 
G. Aranha
Loyola University Medical Center, Maywood, IL
Introduction: The most common complication after open 
distal pancreatectomy (DP) is pancreatic fi stula (PF). Causes 
for PF are still debated in the surgical literature.
Purpose: We sought to determine if post-operative patient 
controlled analgesia (PCA) or patient controlled epidural 
analgesia (PCEA) had any relation to PF formation after DP, 
which has not been previously published. PCEA delivers 
intrathecal narcotics, whereas PCA introduces narcotics into 
the bloodstream, which may act directly on the ampulla. 
Since narcotics are known to cause ampullary spasm, which 
could lead to increased pancreatic intraductal pressure, we 
hypothesized that patients who have PCA are more likely for 
PF formation.
Methods: Our database identifi ed 153 patients. Measuring 
drain amylase, PF was defi ned as none, Grade A, B, or C 
according to the severity classifi cation system of the ISGPS. 
Other factors studied were gender, patient age, body mass 
index (BMI), ASA class, albumin, creatinine, estimated 
blood loss (EBL), texture of pancreatic remnant, and type of 
closure (oversewn, stapled, or both). Data were analyzed 
with Chi Squared test, Fisher’s Exact Test, and ANOVA, 
where appropriate.
Results: The two analgesia groups were found to be similar, 
and there was a statistical trend showing increased PF rate 
in the PCA group (see Table 1).
Conclusions: These data show that there is no statistical 
signifi cance, but a trend (p = 0.10) favoring PCEA over PCA 
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COAGULOPATHY FOLLOWING LIVER 
RESECTION: IS IT OVERDIAGNOSED 
AND OVERTREATED?
J. S. Barton, G. M. Riha, J. A. Differding, S. J. Underwood, 
J. L. Curren, B. C. Sheppard, R. F. Pommier, S. L. Orloff, 
M. A. Schreiber and K. G. Billingsley
Oregon Health And Science University, Portland, OR
Introduction: International Normalized Ratio (INR) is 
widely utilized to determine the need for plasma replacement 
and timing of initiation of thromboprophylaxis in liver resec-
tion patients. This practice is based on the concept that insuf-
fi ciency in coagulation factors in the postoperative period is 
associated with elevation in INR and associated functional 
coagulopathy, a link that remains poorly understood. 
Thrombelastography (TEG) monitors shear elasticity, which 
is sensitive to cellular and plasma components in blood, 
allowing for functional assessment of the natural history of 
the clot. The aim of this study was to prospectively compare 
INR and TEG in liver resection patients.
Methods: Forty patients were enrolled prior to undergoing 
elective hepatectomy. Patients underwent liver resection uti-
lizing low CVP anesthetic technique and intermittent Pringle 
maneuver. INR and TEG were drawn prior to incision, post-
operatively, and post-operative days 1, 3, and 5.
Results: All post-operative INR values increased signifi -
cantly when compared to pre-operative INR (p < 0.01). The 
time to onset of clot (R-value) decreased signifi cantly at the 
post-operative time point (p = 0.04) consistent with relative 
hypercoagulability. Subsequent R-values were not statisti-
cally different when compared to the pre-operative R-value. 
The strength of the clot (maximum amplitude (MA)) was 
unchanged when comparing pre- and post-operative time 
points.
Conclusions: Despite an elevation in INR, patients who 
underwent liver resection did not demonstrate a hypocoagu-
lopathic state, but demonstrated a brief hypercoagulable state 
based on TEG. These data call into question the practice of 
utilizing the INR to guide plasma transfusion and timing of 
prophylactic anticoagulation after liver resection.
quently recurred in the right retroperitoneum in 2004 (18.5 
× 20 cm), resected with en-bloc radical right nephrectomy. 
The patient did well until 2011, when he presented with 
severe hypoglycemia (glucose levels 20 mg/dL) and a 25 × 
20 × 30 cm liver mass involving all segments of the liver 
including a portion of 2 and 3, and the IVC with massive 
lower body edema (a 2 cm satellite was also observed in 
segment 2). Three-dimensional volumetrics were performed 
with a functional liver remnant estimated at 782 mL or 
20.1%. Standard resection was not felt feasible, so ex-vivo 
resection (pump time 2 hours 20 minutes) with veno-venous 
bypass was performed. Segments 2 and 3 were reimplanted, 
and the inferior vena cava reconstructed with a 20 mm 
goretex graft. The patient did well post-operatively with 
immediate resolution of his hypoglycemia. He underwent 
radiofrequency ablation (RFA) of the 2 cm lesion 2 months 
post-op. HPC is a rare neoplasm and, to our knowledge, this 
is only the second reported case of primary retroperitoneal 
metastasis to the liver. Although the prognosis for HPC is 
usually favorable (71 and 54 percent survival rates at 5 and 
10 years), associated hypoglycemia necessitates immediate 
resection.
SMA FIRST DISSECTION TO FACILITATE 
VENOUS RESECTION DURING 
PANCREATICODUODENECTOMY
D. Bourgeois, D. Schuitevorder, J. Bolton and W. Conway
Ochsner Medical Center, New Orleans, LA
Background: To facilitate pancreaticoduodenectomy (PD) 
with vascular resection while maintaining adequate retro-
peritoneal margin clearance, we have adopted the SMA fi rst 
technique of pancreatic head dissection.
Methods: A retrospective chart review was undertaken to 
patient outcomes after PD with major venous resection; 
minor tangential venous resections and patients with other 
organs/vasculature resected were excluded. Technique: After 
medial colon rotation, generous Kocher maneuver, and 
biliary division, the inferior border of the foramen of Winslow 
is divided to obtain access to the celiac axis. Dissection 
inferiorly exposes the origin of the SMA. Immediate skele-
tonization with separation of the uncinate/pancreatic head 
from the SMA is undertaken. After jejunal division and 
refl ection, complete devascularization of the pancreatic head 
is obtained prior to venous resection, allowing controlled 
resection without SMA margin compromise, risk of vessel 
injury, or excessive venous backbleeding. A short technique 
video will be shown.
Results: Since 2000, 34 PD with major SMV/PV resection 
were performed. After, 9/2009, 17 of these utilized the SMA 
fi rst technique. The 2 groups did not differ in terms of age, 
T-stage, or pre-operative hemoglobin. Intra-operative vari-
ables indicated a similar amount of crystalloid and blood 
usage, and length of surgery. Although not statistically 
signifi cant, there appeared to be a trend toward reduced 
blood loss in the SMA fi rst group (mean 960+624 cc vs. 
1363+922 cc).
Discussion: We believe the SMA fi rst dissection technique 
facilitates PD with vascular resection. Early devasculariza-
tion of the pancreatic head allows maximal retroperitoneal 
clearance, reduced risk of SMA injury, and may reduce blood 
loss.
METASTATIC HEMANGIOPERICYTOMA 
REQUIRING EX VIVO LIVER 
RESECTION
S. L. Bokshan1, M. B. Doyle1,2 and W. C. Chapman1,2
1Washington University School Of Medicine, Saint Louis, 
MO; 2Barnes-Jewish Hospital, Saint Louis, MO
Hemangeopericytoma (HPC) is a rare neoplasm derived 
from Zimmerman’s pericytes within capillary walls, some-
times characterized by severe hypoglycemia (including fatal 
reports) as a result of excessive tumor production of insulin-
like growth factor 2 (IGF-2). A 44-year-old male initially 
presented in 1997 with a large HPC in the back that subse-
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EVALUATION OF STAPLER 
HEPATECTOMY DURING 
LAPAROSCOPIC LIVER RESECTION
J. F. Buell, B. Gayet, H. Han, G. Wakabayashi, K. Kim, 
G. Belli, R. Cannon, H. Keneko, C. Gamblin, G. Brock 
and I. Dagher
International Consensus Group For Laparoscopic Liver 
Surgery, And Tulane University, New Orleans, LA
Parenchymal transection has traditionally been the most 
challenging aspect of hepatectomy. Since the inception of 
laparoscopic liver resection two techniques have evolved: 
electrosurgery and stapler hepatectomy. This study evaluates 
the benefi ts and defi ciencies of these approaches.
Methods: An international database of 1499 laparoscopic 
liver resections was established and patient outcomes were 
analyzed using univariate, and multivariate analysis.
Results: 735 electrosurgical resections (ER) were compared 
to 764 stapler hepatectomies (SH). Age Gender (Male) 
Cirrhosis (Yes) Cancer (Yes) Tumor size (cm) Electro-ER 
56.1 354 (47%) 245 (33.0%) 375 (51.5%) 4.89 Stapler-SH 
54.3 308 (40%) 97 (12.6%) 282 (37.1%) 5.83 p-value 0.019 
0.002 < 0.0001 < 0.0003 0.0006 Surgical outcomes are 
described below: Lobe Rsxn OR time (hr) EBL (CC) 
Transfuse Convert Comps LOS (d) Margin (cm) Recurrence 
Mortality ER 98 (13.3%) 3.5 334 65 (8.9%) 16 (2.2%) 93 
(12.6%) 8.9 1.28 137 (18.6%) 66 (8.9%) SH 193 (25.3%) 
1.6 171 39 (5.1%) 12 (1.6%) 122 (15.9%) 3.2 1.02 81 
(10.6%) 53 (6.9%) p-value 0.0001 < 0.0001 < 0.006 0.004 
0.4 0.067 < 0.003 < 0.0029 < 0.0001 0.31 Stapler hepatec-
tomy (SH) was utilized for larger tumors and subsequently 
a higher percentage of lobar resections. A trend toward 
higher complication rates were identifi ed in the SH group 
including bile leaks (26/735, 3.5% vs. 16/764, 2.1%: p = 
0.09). Post-operative liver failure was equivalent between 
the two groups (7/735, 1.0% for ER vs. 6/764, 0.9% for SH). 
However, despite smaller margins, SH had an overall reduced 
odds of tumor recurrence, after adjustment for age, gender, 
cirrhosis, tumor size, major lobe resection, transfusion 
(OR = 0.34, 95% CI 0.19–0.60, p = 0.0002).
Conclusions: Stapler hepatectomy appears to provide 
several advantages over ER including diminished blood loss, 
and shorter OR times. SH incurred a trend toward higher 
incidence of complications and statistically smaller margins. 
Despite smaller surgical margins, SH patients demonstrated 
an improved OR for recurrences. This data suggests tradi-
tional pathologic margins maybe underestimated.
RESIDUAL DISEASE (RD) PREDICTS 
OUTCOME AFTER DEFINITIVE 
RESECTION FOR INCIDENTAL 
GALLBLADDER CANCER (IGBC)
J. M. Butte1, M. G. Gonen2, M. I. DAngelica1, P. J. Allen1, 
T. P. Kingham1, Y. Fong1, R. P. DeMatteo1 and 
W. R. Jarnagin1
1Department Of Surgery, Memorial Sloan-Kettering Cancer 
Center, New York, NY; 2Department Epidemiology And 
Biostatistics, Memorial Sloan-Kettering Cancer Cent, 
New York, NY
Background: The fi nding of RD at reoperation and defi ni-
tive resection of IGBC may infl uence outcome, but its fre-
quency and clinical relevance, particularly with respect to 
anatomic site, are incompletely characterized.
Methods: Consecutive patients with IGBC undergoing re-
exploration between 1998 and 2009 were identifi ed; those 
submitted to curative intent resection were analyzed. 
Demographics, tumor and treatment-related variables were 
correlated with RD and survival. Sites of RD were classifi ed 
as: gallbladder bed (GB) and/or bile duct (BD) alone, lymph 
nodes (LN) alone, GB bed and/or BD + LN, and distant 
(discontiguous liver, port site, other peritoneal).
Results: RD was found in 83 (61%) of 136 of patients 
undergoing re-exploration and in 64 (54.7%) of 117 treated 
with curative intent, mainly involving the liver and LNs 
(table 1). T stage of the GB specimen was the only indepen-
dent predictor of RD (T1b = 35.7%, T2 = 49.2%, T3 = 70%, 
p = 0.016). Any RD dramatically reduced median DFS (11.2 
vs. 93.4 months, p < 0.0001) and DSS (24.1 months vs. not 
reached, p < 0.0001) compared to no RD, respectively. In 
patients with RD, survival was not stratifi ed by location, with 
all anatomic sites being equally poor (p = 0.9) (fi gure). RD 
at any site predicted DFS (HR 2.4, 95% CI 1.3–4.4, 
p = 0.003) and DSS (HR 2.7, 95% CI 1.3–5.2, p = 0.004), 
independent of all other tumor-related variables.
Conclusion: RD is a common fi nding in patients IGBC and 
is an independent predictor of recurrence and survival. 
Patients with RD after resection should be considered for 
adjuvant therapy, and those at high risk (i.e. T3) may benefi t 
from a neoadjuvant treatment strategy.
Table 1. Location of residual disease
Location of residual disease N (%)
Gallbladder bed and/or bile duct alone 23 (35.9)
Distant 19 (29.7)
Gallbladder bed and/or bile duct + lymph nodes 12 (18.8)
Lymph nodes alone 10 (15.5)
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PANCREATIC FISTULA AFTER 
RESECTION OF PANCREATIC DUCTAL 
ADENOCARCINOMA DOES NOT 
ADVERSELY AFFECT DISEASE FREE 
SURVIVAL
R. M. Cannon, G. G. Callender, K. M. McMasters and 
C. R. Scoggins
University Of Louisville Department Of Surgery Division 
Of Surgical Oncology, Louisville, KY
Introduction: Pancreatic fi stula (PF) has recently been sug-
gested to adversely affect disease free survival (DFS) follow-
ing resection for pancreatic ductal adenocarcinoma (PDAC). 
This study was undertaken to evaluate the effect of PF on 
recurrence following pancreatic resection for PDAC.
Methods: With IRB approval, a retrospective review of 74 
consecutive patients undergoing resection of PDAC by two 
surgeons at a single institution was performed. PF was 
graded according to the ISGPF classifi cation, with grade B/C 
fi stulas being considered signifi cant. OS and DFS were cal-
culated according to Kaplan-Meier, with comparisons made 
between those with signifi cant fi stulas and those who did not. 
p < 0.05 was considered signifi cant.
Results: There were 74 patients in the study, at a mean age 
of 65 years. Any PF occurred in 12 (16.2%), with 6 being 
grade B or C. Patients with signifi cant PF were of similar 
age, with a nonsignifi cant trend towards more and larger 
tumors. Resection margins and lymph node positivity were 
also similar between groups. One, three, and fi ve year OS in 
the PF and non-PF groups were 66.7%, 25.0%, and 0% vs. 
51.4%, 23.7%, and 10.1% (p = 0.792). DFS at one, three, 
and fi ve years in the PR and non-PF groups were 66.7%, 
25.0%, and 0% vs. 44.1%, 22.7%, and 9.0% (p = 0.630). The 
hazard ratio of PF for OS and DFS on multivariate control-
ling for tumor size and number, margin status, and lymph 
node invasion was 0.884 (95% CI 0.353–2.215; p = 0.792) 
and 0.799 (95% CI 0.319–2.001; p = 0.632).
Conclusion: Although PF is a signifi cant complication, it 
does not appear to adversely affect survival following resec-
tion of PDAC.
Age 
(mean)
# of Tumors 
(mean)
Size of Largest
Tumor (cm, mean)
Blood Loss
(ml, mean)
Positive 
Margins
LN 
Invasion
Minor or No Fistula (n = 68) 66 2.5 4.9 693 20.6% 67.7%
Signifi cant Fistula (n = 6) 62 1.0 2.9 600 33.3% 66.7%
P-value 0.510 0.316 0.174 0.654 0.604 0.961
SAFETY AND EARLY EFFICACY OF 
IRREVERSIBLE ELECTROPORATION 
FOR HEPATIC TUMORS IN PROXIMITY 
TO VITAL STRUCTURES
R. M. Cannon1, D. Hays2, W. Goodwin2, S. Bagla3, 
G. McLennan4, G. Narayanan5 and R. C. Martin1
1University Of Louisville, Department Of Surgery, Division 
Of Surgical Oncology, Louisville, KY; 2Baptist Health, 
Little Rock, AR; 3INOVA, Springfi eld, VA; 4Cleveland 
Clinic, Cleveland, OH; 5University Of Miami, Miami, FL
Introduction: Thermal ablation of hepatic tumors is an 
accepted treatment modality when resection is not feasible. 
Current thermal ablation technologies such as RFA, 
Microwave, and Cryo are often limited by tumor location, 
particularly proximity to major vascular and biliary struc-
tures. This study was undertaken to evaluate the safety and 
early effi cacy of irreversible electroporation (IRE) for hepatic 
tumors.
Methods: An IRB approved prospective, multi-institutional, 
treatment registry of 150 patients undergoing 175 treatments 
for primary or secondary cancers in the liver was evaluated 
from 8/2009 to 10/2011. Outcomes were compared and 
stratifi ed by treatment approach and tumor histology. 
Ablation success was determined by Kaplan-Meier. Proximity 
to vital structures was defi ned as within < 5 mm distance.
Results: There were 45 patients undergoing 51 IRE proce-
dures, with 40 (88%) patients having lesions in proximity to 
major vasculature, bile duct, or other organs. IRE was per-
formed via an open (19.6%), laparoscopic (3.9%), or percu-
taneous (76.5%) approach. The median number of tumors 
treated per procedure was 1, with a maximum of three. The 
most common diagnosis was colorectal metastasis (43.1%), 
followed by HCC (33.3%). There were 9 adverse events 
occurring after 5 procedures, with only 3 possibly directly 
related to the procedure. These included neurogenic bladder 
in one patient, and abdominal pain in two. All three resolved 
spontaneously. Overall, successful ablation was maintained 
in 59.5% at 12 months.
Conclusion: IRE is safe and effective for palliation of 
hepatic tumors not amenable to resection. Continued optimi-
zation for patient selection, tumor size and number of probe 
to be utilized needs to be defi ned to reduce overall ablation 
recurrences.
Histology #Procedures Size of Tumors 
(cm, median, 
range)
# Probes 
(median, 
range)
Adverse 
Events
Ablation 
Success
6 month 
Ablation 
Success
12 month 
Ablation
Success
Metastatic CRC 22 2.7 (1.2–11) 3 (2–5) 9.1% 95% 94.1% 58.8%
HCC 17 2.1 (1.3–4.5) 3 (2–4) 5.9% 100% 90.0% 50.0%
Other 12 2.5 (1.1–5.0) 4 (3–5) 16.7% 100% 100.0% 100.0%
P-value n/a 0.290 0.111 0.706 0.523 0.573 0.573
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A DECADE OF MIMINALLY INVASIVE 
LIVER RESECTION (MILR) IN 432 
PATIENTS AT A HIGH VOLUME LIVER 
CANCER CENTER
J. S. Cardinal, A. Tsung, J. Marsh, S. Reddy, D. L. Bartlett 
and D. A. Geller
University Of Pittsburgh Medical Center Department Of 
Surgery, Pittsburgh, PA
Background: This study analyzes the outcomes of mini-
mally invasive liver resections at a Western Center over the 
last decade.
Methods: Retrospective review of a prospective database. 
Outcomes included lesion size, MILR technique, OR time, 
pRBC used, ICU admission, LOS, and actuarial overall 
survival (OS).
Results: From 2001–2011, 432 patients (25% of all liver 
resections performed) underwent MILR. A pure laparoscopic 
approach was utilized in 245 cases (57%), hand-assisted in 
126 (29%), hybrid in 22 (5%), or robotic in 39 (9%) cases. 
317 (73%) of the patients had solid lesions, of which 175 
(55%) were malignant. Median tumor size was 3.3 cm for 
malignant, and 7.6 cm for benign lesions. 5-year OS after 
MILR of HCC (61 cases) and CRC mets (59 cases) was 61% 
and 47%, respectively. Average OR time was 190 minutes. 
Conversion to open resection occurred in 8/432 (1.8%) cases. 
13 patients (3%) received blood transfusion(s) (max 2 u 
pRBC), and 14 patients (3.2%) required ICU admission. 
Median LOS was 3 days. There were no intra-operative 
deaths. Since 2007, use of the robot has expanded the volume 
of major hepatectomies, defi ned as resection of 4 or more 
segments, with 14/64 (22%) of the major hepatectomies 
being performed via a robotic approach.
Conclusions: This is the largest single center experience 
reported for MILR. 5-year OS for cancer is comparable to 
that reported in open series. As technologic advances con-
tinue in both laparoscopic and robotic instrumentation, we 
expect the percentage of minimally invasive liver resections 
to increase.
RECURRENCE, SALVAGE, AND 
SURVIVAL AFTER TWO-STAGE 
HEPATECTOMY FOR COLORECTAL 
LIVER METASTASES
K. Cardona, D. Donataccio, N. Kemeny, T. P. Kingham, 
P. J. Allen, R. P. DeMatteo, Y. Fong, W. R. Jarnagin and 
M. I. D’Angelica
Memorial Sloan-Kettering Cancer Center, New York, NY
Introduction: Two-stage hepatectomy has been advocated 
has a treatment modality for resection of advanced colorectal 
liver metastases (CRLM) in selected patients. This study 
analyzes the recurrence pattern, salvage rate, and survival 
after two-stage hepatectomy for CRLM.
Methods: Retrospective review of a prospective database 
identifi ed patients who underwent potentially curative 2-stage 
hepatectomy for CRLM and outcome data was analyzed.
Results: From September 2000 to August 2009, 40 patients 
were eligible for 2-stage hepatectomy and 88% completed 
both resections. The median number of tumors was 8, with 
38% having a tumor > 5 cm and 35% having a CEA > 
200 ng/ml. All patients received systemic perioperative che-
motherapy and 86% received regional therapy with hepatic 
artery infusion. Median follow-up for survivors was 40 
months; median disease-specifi c (DSS) was 52 months and 
5-year DSS was 49%. Combined morbidity for both proce-
dures was 63% with no operative deaths. Median recurrence-
free survival was 11 months with a 3-year probability of 
recurrence of 81%. Disease recurrence occurred in 27 
patients (77%), with the liver (42%) and lung (37%) being 
the most common sites of recurrence. Sixteen of these 
patients (60%) were salvaged with either surgery and/or 
ablation; 7 (44%) of whom were disease-free at a median 
follow-up of 44 months with a 5-year survival of 53%.
Conclusions: Two-stage hepatectomy, combined with 
extensive systemic and regional chemotherapy, is an effec-
tive treatment for selected patients with advanced CRLM. 
These patients are at considerable risk of local and distant 
recurrence; however, the majority can be salvaged and long-
term survival can be achieved.
ROBOT-ASSISTED RESECTION OF 
CHOLEDOCHOCELE IN AN ADULT 
WITH HEPATICOJEJUNOSTOMY AND 
INTRACORPOREAL ROUX-EN-Y 
ANASTOMOSIS
S. G. Carpenter1, T. A. De Masters1, E. P. Castle2 and 
D. C. Mulligan1
1Mayo Clinic Arizona, Division Of Transplant Surgery, 
Phoenix, AZ; 2May Clinic Arizona, Department Of 
Urology, Phoenix, AZ
Background: Robotic surgery offers three dimensional 
visualization and precision of movement that could be of 
great value to hepatobiliary surgeons. However, surgeons are 
reticent to undertake more complex hepatobiliary (HB) pro-
cedures with robotic assistance due to steep learning curves 
and extended operative times. This video shows a robotic 
excision of a choledochal cyst and this study reviews the 
literature in order to assess the potential for the propagation 
of robotic techniques in HB surgery.
Methods: A 58 year old woman underwent a robotic exci-
sion of a small choledochocele with hepaticojejunostomy 
and intracorporeal Roux-en-Y using the Da Vinci surgical 
robot (Intuitive Surgical, Sunnyvale, CA). A literature review 
was performed searching for articles in English concerning 
robotic and minimally invasive techniques in HB surgery.
Results: Port placement was determined via collaborative 
surgical discussion and previously reported robotic right 
hepatectomies. Total operative time was 386 minutes and 
total robot working time was 330 minutes. The hepaticoje-
junostomy was performed using 5–0 PDS suture with para-
chuted running back wall and running front wall sutures. No 
complications occurred intraoperatively. Estimated blood 
loss was less than 100 milliliters. The patient was ambulating 
and tolerating oral intake on post-operative day one, and was 
discharged home on post-operative day two. Literature 
review reveals that very few United States centers (mostly 
pediatric) are pursuing robotic techniques for complex 
biliary procedures.
Conclusions: Robotic resection of choledochal cyst is safe 
and effective, with many advantages over open surgery such 
as superior visualization, instrument articulation, precision, 
and post-operative patient recovery.
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SUCCESSFUL ABDOMINAL ORGAN 
DONATION AFTER BRAIN DEATH IN A 
PATIENT WITH A BIVENTRICULAR 
ASSIST DEVICE: EXTENDING 
EXTENDED CRITERIA
S. G. Carpenter1, D. E. Steidley2, D. D. Douglas3, 
S. Reddy1, D. C. Mulligan3 and A. A. Moss1
1Mayo Clinic Arizona, Division Of Transplant Surgery, 
Phoenix, AZ; 2Mayo Clinic Arizona, Department Of 
Cardiovascular Diseases, Phoenix, AZ; 3Mayo Clinic 
Arizona, Division Of Transplant Hepatology, Phoenix, AZ
Background: Few studies address the potential for donation 
after brain death (DBD) in the limited population of patients 
with mechanical circulatory support (MCS).
Methods: A case study was conducted reviewing available 
records of both donor and recipient.
Results: The donor was a 47-year-old female smoker 
who suffered an acute MI. An emergent off-pump 2-vessel 
CABG was performed but was complicated by profound 
cardiogenic shock refractory to both inotropic agents and 
intra-aortic balloon pump. A percutaneously placed LVAD 
(TandemHeart®) improved her hemodynamics but she 
remained with signifi cant hypotension and depressed cardiac 
output. She started on heparin infusion. She was transferred 
to our institution where a surgical biventricular assist device 
(CentraMag®) was placed and hemodynamics normalized. 
Two days post-operatively she developed an intracranial cer-
ebellar hemorrhage and was declared brain dead. Pre-
donation blood chemistry showed creatinine of 0.7, AST 88, 
ALT 21, INR 1.46, and pH of 7.33 and paO2 85.3. She was 
consented for organ donation. Both kidneys were placed 
locally. The liver was turned down for two regional status 1 
patients and by all other local centers. We accepted the liver 
for a 44 year old patient with massively enlarged liver due 
to polycystic liver disease with a MELD exception score of 
20. The peri-operative course was uneventful and the recipi-
ent is now almost 4 years post-transplant with excellent graft 
function.
Conclusion: Extending donor criteria to include MCS 
patients can result in successful transplantation and should 
be considered in selected circumstances once satisfactory 
donor end-organ function is established.
PREDICTORS OF SURVIVAL IN 
GALLBLADDER CANCER: A REVIEW OF 
90 PATIENTS SUBMITTED TO SURGERY 
WITH CURATIVE INTENT
D. Cavallucci, A. Fox and S. Cleary
University Health Network, Toronto General Hospital, 
Toronto, ON
Introduction: Long-term survival from gallbladder cancer 
remains poor. One diffi culty remains identifying patients 
who despite presenting with early disease, have an increased 
risk of recurrence and may benefi t from more aggressive 
adjuvant treatment.
Methods: Retrospective review of all patients with gall-
bladder cancer submitted to surgery with curative intent in 
the past 10 years.
Results: 90 patients were identifi ed. 51 had previous surgery 
with 47 cholecystectomies. Those patients who had under-
gone previous surgery had superior overall survival (p = 
0.0002) which was maintained across all stages of disease. 
A positive cystic duct margin predicted residual disease and 
poorer overal survival on univariate analysis (HR 1.86, p = 
0.048). Presenting with jaundice is confi rmed as a stong 
predictor of unresectability and poorer overall survival (HR 
2.68, p = 0.003) with essentially all patients having recurrent 
disease. If residual disease was present at re-resection fol-
lowing cholecystectomy, the survival is no better than 
patients not diagnosed incidentally. The extent of liver resec-
tion had no signifi cant impact on overall survival once unre-
sectable patients are excluded. In this series with a small 
number of margin positive patients, R status did not appear 
to have an affect on overall survival. En bloc resection of the 
bile duct or adjacent directly involved organs (colon, duode-
num, pancreas) when required did not signifi cantly impact 
overall survival.
Conclusions: Patients whose gallbladder cancer is diag-
nosed incidentally at cholecystectomy have improved sur-
vival even when stage is taken into account. The presence of 
residual disease at re-resection however, removes this sur-
vival advantage.
LIVER-SPLEEN ATTENUATION RATIO 
PREDICTS CHEMOTHERAPY-
ASSOCIATED STEATOHEPATITIS IN 
MULTIDISCIPLINARY TREATMENT OF 
COLO-RECTAL LIVER METASTASES
S. Cecchini1,2, E. Alfaro1, M. Ligorio1, D. Sahani1, 
D. L. Berger1, K. K. Tanabe1, L. Y. Gregory1 and 
C. R. Ferrone1
1Massachusetts General Hospital, Boston, MA; 
2Parma University, Parma, Italy
Background: Chemotherapy associated-liver injury 
increases post-operative morbidity and mortality after 
hepatic resection of colorectal metastases (CRCM), but its 
assessment is diffi cult. The aim of this study is to evaluate 
the radiologic variation of the liver-spleen attenuation ratio 
(LSAR) on preoperative imaging in the evaluation of 
steatohepatitis.
Methods: Between 1998 and 2009, 419 patients underwent 
hepatic resection for CRC metastases. The variation of 
LSAR on the pre- and post-chemotherapy CT-scans of 55 
patients undergoing neo-adjuvant treatment followed by 
hepatic resection for CRCM were randomly selected. 
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Resected specimens were re-reviewed for steatosis and ste-
atohepatitis by a GI pathologist.
Results: Of the 55 patients evaluated steatosis and steato-
hepatitis were identifi ed in 36% and 29% respectively. Only 
patients with steatohepatitis showed a signifi cantly higher 
variation of LSAR (20.7% vs 6.6%; p = 0.019). Logistic 
regression confi rmed that percent variation of LSAR was an 
independent predictor of steatohepatitis (HR 1.051; CI: 
1.006–1.098, p = 0.026). ROC curve analysis demonstrated 
that the area under the curve for percent variation of LSAR 
for steatohepatitis was 0.711 (CI: 565–857, p = 0.020) with 
an optimal cut-off point for preoperative diagnosis of steato-
hepatitis at 8% (sensitivity = 80%, specifi city = 58%, FPR = 
42%, FNR = 20%, PPV = 46%, NPV = 86%).
Conclusions: Non invasive measurement of the variation of 
LSAR on the pre- and post-chemotherapy CT-scans demon-
strated a high sensitivity for the assessment of chemotherapy 
associated-steatohepatitis prior to hepatic resection.
REDUCING SURGICAL SITE 
INFECTIONS IN HEPATO-PANCREATO-
BILIARY SURGERY
E. P. Ceppa1, M. G. House1, H. A. Pitt1, E. M. Kilbane1, 
S. K. Janitz1, A. Nakeeb1, T. J. Howard1, C. M. Schmidt1, 
M. A. Maluccio1, N. J. Zyromski1 and K. D. Lillemoe2
1Indiana University Medical Center, Indianapolis, IN; 
2Massachusets General Hospital, Boston, MA
Introduction: Patients undergoing complex hepato-pancre-
ato-biliary (HPB) operations are at high risk for surgical site 
infection (SSI). Patient factors, preoperative biliary drainage, 
operative techniques, and major postoperative complications 
all contribute to the high rate of SSI. The purpose of this 
study was to analyze whether a multifactorial approach 
towards decreasing SSI is benefi cial.
Methods: From January, 2007 through December, 2009, 
895 complex HPB operations were monitored for SSI 
through the American College of Surgeons-National Surgical 
Quality Improvement Program (ACS-NSQIP). In 2008, 
guidelines for preoperative nutrition, perioperative antibiotic 
management, wound protection, surgical technique, hyper-
glycemia, hypothermia, and blood transfusion were estab-
lished. Protocols for postoperative euglycemia as well as 
drain management were addressed. Feedback of surgeon-
specifi c SSI rates was provided to all HPB surgeons. 
Observed SSI rates were monitored before and after these 
interventions. Expected SSI rates from 2008–09 were deter-
mined from the ACS-NSQIP Participant Use File. Hospital 
cost data were compared between patients with and without 
SSI.
Results: Observed SSI rates for hepatic, pancreatic and 
complex biliary operations as well as expected rates are 
presented in the table. The excess cost per SSI was $11,462 
and was driven by increased length of stay as well as hospital 
readmission for infection. Surgeon feedback suggested that 
surgical technique and wound protection were thought to 
play the greatest role in improvements.
Conclusions: High surgical site infection rates following 
complex HPB operations can be improved by a multifactorial 
approach which features process improvements, individual 
surgeon feedback, and reduced variation in patient 
management.
Expected 
SSI %
Observed 
SSI %
2007 2008 2009 2008–09
Hepatic 27.5 16.5 13.5 11.3
Pancreatic 24.2 21.3 16.5 19.6
Biliary 23.9 19.5 10.5 19.8
HPB 24.8 20.3 15.2* 18.2
*p < 0.03 vs 2007 and 2008.
REDUCED POST-OPERATIVE 
COMPLICATIONS WITH 
LAPAROSCOPIC VERSUS OPEN DISTAL 
PANCREATECTOMY: A META-ANALYSIS
S. A. Chadi, K. P. Croome, C. Schlachta and 
R. Hernandez-Alejandro
University Of Western Ontario, London, ON
Laparoscopic distal pancreatectomy (LDP) has been com-
pared to open techniques (ODP) in institutional experiences, 
however these have largely consisted of smaller sample 
sizes. Our objective was to compare the literature and assess 
the results of LDP and ODP using meta-analysis techniques. 
MEDLINE, CENTRAL and EMBASE databases were 
searched for all comparative studies of LDP and ODP for 
benign and malignant disease. Cochrane Collaboration and 
PRISMA reporting guidelines were used. A secondary sen-
sitivity analysis was performed on patient selection, group 
comparability and procedural outcomes. Eighteen studies 
were included with a total of 726 patients in the LDP and 
1027 patients in the ODP group. Blood loss was found to be 
312 cc lower in the LDP group (p < 0.001) however there 
was no signifi cant difference in the operative time. The rela-
tive risk of all post-operative complications was signifi cantly 
lower in the LDP group (Risk ratio 0.81; p = 0.003) with no 
signifi cant difference in the risk of pancreatic leak. Length 
of hospital stay was 4.06 days shorter (p < 0.001) as was the 
time to oral intake (1.21 days) in the LDP group (p = 0.003). 
There was no signifi cant difference in the 30-day mortality. 
All differences remained unchanged in a subsequent sensitiv-
ity analysis on studies with greater than 20 patients and of 
higher study quality. LDP is a safe alternative to the conven-
tional open technique of distal pancreatic resections. Here 
we demonstrate clear benefi ts of LDP in operative blood loss, 
length of hospital stay and post-operative complications with 
no signifi cant difference in 30-day mortality or pancreatic 
leak rate.
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LAPAROSCOPIC EXCISION OF TYPE IV 
A CHOLEDOCHAL CYST INCLUDING 
LEFT HEPATECTOMY
J. Chavez, E. Lin and J. Sarmiento
Emory University, Atlanta, GA
Choledochal cysts typically are treated with complete exci-
sion plus biliary reconstruction; specifi cally, type IVA cysts 
require additionally the performance of en bloc hepatic 
lobectomy of the affected side. Indications for resection 
include possibility of malignancy, cholangitis and hepatoli-
thiasis. There have been reports of laparoscopic excision of 
choledochal cysts, but to the best of our knowledge, there is 
only one case of laparoscopic resection of a type IVA chole-
dochal cyst. In this video we present a case of a laparoscopic 
excision of the extrahepatic bile duct (cyst) combined with 
left hepatectomy for the management of a type IVA chole-
dochal cyst. A 35 years old female patient presented with 
symptoms of pain in the right upper quadrant and altered 
liver enzymes. The MRI showed a type IVA choledochal cyst 
(Alonso-Lej) with contiguous involvement of the left intra-
hepatic bile duct. Biliary drainage was not performed prior 
to surgery. We performed laparoscopic (hand-assisted) exci-
sion of the extrahepatic bile duct and left hepatectomy with 
Roux en Y hepaticojejunostomy. The total operative time 
was 260 minutes, the estimated total blood loss was 150 ml; 
no perioperative transfusion was needed. There was minimal 
bile leak temporarily but the patient was discharged at post-
operative day 5 without drains. The post operative follow-up 
was uneventful and remains so (120 days follow up); her 
symptoms are not present anymore. We believe that laparo-
scopic excision including of a major hepatectomy is a good 
treatment option for patients with type IVA choledochal 
cysts.
DOES HEALTH INSURANCE PLAY A 
ROLE IN THE OUTCOME OF PEOPLE 
WITH HEPATOBILIARY CANCER?
P. V. Cherian1 and D. J. Christian2
1University Of Arizona UMC SOUTH, Tucson, AZ; 
2Saint Francis Medical Center, Trenton, NJ
Introduction: Biliary tract tumors, primary pancreatic 
cancers and metastatic liver tumors tend to be lethal at time 
of diagnosis. This is mainly due to location, and lack of a 
good screening modality. We further hypothesize that 
absence of insurance would be one more parameter to add 
to the late diagnosis. Our study looks at the insured and 
uninsured patient population correlating with the stage of 
their hepatobiliary malignancies. We hypothesized that unin-
sured patients would be diagnosed with more advanced 
cancer and therefore have signifi cantly worse outcome.
Methods: We conducted a retrospective review of patients 
with hepatobiliary malignancy at a single institution from 
2000–2011. Data was compiled of the stage of diagnosis, 
gender and insurance status. This data was then analyzed 
using paired T-Test.
Results: Out of 250 patients with malignancy 38 had hepa-
tobiliary cancer. Surprisingly only 2 of these patients did not 
have insurance, one of which had stage III and the other 
Stage IV cancer. Among the insured patients two had stage 
2b, two had stage 3 and 17 had stage four and 17 pending.
Conclusion: After analyzing this small data from a single 
institution, data trend did not support the hypothesis. 
However, this needs to be further assessed by conducting a 
multi-institutional study within the state of NJ.
LAPAROSCOPIC CHOLECYSTECTOMY 
IN PATIENTS WITH ASCITES AND/OR 
ESOPHAGEAL VARICES; PREDICTORS 
OF MORTALITY
S. W. Cho, M. Cassera, N. Bhayani, P. Newell, 
C. Hammill, R. Wolf and P. Hansen
Liver And Pancreas Surgery Program, Providence 
Portland Medical Center, Portland, OR
Introduction: We sought to determine complication rates 
and predictors of mortality following laparoscopic cholecys-
tectomy in patients with ascites and/or esophageal varices.
Methods: Using the National Surgical Quality Improvement 
Program database (2005–09) we identifi ed patients with 
ascites and/or esophageal varices who underwent laparo-
scopic cholecystectomy. A control group of randomly 
selected patients without ascites or varices was also selected. 
Patients with congestive heart failure or malignancy were 
excluded. Demographic, preoperative, perioperative and 
postoperative data were assessed.
Results: 409 patients were identifi ed in each group. In the 
study group of patients with ascites and/or esophageal 
varices, 16 had both ascites and varices, 50 had varices only, 
and 343 had ascites only. 16.1% of cases were emergent. 
Median hospital stay was 4 days. The most common com-
plications were respiratory (n = 29), followed by sepsis (n = 
21), and re-operation (n = 15). Comparing the two groups 
with and without ascites or varices, morbidity rates were 
14.9% vs. 3.9% (p < 0.001), and 30-day mortality rate was 
4.6% vs. 0%, respectively (p < 0.001). Univariate analysis 
showed that age ≥65 (p = 0.001), COPD (p = 0.034), pre-
operative septic shock (p = 0.002), MELD score ≥15 (p < 
0.001) were predictive of postoperative mortality. Logistic 
regression analysis confi rmed that age ≥65 (p = 0.006; odds 
ratio = 8.64), and MELD ≥ 15 (p = 0.001; odds ratio = 6.81) 
predicted postoperative mortality. For patients aged ≥65 and 
MELD ≥ 15 mortality rate was 26.1%, whereas for patients 
aged < 65 and MELD < 15, it was 0.34%.
Conclusion: Laparoscopic cholecystectomy in patients with 
esophageal varices and/or ascites carries signifi cant morbid-
ity and mortality. However, patients age < 65 and with 
MELD < 15 fare better.
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DISTAL SPLENORENAL AND 
MESOCAVAL SHUNTING AT THE TIME 
OF PANCREATECTOMY FOR CANCER
K. K. Christians1, K. Riggle1, R. Keim2, S. Pappas1, 
P. Ritch1, B. A. Erickson1, P. P. Tolat1 and D. B. Evans1
1Medical College Of Wisconsin, Milwaukee, WI; 
2Albany Liver And Pancreas Surgery, Albany, NY
Background: Vascular resection/reconstruction during pan-
creaticoduodenectomy (PD) is performed when blood vessel 
involvement represents the only barrier to complete resec-
tion. Transection of the splenic vein (SV) greatly facilitates 
resection/reconstruction of the superior mesenteric (SMV)-
portal vein (PV) confl uence, but may result in sinistral portal 
hypertension. In such cases, we perform a distal splenorenal 
shunt (DSRS) prior to SMV-PV resection/reconstruction. We 
also use a DSRS with/without a temporary mesocaval shunt 
to treat cavernous transformation of the PV. The study’s 
purpose is to review clinical outcomes of these techniques.
Methods: A prospective database identifi ed patients who 
underwent PD or total pancreatectomy (TP) with vascular 
resection/reconstruction coupled with DSRS and/or a tempo-
rary mesocaval shunt between June, 2009 and August, 2011.
Results: PD (8) or TP (2) required SMV-PV resection com-
bined with a DSRS (8) and/or a mesocaval shunt (3) in 10 
patients. Histology included 9 adenocarcinomas and 1 neu-
roendocrine carcinoma. A complete gross resection was 
achieved in all 10 patients and all had negative margins (R0). 
Median blood loss was 1.25 L (450 mL–3.5 L) and median 
hospital stay was 10 days (7–35). There was no mortality. 
Median follow up was 8 months (2–24 months). There were 
two late deaths (9.1, 19.1 months) related to disease 
progression.
Conclusion: Traditionally, these patients were classifi ed 
surgically unresectable. This report provides proof of concept 
that extended resections in highly selected patients can be 
performed safely. This is the fi rst report using DSRS and/or 
mesocaval shunt to manage cavernous transformation of the 
PV during PD or TP.
INDICATIONS, TECHNIQUE AND 
OUTCOMES FOR CENTRAL 
PANCREATECTOMY. AN UPDATED 
EXPERIENCE
C. Correa-Gallego, J. LaFemina, M. D’Angelica, 
R. DeMatteo, P. Kingham, Y. Fong, W. R. Jarnagin and 
P. J. Allen
Memorial Sloan-Kettering Cancer Center, New York, NY
Background: We previously reported an early experience 
with central pancreatectomy (CP). As interest in pancreatic 
sparing resection increases, we seek insight into the evolu-
tion of this procedure at a tertiary-care referral center by 
comparing indications, technique and outcomes between our 
previously published and recent cohorts. 
Methods: A query of our prospectively collected database 
identifi ed 3582 pancreatic resections since 1992. Of these, 
43 (1%) were CP. Our initial report included 9/43 performed 
by 04/2005 (group I); the remaining 34 (79%), were per-
formed between 05/2005–07/2011 (group II). (Table) 
Results: The majority of patients were women 29/43 (67%) 
with a median age of 60 (IQR 47–70). The most common 
indications were: neuroendocrine tumor (35%), serous cyst-
adenoma (26%), and IPMN (21%). Pancreaticogastrostomy 
for reconstruction was used in 33/43 (77%) patients. An 
anastomosis-associated complication was found in 26% and 
post-pancreatectomy hemorrhage in 9%. Readmission was 
necessary in 28% of patients, an interventional radiology 
procedure in 14% and reoperation in 1 patient (2%). There 
were no perioperative deaths. Median hospital stay was 7 
days (IQR 6–9). At a median follow-up of 14 months (IQR 
13–25), no patients had developed exocrine insuffi ciency but 
3/43 (7%) had new-onset diabetes. Table 1 shows demo-
graphics, indications and operative outcomes comparing 
groups I and II. 
Conclusions: Central pancreatectomy is being used with 
increasing frequency at our institution. Postoperative morbid-
ity remains signifi cant but hospital length of stay is statistically 
shorter in the most recent experience. We have adopted pan-
creaticogastrostomy as a reconstruction technique with equiv-
alent anastomosis-associated complications.
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Table 1. Characteristics, indications an outcomes
Initial group (I) Late group (II) Total
9 (21%) 34 (79%) 43 P value
Characteristics n (%)
Pancreaticogastrostomy 1 (0.1%) 32 (94%) 33 (77) P < 0.001
Gender
 Female 5 (55) 24 (76) 29 (67) P NS
Age, years median (IQR) 52 (43–64) 61 (49–72) 60 (47.5–70) P NS
LOS, days median (IQR) 9 (7–14) 7 (5–8) 7 (6–9) P = 0.009
Followup, months median (IQR) 45 (14–95) 7 (2–17) 14 (3–25) P = 0.01
Postoperative pathologic diagnosis
 IPMN 9 (26) 9 (21)
 Serous cystadenoma 4 (44) 7 (21) 11 (26) P NS
 Neuroendocrine tumor 4 (44) 11 (32) 15 (35) P NS
 MCN 2 (6) 2 (5)
 Solid Pseudopapillary 1 (12) 1 (3) 2 (5) P NS
 Mixed pathology 3 (9) 3 (7)
 Adenocarcinoma 1 (3) 1 (1)
Complication n (%)
Postoperative pancreatic fi stula 4 (44) 7 (21) 11 (26) P NS
 Postoperative pancreatic leak 1 (11) 3 (9) 4 (9) P NS
 Intraabdominal abscess 3 (33) 4 (12) 7 (16) P NS
Gastrointestinal hemorrhage 1 (11) 3 (9) 4 (9) P NS
New onset endocrine insuffi ciency 2 (22) 1 (3) 3 (7) P NS
Exocrine insuffi ciency 0 0 0
Need for reoperation 1 (11) 0 1 (2) P NS
Need for readmission 1 (11) 11 (29) 12 (28) P NS
Need for IR procedure 1 (11) 5 (15) 6 (14) P NS
Death 0 0 0
IQR = Interquartile Range.
TECHNICAL REFINEMENT OF 
ROBOT-ASSISTED 
PANCREATICODUODENECTOMY: 
IMPROVING OUTCOMES AT A SINGLE 
INSTITUTION
M. Daouadi1, A. H. Zureikat1, M. S. Zenati2, 
S. Chalikonda3, D. L. Bartlett1, H. J. Zeh1 and A. J. Moser1
1UPMC Cancer Pavilon, Pittsburgh, PA; 
2UPMC Presbyterian, Pittsburgh, PA; 3Cleveland Clinic 
Main Campus, Cleveland, OH
Background: Although robot-assisted pancreaticoduode-
nectomy (RAPD) is safe and feasible at selected centers, 
technical refi nements are required to standardize the opera-
tive technique prior to comparing its effectiveness to open 
or laparoscopic approaches. We analyzed the cumulative 
effects of surgical experience and procedural refi nements on 
important metrics of RAPD outcome in order to optimize 
intraoperative techniques.
Methods: Retrospective analysis of a prospective database 
of 76 RAPD divided into two cohorts of 38: early (Oct 
2008–May 2010) and late (Jun 2010–Aug 2011).
Results: Preoperative characteristics of the two cohorts 
were equivalent: age, gender, BMI, comorbidities, prior 
abdominal surgery, frequency of malignancy, and tumor size. 
Although mean operative duration did not change, the vari-
ability in case duration decreased signifi cantly while par-
ticipation by surgical trainees increased. The rate of 
pylorus-sparing RAPD increased (11% vs. 74%, p < 0.001), 
estimated blood loss (median 400 vs. 225 ml, p = 0.01), 
probability of blood loss greater than 500 ml (45% vs. 16%, 
p = 0.006) and conversion to open PD (21% vs. 2.6%, p < 
0.03) decreased signifi cantly. Margin status, lymph node 
harvest, severity of complications (Clavien scale) and length 
of stay did not change, although trends toward reduced rates 
of reoperation (p = 0.12) and readmission (p = 0.07) were 
observed. The rate and severity of pancreatic fi stula was 
constant (p = 0.15).
Conclusion: Outcomes of RAPD achieved technical matu-
rity after approximately forty cases. The absence of decreas-
ing operating room time in this study may refl ect the 
increasing participation of surgical trainees. Well-designed 
studies comparing the effectiveness of this approach with 
open surgery are now appropriate.
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COMBINED RADIOFREQUENCY 
ABLATION AND RESECTION FOR 
METASTASIC COLORECTAL CANCER 
TO THE LIVER
S. G. De La Fuente, J. M. Weber, T. J. Yeatman, 
M. P. Malafa, J. Choi and D. Shibata
H. Lee Moffi tt Cancer Center, Department Of 
Gastrointestinal Oncology, Tampa, FL
Background: In patients with extensive bilobar metastases 
to the liver from colorectal cancer (CRC), lesions may often 
not be amenable to surgical resection alone due to tumor 
location or concerns regarding parenchymal preservation. 
Radiofrequency ablation (RFA), in combination with resec-
tion is often utilized for the surgical management of these 
patients. We sought to determine outcomes in patients with 
metastatic CRC to the liver treated by this multimodal surgi-
cal approach.
Methods: By retrospective review from 1999–2009, we 
identifi ed a total of 53 patients having undergone simultane-
ous RFA and liver resection for metastatic CRC. Kaplan-
Meier analyses were used to calculate disease-free (DFS) and 
overall survival (OS).
Results: All patients were Caucasians with a median age of 
62.5 years old (range 36–86). Sixty four percent were males. 
The median number of lesions per case was 3 (range 1–8). 
Associated resections included extended resection (n = 1), 
hemi-hepatectomy (n = 6), segmentectomy (n = 23), wedge 
resections (n = 21), and other (n = 2). Overall, 40 (74%) 
patients had recurrence, 34 (68%) of which had hepatic 
recurrence. The median DFS for the entire cohort was 11 
months (range 0–67), with a median OS of 32 months (range 
0–85). Kaplan-Meier analyses showed 3-and 5-year survival 
rates of 33% and 19% respectively.
Conclusions: Aggressive combined use of resection and 
RFA for patients with metastatic CRC that is not amenable 
to resection alone is associated with a high rate of hepatic 
recurrence. However, reasonable long term DFS and OS may 
be achieved in these selected patients that may have other-
wise been considered unresectable.
INCREASING AGE AND DECREASED 
FUNCTIONAL STATUS ARE 
INDEPENDENT PREDICTORS OF 
POSTOPERATIVE COMPLICATIONS AND 
DEATH FOLLOWING HEPATIC 
RESECTIONS
S. G. De La Fuente1, D. Shibata1, B. M. Clary2, 
K. M. Bennett2 and J. E. Scarborough2
1H. Lee Moffi tt Cancer Center, Tampa, FL; 
2Duke University Medical Center, Durham, NC
Background: With the aging population and increasing 
incidence of hepatic malignancies in elderly patients, estab-
lishing the safety of hepatic resections is crucial. The present 
study investigates early postoperative morbidity and mortal-
ity in elderly patients undergoing hepatic resection using a 
nationally-validated database.
Methods: The National Surgical Quality Improvement 
Program Participant User Files (NSQIP-PUF) for 2005 
through 2009 were used for the retrospective analysis of all 
patients undergoing hepatic resection. The primary outcome 
measures were 30-day postoperative mortality, major com-
plication rate and overall complication rate. The primary 
predictor variable was patient age, which was treated as a 
dichotomous variable (age < 70 years, age ≥ 70 years).
Results: 5706 patients were included in the fi nal analysis, 
1280 of which were ≥70 years of age. 30-day postoperative 
mortality (< 70 years 1.9% vs. ≥70 years 3.4%, p < 0.0001), 
serious complications (< 70 years 15.2% vs. ≥70 years 
18.4%, p < 0.006) and overall complications (< 70 years 
23.1% vs. ≥70 years 26.6%, p < 0.01) were more common 
in the elderly group. Elderly patients had signifi cantly more 
wound infections, pneumonia, prolonged ventilator support, 
unplanned re-intubations, renal failure, strokes, myocardial 
infarction, cardiac arrests, and septic shock. The median 
length of hospitalization was also signifi cantly longer in the 
elderly. Other independent predictors for complications and 
mortality are shown in table 1.
Conclusions: This study shows signifi cantly higher compli-
cation rates and mortality following hepatic resections in 
elderly patients. These fi ndings should be taken into account 
when considering hepatectomy in this population.
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Table 1. Predictors of Primary Outcomes After Hepatic Resection on Multivariate Analysis, Using Entire NSQIP Sample
Any Complication Serious Complication 30-Day Postoperative Death
Age > 70 years old 1.19 (1.02–1.39) p = 0.03 1.27 (1.06–1.51) p = 0.009 2.32 (1.61–3.33) p < 0.0001
Intraoperative Transfusion 1.69 (1.46, 1.95) p < 0.0001 2.06 (1.76–2.43) p < 0.0001 2.87 (1.95–4.22) p < 0.0001
Non-Independent 
Functional Status
6.59 (2.46–17.6) p < 0.0001 5.55 (2.12–14.5) p < 0.0001 6.11 (1.59–23.5) p = 0.008
Diabetes 1.30 (1.09–1.55) p = 0.003 1.38 (1.14–1.68) p = 0.001 1.78 (1.18–2.67) p = 0.006
Extended hepatectomy 1.44 (1.17–1.77) p = 0.001 1.50 (1.19–1.89) p = 0.001 2.05 (1.27–3.32) p = 0.003
High ASA Classifi cation 1.36 (1.03–1.80) p = 0.03 1.68 (1.24–2.26) P = 0.001 2.04 (1.18–3.55) p = 0.01
LONG TERM SURVIVAL IN PATIENTS 
WITH METASTATIC 
GASTROINTESTINAL STROMAL 
TUMORS TO THE LIVER AND OTHER 
LOCATIONS
S. G. De La Fuente, J. L. Deneve, C. Parsons, A. Conly 
and R. J. Gonzalez
H. Lee Moffi tt Cancer Center, Tampa, FL
Background: Metastasectomy in patients with isolated 
hepatic metastases from gastrointestinal stromal tumors 
(GIST) provides survival benefi t. However, outcome with 
synchronous metastases to the liver and other locations in the 
era of tyrosine kinase inhibitor (TKI) therapy is unclear. In 
this study we determine overall survival (OS) in patients 
presenting with isolated hepatic metastases versus synchro-
nous metastatic disease to liver and other locations.
Methods: We identifi ed patients presenting with metastatic 
GIST from 1999–2009. Survival between groups was 
analyzed.
Results: Of the 193 patients with GIST, 43 patients pre-
sented with isolated liver metastases while 16 patients pre-
sented with synchronous metastases to liver and other 
locations. Of these n = 6 presented with liver and peritoneal 
disease. There were no differences in gender or mean age 
between groups. 13 (81%) of patients with liver + other loca-
tion underwent surgery, while 34 (79%) had surgery in the 
liver only group, p < 0.85. There were no differences in the 
number of patients that had neoadjuvant TKI therapy (liver 
only 26% vs. liver + other 25%, p = 0.82). Kaplan-Meier 
analysis showed similar OS between groups (liver only 
40.5 mos vs. liver + other 28.7 mos, p < 0.62).
Conclusions: Patients with GIST and metastatic disease to 
the liver and other locations at presentation have similar OS 
than patients with isolated metastatic liver disease. Although 
presumably patients with greater disease burden would have 
worse survival these data do not refl ect this assumption. It 
remains unknown whether this fi nding results from systemic 
therapy alone or in combination with aggressive debulking 
surgery.
MULTIDISCIPLINARY MANAGEMENT 
OF METASTATIC EWING SARCOMA TO 
LIVER: A FOCUS ON REGIONAL 
THERAPY AND REVIEW OF THE 
LITERATURE
S. G. De La Fuente, A. Conley, D. Reed, J. Choi, 
D. Letson and R. J. Gonzalez
H. Lee Moffi tt Cancer Center, Tampa, FL
Background: Prior reports demonstrate survival benefi t 
with metastasectomy in patients with Ewing sarcoma and 
lung metastases; however management of isolated hepatic 
metastases is unclear. Herein we report outcome in a patient 
with Ewing sarcoma that underwent hepatic resection after 
regional therapy, and review the literature regarding manage-
ment of Ewing/primitive neuroectodermal tumor (PNET) 
sarcomas with liver metastases.
Methods: Records of a 27 year old patient diagnosed with 
pelvic Ewing sarcoma that developed isolated hepatic metas-
tasis were examined. All cases of Ewing sarcoma/PNET with 
hepatic metastatic disease published were reviewed.
Results: Ten years after chemotherapy, followed by radia-
tion and excision of the primary pelvic disease, the patient 
developed a 17 × 8 cm metastatic liver lesion. Maximum 
dose adriamycin-based systemic chemotherapy resulted 
in stable disease; however preoperative liver biopsy was 
worrisome for chemotherapy-associated liver injury. Arterial 
chemoembolization with 300–500-micron LC beads loaded 
with 50 mg Doxorubicin resulted in a 10% partial response 
and a 20% increment in a calculated remnant liver volume. 
She underwent an extended right hepatectomy with negative 
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margins after biopsy of the liver remnant demonstrated reso-
lution of infl ammation. Postoperative surveillance showed 
no evidence of recurrence at one year following resection. 
She succumbed 12 years after diagnosis with skeletal and 
pulmonary metastases. The table shows all cases in the lit-
erature published to date.
Conclusion: Resection of isolated liver metastases in 
patients with Ewing sarcoma may provide relatively long-
term local control. In select cases the use of combination 
liver directed regional therapy and resection may be a rea-
sonable option.
MULTIDISCIPLINARY MANAGEMENT 
OF PANCREATIC VIPOMAS: 
EXPERIENCE FROM A LARGE 
REFERRAL CENTER
S. G. De La Fuente, A. S. Cheema, J. R. Strosberg, 
D. Coppola, J. Weber, P. J. Hodul, M. Malafa and 
L. K. Kvols
H. Lee Moffi tt Cancer Center, Tampa, FL
Background: Vasoactive intestinal polypeptide secreting 
islet cell tumors (VIPomas) are rare neuroendocrine tumors 
that typically present with severe symptoms and metastatic 
disease. We report our experience in the multidisciplinary 
management of patients presenting with pancreatic VIPomas.
Methods: A retrospective review of patients referred to a 
tertiary referral center from 1995–2010 was performed. 
Basic demographics, symptoms, therapy and survival were 
recorded.
Results: Fourteen patients were analyzed. Most patients 
were Caucasian females with a median age at diagnosis of 
56 years old and an AJCC stage IV at presentation. All 
patients had watery diarrhea, 43% of which required hospi-
talization for management of severe dehydration. Nine out 
of 14 patients had the primary tumor located in the tail of 
the pancreas with a mean tumor size of 4.6 cm. Recurrence 
or disease progression was associated with a 48% increase 
in serum VIP levels, 34% in pancreatic polypeptide levels, 
and 353% in chromogranin A levels. Ten patients received 
chemotherapy with capecitabine and temozolomide at some 
point during therapy. Surgical intervention with curative 
intent was performed in 64% of patients, while 9 out 14 
patients had interventions for symptomatic relief during the 
course of the disease. Median survival was 81 months with 
a 5-year survival rate of 77%.
Conclusions: Patients with VIPomas typically present with 
severe symptoms of diarrhea and dehydration requiring hos-
pitalization. Even in patients that present with metastatic or 
recurrent disease, an aggressive multidisciplinary approach 
provides symptomatic relief and relative long-term survival.
PRE AND INTRAOPERATIVE VARIABLES 
AFFECTING EARLY OUTCOMES IN 
ELDERLY PATIENTS UNDERGOING 
PANCREATICODUODENECTOMY
S. G. De La Fuente1, K. M. Bennett2, T. N. Pappas2 and 
J. E. Scarborough2
1H. Lee Moffi tt Cancer Center, Tampa, FL; 2Duke 
University Medical Center, Durham, NC
Background: Confl icting data exist regarding the safety of 
pancreatic resections in elderly patients. In this study we 
compared early complication and mortality rates between 
patients younger and older than 80 years of age who under-
went pancreaticoduodenectomy.
Methods: The National Surgical Quality Improvement 
Program (NSQIP) database for 2005 through 2009 was used 
for this retrospective analysis. The primary outcome mea-
sures were 30-day postoperative mortality, major complica-
tion rates and overall complication rate.
Results: 6293 patients that underwent pancreaticoduode-
nectomy for all causes were included in the analysis. Of 
these, 9.4% were older than 80 years old. The incidence of 
30-postoperative mortality was signifi cantly higher in 
patients older than 80 years old (2.7% < 80 years old vs. 
6.3% ≥ 80 years old). Older patients were also noted to have 
higher rates of overall complications and serious complica-
tions. On multivariate analysis, age, ASA classifi cation, 
reduced functional status, history of dyspnea, and the need 
for intraoperative transfusions were risk factors associated 
with overall complications, serious complications, and post-
operative mortality.
Discussion: This study shows that age among other factors 
is a determinant for postoperative morbidity and mortality 
following pancreaticoduodenectomy.
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DO INDETERMINATE PULMONARY 
NODULES REPRESENT LUNG 
METASTASES IN PATIENTS 
UNDERGOING LIVER RESECTION FOR 
HEPATOBILIARY MALIGNANCIES?
S. Downs-Canner, R. Bahar, S. K. Reddy, J. S. Cardinal, 
J. W. Marsh, D. A. Geller and A. Tsung
University Of Pittsburgh Medical Center, Liver Cancer 
Center, Pittsburgh, PA
Purpose: The objective of this study is to determine how 
often indeterminate pulmonary nodules (IPN) noted on pre-
operative computed tomography represent lung metastases 
in patients with hepatobiliary malignancies.
Methods: Demographics, clinicopathologic tumor charac-
teristics, and long-term outcomes among patients with IPN 
who underwent hepatic resection for malignancy were 
reviewed.
Results: From 2000–2010, 87 patients with IPN underwent 
liver resection for colorectal cancer metastases (n = 44), 
primary hepatobiliary cancers (n = 29), and other metastatic 
diseases (n = 14). Median number and size of largest IPN 
were one and 4 mm. 19.5% of patients had bilateral nodules 
(Table). After median follow-up of one year after liver resec-
tion, 23% of patients developed isolated pulmonary metas-
tases as the fi rst site of recurrence and 8% of patients 
developed synchronous pulmonary and extra-pulmonary 
metastases. There was no difference in median number (one 
vs. one), median size of largest nodule (5 mm vs. 4 mm), 
bilaterality (25.9% vs. 14.9%), or smoking history (37% vs. 
48.3%) between patients with and without pulmonary disease 
recurrence (all p > 0.05). More patients with colorectal 
cancer liver metastases developed pulmonary disease recur-
rence compared to patients with primary hepatobiliary 
cancers (45.5% vs. 10.3%, p = 0.04).
Conclusion: IPN represents pulmonary metastases in a sub-
stantial proportion of patients undergoing hepatic resection 
for malignancy – especially for colorectal cancer liver 
metastases.
All patients Colorectal cancer Hepatobiliary cancer Other metastatic diseases
Number of patients 87 44 29 14
Median # IPN 1 1 1 1
Median size of largest IPN (mm) 4 4 5 3
Bilateral IPN 19.5% 20.5% 17.2% 21.4%
Isolated pulmonary recurrence 23.0% 34.1% 10.3% 14.3%
Pulmonary and extra-pulmonary 
recurrence
 8.0% 11.4%  0.0% 14.3%
CLINICAL PREDICTORS OF EPCAM 
OVER-EXPRESSION IN PATIENTS WITH 
HEPATOCELLULAR CARCINOMA: AN 
EVALUATION
E. M. Dunki-Jacobs, Y. Li, C. R. Scoggins, 
K. M. McMasters, G. G. Callender and R. C. Martin
University Of Louisville, Louisville, KY
Introduction: The aim of this study was to evaluate the 
clinical predictors of EpCAM over-expression in patients 
with hepatocellular carcinoma (HCC).
Methods: EpCAM expression was assessed using immuno-
histochemical (IHC) staining in patients undergoing liver 
resection for HCC (n = 24). EpCAM expression was classi-
fi ed as low (< 10%), intermediate (11–60%), or high 
(> 60%). Expression in malignant tissue was compared 
to benign adjacent tissue. Age, cirrhosis, and lymphovascular 
invasion (LVI) were evaluated as clinical predictors of 
increased EpCAM expression. Disease-free survival (DFS) 
and overall survival (OS) were evaluated.
Results: The median age of the patient population was 67 
years and the median tumor size was 7.5 cm. Cirrhosis and 
LVI occurred in 4% and 58% of patients respectively. Low, 
intermediate, and high EpCAM expression in malignant 
tissue occurred in 8%, 58%, and 33% of patients respectively 
and in 25%, 50%, and 21% of benign adjacent tissue respec-
tively. EpCAM expression in malignant tissue was signifi -
cantly higher than EpCAM expression in benign adjacent 
tissue (p = 0.03). Clinical variables of age, cirrhosis, and LVI 
did not predict level of EpCAM expression (p = 0.2, p = 0.6, 
and p = 0.7 respectively). Median DFS and OS were 6 
months and 60 months respectively. DFS and OS did not 
correlate with EpCAM expression (p = 0.6 and p = 0.7 
respectively). Median survival after recurrence was 9 months 
and did not correlate with EpCAM expression (p = 0.7).
Conclusion: EpCAM expression is signifi cantly increased in 
HCC tissue compared to benign hepatic parenchyma. Further 
evaluation is needed to evaluate the effects of EpCAM over-
expression in chemotherapy resistance and recurrence.
HEPATIC RESECTION OFFERS SIMILAR 
OVERALL SURVIVAL TO 
TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA
T. M. Earl1,2, S. Naugler1,2, D. Scott1,2, K. Roayaie1,2, 
K. Billingsley1,2, A. Zaman1,2, M. Chang1,2, A. W. Sasaki1,2, 
B. Sheppard1,2 and S. L. Orloff1,2
1Oregon Health And Science University, Portland, OR; 
2Portland VA Medical Center, Portland, OR
Background: The results of hepatic resection for HCC are 
commonly thought inferior to transplantation; however, 
resection is frequently utilized in select individuals due to 
the disparity in allograft need and availability. The aim of 
this study is to compare the outcomes of hepatic resection 
and transplantation for HCC.
Methods: Retrospective univariate and multivariate sur-
vival analysis of adult patients who underwent liver resection 
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or transplantation for HCC at a single-center from 
1997–2009.
Results: A total of 188 patients were identifi ed, 121 trans-
planted and 67 resected. Resected patients were older (62.3 
± 11.9 vs. 55.3 ± 6.7 years, p < 0.001), had a lower preva-
lence of HCV infection (37.3% vs. 71.1%; p < 0.001), larger 
median tumor size (5.50 vs. 2.78 cm; p < 0.001) and were 
less likely to be within Milan criteria (43.3% vs. 92.4%; p < 
0.001). On univariate analysis, fi ve-year overall and disease-
free survival was greater in transplanted patients (overall: 
60% vs. 45%, p = 0.004; disease-free: 56% vs. 25%, p < 
0.001). On multivariate analysis controlling for age, HCV 
infection, meeting Milan criteria and pre-operative tumor 
therapy; transplantation did not offer a signifi cant overall 
survival advantage (HR 1.45, p = 0.317) (Table 1). HCV 
infection and tumors beyond Milan were associated with 
worse overall survival (HR 1.84, p = 0.033 and HR 2.53, 
p = 0.005 respectively). Transplantation did offer a disease-
free survival advantage on multivariate analysis (HR 2.18, 
p = 0.019).
Conclusion: Overall survival following resection for HCC 
is not different than that of transplantation despite a poorer 
disease-free survival. Hepatic resection should be utilized as 
primary surgical therapy for HCC in suitable candidates.
Table 1. Covariates included within a Cox proportional 
hazard model of factors associated with overall and disease 
– free survival
Overall Survival
Covariate HR 95% CI p
Transplant 1.45 0.70–3.01 0.317
Age 1.01 0.98–1.05 0.366
Within Milan 2.53 1.33–4.84 0.005
Pre-Surgical Therapy 1.21 0.69–2.11 0.507
Hepatitis C infection 1.84 1.05–3.23 0.033
Disease-Free Survival
Covariate HR 95% CI Sig
Transplant 2.18 1.14–4.19 0.019
Age 1.02 0.99–1.05 0.145
Within Milan 2.05 1.17–3.62 0.013
Pre-Surgical Therapy 1.32 0.78–2.24 0.30
Hepatitis C infection 1.41 0.86–2.31 0.175
Methods: 69 patients from two institutions were identifi ed 
with a clinical diagnosis of GBC. 32 patients were unresect-
able at presentation. The remaining 37 patients that under-
went resection comprised the study population. Survival was 
assessed using Kaplan Meier estimate. Univariate analysis 
was done performed using log rank analysis; multivariate 
analysis was by Cox Model.
Results: The median age at diagnosis of the study group was 
62 years, 42% were male. Median disease specifi c survival 
(DSS) and disease free survival (DFS) were 28.5 and 22.6 
months respectively. 30/37 (81%) of the study population was 
diagnosed incidentally after initial cholecystectomy. 29/37 
(78%) received a liver resection. 27/37 (73%) had at least 1 
lymph node sampled. 9/37 (24%) had a common bile duct 
resection. On univariate analysis common bile duct (CBD) 
involvement was signifi cantly associated with decreased DSS 
(p ≤ 0.001) and DFS (p ≤ 0.001). Positive fi nal margin status 
was associated with decreased DSS (p = 0.019) and DFS (p = 
0.017). Lymph node involvement was not associated with DSS 
or DFS (p = 0.73, p = 0.85). On multivariate analysis CBD 
involvement was associated with decreased DFS (p = 0.009).
Discussion: The subset of patients with potentially resect-
able GBC and involvement of the CBD indicates a group that 
is at higher risk for recurrence. Patients with CBD involve-
ment should receive appropriate aggressive surgical resec-
tion and should be considered for adjuvant therapy.
Multivariate Analysis
Variable Hazard 
Ratio
Signifi cance 95% 
Confi dence 
Interval
T Stage 2.3 0.29 0.49–11.0
N Stage 0.88 0.89 0.16–5.0
Grade 2.6 0.17 0.66–10.3
Initial Cystic 
Duct Margin
0.7 0.69 0.12–4.13
Common Bile 
Duct 
Involvement
8.0 0.009 1.7–37.7
Positive Final 
Margin
4.2 0.13 0.64–27.6
Hepatectomy 0.89 0.90 0.13–6.12
Lymph Node 
Dissection
1.81 0.46 0.38–8.68
Common Bile 
Duct 
Resection
0.31 0.19 0.06–1.79
Chemotherapy 0.48 0.28 0.13–1.85
Radiation 0.76 0.72 0.17–3.39
META-ANALYSIS OF PHASE 3 
RANDOMIZED TRIALS ASSESSING THE 
ROLE OF MOLECULAR TARGETED 
THERAPIES IN THE MANAGEMENT OF 
ADVANCED PANCREATIC CANCER
K. M. Eltawil and M. Molinari
Department Of Surgery, Dalhousie University, Halifax, 
Nova Scotia, Canada
Background: The effi cacy and safety of new molecular tar-
geted agents (MTAs) in addition to Gemcitabine for advanced 
BILE DUCT INVOLVEMENT PORTENDS 
POOR PROGNOSIS IN RESECTED 
GALLBLADDER CARCINOMA
R. L. Eil1, P. D. Hansen2, M. Cassera1, S. L. Orloff1, 
B. C. Sheppard1, B. Diggs1 and K. G. Billingsley1
1Division Of Surgical Oncology, Oregon Health And 
Sciences University, Portland, OR; 2Hepatobiliary And 
Pancreatic Surgery Program, Providence Portland Medical 
Center, Portland, OR
The aim of this retrospective study was to identify prognostic 
factors following defi nitive resection of gallbladder carci-
noma (GBC) to assist with selecting an appropriate popula-
tion for adjuvant therapy.
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adenocarcinoma of the pancreas (PC) are not well estab-
lished. Published randomized controlled trials (RCTs) have 
reported confl icting results. The aim of this study was to 
perform a systematic literature research and metaanalysis of 
the data if appropriate.
Methods: The literature search was performed by electronic 
standard techniques, and fi ve phase 3 RCTs comparing pal-
liative chemotherapy with the combination of Gemcitabine 
and MTAs versus Gemcitabine only were identifi ed. MTAs 
were administered to 1382 patients while Gemcitabine alone 
was administered to 1394 individuals. Meta-analysis of the 
data on overall survival (OS), progression-free survival 
(PFS), overall response rates (ORR) and grade 3 & 4 toxici-
ties was performed using the random effect model.
Results: There was no signifi cant OS benefi t for patients 
receiving MTAs in addition to Gemcitabine (HR = 0.93, 95% 
CI = 0.85–1.02, p = 0.13). Similarly, ORR were similar in 
both arms (OR = 0.97, 95% CI = 0.76–1.25, p = 0.86). The 
outcome for PFS favored the use of MTAs (HR = 0.90, 95% 
CI = 0.81–0.99, p = 0.047). The toxicity rate was higher in 
patients that received MTAs, yet it did not reach statistical 
signifi cance (p = 0.43).
Conclusion: Palliation of advanced PC with combination of 
Gemcitabine and MTAs has increased toxicity and no sur-
vival benefi t. The current evidence does not suggest their 
application as a standard therapeutic regimen.
Author Year Country Patients 
number
Drug Arm 1 Drug Arm 2 Outcomes
Kindler et al. 2010 USA 535 Gem+Bevacizumab Gem+Placebo OS, PFS, Response, Toxicities
Philip et al. 2010 USA, Canada 745 Gem+Cetuximab Gem OS, PFS, Response, Toxicities, 
TTF
Moore 2007 International 569 Gem+Erlotinib Gem+Placebo OS, PFS, Response, Toxicities, 
QOL
Bramhall et al. 2002 USA, UK 239 Gem+Marimastat Gem+Placebo OS, PFS, Response, Toxicities
Van Custem 
et al.
2004 International 688 Gem+Tipifarnib Gem+Placebo OS, PFS, Response, Toxicities
USA: United States of America, UK: United Kingdom, Gem: Gemcitabine, OS: Overall Survival, PFS: Progression-Free 
Survival, TTF: Time to Treatment Failure, QOL: Quality Of Life
OUTCOMES OF PANCREATIC SURGERY: 
A RETROSPECTIVE ANALYSIS FROM A 
CANADIAN TERTIARY CARE CENTER
K. M. Eltawil, M. Molinari and M. J. Walsh
Department Of Surgery, Dalhousie University, Halifax, NS, 
Canada
Background: Surgery represents the only potential cure for 
pancreatic cancer (PC). Improvement in surgical techniques 
and advancement in perioperative care have markedly 
improved morbidity and mortality rates in high volume 
centers. There is lack of data regarding outcomes of pancre-
atic surgery from Canadian centers. The aim of this study 
was to evaluate the perioperative outcomes of pancreatic 
surgeries done in a tertiary Canadian centre.
Methods: A retrospective analysis of patients undergoing 
surgery for pancreatic tumors from 1999 to 2010 was con-
ducted. The patient demographics, type of surgery, preopera-
tive investigations, perioperative morbidity and mortality 
rates were evaluated. For the PC subgroup; risk factors, 
tumor staging, surgical margins and overall survival were 
analyzed.
Results: One hundred and eighty four charts were reviewed 
of which 24 were found nonresectable at the time of explora-
tion or underwent resection for extension of non-pancreatic 
lesions. From the remaining 160 patients 64.4% underwent 
Whipple procedure and 62.3% were found to have PC. The 
30 day postoperative mortality rate was 4.4% and the overall 
morbidity was 48.7% with a pancreatic fi stula rate of 9.5%. 
For the PC group smoking was the main risk factor for cancer 
(39%). The mean tumor size was 3.3 cm (SD: 1.6) and the 
surgical margins were positive in 35.4% of patients. The 1, 
3 and 5 year survival rates were respectively 78%, 25% and 
1.5%.
Conclusion: Pancreatic resection is a safe procedure with 
acceptable complication rates when carried out in experi-
enced centers. Our results were found similar to high volume 
centers.
A SAFE LAPARSCOPIC APPROACH TO 
LEFT PORTAL PEDICLE CONTROL: 
LIGAMENTUM VENOSUM TECHNIQUE
K. Enestvedt2, I. Gur1 and K. G. Billingsley1
1Oregon Health And Science University, Portland, OR; 
2University Of Pennsylvania Health System, Philadelphia, 
PA
Laparoscopic approaches have proven safe and feasible for 
liver resection. However, techniques of infl ow control can be 
challenging. The aim of this presentation is to detail a safe 
and reliable approach to intrahepatic ligation of the proximal 
left portal pedicle using an entirely laparoscopic technique. 
After introduction of pneumoperitoneum, the entire ana-
tomic left liver is freed from the diaphragm. The left lateral 
section is retracted to the right. The ligamentum venosum is 
dissected anterior to the caudate lobe, allowing visualization 
of the vena cava. A 2 cm hepatotomy is made 1 cm above 
the IVC. Direct visualization prevents caval injury. The left 
lateral section is placed on leftward traction using the 
remnant of the ligamentum teres. Parenchymal transection 
along Cantlie’s line down to the base of segment 4B exposes 
the left lobe infl ow pedicle further. A hepatotomy is then 
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made using harmonic scalpel at the base of segment 4 just 
to the right of the umbilical fi ssure. A blunt Glassman forceps 
is passed through the liver parenchyma behind the left portal 
pedicle. This maneuver connects the segment 4 hepatotomy 
to the supracaval hepatotomy. The Glassman is used to 
enlarge the space. A roticulating EndoGIA stapler is placed 
across the pedicle and closed. Laparoscopic duplex ultra-
sound confi rms perfusion to the right liver. The stapler is then 
used to divide the pedicle just distal to caudate infl ow. 
Parenchymal transection is completed and the left hepatic 
vein is divided with the linear stapler. The specimen is 
removed via endocatch bag.
NEW TRICKS FOR AN OLD DOG: 
ACHIEVING HIGH ASSISTED PATENCY 
FOR PERITONEOVENOUS SHUNTS
Z. P. Englert1, M. A. White1, R. K. Padia1, H. Chheda2 and 
E. E. Zervos1
1East Carolina University, Greenville, NC; 2University Of 
South Florida, Tampa, FL
Few treatment options exist for patients with medically 
refractory ascites. Drainage by repeated large volume para-
centesis or long term indwelling ascites catheters is associ-
ated with signifi cant cost, protein waste, renal compromise/
electrolyte disturbance and hemodynamic lability. 
Peritoneovenous shunts ameliorate each of these complica-
tions but have been largely abandoned due high rates of early 
shunt failure. Prolonged secondary and even tertiary patency 
can be achieved with minimal expense and morbidity using 
a standardized approach to the non-functioning shunt. The 
purpose of this presentation is to propose and discuss “tricks 
of the trade” to rapidly assess the source of shunt dysfunction 
and to describe revisional strategies that minimize cost and 
morbidity. The presentation is a case based format describing 
the three sources of shunt dysfunction: venous catheter, 
pump chamber and peritoneal catheter failure. CT, fl uoros-
copy, still and video images of patients undergoing shunt 
revision with long term follow up are presented. Finally, the 
algorithm below is presented to simplify and standardize the 
approach to the failed shunt in hopes that such shunts will 
be considered in the context of “assisted patency” rather than 
primary shunt failure.
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PREOPERATIVE BILIARY DRAINAGE, 
REGARDLESS OF HOW 
ACHIEVED, DOES NOT IMPACT 
OUTCOMES FOLLOWING 
PANCREATICODUODENECTOMY FOR 
CANCER
Z. P. Englert, T. L. Fitzgerald, M. B. Burruss and 
E. E. Zervos
East Carolina University, Greenville, NC
Background: Preoperative biliary drainage has been associ-
ated with increased morbidity and mortality in patients 
undergoing pancreaticoduodenectomy for cancer. The 
purpose of this study was to determine whether failed pre-
operative primary endoscopic and/or percutaneous drainage 
exacerbates this observation.
Methods: A prospective database was queried to identify all 
patients with abnormal bilirubin before undergoing pancre-
aticoduodenectomy. Patients were stratifi ed into 3 categories: 
successful, failed, or no preoperative drainage. Outcome 
measures including operative time, length of stay, complica-
tions, transfusion requirement, mortality, degree of jaundice, 
and costs were compared for each group. Continuous vari-
ables were compared using the student’s t-test and fi xed 
variables were compared using Chi square analysis.
Results: Of 75 patients undergoing pancreaticoduodenec-
tomy at a large tertiary care facility between October 2007 
and August 2011, preoperative biliary decompression was 
attempted in 31 patients. ERCP was attempted on all and 
successful in 19 (61%) patients; salvage PTC was successful 
in 9 (69%) of the remaining 13 and failed in 3 (one patient 
went straight to surgery). No signifi cant differences were 
noted in LOS, operative time, transfusion requirement, com-
plications, or mortality in any group. As expected, maximum 
preoperative bilirubin was highest in patients failing fi rst 
attempt at biliary decompression. Although not statistically 
signifi cant, hospital costs and mortality were highest in the 
salvage PTC group (table).
Conclusions: Preoperative biliary decompression achieved 
primarily or as a salvage procedure neither positively nor 
negatively impacted outcomes in patients undergoing pan-
creaticoduodenectomy at our institution. PTC successfully 
salvaged failed ERCP 75% of the time.
n Age OR time Transfusion 
(mL)
LOS Complication 30 day 
mortality
Preop 
bilirubin
Maximum 
bilirubin
Cost
ERCP 19 70 ± 28.28 5:42 ± 1:25 444.32 ± 829.62 14.11 ± 8.32 68.42% 0% 4.08 ± 5.22 8.93 ± 8.23* 31,779 ± 17,286
PTC 9 65.67 ± 9.63 5:29 ± 0:50 226.66 ± 294.45 11.00 ± 6.34 33.33% 11.11% 5.21 ± 2.96 15.87 ± 5.72* 44,632 ± 24,958
None 43 64.33 ± 11.41 5:40 ± 1:24 382.14 ± 568.95 14.48 ± 9.00 48.83% 4.65% 5.12 ± 7.29 5.74 ± 7.72* 35,246 ± 23,490
*p < 0.05.
CULTURE-DIRECTED TREATMENT OF 
BACTERIOBILIA AND BILIARY 
CANDIDIASIS AFTER WHIPPLE 
DECREASES POST-OPERATIVE 
INFECTIONS
C. H. Evans1,4, S. E. Hodges1,4, C. J. Balentine1,2,3 and 
W. E. Fisher1,4
1Baylor College Of Medicine, Houston, TX; 2Houston VA 
HSR&D Center Of Excellence, Houston, TX; 3Michael E. 
DeBakey VA MC, Houston, TX; 4Elkins Pancreas Center, 
Houston, TX
Background: The aim of this study was to determine if 
treatment of positive intra-operative bile cultures reduces 
infectious complications following the Whipple procedure.
Methods: Forty consecutive patients underwent a Whipple 
procedure with intra-operative bile cultures and treatment of 
bacteriobilia and biliary candidiasis. This group was retro-
spectively compared to 149 consecutive patients who under-
went a Whipple procedure without treatment of bacteriobilia 
or biliary candidiasis. All patients were given a preoperative 
prophylactic dose of a carbapenem. The study group remained 
on antibiotics post-operatively, with tailoring of antibiotic 
choices based on gram stain and culture results. Infection 
rates for these two cohorts were compared using Fisher’s 
exact test.
Results: Demographic, surgical and pathologic details were 
similar between the two cohorts. For the treatment group, 
(10/40) 25% underwent preoperative biliary stenting, (23/40) 
58% had positive bile cultures, of which (19/23) 83% grew 
an aerobic organism, (7/23) 30% grew an anaerobic organ-
ism, and (10/23) 43% grew a fungal organism. In the treat-
ment group, none of the patients developed a wound infection 
vs (13/149) 9% in the control group (P = 0.07).
Conclusion: This small retrospective study suggests that 
intra-operative culture-directed treatment of bacteriobilia 
may decrease wound infection after the Whipple procedure. 
Additionally, the unexpectedly high rate of biliary candidia-
sis supports the use of antifungal therapy. Further studies are 
indicated to determine the clinical signifi cance of biliary 
candidiasis and its treatment in the post-operative period.
Most Common Organisms Isolated From Bile Culture
Organism Number Percentage
Enterococcus 14 61%
Klebsiella 12 52%
E. coli 9 39%
VRE 5 22%
Enterobacter 3 13%
Yeast 10 43%
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CELLULAR ATYPIA IN PANCREATIC 
CYST CYTOLOGY ASSESSMENTS: 
SURGERY IS OFTEN REQUIRED
G. A. Falk1, G. Morris-Stiff1, S. Chalikonda1, C. Biscotti2 
and R. M. Walsh1
1Department Of General Surgery, Section Of Surgical 
Oncology/HPB, Cleveland, OH; 2Department Of 
Cytopathology, Cleveland, OH
Background: Cytological assessment of pancreatic cystic 
lesion aspirates is a useful diagnostic tool. However the 
signifi cance of identifying atypical cells is not clear.
Aims: To determine the clinical outcome of patients in 
whom cytological assessment demonstrated atypical cells.
Methods: All pancreatic cyst cytology assessments during 
the period January 2000 to February 2010 were identifi ed. 
Patients in whom atypical cells but no defi nite malignant 
cells were seen were identifi ed. For this cohort, clinical notes 
were reviewed and the patient management pathway follow-
ing cytological assessment was examined. The minimum 
period of follow-up was 18 months.
Results: During the period 2000–2010, 421 cytological 
assessments were performed on pancreatic cyst aspirates. In 
54 (12.8%) cases, the cytology report noted the presence of 
atypical cells. The cohort consisted of 35 females and 19 
males with a median age of 65.9 years. To-date, 32 patients 
have undergone surgical exploration with resection in 29 
cases. Final pathology of these surgically treated patients 
revealed 12 malignant neoplasms [pancreatic carcinoma n = 
6; IPMN carcinoma n = 4; NET carcinoma n = 1; ampullary 
carcinoma n = 1], 17 pre-malignant [IPMN n = 12; MCN 
n = 5; SPEN n = 1], and 2 benign lesions [CP n = 1; 
Lymphoepithelial cyst n = 1], In the 12 patients with malig-
nant lesions there were no features on cross-sectional imaging 
to indicate these lesions were carcinomas.
Conclusions: Cytological assessment of cyst aspirates is an 
important component of the multi-disciplinary assessment of 
cystic pancreatic lesions. When an experienced cytologist 
reports atypical cells careful consideration should be given 
to the presence of an underlying malignant neoplasm.
MICROWAVE ABLATION FOR 
CIRRHOTIC PATIENTS WITH 
HEPATOCELLULAR CARCINOMA WITH 
AND WITHOUT COMBINATION OF 
OTHER LIVER DIRECTED THERAPIES: 
LONG TERM FOLLOW UP
E. Feinberg, M. Vivanco, S. Bellemare, M. Kinkhabwala 
and J. Chapochnick Friedmann
Montefi ore Medical Center/Albert Einstein College Of 
Medicine, Bronx, NY
Introduction: Multiple modalities of liver directed therapy 
(LDT) are used in patients with HCC awaiting liver trans-
plantation to avoid progression of disease, minimize dropout 
from the waiting list and downstaging to transplant criteria. 
This study analyzed the long term outcomes of cirrhotic 
patients with portal hypertension that underwent microwave 
ablation alone (MWA) for HCC with similar patients that 
were previously treated with other forms of LDT (transarte-
rial chemoembolization and/or percutaneous radiofrequency 
ablation).
Patients and methods: IRB was obtained and data was 
prospectively collected from July 2009 to August 2011 for 
32 patients with cirrhosis and portal hypertension who under-
went MW to treat 45 HCCs. Nineteen of these patients had 
prior LDT. Statistical analysis was done using t-test and 
Fisher’s exact.
Results: There were no differences between the groups in 
terms of demographics, severity of the underlying liver 
disease (Child-Pugh and MELD score) and etiology of liver 
disease. Patients were followed for a mean of 414 ± 170 
days. The residual tumor at one month post ablation, tumor 
recurrence and incidence of new tumors during the follow-up 
period were 15%, 18% and 25% respectively for the entire 
group and rates were similar among both subgroups (MWA 
versus TACE/RFA + MWA). Patients receiving MWA 
required one procedure whereas patients who had TACE/
RFA + MWA required 2.7 ± 0.6 procedures.
Conclusion: Patients treated with MWA alone had similar 
outcomes than patients that also received other forms of LDT 
but required signifi cantly less procedures.
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Variable Total MWA TACE/RFA+MW p
Patients, n 32 14 19
Surgeries, n 33 14 19
Tumors, n 45 18 27
Age (mean ± SD), years 61 ± 7 61 ± 7 62 ± 8
Gender, n (%)
Male 26 (79) 11 (79) 15 (79)
Female  7 (21)  3 (21)  4 (21)
Follow up (mean ± SD), days 414 ± 170
Classifi cation, n (%)
Milan 28 (85) 13 (93) 15 (79)
UCSF  2 (6)  1 (7)  1 (5)
OOC  3 (9)  3 (16)
Tumors treated, n 1.4 ± 0.5 1.3 ± 0.5 1.4 ± 0.6 0.56
Tumor size (mean ± SD), cm 2.6 ± 1.8 (0.5–9) 2.2 ± 1.6 (0.8–6) 2.9 ± 1.9 (0.5–9) 0.23
Child-Pugh score, n (%)
A 26 (79) 11 (79) 15 (79) 0.62
B  6 (18)  2 (14)  4 (21)
C  1 (3)  1 (7)
Preop plat (mean ± SD), 113 ± 58 (15–244) 104 ± 47 (15–205) 120 ± 65 (38–244) 0.44
Lap/Open, n (%) 28 (85)/5(15) 11 (100)/0 14 (74)/5 (26)
LOS (mean ± SD), days 3 ± 3 3 ± 4 3 ± 3 0.73
MELD (mean ± SD)
Preop 10 ± 5 (6–22) 13 ± 6 10 ± 4 0.09
Postop 12 ± 5 (6–23) 14 ± 6 11 ± 4 0.09
DMELD 1.6 1.6 1.5
Morbidity, n (%) 6 (18) 1 (7) 5 (26)
Clavien I 4 4 0.20
Clavien II 2 1 1
Residual tumor, n (%) 5 (15% patients) 1 (7% patients) 4 (21% patients) 0.36
(11% tumors) (6% tumors) (15% tumors)
Recurrent tumor, n (%) 6 (18% patients) 1 (7% patients) 5 (26% patients) 0.20
(13% tumors) (6% tumors) (19% tumors)
Median time 6 ± 2.6 
months
4 months Median time 7 ± 3 
months
New Tumors, n (%) 8 (25% pts) 4 (29% pts) 4 (21% pts) 0.67
Median time 5 ± 2 
months
Median time 4 ± 3 
months
Median time 6.5 ± 2 
months
Number of treatments (mean ± SD) 1 2.7 ± 0.6 <0.001
POST-RESECTION DIABETES AFTER 
PANCREATICODUODENECTOMY: 
INCIDENCE AND PREDICTIVE FACTORS
M. J. Ferrara, C. M. Lohse, M. B. Farnell, F. G. Que, 
K. M. Reid-Lombardo, J. H. Donohue, D. M. Nagorney, 
S. S. Vege, S. T. Chari and M. L. Kendrick
Mayo Clinic, Rochester, MN
Background: New-onset, postresection diabetes (PRDM) 
after pancreaticoduodenectomy remains poorly defi ned. Our 
aim was to defi ne the incidence and predictive factors of 
PRDM.
Methods: A retrospective review of patients undergoing 
pancreaticoduodenectomy from January 2004 through July 
2010. PRDM was defi ned as serum glucose ≥ 126 and requir-
ing ongoing pharmacologic treatment within 30 days postre-
section. Follow-up was complete in 97%. Statistical analysis 
was conducted to identify factors associated with and predic-
tive of PRDM.
Results: 764 patients underwent pancreaticoduodenectomy, 
200 were excluded due to diagnosis of diabetes preopera-
tively (n = 192) or death prior to hospital discharge (n = 8). 
The remaining 564 comprised the study population with a 
mean age of 64 years and BMI (kg/m2) of 27. Indication for 
operation included benign (25%) and malignant (75%) diag-
noses. PRDM occurred in 22 patients (4%), who were more 
likely to be male, have preoperative glucose intolerance, an 
increased BMI, preoperative glucose, operative time, tumor 
size or specimen size compared to controls (p < 0.05). 
Factors not associated with PRDM included obesity, family 
history of diabetes, operative approach, pylorus resection or 
tumor type. On multivariate analysis, preoperative glucose 
intolerance (OR 15.5, p < 0.001), preoperative glucose ≥ 126 
(OR 6.43, p < 0.001), and specimen size (OR 1.53, p = 0.002) 
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were independent predictors of PRDM. A predictive model 
using these three factors demonstrated a c-index of 0.842.
Conclusion: New-onset, postresection diabetes occurs in 
only 4% of patients undergoing pancreaticoduodenectomy. 
Factors predictive of PRDM include preoperative glucose 
intolerance, preoperative glucose and specimen size. These 
data are important for patient education and predicting out-
comes of pancreaticoduodenectomy.
QUALITY OF LIFE ASSESSMENT OF 
LOCAL PANCREATIC HEAD RESECTION 
FOR CHRONIC PANCREATITIS
T. D. Fischer, D. S. Gutman, E. A. Warner, J. G. Trevino, 
S. J. Hughes and K. E. Behrns
Department Of Surgery, Gainesville, FL
Local pancreatic head resection (LPHR) has been used liber-
ally in Europe as a surgical treatment for chronic pancreatitis, 
but adoption in the US has been modest and selective. We 
report, to our knowledge, the largest US series of patients 
and hypothesize that quality of life assessment (QOLA) will 
reveal acceptable results. A cohort of consecutive patients, 
medically optimized and opiate dependent, with diffuse 
disease ± dilation of the pancreatic duct underwent LPHR 
and a retrospective chart review of their perioperative care 
was preformed. Quality of life was evaluated by administra-
tion of the European Organization for Research and Treatment 
of Cancer-Quality of Life Questionnaire (EORTC-QLQ-C30 
and PAN(28)CP). Higher scores indicate higher functional 
status or symptomatology profi le. A total of 44 patients from 
2005–2010 were evaluated and found to have a mean age of 
49 ± 11 years (50% men) with chronic alcohol use the etiol-
ogy in 79%. One patient (2%) died within 30 days. On 
average, the ICU stay was 1.8 days and postoperative LOS 
was 12.7 ± 9.4 days with 94% of patients discharged to 
home. Based upon the Clavein-Dindo classifi cation, 10 
patients (13%) had major perioperative complications. 
Biliary stricture was the most common late complication 
(13.6%). Thirty-nine percent completed the QOLA survey 
and the results are consistent with previous data from the US 
with pain, insomnia, and digestive disturbances being more 
prevalent (see table). We demonstrate that LPHR is a safe 
and effective treatment option for a substantial proportion of 
patients with CP with acceptable quality of life assessment.
A MULTI-INSTITUTIONAL STUDY OF 
THE PROGNOSTIC IMPORTANCE OF 
LYMPHOVASCULAR OR PERINEURAL 
INVASION IN INTRAHEPATIC 
CHOLANGIOCARCINOMA: A NEW 
SELECTION CRITERION FOR 
ADJUVANT THERAPY?
S. B. Fisher1, S. H. Patel1, D. A. Kooby1, S. M. Weber2, 
M. Bloomston3, C. S. Cho2, I. Hatzaras3, C. Schmidt3, 
E. Winslow2, C. A. Staley1 and S. K. Maithel1
1Emory University, Division Of Surgical Oncology, Winship 
Cancer Institute, Atlanta, GA; 2University Of Wisconsin, 
Section Of Surgical Oncology, Madison, WI; 3The Ohio 
State University Medical Center, Division Of Surgical 
Oncology, Columbus, OH
Background: Criteria for administering adjuvant chemo-
therapy for intrahepatic cholangiocarcinoma (IHCC) are 
lacking. Some advocate adjuvant therapy for patients with 
lymph node (LN) involvement; however, nodal assessment 
is often inadequate or not performed. We therefore sought to 
identify surrogate criteria based on characteristics of the 
primary tumor.
Methods: All patients between 1/00–1/10 who underwent 
resection for IHCC at three institutions were identifi ed. 
Primary outcome assessed was overall survival (OS).
Results: 58 patients underwent resection. Median age was 66 
years; median follow-up was 22 months, and median OS was 
23 months. Median tumor size was 6.5 cm, median number of 
lesions was 1 (range: 1–7), 16% had positive resection margins, 
38% had perineural invasion (PNI), 40% had lymphovascular 
invasion (LVI), and 22% had positive LN. The median number 
of LNs removed was 1 (range: 0–10); median number of posi-
tive LNs was 0 (range: 0–5). 34% of patients did not have any 
LNs sampled. LVI and PNI were associated with reduced OS 
(9.6 vs 32.7 months, p = 0.02; 10.7 vs 32.7 months, p = 0.008; 
respectively). LN involvement demonstrated a trend towards 
reduced OS (10.7 vs 30 months, p = 0.063). Presence of either 
LVI or PNI in node-negative patients was associated with 
reduced OS (12.1 months) that was similar to node-positive 
patients (Figure). After accounting for known adverse tumor 
factors, only LVI or PNI remained signifi cantly associated 
with decreased OS on multivariate analysis (HR 3.8, 95% CI: 
1.6–8.6, p = 0.002).
Conclusion: Lymphovascular or perineural invasion is 
strongly associated with decreased overall survival similar 
to lymph node positive disease. As nodal dissection is often 
not performed or the number of nodes retrieved is inade-
quate, these tumor-specifi c factors may be considered as 
selection criteria for adjuvant chemotherapy.
28 Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association, HPB, 14 (Suppl. 1), 1–91
IMPACT ON QUALITY OF LIFE AFTER 
BILE DUCT INJURY REPAIR: A 
PROSPECTIVE STUDY COMPARING 
SCORES BEFORE AND A YEAR AFTER 
SURGERY
B. Franssen, I. Dominguez, F. Ramirez-Del Val and 
M. Mercado
Department Of Surgery, Instituto Nacional De La Nutricio 
Mexico City, Mexico
Purpose: Measure the impact on quality of life (QOL) 
caused by benign bile duct injuries (BDI) and compare them 
to scores a year after biliary reconstruction using a specifi c 
and a general instrument.
Methods: A prospective study was performed between 
March 2008 and February 2009 including all post-cholecys-
tectomy bile duct injuries that required a Roux-en-Y 
Hepaticojejunostomy. Both a general (SF-36) and a specifi c 
(FACT-HEP) QOL instrument were used preoperatively 
and a year after surgery. Comparison of preoperative and 
postoperative values were analyzed. SF-36 scores were 
compared with national norms.
Results: 40 consecutive patients with complex BDI and a 
biliary reconstruction completed the QOL evaluation preop-
eratively. Important demographic characteristics include: 
median age of 37 (18–79), 79% female patients, 30% with 
previous attempts of repair, and 36% had loss of the confl u-
ence. One patient was lost to follow-up. All 8 QOL domains 
in the SF-36 questionnaire were signifi cantly higher a year 
after surgery when compared to the preoperative score. The 
biggest difference was a median of 100/100 points in Physical 
Function (p < 0.0001) and Emotional Role (p < 0.001) 
domains and the smallest difference was 16/100 in Mental 
Health (p < 0.004). Fact-Hep [median (range)] scores preop-
eratively 103 (59–154) and a year after surgery 140 (48–170) 
were also signifi cantly different (p < 0.0001).
Conclusions: Bile duct injury severely affects QOL. Bile 
duct repair favorably impacts QOL a year after surgery when 
compared to the preoperative period. QOL as assessed by 
SF-36 is almost equivalent to national norms a year after 
surgery.
PKI-587 IN COMBINATION WITH 
SORAFENIB SYNERGISTICALLY 
INHIBIT HCC CELL PROLIFERATION
R. Gedaly1, P. Angulo2, J. Hundley1, M. F. Daily1, C. Chen1 
and B. M. Evers1,3
1Department Of Surgery, University Of Kentucky, 
Lexington, KY; 2Department Of Internal Medicine, 
University Of Kentucky, Lexington, KY; 3Markey Cancer 
Center, University Of Kentucky, Lexington, KY
Background: PKI-587 is a potent dual inhibitor of PI3K 
and mTOR. Preclinical study has shown that it inhibits 
several cancers in vitro and in vivo. But it has not been tested 
in HCC. Our research is to check its effi cacy on inhibition 
of HCC and to determine how sorafenib and PKI-587 alone 
and in combination inhibit HCC by blocking aberrant 
Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways.
Methods: HCC cell line Huh7 proliferation was assayed by 
3H-thymidine incorporation and by MTT assay. Western-
Blot was used to detect phosphorylation of the key enzymes 
in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Results: PKI-587 is more potent than PI-103 (another dual 
inhibitor of PI3K and mTOR). Combination of sorafenib and 
PKI-587 caused more inhibition of Huh7 proliferation than 
the combination of sorafenib and PI-103 (p < 0.05). MTT 
assay indicated PKI-587 and sorafenib in single agents or in 
combination inhibited Huh7 proliferation and combination 
treatment caused synergistic inhibition of HCC than mono-
drug treatment (p < 0.05). Western-blot experiments shown 
PKI-587 inhibited EGF stimulated mTOR(s2448), S6K(s389) 
and AKT(s473) phosphorylation indicating PKI-587 inhib-
ited both mTOR complex-1 and complex-2. In contrast, rapa-
mycin stimulated AKT(s473) phosphorylation. However, 
PKI-587 did not inhibit EGF activation of Ras/Raf/MAPK 
pathway key enzymes. Sorafenib inhibited MEK (S217/221) 
and ERK Thr202/Tyr204) phosphorylation, but it did 
not inhibit PI3K/AKT/mTOR pathway key enzymes. 
Interestingly, sorafenib even stimulated AKT(s473) phos-
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phorylation. Combination of PKI-587 and sorafenib inhib-
ited phosphorylation of the key enzymes in both pathways.
Conclusion: Combination of PKI-587 and sorafenib can 
synergistically inhibit Huh7 proliferation by blocking both 
PI3K/AKT/mTOR and Ras/Raf/MAPK pathways.
READMISSION FOLLOWING 
PANCREATECTOMY: WHAT CAN WE DO 
BETTER?
S. Gondek1, C. C. Glass1, C. M. Vollmer2, M. P. Callery1 
and T. S. Kent1
1Beth Israel Deaconess Medical Center/Harvard Medical 
School, Boston, MA; 2University Of Pennsylvania Dept Of 
Surgery, Philadelphia, PA
Background: Readmissions after pancreatectomy, largely 
for complication management, may also occur due to failure-
to-thrive or for diagnostic endeavors. Potential mechanisms 
to reduce readmission rates may be elucidated through 
assessing the adequacy of the initial disposition and the real 
necessity for readmission.
Methods: Using previously identifi ed categories of read-
mission following pancreatectomy, details of reasons for, and 
results of, readmission were scrutinized using a root-cause 
analysis approach.
Results: Of 658 pancreatectomies completed between 2001–
2010, 121 patients were readmitted within 30 days (18.4%). 
30.2% of readmitted patients had clinical pathway deviations 
on initial admission. Patients were readmitted at a median of 
9 days after initial discharge (range 1–30) and had a median 
readmission length of stay of 7 days (< 1–52 d, mode = 4). 
Postoperative complications (77, 63.7%) accounted for most 
readmissions, while 17 patients (14%) were readmitted with 
failure to thrive, and 16 (13.2) for diagnostics. Root cause 
analysis detailed subtext reasons for readmission (Table), 
including for example, initiation of new medications that 
could potentially be ordered in an outpatient setting. Post 
discharge care was escalated in 26 patients (21.5%) with 
61.5% of these requiring initiation of home services.
Conclusions: More than one-quarter of readmissions after 
pancreatectomy occurred in the setting of failure to thrive or 
for diagnostic evaluation without identifi cation of an acute 
process. Root cause failure analysis reveals potentially 
avoidable readmissions. Development of stratifi cation for 
patients at risk for readmission or failure of initial disposition 
along with alternate means of effi ciently evaluating patients 
in an outpatient setting could limit unnecessary readmissions 
and resource utilization.
Events prompting Readmission/Failure Analysis (not mutually exclusive)
Likely Necessary Readmission Potentially Avoidable Readmission
Initiation of antibiotic for 
infectious process
Diagnostic evaluation without acute process identifi ed (sometimes in setting of transfer 
from distant facility)
Initiation of insulin Initiation of oral medication
Initiation of enteral/parenteral 
feeding
Inadequate support at home (self-care, meals, nutrition)
IV hydration/resuscitation Inadequate pain control
Percutaneous drain placement Visiting nurse concern prompting ED evaluation given lack of available urgent outpatient 
evaluation.
Feeding tube placement 
(endoscopic)
Patient/family concern prompting ED evaluation given lack of available urgent outpatient 
evaluation.
Reoperation Transfer from outside facility with reinterpretation of imaging results.
HOW DOES LAPAROSCOPIC ASSISTED 
PANCREATICODUODECTOMY 
COMPARE TO THE CONVENTIONAL 
OPEN SURGICAL APPROACH?
J. A. Graham, J. Smirniotopoulos, J. Nusbaum and 
L. B. Johnson
Department Of Surgery, Georgetown University Hospital, 
Washington, DC
Introduction: Laparoscopic assisted pancreaticoduodec-
tomy (LAPD) is a novel and natural extension of the current 
surgical advances for pancreatic disease. Here we compare 
the outcomes in paired cohorts between patients undergoing 
open pancreaticoduodectomy (OPD) and LAPD.
Methods: 53 patients that underwent either OPD or LAPD 
in one year intervals were analyzed to assess outcomes. 33 
patients underwent OPD between February 2009 and 
February 2010, while 20 underwent LAPD from August 
2010 to August 2011. Demographic and outcome data were 
assessed. Variables analyzed included duration of operation, 
estimated blood loss (EBL) and length of stay (LOS).
Results: The average age found in both surgical arms was 
virtually the same at 60. The mean BMI was also similar in 
both groups (23.2 versus 24.81; p = 0.15). In the OPD arm 
the mean duration of the operation was 326 min. and com-
parable to LAPD at 358 min. (p = 0.06). Intraoperatively, the 
mean estimated blood loss (EBL) was not signifi cantly dif-
ferent between OPD (595 ml) versus LAHR (437 ml) (p = 
0.11). However, when analyzing for LOS there was a signifi -
cant difference between the two arms; patients in OPD arm 
had longer stays than LAPD patients (11.61 days versus 6.85 
days respectively; mean difference 4.76 days [95% confi -
dence interval = 2.62 to 6.9] p = 0.0001).
Conclusions: Our study indicates a marked advantage with 
the use of LAPD, namely a strikingly decreased LOS. As 
such, the suggestive shorter convalescence period in the 
patients undergoing LAPD may allow for earlier adjuvant 
chemotherapy and better outcomes.
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SURGICAL RESECTION IN 
HEPATOCELLULAR CARCINOMA 
PATIENTS WITH MINIMAL 
BACKGROUND FIBROSIS; A STRATEGY 
IN THE ERA OF ORGAN SHORTAGE
R. T. Groeschl, S. G. Pappas, K. K. Christians, S. Tsai, 
E. J. Quebbeman, T. C. Gamblin and K. K. Turaga
Medical College Of Wisconsin, Milwaukee, WI
Background: Surgical therapies for hepatocellular carci-
noma (HCC) represent the potentially curative approaches 
and provide patients the greatest survival advantage. The 
optimal use of liver transplantation, local ablation or resec-
tion is an important question to maximize patient benefi t and 
organ allocation. We sought to examine the outcomes of 
patients with HCC treated with surgical resection, transplan-
tation, and local ablation.
Methods: We queried the Surveillance, Epidemiology, and 
End Results (SEER) database for all patients with non-
metastatic HCC from 2004–2007 who underwent therapy to 
Table 1. Characteristics of Patients with HCC, by Therapeutic Approach
Variable Local Ablation*
(n = 1550)
Segmental 
Resection
(n = 703)
Lobectomy 
or Extended 
Resection
(n = 619)
Transplant
(n = 1117)
p-value
Age at diagnosis 62 (55–72) 64 (54–73) 62 (52–71) 55 (51–61) <0.001
Male Gender 73% 68% 72% 79% <0.001
Histology
HCC 1535 (99%) 680 (97%) 581 (94%) 1098 (98%) 0.001
Fibrolamellar HCC 3 (0.2%) 7 (1%) 22 (3.5%) 5 (0.5%)
Scirrhous HCC 2 (0.1%) 0 (0%) 2 (0.3%) 4 (0.4%)
Spindle Cell HCC 0 (0%) 0 (0%) 3 (0.5%) 0 (0%)
Clear Cell HCC 10 (0.6%) 16 (2.2%) 11 (1.8%) 10 (0.9%)
AFP (n = 2921)
Non-elevated 289 (24%) 178 (35%) 144 (34%) 274 (35%) 0.001
Borderline 4 (0.3%) 1 (0.2%) 3 (0.7%) 2 (0.2%)
Elevated 913 (76%) 324 (64%) 271 (65%) 518 (65%)
Fibrosis (n = 1156)
Score 0–4 88 (22%) 98 (52%) 107 (69%) 75 (18%) 0.001
Score 5–6 316 (78%) 92 (48%) 49 (31%) 331 (82%)
Stage (n = 3989)
T1 834 (54%) 374 (53%) 304 (59%) 532 (48%) 0.001
T2 409 (26%) 192 (27%) 151 (24%) 494 (44%)
T3 179 (12%) 95 (14%) 125 (20%) 65 (6%)
T4 35 (2%) 22 (3%) 33 (5%) 9 (0.8%)
Tx 96 (6%) 18 (3%) 6 (1%) 17 (0.5%)
Tumor size 3.7 (2.6–5.1) 4.5 (3.0–7.3) 7 (4.5–11) 2.5 (1.8–3.8) <0.001
Overall 1-year survival 70% 80% 76% 91% <0.001
Overall 3-year survival 34% 50% 54% 74% <0.001
Overall 1-year survival: fi brosis score 0–4 69% 84%† 86%† 92%† 0.001
Overall 1-year survival: fi brosis score 5–6 70% 76% 67% 93% <0.001
*includes radiofrequency ablation.
†comparison of surgical resection techniques to transplantation shows no survival difference, p = 0.5.
the primary tumors. Histological subtype, alpha-fetoprotein 
(AFP) elevation, fi brosis grade (0–4 versus 5–6) and proce-
dure performed (local ablation [LA], segmental resection 
[SR], lobectomy or extended lobectomy [EL], and transplant 
[TP]) were included in the analysis.
Results: Of 16,209 patients diagnosed with HCC, 4554 
(28%) had suffi cient data for inclusion and received the fol-
lowing therapies: 1550 (39%) LA, 703 (18%) SR, 619 (16%) 
EL, and 1117 (28%) TP. AFP was elevated in 69% 
(2026/2921), and fi brosis grade 0–4 was noted in 32% 
(368/1156). Patients undergoing TP were younger and had 
smaller tumors (Table 1). Three-year survival by procedure 
was 34% (LA), 50% (SR), 54% (EL), and 74% (TP), p = 
0.001. In patients with minimal fi brosis, stage-adjusted sur-
vival for patients undergoing resection was similar to TP 
(p = 0.5), but better than LA (Table 1). Patients with paren-
chymal fi brosis had the best survival with transplantation 
(1-year survival 93%, p = 0.001).
Conclusion: Surgical resection confers survival benefi t for 
HCC patients without extensive fi brosis, which is superior to 
ablation and non-inferior to transplantation.
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ANALYSIS OF 787 COMMON BILE DUCT 
EXPLORATIONS FROM THE NSQIP 
DATABASE
J. R. Gutnick1 and A. E. Siperstein2
1Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic, 
Cleveland, OH
Purpose: To analyze the complications of laparoscopic 
(LC) and open (OC) cholecystectomy, with common bile 
duct exploration (CBDE) using the National Surgical Quality 
(NSQIP) database.
Methods: From 66103 cholecystecomies, 316 LC+CBDE, 
56 LC converted to OC+CBDE, 415 OC+CBDE (787 total 
cholecystectomy+CBDE) were extracted from the NSQIP 
database (2007–2009) and analyzed using JMP Version 9.
Results: Table 1 summarizes demographic differences by 
operation. Rates of LC+CBDE, converted to OC+CBDE, 
and OC+CBDE for attending alone were 46.1%, 8.1%, 
45.7%, for attending with resident 37.3%, 6.5%, 56.2% (p = 
0.2). Mean operative times (minutes) (standard error) for 
LC+CBDE was 123.1 (4.2), converted to OC+CBDE was 
195.8 (9.9), OC+CBDE was 170.0 (3.7) (p < 0.0001). 
Comparing complication rates for procedures without and 
with CBDE: for all cholecystectomies 5.7% vs. 7.3%, LC 
3.9% vs. 4.4%, converted 17.4% vs 17.9%, OC 20.1% vs. 
27.0% (p < 0.0001). Figure 1 demonstrates the effect of 
complications on length of stay (LOS). Elevated bilirubin, 
aspartate transaminase, alkaline phosphatase are pre-
operative risk factors for choledocholithiasis. The proportion 
of patients who underwent LC+CBDE, converted, and 
OC+CBDE by the number of risk factors was: zero 40.3%, 
6.6%, 53.1%; one 49.7%, 8.2%, 42.2%; two 38.6%, 6.5%, 
54.9%; three 30.2%, 4.0%, 65.4% (p = 0.0094).
Conclusions: OC but not conversion rates were higher in 
training situations, refl ecting case mix or surgeon preference. 
OC+CBDE had more complications; LOS increased dramati-
cally with each complication. Patients with more laboratory 
choledocholithiasis risk factors were more likely to undergo 
OC+CBDE. These data suggest that more aggressive use of 
laparoscopic CBDE may reduce overall complications.
Table 1. CBDE type by rates (%) of statistically different pre-operative 
demographics
Risk Factor LC+CBDE Converted OC+CBDE p-value
Age > 60 31.2 51.8 53.2 <0.0001
Women 68.6 50.0 55.7 0.0004
Diabetes 7.0 14.3 15.42 0.0084
DNR 0.32 0.0 1.5 0.0104
Dependent 3.8 14.3 16.39 <0.0001
Ventilated 0.3 1.8 2.7 0.0300
COPD 1.6 7.1 6.3 0.0028
Ascities 1.0 0.0 3.6 0.0135
Hypertension 35.8 53.6 49.6 0.0003
Prior CVA 1.0 5.4 3.4 0.0359
Weight loss 1.9 1.8 6.0 0.0099
Sepsis 1.0 1.8 5.3 <0.0001
Septic shock 0.6 1.8 2.4 <0.0001
Do Not Resuscitate order (DNR), Chronic Obstructive Pulmonary Disease (COPD), 
Cerebrovascular Accident (CVA).
MINIMALLY INVASIVE SURGEON IN 
HEPATOPANCREATOBILIARY SURGERY 
FELLOWSHIP: ONE ACADEMIC 
CENTERS MODEL
O. Hamed, N. Gusani, J. Kaifi , E. Kimchi and 
K. Staveley-O’Carroll
Section Of Surgical Oncology, Department Of Surgery, 
Penn State College Of Medicine, Hershey PA, Hershey, PA
Background: Minimally Invasive Surgery (MIS) for 
Hepatopancreatobiliary (HPB) diseases is gaining increasing 
attention. MIS for complex HPB resections requires laparo-
scopic skills mastered during MIS fellowships, while 
complex HPB procedures require a signifi cant amount of 
knowledge and multidisciplinary management mastered 
during HPB fellowships.
Methods: HPB Surgery fellowship at our academic medical 
center has established a model to further advance the applica-
tion of MIS techniques in HPB diseases. Over the last 5 years 
this HPB surgery fellowship has trained 4 fellows with 
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formal MIS fellowship training. To further assess the model 
we provided a survey to faculty and fellows with MIS train-
ing from this fellowship.
Results: Three out of four faculty had previous MIS training 
through Minifellowships only. Three faculty indicated that 
the number of MIS-HPB cases done increased to 25–50 
cases/year after adopting the model. This increase was due 
to the availability of MIS trained fellow, increase interest and 
marketing. All four faculty indicated that the best sequence 
for the fellowships is MIS followed by HPB. Three fellows 
choose to do 2 fellowships based on interest in MIS-HBP 
and one based on advice by a mentor, three fellows had done 
more MIS-HPB cases during the HPB fellowship compared 
to the MIS fellowship.
Conclusion: Lack of well established training programs for 
MIS-HPB procedures represents a challenge to the current 
HPB training paradigm. Performing two fellowships in MIS 
and HPB is a potential solution to master the technical skills 
required for MIS surgery and the knowledge and multidisci-
plinary approach of the HPB surgeon.
SIMULTANEOUS COLORECTAL AND 
HEPATIC PROCEDURES FOR 
COLORECTAL CANCER: INCREASED 
MORBIDITY BUT EQUIVALENT 
MORTALITY TO COLORECTAL OR 
HEPATIC PROCEDURES ALONE – 
OUTCOMES FROM THE NATIONAL 
SURGICAL QUALITY IMPROVEMENT 
PROJECT (NSQIP)
O. Hamed, J. T. Kaifi , E. T. Kimchi, 
K. F. Staveley-O’Carroll and N. J. Gusani
Surgical Oncology – Penn State College Of Medicine, 
Hershey, PA
Background: Simultaneous colorectal and hepatic procedures 
for colorectal cancer (CRC) are increasingly being performed 
as CRC surgery becomes safer, less invasive, and better toler-
ated. NSQIP provides validated, risk-adjusted 30-day periopera-
tive outcome data from over 250 hospitals nationwide, allowing 
large-scale examination of these procedures.
Methods: Data from NSQIP 2005–2008 were used to 
compare 22534 patients (19925 colorectal procedures for 
primary malignancy; 2295 liver procedures for secondary 
malignancy; 314 simultaneous procedures).
Results: An increasing number of simultaneous resections 
was performed per year. Patients undergoing simultaneous 
procedures had higher rates of the following co-morbid con-
ditions compared to colorectal only patients: Dyspnea, 
Coronary Intervention or Surgery, Hypertension, Peripheral 
Vascular Disease, Disseminated Cancer, Weight Loss, 
Chemotherapy, and Radiation (p < 0.05). Fewer complex 
colorectal and liver procedures were performed in the simul-
taneous group (LAR/Total Colectomy 21.5% vs 26% (p = 
0.014), Hemihepatectomy or greater 19.1% vs. 33.5% (p < 
0.001)). Operative time (minutes) varied across groups: 
colorectal 148, liver 216, simultaneous 265 (p < 0.001), as 
did post-operative stay (days): colorectal 6, liver 5, simulta-
neous 7 (p < 0.001). Compared to colorectal and liver pro-
cedures alone, simultaneous surgery resulted in a higher rate 
of the following complications: wound infection (p < 0.001), 
organ space infection (p < 0.001), and septic shock (p = 
0.014). 30-day mortality rate did not differ among the groups 
(colorectal 2.4%, liver 1.2%, simultaneous 1.6%, p = 0.35).
Conclusions: Patients undergoing simultaneous colorectal 
and hepatic procedures have a higher comorbidity profi le, 
and these procedures are associated with an increased opera-
tive time, length of stay, and rate of perioperative complica-
tions. Simultaneous procedures do not, however, increase 
perioperative mortality.
STOMACH PRESERVING DISTAL 
PANCREATECTOMY WITH CELIAC AXIS 
RESECTION: THE BENEFIT AND 
CHALLENGE OF A REPLACED RIGHT 
HEPATIC ARTERY
O. Hamed, N. Gusani, J. Kaifi , E. Kimchi and 
K. Staveley-O’Carroll
Section Of Surgical Oncology, Department Of Surgery, 
Penn State College Of Medicine, Hershey PA, Hershey, PA
Because of delay in symptoms, pancreatic body adenocarci-
noma typically presents with advanced stage and has a lower 
resectability rate, they tend to involve the Celiac Axis (CA) 
early; this would make it unresectable in the vision of many 
surgeons and oncologists. Distal Pancreatectomy with CA 
Resection (DP-CAR) has been described as a curative pro-
cedure in this situation. Normally the liver and stomach will 
be perfused through collateral formed by the gastrodoudenal 
(GDA) and right gastroepiploic artery; sometimes this is not 
well developed and can result in post operative ischemic 
gastropathy and liver necrosis. A 71 year old male patient 
with locally advanced pancreatic body cancer involving the 
CA was referred to our institution after being deemed unre-
sectable. Patient had replaced right hepatic artery (RHA) off 
the SMA, although his anatomical variant is favorable with 
the planned procedure of DP-CAR, this represent a challenge 
since it represents the only supply to the right liver. First 
complete mobilization of the stomach and left medial vis-
ceral rotation of the spleen and pancreas is performed; this 
is followed by careful dissection of the CA, CHA-GDA junc-
tion and SMA before any irreversible transaction is attempted. 
The CHA is clamped to check the fl ow to the left liver via 
the GDA before arterial resections. The replaced RHA is 
carefully identifi ed at its origin off the SMA and dissected 
free as it dives behind the Portal Vein posteriorly. This is 
followed by transaction of the pancreas to the right of the 
body-tumor with complete regional lymphadenectomy.
 Abstracts 33
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association, HPB, 14 (Suppl. 1), 1–91
CLINICAL EXPERIENCE WITH A 3-D 
IMAGE-GUIDANCE SYSTEM IN 
LAPAROSCOPIC LIVER 
RADIOFREQUENCY ABLATION
C. W. Hammill1, M. A. Cassera1, L. W. Clements2, 
R. F. Wolf1 and P. D. Hansen1
1Liver And Pancreas Surgery Program, Portland, OR; 
2Pathfi nder Therapeutics, Inc., Nashville, TN
Purpose: The Explorer™ Minimally Invasive system is a 
3-D image-guidance device that is intended to act as an 
adjunct to intraoperative ultrasound (iUS) during laparo-
scopic ablation procedures via intraoperative integration of 
preoperative tomographic imaging. The objective of the 
clinical study was to compare the guidance accuracy of the 
Explorer™ MI device with that provided by iUS.
Methods: A radiofrequency ablation probe, tracked using 
the Explorer™ MI device, was placed for lesion treatment 
under iUS guidance. The location of the tracked ablation 
probe was recorded within the 3-D guidance system prior to 
lesion treatment and compared directly to the recorded iUS 
imaging. The inter-modality comparison was performed via 
two measurements: (i) the closest distance between the 
lesions boundary and the ablation instrument cannula tip and 
(ii) the distance between the lesion centroid and the cannula 
tip.
Results: Over the three clinical cases in which both iUS and 
guidance system tracking data were acquired, the absolute 
difference between the modalities in the cannula tip to tumor 
boundary distance and the cannula tip to lesion centroid 
distance was found to be 5.4 ± 3.2 mm and 6.6 ± 0.3 mm, 
respectively.
Conclusion: The initial clinical experience with the 
Explorer™ MI device has indicated that there is a correlation 
between the guidance display and the iUS imaging of abla-
tion instrumentation relative to the lesion of interest. The 
Explorer™ MI device is a promising tool in providing sup-
plemental 3-D guidance information within laparoscopic 
ablation procedures.
A 21-YEAR ANALYSIS OF T1 
GALLBLADDER CARCINOMA: IS 
CHOLECYSTECTOMY ALONE 
ADEQUATE?
D. M. Hari1, J. Howard1, C. G. Chiu1, A. M. Leung1, 
M. Sim1 and A. J. Bilchik1,2,3
1John Wayne Cancer Institute, Santa Monica, CA; 
2David Geffen School Of Medicine At University Of 
California, Los Angeles, CA; 3California Oncology 
Research Institute, Los Angeles, CA
Hypothesis: Gallbladder carcinoma (GBCA) is a rare 
disease that is often diagnosed incidentally in early stages. 
Simple cholecystectomy is considered the standard treatment 
for T1 GBCA. We hypothesized that the extent of surgery 
might affect survival in a large cohort of patients with T1 
GBCA.
Methods: The Surveillance, Epidemiology, and End Results 
(SEER) Database was queried to identify patients whose 
microscopically confi rmed, localized GBCA (Stage I) was 
diagnosed between 1988 and 2008. Surgical treatment was 
categorized as cholecystectomy alone (CS), cholecystectomy 
with lymph node dissection (CS+LN) or radical cholecystec-
tomy (RCS). Age, gender, race, ethnicity, T1 sub-stage (T1a, 
T1b or T1NOS), radiation treatment, extent of surgery, cause 
of death, and survival were assessed by Logrank and Cox 
regression analysis.
Results: Of 2788 patients with localized GBCA, 1159 had 
pathologically confi rmed T1a (confi ned to mucosa, lamina 
propria, or submucosa), T1b (confi ned to muscularis propria) 
or T1NOS (less than T2 but not specifi ed) cancer. At a 
median follow-up of 22 months, 336 patients (29%) died of 
GBCA. The 5-year survival associated with CS, CS+LN, and 
RCS was 50%, 70% and 79% respectively (p < 0.0001). On 
regression analysis, surgical treatment and younger age were 
predictive of improved survival (p < 0.0001) while radiation 
therapy portends worse survival (p = 0.0002).
Conclusions: In the largest series of T1 GBCA reported, 
survival was signifi cantly impacted by the extent of surgery 
(LN dissection and RCS) in T1 GBCA. Cholecystectomy 
alone is inadequate for T1 GBCA and should not be consid-
ered standard treatment.
DECREASING TRENDS IN SURGERY 
FOR PANCREATIC CANCER: A 21-YEAR 
POPULATION-BASED ANALYSIS
D. M. Hari1, A. M. Leung1, C. G. Chiu1, S. L. Stern1 and 
A. J. Bilchik1,2,3
1John Wayne Cancer Institute, Santa Monica, CA; 
2David Geffen School Of Medicine At University Of 
California, Los Angeles, CA; 3California Oncology 
Research Institute, Los Angeles, CA
Purpose: Resection is the only curative option for patients 
with pancreatic cancer. This population-based study exam-
ines trends in surgery offered and performed for patients with 
localized (Stage I) and regional (Stage II & III) pancreas 
cancer and the impact on survival over two decades.
Methods: The Surveillance, Epidemiology, and End Results 
(SEER) Database was queried to identify patients with local-
ized and regional pancreatic cancer (Stages I–III) that were 
diagnosed between 1988 and 2008. Interval trends in surgery 
offered and performed were evaluated over time (Year 
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Stratums (YS): 1988–1993, 1994–1998, 1999–2003 and 
2004–2008) and correlated with survival. Results (see Table): 
Patients with local (3411) and regional (14,505) disease had 
an increase in surgery offered from 1988–2003, yet between 
2004 and 2008, less surgery was offered (p < 0.0001). This 
correlated with a decrease in surgeries performed (p < 
0.0001). However, 3-yr survival for surgically treated 
patients increased over time for local (31% to 55%, p < 
0.0001) and regional disease (11% to 24%, p < 0.0001). 
More importantly, 3-yr survival was more than 10-fold 
higher compared to unresected patients for local disease and 
5–8-fold higher for regional disease (p < 0.0001).
Conclusions: In the largest temporal analysis of local and 
regional pancreatic cancer, we demonstrate a recent decrease 
in surgical resections offered and performed. Furthermore, 
not only has survival continued to increase over time after 
surgical resection, it has remained signifi cantly higher com-
pared to unresected patients. Further studies are needed to 
determine why pancreatic resections are declining for 
pancreatic cancer.
Localized Disease Year stratum
1988–1993 
N = 560
1994–1998 
N = 556
1999–2003 
N = 944
2004–2008
N = 1315
# pts (%) 3-yr 
OS (%)
# pts (%) 3-yr 
OS (%)
# pts (%) 3-yr 
OS (%)
# pts (%) 3-yr 
OS (%)
Surgery Offered: Yes 242 (43%) 19.0 263 (47%) 19.2 521 (55%) 28.7 587 (44%) 42.5
No 318 (57%) 3.5 293 (53%) 2.7 423 (45%) 3.5 764 (66%) 5.6
Surgery Performed: Yes 139 (25%) 30.9 169 (30%) 28.7 352 (37%) 41.5 445 (33%) 54.8
No 421 (75%) 3.1 387 (70%) 2.6 592 (63%) 3.0 906 (67%) 5.2
Regional Disease Year stratum
1988–1993
N = 1914
1994–1998
N = 2229
1999–2003
N = 4524
2004–2008
N = 5838
# pts (%) 3-yr 
OS (%)
# pts (%) 3-yr 
OS (%)
# pts (%) 3-yr 
OS (%)
# pts (%) 3-yr 
OS (%)
Surgery Offered: Yes 797 (42%) 7.4 1028 (46%) 13.1 2380 (53%) 13.8 2457 (42%) 21.6
No 1117 (58%) 2.4 1201 (54%) 2.5 2144 (47%) 2.4 3381 (58%) 4.2
Surgery Performed: Yes 545 (28%) 10.5 798 (36%) 16.1 1886 (42%) 16.8 2200 (38%) 24.1
No 1369 (72%) 2.1 1431 (64%) 2.5 2638 (58%) 2.4 3638 (62%) 4.0
RESECTION OF RENAL CELL 
CARCINOMA METASTATIC TO THE 
LIVER: A DUAL-CENTER ANALYSIS
Y. Hatzaras1, C. Pulitano2, L. Aldrighetti2, R. Schulick1, 
M. Choti1, B. Edil1, K. Hirose1, C. Wolfgang1 and 
T. M. Pawlik1
1Johns Hopkins Hospital, Baltimore, MD; 2Liver Unit, 
Scientifi c Institute San Raffaele, Milan, Italy
Background: Management of liver metastasis from a non-
colorectal, non-neuroendocrine primary carcinoma remains 
controversial. Little data exist on the management of hepatic 
metastasis from primary renal cell carcinoma (RCC). We 
sought to determine the safety and effi cacy of surgery for 
RCC hepatic metastasis.
Methods: Between 1994–2010, 31 patients with RCC 
hepatic metastasis were identifi ed from a dual center institu-
tional hepatobiliary database. Clinicopathological, operative, 
and outcome data were collected and analyzed.
Results: Mean patient age was 59 years and most patients 
(63%) were male. Regarding the primary RCC, mean tumor 
size was 7.3 cm and most tumors were designated as clear 
cell carcinoma (72%) as well as being poorly differentiated 
(70%). Six patients (18%) presented with synchronous liver 
metastasis; among the 27 patients with metachronous disease, 
mean time from the primary RCC diagnosis to treatment of 
the liver metastasis was 51 months. The mean size of the 
liver RCC metastasis was 5.4 cm and most patients (55%) 
had a solitary metastasis. Most patients underwent a minor 
resection (≤3 segments) (88%). On fi nal pathology, margin 
status was R0 (63%) or R1 (6%). Post-operative morbidity 
was 23% and there were no peri-operative mortalities. 31% 
of patients received peri-operative chemotherapy. Overall 
5-year survival was 74%. At last follow-up, 52% patients had 
recurred; sites of recurrence included local/primary tumor 
(n = 1), extra-hepatic (n = 3) and intra-hepatic (n = 12).
Conclusion: Resection of RCC hepatic metastasis is safe with 
a low morbidity and near zero mortality. While recurrence 
occurs in up to 50% of patients, resection can be associated with 
long-term survival in a well-selected subset of patients.
A COMPARISON OF 
CLINICOPATHOLOGICAL FEATURES 
AND LONG-TERM SURVIVAL FOR 
RESECTED PERIAMPULLARY 
ADENOCARCINOMAS
J. He1, N. Ahuja1, M. A. Makary1, J. L. Cameron1, 
T. M. Pawlik1, M. A. Choti1, R. H. Hruban2, 
R. D. Schulick1, B. H. Edil1 and C. L. Wolfgang1
1Johns Hopkins Medical Institutions, Department Of 
Surgery, Baltimore, MD; 2Johns Hopkins Medical 
Institutions, Department Of Pathology, Baltimore, MD
Introduction: Despite the close proximity in tissue of origin 
for periampullary adenocarcinomas (PACs), the long term 
 Abstracts 35
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association, HPB, 14 (Suppl. 1), 1–91
outcomes following pancreaticoduodenectomy vary 
greatly.
Methods: From April 1970 to June 2010, patients undergo-
ing pancreaticoduodenectomy for PACs were identifi ed from 
our prospectively gathered database. We retrospectively ana-
lyzed their pathologic diagnosis, therapy and outcome.
Results: During the study period a total of 2574 pancreati-
coduodenctomies were performed for PACs. The primary 
sites were comprised of pancreas (67.5%), ampullary (15%), 
bile duct (11.8%) and duodenum (5.7%). Positive resection 
margins were signifi cantly higher in pancreatic adenocarci-
noma (26.9%) as compared to those from bile duct (15.3%), 
ampulla (3.4%) and duodenum (7.1%), (p < 0.0001). 
Pancreatic adenocarcinoma had a signifi cantly higher pro-
portion of tumor within 1 mm of margin, as compared to the 
other PACs (p < 0.0001). Pancreatic adenocarcinoma was 
associated with a higher median total (p < 0.01) and median 
positive lymph nodes (p < 0.0001) retrieved. Non-pancreatic 
adenocarcinomas were associated with a signifi cantly higher 
incidence of postoperative pancreatic fi stula as compared to 
pancreatic adenocarcinoma (p < 0.0001). Despite this, 
patients with different PACs had similar 30-day (p = 0.89) 
and 90-day (p = 0.47) mortality. Pancreatic adenocarcinoma 
was associated with the worst survival outcome with a 
median survival of 17 months as compared to bile duct 
adenocarcinoma (21 months), ampullary adenocarcinoma 
(45 months), and duodenal adenocarcinoma (53 months).
Conclusions: PACs have signifi cant differences in clinico-
pathological features and long-term survival following pan-
creaticoduodenectomy. Although the fi stula rate is higher for 
non-pancreatic primaries, the perioperative mortality is the 
same for all cancer types. Long-term outcome is strongly 
dependent on the tumor biology of PACs.
TRANSTHORACIC 
TRANSDIAPHRAGMATIC VIDEOSCOPIC-
ASSISTED MICROWAVE ABLATION 
(MWA) OF SMALL HCC IN SEGMENT VII
W. S. Helton, R. Kohler, M. Fotoohi, A. Alseidi, F. Rocha 
and T. Biehl
Virginia Mason Medical Center, Seattle, WA
Very early HCC is effectively treated with ultrasound-guided 
percutaneous microwave ablation (MWA). Unfortunately, 
high posterior lesions in segment VII are often diffi cult to 
target and safely treat percutaneously or laparoscopically. We 
demonstrate a very easy, safe, and accurate method of per-
cutaneous ablation of a 2 cm HCC located in segment VII of 
the liver in a man with cirrhosis. He had a previous open 
liver resection and mobilization of his liver was expected to 
be diffi cult. The lesion could not be accessed safely percu-
taneously given its location for fear of pneumothorax. He 
was positioned left lateral decubitus and had general anes-
thesia via double lung ventilation. The right lung was defl ated 
and a two 5 mm trocars were placed into the right chest; one 
served as camera port and the other as a working port and to 
fi ll the right chest with saline. Cutaneous ultrasound per-
formed through the hydrothorax visualized the lesion well. 
A 1.8 mm 2.5 GHz microwave needle was inserted under 
direct vision through the right chest and right hemidiaphram 
into the center of the lesion. MWA was performed and the 
needle withdrawn without bleeding. The hydrothorax was 
evacuated with a catheter and the incision closed. The patient 
was discharged home as an out patient. CT scan 3 months 
later showed a complete ablation zone without evidence of 
residual tumor.
Conclusion: Early HCC located deep and posterior in 
segment VII can be easily and safely imaged by Ultrasound 
and ablated percutaneously via a transthoracic approach with 
minimal morbidity.
COMPLETE RESPONSE TO TACE FOR 
HCC DOES NOT MEAN CURE
J. C. Henry, L. Malhotra, M. Bloomston and C. R. Schmidt
Ohio State University Department Of Surgery, Columbus, 
OH
Introduction: Regional therapy with trans-arterial chemo-
embolization (TACE) is a common treatment for unresect-
able hepatocellular carcinoma (HCC). We have observed 
some patients to have a complete radiologic response (CR) 
after the initial TACE.
Methods: We reviewed our patients who underwent TACE 
as the initial treatment for HCC between years 2000–2010. 
CR was defi ned as complete disappearance or no tumor 
enhancement on the fi rst cross-sectional imaging study after 
TACE with no subsequent TACE or other therapy for at least 
3 months.
Results: Of 104 patients who underwent TACE for initial 
treatment of HCC, there were 18 (17%) who achieved CR 
and 86 (83%) without CR. In this group, 8 patients (44%) 
had solitary tumors and no patients had major vascular inva-
sion, extrahepatic or bilobar disease. Median overall survival 
in the CR group was 11.4 months compared to 15.1 months 
in the group without CR (P = 0.86, Figure 1). Over half of 
patients in the CR group (n = 12, 67%) experienced disease 
recurrence at a median of 8.4 months, and the majority (n = 
8, 67%) of fi rst recurrences were local disease progression 
in the liver. The most common treatment after recurrence was 
another TACE (n = 6, 50%).
Conclusions: CR to initial TACE for HCC is associated 
with comparable survival to those without CR and a high rate 
of local progression. It is reasonable to consider further 
therapy such as thermal ablation if feasible or repeat TACE 
in patients with HCC even when radiologic response to 
initial TACE is favorable.
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Operation 
Category
# pts Overall 
Morbidity
30-day 
Mortality
Organ space 
infection
Sepsis or 
septic shock
P 820 33%  3% 10% 17%
C 356 39%  4% 12% 18%
P + C  20 70%* 10% 45%* 60%*
SPONTANEOUS REGRESSION OF HCC IS 
MOST OFTEN ASSOCIATED WITH 
TUMOR HYPOXIA OR SYSTEMIC 
INFLAMMATORY RESPONSE
J. I. Huz, M. Melis and U. Sarpel
New York University School Of Medicine, New York, NY
Introduction: Spontaneous regression of hepatocellular carci-
noma (HCC) has been well documented in the literature, 
however the mechanism of this phenomenon remains unknown. 
This manuscript evaluates all published cases of regression and 
attempts to classify them by the underlying etiology.
Methods: A search of the English literature was performed for 
reports on spontaneous regression of HCC. Cases were only 
included if regression occurred in the absence of accepted thera-
peutic modalities. Reports were assessed for clinical informa-
tion suggesting the underlying mechanism of regression.
Results: An initial search identifi ed 81 cases of HCC regres-
sion, however only 71 met our defi nition of spontaneous. The 
most common mechanisms were tumor hypoxia (n = 21, 
29.5%), systemic infl ammatory response (n = 20, 28.2%), 
and unknown (n = 30, 42.3%). No other mechanism was 
suggested by more than two reports. Examples of tumor 
hypoxia cases included spontaneous thrombosis of a feeding 
artery or a sustained period of hypotension. Examples of 
systemic infl ammatory response cases included cholangitis 
and other acute infections, tumor rupture, or elevated levels 
of cytokines.
Conclusion: Tumor hypoxia and systemic infl ammatory 
response are commonly associated with regression of HCC. 
Future publications of spontaneous regression of HCC 
should include consideration of the underlying mechanism. 
Determining of the etiology of spontaneous regression may 
help identify therapeutic pathways for HCC treatment. 
Tumor hypoxia is already the basis of treatment modalities 
such as hepatic artery embolization and the anti-angiogenic 
agent sorafenib. However, treatment modalities for HCC do 
not currently include immune-directed therapies; this may 
prove to be a worthy target for future research.
EFFICACY AND COST-BENEFIT 
ANALYSIS OF MESH REINFORCEMENT 
OF STAPLED LEFT PANCREATECTOMY: 
RESULTS OF A RANDOMIZED 
CONTROLLED TRIAL
K. Idrees1, J. R. Edler2, D. C. Linehan1, S. M. Strasberg1, 
N. A. Hamilton1, R. Fields1, D. Lambert2, S. Kymes2 and 
W. G. Hawkins1
1Department Of Surgery, Washington University, St. Louis, 
MO; 2Center For Economic Evaluation In Medicine, 
Washington University, St. Louis, MO
Introduction: Pancreatic leak is a morbid complication fol-
lowing left pancreatectomy resulting in prolonged hospital-
izations, additional diagnostic testing and procedures. We 
hypothesized that mesh reinforcement of stapled left pancre-
atectomy would result in decreased pancreatic leak rate and 
cost benefi ts for the health care system.
Methods: A randomized, single-blinded, parallel-group trial 
of mesh versus no mesh reinforcement of left pancreatec-
tomy was performed. Clinically signifi cant leak, length of 
stay and cost benefi ts were compared. A cost-benefi t model 
was developed to estimate net cost savings from payor’s 
perspective based on 2010 Medicare allowable charges and 
our institutional fi xed mesh cost of $165/procedure.
Results: One-hundred patients were randomized. Pancreatic 
leaks (ISGPF grade B & C) were seen in 24% (11/46 patients) 
with no mesh compared to 1.9% (1/54 patients) with mesh 
reinforcement (p = 0.0007). The no-mesh group had longer 
median days with a drain (17 vs. 9, p = 0.0009) and an 
increased number of drain replacements (11 patients vs. 1 
SIMULTANEOUS PANCREATECTOMY 
AND COLECTOMY: A SAFE 
COMBINATION?
M. G. House, M. Kilbane, E. P. Ceppa, A. Nakeeb, 
T. J. Howard, C. M. Schmidt, N. J. Zyromski, 
K. D. Lillemoe and H. A. Pitt
Department Of Surgery, Indianapolis, IN
Introduction: Postoperative complication rates following 
pancreatectomy remain high in the modern era. Substantial 
surgical procedures performed with pancreatectomy may 
result in additional postoperative morbidity and mortality. 
The aim of this study was to analyze the complications which 
occur after simultaneous pancreatectomy and colectomy.
Methods: All cases of regional pancreatectomy (P), segmental 
colectomy (C), and simultaneous pancreatectomy and colec-
tomy (P+C) were reviewed at a single high-volume institution 
between November 2006 and May 2011. All cases were moni-
tored with complete 30-day outcomes through the American 
College of Surgeons-National Surgical Quality Improvement 
Program (ACS-NSQIP). Two and three-way statistical analyses 
were performed among the operation categories.
Results: Twenty patients with a diagnosis of cancer and a 
median age of 54 yrs underwent P+C. Pancreatoduodenectomy 
was performed in 9 patients, and distal pancreatectomy in 
11. 30-day mortality was 10% for the P+C group (9% distal 
pancreatectomy, 11% pancreatoduodenectomy, p = NS). 
Postoperative outcomes for the 3 groups of patients are sum-
marized in the table. Signifi cant differences (*, p<0.01) 
among the groups are indicated.  Superfi cial surgical site 
infection occurred in 15% of the P+C patients versus 10% 
in the P and C groups, p=0.31.  The median postop hospital 
stay was 17 days (range, 6–60d) for P+C patients compared 
to 7d and 6d for P and C patients, respectively (p=0.01). 
Conclusions:  Extraordinarily high complication rates are 
observed after simultaneous regional pancreatectomy and 
colectomy which exceed the cumulative morbidities after 
each operation separately.  Careful patient selection and 
strategies to prevent and/or control anastomotic leaks are 
necessary to improve outcomes in these patients. 
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patient, p = 0.001) compared to the mesh group. Average 
total costs for an episode of care were $7410 and $7760 for 
subjects receiving mesh or no-mesh respectively, resulting in 
savings of $350. With a 1.9% probability of developing a 
clinically signifi cant leak using mesh reinforcement, the 
strategy remains cost-saving if mesh is priced < $514 based 
on two-way sensitivity analysis.
Conclusions: Mesh reinforcement decreases clinically sig-
nifi cant pancreatic leaks. Despite the additional cost of mesh, 
this also results in overall cost savings for the health care 
system. Mesh reinforcement of stapled left pancreatectomy 
should be incorporated into routine practice.
STAGED LIVER RESECTIONS FOR 
BILOBAR HEPATIC COLORECTAL 
METASTASIS: A SINGLE CENTER 
EXPERIENCE
M. H. Jamal, M. Hassanain, P. Chaudhury, Y. Yousef, 
S. Wong, T. T. Tran, Y. Jozaghi, S. Jabbour, A. Salman, 
E. Simoneau, J. Kwan, S. Al-Abbad, M. Al-Jiffry, 
G. Arena, A. Neville and P. Metrakos
McGill University Health Center, Montreal, QC, Canada
Background: Bilobar colorectal cancer liver metastasis 
(BCLM) are challenging resection. Given the survival 
advantage for resection a portion of these patients may 
benefi t from a staged liver resection strategy. In this study 
we describe our staged resection experience.
Methods: From January 2003 to January 2011 patients that 
were put on the staged resection pathway were identifi ed 
from the MUHC HPB Database. All patients underwent neo-
adjuvant chemotherapy, liver resection (LR) to clear one side 
of the liver, portal vein embolization of the contralateral side, 
followed by the second stage LR. Those who had only a 
single LR were considered a failed staged resection (FSR), 
while those who completed the second stage were considered 
to have had a successful staged resection (SSR). Survival 
was calculated from the date of diagnosis BCLM. Complete 
follow up and dates of deaths were obtained from the 
Government of Quebec populational database. Data are 
expressed as median and interquartile range.
Results: A total of 90 patients were identifi ed. 51 patients 
(57%) had an SSR, while 39 patients (43%) had an FSR. 
Median number of lesions was 7 [3.0–7.0]. The overall 5-year 
survival and median survival were 19% and 1.8 [1.3–3.0] years 
respectively for the entire group. The SSR median survival was 
2.5 [1.6–3.9] years vs. 1.4 [1.0–1.9] years in the FSR group (p 
< 0.01). The SSR 5-year survival was 43% vs. 5% in FSR group.
Conclusion: Staged resection for BCLM is feasible and 
offers a survival benefi t.
PATIENT AND CLINICOPATHOLOGICAL 
FEATURES, AND PROGNOSIS OF CK19+ 
HEPATOCELLULAR CARCINOMAS: A 
CASE-CONTROL STUDY
J. Jang1, P. T. Kim2, P. D. Greig2, S. Gallinger2, 
C. Moulton2, A. C. Wei2, S. E. Fischer2 and S. P. Cleary2
1Faculty Of Medicine, University Of Toronto, Toronto, 
Ontario, Canada; 2Toronto General Hospital, Toronto, 
Ontario, Canada
Background/purpose: Cytokeratin 19 (CK19) expression 
is a poor prognostic factor of hepatocellular carcinoma 
(HCC). We sought to identify patient and clinicopathological 
features that differentiate CK19+ and CK19− tumors and 
describe their respective survivorship post-resection.
Methods: 386 patients who underwent liver resection for 
HCC between 1992–2011 at our institution were identifi ed 
through retrospective chart review. Of these, 11 CK19+ cases 
were identifi ed and matched 1:2 with CK19− controls on 
underlying liver disease and number of tumors. Age, micro-
vascular invasion, and tumor size were adjusted for statisti-
cally in regression models.
Results: Mean average age for cases (n = 11) and controls (n 
= 22) was 63 years (SD cases: 11 years, SD controls: 13 years), 
and the majority were males (cases: 73%, controls: 68%). 
Underlying liver diseases were Hepatitis B (55%), Hepatitis 
B & C (18%), Hepatitis C (9%), and alcohol use (18%). Most 
patients had largest lesions between 2–5 cm (cases & controls: 
70%) and no microvascular tumor invasion (cases: 64%, con-
trols: 71%). While CK19+ tumors initially appeared to be 
associated with poor tumor grade (OR = 10.67, 95% CI: 1.91, 
59.62), this association was null after multivariate adjustment. 
Being overweight/obese, receiving hepatitis treatment pre-
resection, and tumor size on pre-operative imaging were not 
signifi cantly associated with CK19+ tumors. Post-resection, 
median overall survivals were 30 and 44 months while median 
survivals after recurrence were 19 and 30 months for cases 
and controls, respectively.
Conclusions: Congruent with previous fi ndings, patients 
with CK19+ tumors appear to have shorter survivorship. 
Patient and clinicopathological features differentiating 
CK19+ and CK19− HCCs were not identifi ed.
CENTRAL PANCREATECTOMY
A. Kamyab and M. J. Jacobs
Providence Hospital And Medical Centers, Southfi eld, MI
Background: Central pancreatectomy can be used in the treat-
ment of lesions located in the body of the pancreas, with the 
advantage of preserved pancreatic parenchyma compared to 
pancreaticoduodenectomies or distal splenopancreatectomies.
Methods: The central pancreatectomy was performed through 
a subcostal incision. An intraoperative ultrasound was per-
formed, and the pancreas was divided using electrocautery. The 
proximal pancreatic duct (PD) was over-sown with layered 
interrupted U stitches. A pancreaticojejunostomy was performed 
for the distal PD, using radially oriented sutures over a stent.
Results: A 38 year old female with a family history of pan-
creatic cancer was found to have an increase in size of a 
known pancreatic cyst with no history of pancreatitis. 
Endoscopic ultrasound revealed mural nodules raising the 
suspicion of a pancreatic cystic neoplasm. She underwent a 
central pancreatectomy with pancreaticojejunal Roux-en-Y 
anastomosis. There were no intraoperative or postoperative 
complications. Final pathology revealed a low-grade pancre-
atic intraepithelial neoplasia (PanIN1B).
Conclusion: Central pancreatectomy is a viable option for 
lesions located in the pancreatic body.
CHOLEDOCHODUODENOSTOMY FOR 
BENIGN BILIARY STRICTURE
A. Kamyab and M. J. Jacobs
Providence Hospital And Medical Centers, Southfi eld, MI
Background: Choledochoduodenostomy is used in the 
treatment of selected patients with choledocholithiasis 
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or benign biliary strictures. It has been surpassed by 
improved techniques in endoscopic retrograde cholangiopan-
creatography (ERCP), stone retrieval and sphincterotomy. 
We present a choledochoduodenostomy procedure with 
choledochoscopy.
Methods: A right subcostal incision was used, and the duo-
denum was widely mobilized by a Kocher maneuver. The 
common bile duct was isolated and divided. An intraopera-
tive cholangiogram was performed, bile duct stones were 
retrieved, and a choledochoscopy was performed to rule out 
retained stones. The choledochoduodenostomy was per-
formed with a row of 3–0 interrupted absorbable sutures.
Results: A 60 year old male with a previous Billroth 1, 
presented with obstructive jaundice, secondary to choledo-
cholithiasis not amenable to ERCP. Intraoperatively, there 
were numerous earth-like choledocholiths and a distal benign 
stricture confi rmed by cholangiogram. A common bile duct 
exploration, stone retrieval, and a choledochoduodenostomy 
were performed without intraoperative or postoperative 
complications.
Conclusion: Choledochoduodenostomy for benign bile duct 
strictures is a viable defi nitive option for biliary bypass, par-
ticularly in the presence of severe adhesions and in patients 
not suitable for endoscopic or percutaneous techniques.
PANCREATICODUODENECTOMY: 22 
YEAR COMPARATIVE OUTCOME 
ANALYSIS IN A SINGLE INSTITUTION 
AND THE EFFECT OF ACQUIRING A 
FELLOWSHIP TRAINED 
HEPATICOPANCREATICOBILIARY 
SURGEON
A. Kamyab, L. Bolo and M. J. Jacobs
Providence Hospital And Medical Centers, Southfi eld, MI
Introduction: Pancreaticoduodenectomy (PD) outcome 
prior to and subsequent to acquiring a hepatopancreaticobili-
ary (HPB) surgeon has not been previously studied. We com-
pared our single-institution data prior to procuring a HPB 
surgeon, to the data that ensued.
Methods: A retrospective review was performed of patients 
that underwent a PD at our institution between January 1990 
and August 2011. Data acquired included demographic data, 
operative time, blood loss, length of stay, and pathology. A 
HPB surgeon started in 2003; the data was therefore divided 
into those performed between January 1990 and December 
2002 (Group 1), and those performed between January 2003 
and July 2011 (Group 2).
Results: Thirty-nine patients underwent a PD in Group 1, 
compared to 86 patients in Group 2. The average age was 
68.5 vs. 67, the median operating time was 7.5 hours vs. 5.3 
hours, median blood loss was 950 vs. 400 mL, median length 
of stay (LOS) was 21 vs. 10 days, and overall complication 
rates were 62.5% vs. 22.1% (group 1 vs. group 2 respec-
tively), of which gastric emptying was the most common in 
both groups. When excluding PDs performed by general 
surgeons in group 2, 66 PDs (76.7%) were performed by the 
HPB surgeon, with a median operative time unchanged at 
5.3 hours, however median blood loss decreased to 300 mL, 
median LOS decreased to 9 days, and complication rates 
decreased to 15.1%.
Conclusion: Pancreaticoduodenectomies performed since 
acquiring a HPB surgeon were performed more effi ciently, 
with decreased operating time, blood loss, complication 
rates, and length of stay.
TOTAL LAPAROSCOPIC 
PANCREATICODUODENECTOMY: 
EARLY SINGLE INSTITUTION 
EXPERIENCE
A. Kamyab, K. Khatlani and M. J. Jacobs
Providence Hospital And Medical Centers, Southfi eld, MI
Background: Total laparoscopic pancreaticoduodenectomy 
(TLPD) remains one of the most advanced laparoscopic pro-
cedures. With evolution in laparoscopic technology and 
instrumentation in the last decade, laparoscopic pancreatico-
duodenectomy is beginning to achieve wider acceptance.
Methods: Data was collected for all patients who underwent 
a TLPD at our institution from March until July 2011. 
Preoperative evaluation consisted of CT scan with pancreatic 
protocol, and selective use of MRI and/or endoscopic ultra-
sound. The TLPD was done with 6 ports on three patients, and 
5 ports on one patient, and included a celiac, periportal, peri-
pancreatic and periduodenal lymphadenectomy. Pancreatic 
stents were used in all 4 cases, and intestinal continuity was 
reestablished by intracorporeal anastomoses.
Results: Four patients underwent a TLPD for suspicion of a 
periampullary tumor. There were 3 females and 1 male with 
a mean age of 65 years and mean BMI of 30.5. Intraoperatively, 
the mean operative time was 9 hours and 31 minutes with a 
mean blood loss of 120 mL. Postoperatively there were no 
complications with a mean length of stay of 6.5 days. Mean 
follow up time was 4 months. There was no lymph node 
involvement in any of the 4 specimens. The pathologies 
included IPMN in two, pancreatic adenocarcinoma in one (R0 
resection), and benign 4 cm periampullary adenoma in one.
Conclusion: TLPD is a safe and viable alternative to the 
standard Whipple procedure. Our early experience suggests 
decreased length of stay, quicker recovery, and improved 
quality of life. Complication rates appear to be improved or 
equivalent.
HOSPITAL READMISSION AFTER 
PANCREATICODUODENECTOMY: AN 
EMERGING QUALITY METRIC
Z. J. Kastenberg, J. M. Morton, B. C. Visser, J. A. Norton 
and G. A. Poultsides
Department Of Surgery, Stanford University Medical 
Center, Stanford, CA
Purpose: Reducing rates of hospital readmission has 
attracted attention from policymakers as a way to improve 
quality of care and reduce costs. We sought to evaluate the 
frequency and patterns of hospital readmission after pancre-
aticoduodenectomy (PD) in a contemporary cohort of 
patients.
Methods: Medical and billing records of all patients who 
underwent PD at a tertiary referral academic medical center 
between 2006 and 2011 were retrospectively reviewed. The 
incidence, etiology, length, and predictors of subsequent hos-
pital readmission(s) within one year from the operation were 
analyzed.
Results: From 2006 to 2011, 257 consecutive patients 
underwent PD. Median length of stay was 11 days and in-
hospital mortality was 1.9%. Hospital readmission rates were 
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14% at 1 month, 22% at 3 months, 25% at 6 months, and 
36% at 12 months following PD. Reasons for readmission 
(n = 123) were infection (37%), diet intolerance (22%), 
disease progression (13%), hemorrhage (8%), thromboem-
bolism (5%), planned unrelated procedures (4%), incisional 
hernia repair (3%), and other (8%). Median length of each 
readmission was 6 days with 12% of readmissions being 
1-day and 15% 2-days long. There was no correlation found 
between the need for hospital readmission at 1 and 3 months 
and patient demographics, comorbidities, procedural details, 
complications or disposition (Table).
Conclusions: More than one fi fth (22%) of patients require 
hospital readmission within 3 months of PD. More than one 
quarter (27%) of rehospitalizations after PD are short (2 days 
or less); a fraction of these may be preventable or manage-
able in the outpatient setting.
Readmission
within 1 Month
Readmission
within 3 Months
No
(n = 220)
Yes
(n = 37)
P No
(n = 196)
Yes
(n = 55)
P
Age (years)* 64 66 0.66 64 65 0.53
Male Gender 58% 59% 0.88 61% 49% 0.27
Hypertension 45% 43% 0.89 47% 40% 0.17
Diabetes 24% 22% 0.88 25% 20% 0.91
Coronary Artery Disease 14% 8% 0.55 15% 7% 0.64
Any Smoking History 42% 43% 0.38 42% 38% 0.42
Estimated Blood Loss (ml)* 681 537 0.14 694 558 0.10
Vascular Reconstruction 10% 3% 0.22 12% 2% 0.06
Pylorus Preservation 77% 73% 0.61 77% 75% 0.79
Malignant Disease 71% 73% 0.79 71% 71% 0.96
Index Admission Length of Stay (days)* 15 14 0.37 15 16 0.33
Any Postoperative Morbidity 60% 70% 0.25 59% 73% 0.16
Delayed Gastric Emptying 28% 32% 0.59 29% 29% 0.97
Pancreatic Fistula 15% 19% 0.54 14% 20% 0.58
Wound Infection 8% 16% 0.11 7% 15% 0.18
Disposition
 to Home 82% 78% 0.79 84% 71% 0.55
 with Home Health Services 8% 14% 7% 18%
 to Skilled Nursing Facility 7% 8% 6% 11%
*, mean values.
EVALUATION OF SERUM MESOTHELIN 
AS A DIAGNOSTIC AND PROGNOSTIC 
BIOMARKER FOR PANCREATIC 
ADENOCARCINOMA
Z. W. Kendrick1, M. A. Firpo1,4, C. L. Scaife1,4, 
D. G. Adler2,4, K. M. Boucher3,4 and S. J. Mulvihill1,4
1Department Of Surgery, Salt Lake City, UT; 2Division Of 
Gastroenterology, Salt Lake City, UT; 3Department Of 
Oncological Sciences, Salt Lake City, UT; 4Huntsman 
Cancer Institute, Salt Lake City, UT
Background: Development of biomarkers for early diagno-
sis and establishing prognosis are currently key research 
priorities in pancreatic adenocarcinoma (PA). The secreted 
protein, mesothelin (MSLN), is over expressed in PA and is 
predicted to be coordinately regulated with TIMP-1, a previ-
ously identifi ed PA serum biomarker. We evaluated MSLN 
as a potential diagnostic and prognostic biomarker in PA and 
correlated MSLN and TIMP-1 levels in diseased and normal 
human samples.
Methods: MSLN and TIMP-1 were determined in sera by 
ELISA in a cohort of 85 PA patients, 86 healthy control 
subjects, and 40 chronic pancreatitis (CP) patients. Linear 
regression models were used to relate MSLN to gender, age, 
stage, class, treatment, survival, and TIMP-1.
Results: Serum levels of MSLN were signifi cantly elevated 
in PA subjects relative to both CP patients (P = 0.014) and 
healthy control subjects (P < 0.0001). MSLN levels were also 
related to age (P < 0.0001). After adjusting for age, serum 
levels of MSLN were signifi cantly elevated in PA subjects 
relative to healthy control subjects (P < 0.0001), but not CP 
patients (P = 0.85). There was no signifi cant relationship 
between MSLN and TIMP-1 (P = 0.22). Serum MSLN as a 
predictor of survival did not reach the level of signifi cance 
(P = 0.064).
Conclusions: Serum MSLN is potentially useful as a diagnos-
tic biomarker for PA, particularly in age-adjusted models devel-
oped from biomarker panels. Our data does not support the 
proposed coordinated regulation between MSLN and TIMP-1, 
thus both biomarkers could be used in a biomarker panel.
RADIOFREQUENCY-ASSISTED LIVER 
RESECTION
M. Kerem, O. Sakrak, K. Dikmen and H. Bostanci
Gazi University, Medical Faculty, General Surgery 
Department, Ankara, Turkey
Background: Liver resection represents the only curative 
treatment option in liver tumors. There are many bloodless 
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techniques that can be used in liver surgery. Radiofrequency-
assisted (RF) has been described for bloodless liver surgery. 
The aim of this study is to evaluate RF liver surgery resection 
technique and effects of it on postoperative complications.
Methods: Patients undergoing liver resection during the 
period 2009–2011 were identifi ed from a prospectively 
maintained. RF-assisted precoagulation was performed using 
a RF device (Habib 4X, AngioDynamics).
Results: RF liver resection technique were utilized in 19 
patients with liver tumors. Procedures performed included 
segmentectomy/wedge resection in 13 patients and biseg-
mentectomy in 2 patients and lobar resection in 4 patients. 
Time required for precoagulation was 27 ± 4 min. There was 
no postoperative hemorrhage, but long sterile drainage was 
seen in two patients (%10.5). The length of the drainage were 
eight and eleven days, in the patients. The drains were 
removed when the drainage had stopped.
Conclusions: RF liver resection technique is safe, feasible, 
and effective, but discharge rate is ten percent.
IMPACT OF ABERRANT RIGHT HEPATIC 
ARTERY ON ONCOLOGIC MARGINS 
AND OUTCOMES AFTER 
PANCREATICODUODENECTOMY
P. T. Kim, S. Temple, I. D. McGilvray, S. Gallinger, 
P. D. Greig and A. C. Wei
Toronto General Hospital, Toronto, ON, Canada
Aberrant right hepatic artery (aRHA) arising from the supe-
rior mesenteric artery encountered during pancreaticoduode-
nectomy (PD) may pose technical and oncologic challenges. 
This study was conducted to outline the impact o aRHA on 
oncologic margins and post operative morbidity after PD. A 
retrospective cohort study of patients with aRHA who under-
went PD at a tertiary academic institution from 2000 to 2010 
for pancreatic adenocarcinoma (n = 32) was performed and 
the outcomes were compared to the patients with standard 
PD with no aRHA (n = 32). Of 654 patients who underwent 
PD, 55 (8.4%) patients had aRHA and 32 of them had pan-
creatic adenocarcinoma confi rmed on histology. There was 
no difference in demographic (age, gender) or tumor charac-
teristics (tumor size, lymphovascular, perineural invasion, 
and grade) between the two groups. The rate of R1 resection 
was similar between the two groups (9% vs. 18%, P < 0.5). 
The two groups had similar major complication rates 
(Clavien-Dindo class 3 or higher) including post operative 
bleeding, pancreatic leak, intraabdominal sepsis, and delayed 
gastric emptying. There was no in-hospital mortality in both 
groups. These results demonstrate that the presence of aRHA 
in PD does not have a negative impact on oncologic margins 
and the post operative morbidity. This is most likely a refl ec-
tion of careful patient selection in patients with aRHA who 
require PD.
Demographic, tumor characteristics and post operative mor-
bidity in patients with and without aberrant right hepatic 
artery in pancreaticoduodenectomy
PD + 
aRHA
Standard 
PD
P value
Age (Years) 63 + 10 65 + 10 0.3
M : F 19:13 15:17 0.2
Preoperative 
Chemotherapy
3% 3% 0.8
Tumor Size (cm) 3.4 + 1.3 3 + 1.2 0.3
R1 Resection Rate 9% 18% 0.5
Pancreatic Leak 3% 6% 0.2
Biliary Leak 0% 0% 1
Delayed Gastric 
Emptying
12.5% 6.3% 0.3
Intrabdominal 
Sepsis
12.5% 12.5% 0.5
Post Operative 
Bleed
3% 6% 0.2
Clavien-Dindo 
Scale (> 2)
12.5% 12.5% 0.5
INTRAOPERATIVE ULTRASOUND 
GUIDED DISSECTION DURING THE 
WHIPPLE PROCEDURE
I. Koleilat1, P. Parikh1, R. Chiu1, N. Zeinomar2, R. Petrov1, 
S. Stain1 and A. Nigam1
1Department Of Surgery, Albany Medical College, Albany, 
NY; 2Department Of Epidemiology & Biostatistics, School 
Of Public Health, University At Albany, SUNY, Rensselaer, 
NY
Pancreaticoduodenectomy is a complex and diffi cult proce-
dure to perform even in the most experienced hands. Although 
typically employed to identify metastatic disease, real-time 
intraoperative ultrasound (IOUS) facilitates identifi cation 
and navigation of the safest passages through which surgical 
instruments can be directed during pancreaticoduodenec-
tomy. IOUS is not only used to assess for metastases but also 
to defi ne tumor and native anatomy and to plan and guide 
the dissection at any point where the anatomy and surgical 
planes may be indistinct. Initially, IOUS is used to evaluate 
the head, neck and body of the pancreas transgastrically or 
via the lesser sac. Vascular and biliary anatomy are then 
delineated (the celiac, hepatic gastroduodenal and superior 
mesenteric arteries; splenic, superior mesenteric and portal 
veins; and the bile and pancreatic ducts) and their position 
relative to the tumor elucidated. Aberrant or atypical anatomy 
is easily identifi ed as a result. The direction of operative 
instruments is thus dictated by direct visualization and real 
time IOUS-guidance. This allows for an easier and safer 
dissection in patients with obesity, aberrant anatomy, or 
unclear planes from signifi cant fi brotic reaction. A retrospec-
tive review of all pancreaticoduodenectomies performed at 
our institution with and without IOUS showed a reduced 
operative time and decreased estimated blood loss. In expe-
rienced hands, IOUS-guided dissection makes pancreatico-
duodenectomies technically easier, faster and safer.
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TRIPTOLIDE-INDUCED CELL DEATH IN 
HEPATOCELLULAR CARCINOMA
T. C. Krosch, V. Sangwan, S. Banerjee, A. K. Saluja, 
E. H. Jensen and S. M. Vickers
University Of Minnesota Department Of Surgery, 
Minneapolis, MN
Purpose: Systemic treatment of hepatocellular carcinoma 
(HCC) has been limited to sorafenib, a broad spectrum tyrosine 
kinase inhibitor, with suboptimal outcomes. Heat shock proteins 
HSP70 and HSP27 are upregulated in HCC. Triptolide, derived 
from a Chinese herb, as been found to inhibit these survival 
proteins. We evaluated the response of HuH-7 and Hep3B HCC 
cells to triptolide, as an alternative therapy option.
Methods: HuH-7 and Hep3B cells were treated in vitro with 
triptolide as well as sorafenib, and assessed for viability 
(MTT assay), caspase activation (Promega), and Annexin V 
positivity (Guava Nexin). Real-time PCR and western blots 
were used to determine mRNA and protein levels.
Results: Triptolide treatment of HuH-7 and Hep3B cells 
resulted in dose- and time-dependent cell death, occurring 
within 72 hours at a 100 nM concentration (80% death in 
Hep3B, 60% in HuH-7). Signifi cant increases in caspase-3 
activation and Annexin V positivity was seen in both cell 
lines, consistent with apoptosis. Levels of HSF-1, the tran-
scription factor for HSP70 and HSP27, as well as HSP70 and 
HSP27, signifi cantly decreased with treatment in both cell 
lines, both at the RNA and protein levels. Sorafenib treat-
ment of 2.5 uM at 72 hours showed equivalent cell death in 
HuH-7 cells (60% death), with similar effectiveness in 
Hep3B cells (90% death).
Conclusions: Triptolide treatment of HCC cells in vitro 
induces cell death by apoptosis, with equivalent effi cacy of 
sorafenib, leading to decreased expression of HSP70 and 
HSP27. Triptolide may provide a treatment option for HCC. 
Potential synergistic effects will be investigated.
SORAFENIB ABROGATES THE 
EXPANSION OF LIVER CD8+ 
REGULATORY T CELLS FOLLOWING 
PARTIAL HEPATECTOMY
P. C. Kurniali1,2, C. Nguyen1, L. Licata1, V. Falanga1,2, 
N. J. Espat1,2 and S. C. Katz1,2
1Roger Williams Medical Center, Providence, RI; 2Boston 
University School Of Medicine, Boston, MA
Background: FoxP3+ regulatory T cells (Treg) suppress the 
host response to intrahepatic neoplasms and both CD4+ and 
CD8+ subsets have been described. Sorafenibis being studied 
as an adjuvant agent for hepatocellular carcinoma (HCC) but 
its effects on Treg in the regenerating liver are not known. 
We explored the effects of sorafenib on liver Treg following 
partial hepatectomy (PH) in mice.
Methods: Sorafenib (60 mg/kg) was administered daily to 
adult C57BL/6 mice via orogastric tube. Livers were har-
vested 3 days following PH and T cells purifi ed with immu-
nomagnetic beads. Flow cytometry was used to determine 
the frequencies of liver T cell (LTC) populations.
Results: The frequency of CD4+ LTC was not affected by PH 
or sorafenib (see fi gure). In contrast, the CD8+ LTC population 
expanded following PH (45.7% vs 34.6%, p = 0.01). The CD8+ 
LTC increase following PH was not affected by sorafenib 
administration. PH did not lead to a change in the frequency of 
CD4+FoxP3+ LTC. The CD4+FoxP3+ population increased 
from 4.1% to 5.4% in association with sorafenib treatment fol-
lowing resection, but the results were not signifi cant (p = 0.07). 
PH led to an increase in the CD8+Foxp3+ population compared 
to SHAM animals (3.7% vs 6.1%, p = 0.03). Treatment with 
sorafenib reversed the CD8+FoxP3+ LTC population expansion 
following PH (6.1 vs 3.4%, p = 0.01).
Conclusions: PH led to an expansion of putatively suppres-
sive CD8+FoxP3+ LTC which was prevented by treatment 
with sorafenib. Use of sorafenib in the adjuvant setting for 
HCC may have immunologic benefi ts in addition to direct 
anti-tumor effects.
THE ROLE OF PROPROTEIN 
CONVERTASES IN COLON CANCER 
PROGRESSION
J. Kwan, C. Benay, D. Antonatos, E. Simoneau, M. Jamal, 
M. Hassanain and P. Metrakos
McGill University Health Centre, Montreal, QC, Canada
Background: Proprotein convertases (PC) are proteases that 
regulate mediators crucial for cancer progression. The expres-
sion pattern of PCs is altered in various human tumors compared 
to normal. Most patients with colorectal cancer (CRC) will die 
of their disease. Predicting which cancers are more aggressive 
remains a challenge. A specifi c profi le of PC expression may 
predict which CRC will result in liver metastases.
Methods: To determine the effect of PCs (PACE4, PC5/6, 
PC7, Furin, PC1/3) and 7B2 (PC2 chaperone) in CRC, 
human colon adenocarcinoma cell line HT-29 was trans-
fected with shRNA to each gene, downregulating its expres-
sion. Copy number was verifi ed by qRT-PCR. Cell lines were 
characterized by Ki67 expression using fl ow cytometry, 
caspase activity using Caspase 3/7 Glo®/luminescence, and 
colony number using soft agar assay. Nonparametric statisti-
cal analyses were performed.
Results: Comparison between parental HT-29 cell line, and 
those expressing hPACE4, hPC5/6, hPC7, h7B2, hFur and 
hPC1/3 showed no difference in Ki67 expression (P = 
0.8638), thus proliferation was unaltered. There were signifi -
cant differences in caspase activity (P = 0.0016) and colony 
growth (P = 0.0003) indicating changes in apoptotic and 
oncogenic capacity respectively. Further analysis revealed 
lower apoptotic activity in hPC5/6 expressors (P = 0.009) 
and higher in h7B2 and hFur expressors (both P = 0.009); 
cells expressing hPC5/6 (P = 0.0008) and hPC1/3 (0.0141) 
showed greater growth potential in soft agar.
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Conclusion: Altered PC profi les affected CRC cell behav-
ior. Most signifi cantly, decreased expression of PC5/6 
decreased apoptotic activity and increased adhesion-
independent growth. PC5/6 may therefore be protective 
against local tumor burden. Studies evaluating invasive and 
metastatic potential are underway.
HEPATIC ARTERIAL NODAL 
METASTASES IN PANCREATIC CANCER: 
IS THIS THE NODE OF IMPORTANCE?
J. LaFemina, C. Correa-Gallego, J. F. Chou, M. Gonen, 
T. P. Kingham, R. P. DeMatteo, M. D’Angelica, 
W. R. Jarnagin and P. J. Allen
Memorial Sloan-Kettering Cancer Center, New York, NY
The hepatic artery lymph node (HALN) is frequently sampled 
during pancreaticoduodenectomy (PD). Available data 
suggest that survival with HALN metastases is similar to that 
of stage IV disease. The aim of this study was to describe 
the prognostic signifi cance of PDAC metastases to the 
HALN. Between January 2000–October 2010, 147 patients 
who had pathologic evaluation of the HALN after PD were 
identifi ed from a prospective database. Patients with R2 
resection were excluded. HALN was positive in 23 of 147 
patients (16%). Median follow up for survivors was 10 mo. 
There was no signifi cant difference in survival based on 
vascular invasion, perineural invasion, or margin status. In a 
multivariable model, positive HALN and tumor differentia-
tion predicted overall survival (OS). Poorly differentiated 
tumors exhibited a median survival of 14 mo, compared to 
26 and 41 mo for moderately and well differentiated tumors, 
respectively (P = 0.001). Median OS for patients with a posi-
tive HALN was 13 mo, signifi cantly less than 20 mo in those 
with a negative HALD (P = 0.02). Total lymph node ratio 
was signifi cantly associated with OS (P = 0.004). One unit 
increase of the node ratio increased the risk of death more 
than 4-fold [HR = 4.4, 95% CI: 1.619–12.060]. The hazard 
of death increased by a factor of 2.4 [95% CI: 1.23–4.48] for 
patients with positive HALN after adjusting for tumor dif-
ferentiation. In this study the presence of PDAC metastases 
to the HALN was an independent predictor of death after 
resection. HALN status may help identify high-risk patients 
who may be candidates for novel treatment strategies.
POSTOPERATIVE VENOUS 
THROMBOEMBOLISM FOLLOWING 
HEPATECTOMY: A NATIONWIDE 
ANALYSIS TO EXTEND THE CASE FOR 
ROUTINE PROPHYLAXIS
D. J. LaPar, D. M. Walters, T. W. Bauer, S. C. Kumer, 
R. B. Adams, K. L. Brayman and T. M. Schmitt
University Of Virginia, Charlottesville, VA
Objective: Recent guidelines suggest routine prophylaxis to 
prevent postoperative venous thromboembolism (VTE) fol-
lowing major operations. Despite published recommenda-
tions, the use of routine prophylaxis following hepatectomy 
varies. The purpose of this study was to examine the con-
temporary impact of postoperative VTE following hepatic 
resections within the United States.
Methods: A total of 3973 patients underwent hepatic resec-
tions within the ACS NSQIP (2005–2008). Patient character-
istics, operative features, and postoperative correlates of VTE 
were compared to identify risk factors for VTE and to assess 
its overall impact on postoperative morbidity and mortality.
Results: The overall incidence of postoperative VTE was 
2.4%. The distribution of hepatic resections included: partial 
lobectomy (58.9%), total right lobectomy (21.1%), total left 
lobectomy (10.1%) and trisegmentectomy (9.8%). Risk 
factors for postoperative VTE included older age, male 
gender, compromised functional status, degree of intraopera-
tive blood transfusion, preoperative albumin level (all p < 
0.05), and extent of hepatic resection (p = 0.004). VTE was 
associated with a higher incidence of other postoperative 
complications, including reintubation, prolonged ventilation, 
cardiac arrest, and reoperation (all p < 0.05). Operative mor-
tality was increased following VTE (6.5% vs. 2.4%, p = 
0.03), and patients with VTE has a 2-fold increase in hospital 
length of stay (12.0 vs. 6.0 days, p < 0.001).
Conclusions: Postoperative venous thromboembolism 
remains a signifi cant source of morbidity and mortality fol-
lowing hepatectomy in the United States. Postoperative VTE 
is more common following extended hepatic resections. 
Routine postoperative VTE prophylaxis should be consid-
ered to improve outcomes following hepatectomy. Further 
prospective trials are needed to determine optimal, cost-
effective anticoagulation strategies for these patients.
A SYSTEMATIC REVIEW OF SURGICAL 
MANAGEMENT OF NEUROENDOCRINE 
LIVER METASTASES
S. Y. Lee1,2, J. Y. Teo2, P. C. Cheow2 and L. L. Ooi1,2
1Department Of Surgical Oncology, National Cancer 
Centre, Singapore, Singapore; 2Department Of General 
Surgery, Singapore General Hospital, Singapore, 
Singapore
Introduction: Management of Neuroendocrine liver metas-
tases (NELM) is challenging. Almost 10% of all liver metas-
tases are neuroendocrine in origin. There is no fi rm consensus 
on the optimal treatment strategy for NELM.
Aims and material and methods: The aim is to collate the 
current information on the management of NELMand to 
formulate a sound management algorithm. A systematic 
search of the PubMed database for English articles was 
performed from 1995–2010.
Results: There are 22 case series with a total of 793 patients 
that has undergone surgery for NELM. The overall survival 
ranges from 46–86% at 5 years; 35–79% at 10 years and the 
median survival ranges from 52–123 months. After success-
ful cytoreductive surgery, the mean duration of symptom 
reduction is between 16–26 months and the 5-year recur-
rence/progression rate ranges from 59–76%. Liver transplan-
tation as a treatment for NELM, its 5-year survival rate was 
47%; 5-year disease free rate was 24%. Five studies evalu-
ated the effi cacy of a combination strategy reporting survival 
rate of ranging from 83% at 3 years to 50% at 10 years. To 
date, there is no level 1 evidence comparing surgery versus 
other liver-directed treatment options for NELM.
Conclusion: An aggressive surgical approach is recom-
mended as it leads to long-term survival and signifi cant long-
term palliation can be achieved. Additional liver directed 
procedures may be required or combined with surgery to 
achieve effectiveness for a good quality of life. A multidis-
ciplinary approach should be established as the platform for 
decision making.
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SPONTANEOUS RUPTURE OF 
PYOGENIC LIVER ABSCESS – AN ASIAN 
PERSPECTIVE
S. Y. Lee1,2, C. Chia2 and Y. M. Tan1
1Department Of Surgical Oncology, National Cancer 
Centre, Singapore, Singapore; 2Department Of General 
Surgery, Singapore General Hospital, Singapore, 
Singapore
Introduction: Pyogenic liver abscess (PLA) is a potentially 
fatal intra-abdominal infection, despite advancements in diag-
nostics, antibiotics and introduction of minimally invasive 
techniques for treatment, PLA remains a challenging condi-
tion. The proportion of PLA that rupture is about 5–15%. We 
aim to determine the clinical and radiological risk factors that 
may help us to identify patients at risk of rupture so that these 
patients can be identifi ed early and treated more aggressively 
to minimize complications and mortality.
Methods: A multi-centre prospective study was performed 
identify 109 patients with PLA treated between 1999 and 
2005. The clinical data, clinical progress, operative informa-
tion and radiological reports of these patients were reviewed 
to identify risk factors.
Results: 109 patients with pyogenic liver abscesses were 
treated during the study period. 12.8% had spontaneous 
rupture of their liver abscesses. The overall mortality is 
4.6%. There was no signifi cant difference between the 2 
groups in terms of age, sex, incidence of diabetes mellitus 
and hematological investigations. The PLA on the left side 
has a signifi cantly higher chance of rupture (p = 0.033). 
There was no difference in size, number and loculation of 
the abscesses. There was also no difference between the 2 
groups in terms of mortality, intensive care unit stay and 
complications.
Conclusion: The assumption that patients with ruptured 
liver abscesses have a poorer outcome may not be accurate. 
We did not fi nd a signifi cant difference in outcome between 
the 2 groups. The only signifi cant difference is that abscesses 
on the left have a higher incidence of rupture.
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Table. Comparison of the liver abscess characteristics in the 2 groups of patients
Size (mean, cm) No rupture (n = 95)
7.77
Rupture (n = 14)
8.87
p value
0.23
Location
 Right 70 (73.7%) 6 (42.9%) 0.033 
 Left 18 (18.9%) 7 (50.0%)
 Bilateral 7 (7.4%) 1 (7.1%)
Loculations
 No 19 (20%) 4 (28.6%) 0.488
 Yes 76 (80%) 10 (71.4%)
Number of abcesses
 Solitary 75 (78.9%) 13 (80.7%) 0.297
 Multiple 20 (21.1%) 1 (19.3%)
Gas forming
 Yes 12 (12.6%) 3 (13.8%) 0.151
 No 83 (87.4%) 11 (86.2%)
DOES RADICAL RESECTION CURE 
INCIDENTAL GALLBLADDER CANCER? 
A CRITICAL VIEW
J. Lendoire, L. P. Gil, G. A. Raffi n, F. Duek, C. M. Quarin, 
V. B. Garay, M. Rivaldi and O. C. Imventarza
Hospital Cosme Argerich, Liver And Transplant Division, 
Buenos Aires, Argentina
Background: Surgical management of gallbladder cancer 
(GC) is still controversial. OBJECTIVE: to analyze the 
results of liver resection in patients with incidental GC and 
determine factors associated with long term survival.
Methods: Retrospective analysis of patients referred with 
diagnosis of incidental GC between June 1999–June 2010 
was performed. Incidental (I) tumors were included. Data 
covering demographic features, clinical characteristics, local 
pathological stage, surgical procedure, morbidity, histologi-
cal features and factors for long term survival were 
analyzed.
Results: 24 patients with IGC were resected: 20 females 
(83.3%). Median age 57.4 years (range 38–78). Local patho-
logical stage T1 (1), T2 (12), T3 (11). All treated by: Resection 
of segments 4b-5 and lymphadenectomy. Histological exami-
nation revealed microscopic tumor involvement in 29%, posi-
tive nodes in 12.5% and peritoneal invasion in 4.1% (T2 16%/
T3 72% p 0.01). All patients with residual disease in the his-
topathological analysis developed recurrence and died in a 
term of 15 months of follow-up. Overall 5-year survival was 
53% (stage AJCC 7thed. II 90%, IIIA 28%, IIIB and VI 0%) 
and was signifi cantly associated with T stage (p < 0.001), 
TNM stage (p < 0.001), and residual tumor in histopathologi-
cal examination of the resected liver (p < 0.001).
Conclusions: Effi cacy of radical resection, the recom-
mended treatment for incidental gallbladder cancer depends 
on the extent of the disease found at the initial operation. 
Patients with an R0 resection and residual tumor in the his-
topathological analysis didn’t show any benefi t in survival. 
T stage, positive nodes and parenchymal invasion correlated 
with disease free survival in the present study.
DISSECTING SURVIVAL FOR RESECTED 
PANCREATIC DUCTAL 
ADENOCARCINOMA (PDAC) IN THE 
CONTEMPORARY ERA
R. S. Lewis1, J. A. Drebin1, M. P. Callery2, D. L. Fraker1, 
T. S. Kent2, J. L. Gates1 and C. M. Vollmer1
1The University Of Pennsylvania School Of Medicine, 
Philadelphia, PA; 2Beth Israel Deaconess Medical Center, 
Harvard Medical School, Boston, MA
Background: Survival following resected PDAC appears to 
be improving compared to historical benchmarks. Yet, 
despite advancements in patient selection, surgical tech-
nique, and adjuvant therapies, prognosis remains disappoint-
ing. We analyze a contemporary experience to better 
understand current clinical dilemmas.
Methods: Kaplan-Meier survival analysis was conducted 
for all pancreatic resections for PDAC from two pancreatic 
surgical specialty programs from 2001–2011.
Results: Five surgeons performed 387 resections with 
30/90-day mortalities of 0.5%/1.6% and median LOS of 8 d. 
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The mean age was 66.8 yrs (24% ≥75 yrs). Overall, median 
and actuarial 5-yr survivals were 20.9 months and 24%. 
Three-fourths of patients survived the fi rst year. With an 
initial intention-to-treat for cure, patients were categorized 
by ultimate treatment courses which demonstrate marked 
survival variation (Table). The majority of patients (71%) 
received adjuvant therapy (predominately gemcitabine-
based chemoradiation) and they had an improved median 
survival by 10 months (p < 0.001). Downstaging locally-
advanced patients had equivalent survival from diagnosis 
compared to resected Stage I/II patients who received adju-
vant therapy. Median and 5-yr survivals for total pancreatec-
tomy (40% performed for IPMN) were 32.2 mo/45%. For 98 
“favorable biology” cases (LN-/R0) they were 31.8 m/36%. 
Patients with IPMN-associated tumors (7% overall) had 
equivalent survival to others. Patients who suffered major 
complications (Clavien IIIb-V; 7%) initiated adjuvant 
therapy less frequently (23%) – equating to a poor median 
survival of 9.8 mo, while minor/total complications had no 
impact. Conditional survival escalates over time.
Conclusion: This modern, multi-institutional experience 
with resected PDAC shows improving short-term morbidity 
and mortality rates with encouraging survival for certain 
subgroups of PDAC patients.
IL-10 AND PD1 MEDIATE T CELL 
SUPPRESSION IN JAUNDICED ANIMALS 
WITH OPPOSING EFFECTS ON 
INFLAMMATORY CYTOKINE 
PRODUCTION
L. A. Licata1, C. Nguyen 1, S. Naheed1, N. J. Espat1 and 
S. Katz1,2
1Roger Williams Medical Center, Providence, RI; 
2Boston University, Boston, MA
Introduction: Bile duct ligation (BDL) results in a signifi -
cant decrease in liver T cell (LTC) proliferation associated 
with an expansion of Treg. As PD-1 and IL10 have been 
shown to affect Treg and modulate infl ammatory responses, 
we examined the effects of PD-1 and IL10 on LTC function 
and infl ammatory cytokine production following BDL.
Methods: BDL or sham laparotomy (SL) were performed 
in wild type C57Bl/6 (WT), PD-1 −/− and IL10 −/− mice. 
LTC (Thy 1.2+) were purifi ed on day 7 and stimulated with 
dendritic cells (DC). LTC were labeled with a green cyto-
plasmic dye (CFSE) and cell division determined by fl ow 
cytometry. Cytokine measurements were performed by cyto-
metric bead array.
Results: LTC from PD1 −/− mice had a 110% increase in 
proliferation compared to LTC from WT mice following 
BDL (p = 0.001), despite a nearly 2-fold increase in the Treg 
population (p = 0.04). While loss of PD-1 improved LTC 
function, production of TNFa from PD-1 −/− mice was mark-
edly diminished (572.9 vs. 387.4 pg/mL, p < 0.001). 
Similarly, LTC purifi ed from IL10 −/− mice also had a sig-
nifi cant increase (74%) in division following BDL compared 
to WT (p = 0.009). Unlike the PD-1 −/− LTC, IL10 −/− LTC 
produced more TNFα (493.8 vs. 384.4 pg/mL, p < 0.001).
Conclusion: Loss of IL10 in the setting of obstructive jaun-
dice restores LTC function but results in increased infl am-
matory cytokine production. Targeting the PD-1 pathway 
may represent a means by which intrahepatic immunity can 
be restored in the setting of obstructive jaundice while limit-
ing tissue damage.
PALLIATIVE SURGERY IN 
UNRESECTABLE PERIAMPULLARY 
CANCER: DOES OPERATIVE BYPASS 
DECREASE POSTOPERATIVE 
PROCEDURES AND HOSPITAL DAYS?
J. M. Lyons, A. M. Karkar, C. Correa-Gallego, 
M. I. D’Angelica, R. P. DeMatteo, T. P. Kingham, 
W. R. Jarnagin, M. F. Brennan and P. J. Allen
Memorial Sloan-Kettering Cancer Center, New York, NY
With improvements in endoluminal stenting, optimal surgi-
cal management for asymptomatic patients found to have 
unresectable periampullary cancer at exploration is unknown. 
We reviewed the records of patients who underwent non-
therapeutic laparotomy for periampullary carcinoma from 
2000–2009 and who were followed at our institution until 
death. We identifi ed 157 patients who had laparotomy only 
(21%), gastric bypass (11%), biliary bypass (30%), or double 
bypass (38%). There were 44 (28%) complications and 3 
(2%) perioperative deaths (1 after biliary, 2 after double 
bypass). Patients having laparotomy only were discharged 
from hospital sooner than those having double bypass 
(median LOS = 5 vs. 8 days, p < 0.05), but the total number 
of days patients spent in hospital prior to death was similar 
regardless of what was done at initial operation (median 
days: laparotomy = 16; gastric = 12; biliary = 18; double = 
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16, p = NS). Seventy-six patients needed surgical, endo-
scopic, or radiologic interventions (n = 216) following opera-
tion. Patients having gastric or double bypass required fewer 
postoperative duodenal stents while those having biliary and 
double bypass required fewer postoperative biliary stents. 
The proportion of patients requiring interventions was 
similar regardless of operative procedure: 58% following 
laparotomy, 41% following gastric, 53% following biliary, 
42% following double bypass. In this study, gastric, biliary, 
or double bypass in unresectable patients was not associated 
with fewer invasive procedures following non-therapeutic 
laparotomy, and did not appear to reduce the total number of 
days these patients spend in hospital prior to death.
Laparotomy Only Gastric Bypass Biliary Bypass Double Bypass
N 33 17 47 60
LOS (days) 5 6 7 8
Total Hospital Days 16 12 18 16
Post Op Interventions 19 (57%) 4 (41%) 25 (53%) 25 (42%)
LAPAROSCOPIC LEFT 
HEMIHEPATECTOMY FOR LEFT-SIDED 
HILAR CHOLANGIOCARCINOMA WITH 
BILIARY RECONSTRUCTION BY THE 
HYBRID METHOD
M. A. Machado, M. Mochizuki, R. C. Surjan and 
F. F. Makdissi
University Of Sao Paulo, Sao Paulo, SP, Brazil
Background: Surgical resection is the only curative treat-
ment for hilar cholangiocarcinoma. Laparoscopic hepatec-
tomy has been used to treat several types of liver neoplasms. 
However, technical issues have limited the adoption of lapa-
roscopy for the treatment of hilar cholangiocarcinoma. So 
far, there is only one report of minimally invasive procedure 
for hilar cholangiocarcinoma in the literature.
Aim: This video shows a laparoscopic resection of hilar 
holangiocarcinoma.
Methods: A 43-year-old female with progressive jaundice 
due to left-sidedhilar cholangiocarcinoma was referred for 
treatment. Based on our previous experience with advanced 
laparoscopic liver resections, including central and extended 
resections, we decided to perform a totally laparoscopic left 
hemihepatectomy with radical lymphadenectomy and resec-
tion of extrahepatic bile ducts. Biliary reconstruction was 
performed using the hybrid method.
Results: Operative time was 300 minutes with minimum 
blood loss and no need for blood transfusion. Recovery was 
uneventful and the patient was discharged on the 7th post-
operative day. Pathology revealed a well-differentiated chol-
angiocarcinoma with negative lymph nodes and clear surgical 
margins. The patient is well with no signs of the disease 10 
months after the procedure. Conclusion, laparoscopic left 
hemihepatectomy extended to segment 1 with extensive 
lymphadenectomy is safe and feasible in selected patients 
and by surgeons with expertise in both liver surgery and 
minimally invasive techniques. The use of hybrid method 
may be needed for biliary reconstruction, especially in cases 
with a very small caliber bile duct. Further studies are still 
needed to confi rm the benefi t of this approach over conven-
tional surgery for hilar cholangiocarcinoma.
CENTER VOLUME AND RESOURCE 
CONSUMPTION IN LIVER 
TRANSPLANTATION
C. W. Macomber, J. J. Shaw, H. Santry, R. F. Saidi, 
N. Jabbour, A. Bozorgzadeh, J. F. Tseng and S. A. Shah
Surgical Outcomes Analysis & Research, UMass Medical 
School, Worcester, MA
Using SRTR/UNOS data, we have previously shown that 
increased liver transplant center volume improves graft and 
patient survival. In the current era of health care reform and 
pay for performance, the effects of center volume on quality, 
utilization and cost are unknown.
Methods: Using the University Healthcare Consortium 
(UHC) database (2009–2010), we identifi ed 52 liver trans-
plant centers that were organized into tertiles based on annual 
center case volume and stratifi ed by the UHC severity of 
illness score. Utilization endpoints included length of stay 
(LOS), ICU days, direct cost and in hospital mortality.
Results: 5935 transplants were performed over the two-year 
period. Center volumes tertiles were low volume (LVC 0–36 
cases), middle volume (MVC 38–71 cases), high volume 
(HVC 72–165 cases). Overall in-hospital mortality was 3.0% 
and there was no difference between tertiles. HVC had a 
lower LOS then LVC (10.5 vs 13.1 days, p = 0.02) as well 
as shorter ICU stay when compared to LVC and MVC (6.92 
vs 9.03 vs. 8.29 days; p < 0.05). Direct cost was also lower 
in HVC compared to LVC and MVC ($122K vs $141.8K 
and $149.1K, p < 0.05); this effect persisted when adjusted 
for severity of illness.
Conclusions: Based on this novel center based cohort of the 
UHC database, increased center volume not only results in 
improved long-term post-liver transplant outcomes but also 
results in more effi cient use of hospital resources thereby 
lowering cost. Better understanding of these mechanisms can 
lead to informed decisions and optimization of the pay for 
performance model in liver transplantation.
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Table 1. Outcomes by transplant center volume tertiles
Center Volume
High Medium Low p-value
Length of Stay (Median) 10.6 11.4 13.1 *
Mortality (Mean, %) 2.9 3.3 3.4 >0.05
Mean ICU Days (Median) 6.9 9 8.3 <0.05
Direct Costs (Mean) $122.70K $149.10K $141.80K <0.05
*Only High-Low Volume p < 0.05.
UTILIZATION AND OUTCOMES OF 
PATIENTS WITH COLORECTAL LIVER 
METASTASES IN THE MEDICARE 
POPULATION
C. W. Macomber, S. Ng, Y. Li, K. Alavi, H. Santry, 
J. F. Tseng and S. A. Shah
Surgical Outcomes Analysis & Research, UMass Medical 
School, Worcester, MA
Aggressive treatment of colorectal liver metastases (CRLM) 
after colectomy is increasing in the last two decades with 
reports of improved survival. Multiple treatment options are 
available for CRLM but their use and utility remains 
unknown.
Methods: Using SEER-Medicare linked database (1991–
2005), we identifi ed 7131 patients who had undergone col-
ectomy with synchronous or metachronous CRLM. 
Demographic, clinical and tumor factors were examined as 
determinants of therapy. Treatment options consisted of liver 
surgery (resection, ablation) or chemotherapy. Univariate 
and multivariate analyses were performed to determine pre-
dictors of overall survival after colectomy.
Results: 52% of patients were female, 85.9% were White 
and 89.4% were treated living in urban areas. 635 patients 
(8.9%) underwent liver directed surgery defi ned as either a 
liver resection (n = 495), ablation (n = 216) or both (n = 76) 
for CRLM. 53% (n = 3789) of patients underwent chemo-
therapy after colectomy. Of the 635 patients who received 
liver surgery, 62.7% received chemotherapy within 6 months 
of liver surgery. There was a survival advantage to receiving 
liver surgery (Figure) or chemotherapy in patients with 
CRLM (p < 0.001). Adjusted overall survival after colectomy 
was greatest in Asian/Other race; poor prognostic indicators 
included increasing comorbidities, advanced age and devel-
opment of complications during liver surgery.
Conclusion: In the Medicare population, patients with 
CRLM who receive liver directed therapy such as resection, 
ablation or chemotherapy experience a substantial survival 
advantage; despite this very few patients received directed 
therapy for their metastasis. Barriers to treatment and its 
underutilization must be identifi ed to improve survival in 
elderly patients diagnosed with CRLM after colectomy.
ISOLATED HEPATIC PERFUSION (IHP) 
FOR ISOLATED UNRESECTABLE 
COLORECTAL LIVER METASTASES 
(CRCLM)
D. Magge1, H. J. Zeh2, D. Lenzner1, J. Young2, 
J. Pingpank2, H. Choudry2, M. Holtzman2, D. Bartlett2 and 
A. Zureikat2
1University Of Pittsburgh Medical Center, Pittsburgh, PA; 
2UPMC Surgical Oncology, Pittsburgh, PA
Introduction: Locoregional therapy via IHP may prolong 
survival in treatment-resistant isolated unresectable CRCLM.
Methods: Aretrospective review of patients undergoing IHP 
for isolated unresectable LM. All CRC patients had concomi-
tant placement of hepatic arterial infusion pumps (HAI) for 
post IHP FUdR administration. Perioperative events, toxici-
ties, response, and overall survival were evaluated.
Results: Between Nov 2003–June 2011, 90 patients under-
went IHP (CRC = 53, non CRC = 37). In the CRC subgroup, 
IHP employed melphalan n = 30, oxaliplatin = 11, 5FU+ 
oxaliplatin = 11, mitomycin C = 1. Median age was 53; 
(M : F 28:27). Median percentage of liver replaced by 
tumor = 30% (range 5%-80%) and 46 patients (87%) had 
prior chemotherapy. Median operative time: 435 mins, 
median EBL: 600 mL. There were 3 perioperative deaths. 
Grade 1/2 and 3/4 toxicities were 100% and 62% respec-
tively. 80% received postoperative HAI-FUdR. In 42 evalu-
able CRC pts, overall response was 69% (n = 29) (PR = 28, 
CR = 1) with SD 19% (n = 8) and PD 12% (n = 5). Median 
OS (from date of IHP) was 23 months (95% CI: 21–32 
months). IHP agent was a signifi cant independent predictor 
of OS (p = 0.024); 5FU+ oxaliplatin (OS = 36 months 95% 
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CI 32 months – not reached) versus melphalan (21 months 
95% CI: 10–25 months p = 0.016) and oxaliplatin (23 
months, 95% CI: 4–31 months p = 0.031). A trend towards 
improved OS was observed with increasing number of cycles 
of FUdR (p = 0.09).
Conclusion: IHP is an effective therapy for isolated unresect-
able treatment-resistant CRCLM. Optimal perfusion agents and 
patient selection criteria need to be further characterized.
THREE-DIMENSIONAL (3-D) CT 
VIRTUAL SIMULATION AND SURGICAL 
PLANNING FOR MINIMALLY INVASIVE 
HEPATIC RESECTION
A. V. Maker1,3 and V. K. Maker2,3
1University Of Illinois At Chicago, Department Of Surgery, 
Division Of Surgical Oncology, Chicago, IL; 2University 
Of Illinois At Chicago, Department Of Surgery, Chicago, 
IL; 3Creticos Cancer Center At Advocate Illinois Masonic 
Medical Center, Chicago, IL
We have begun utilizing three-dimensional computed tomog-
raphy (3-D CT) technology to augment the preoperative 
workup and simulate surgery in GI/HPB malignancies. Here, 
as a proof of concept, we applied and tested this technology 
on the relatively straightforward management of giant 
hepatic cysts to simulate laparoscopic exploration of the cyst 
wall. Using a 3-D workstation attached to the radiology 
server in our offi ce, images are effi ciently constructed that 
simultaneously identify the vascular anatomy and the cyst-
parenchymal interface. As the normal anatomic relationships 
are often displaced/compressed in large cysts, 3-D images 
that visualize both the portal and hepatic venous systems are 
created to aid in operative planning and identify structures 
in attenuated liver parenchyma. Furthermore, these images 
easily identify areas where cyst biopsy or thermal ablation 
would be dangerous. As a surgical simulation tool, the 3-D 
CT reconstructions allow the surgeon to see the cyst from 
the skin to the hepatic veins with transparency which aids in 
laparoscopic port placement. Simulating the laparoscopic 
camera, the lining of the cyst wall can be examined for evi-
dence of malignancy with the ability to rotate the cyst in all 
directions, thereby providing a virtual exploration of the cyst. 
These points will be demonstrated with 3-D CT still and 
dynamic images and corresponding laparoscopic images 
from the same patient. Applications include using this tech-
nology for simulated operative planning of hepatopancreati-
cobiliary tumors in diffi cult locations, and dynamic 3-D 
images of such cases will be shown to demonstrate the func-
tionality and potential utility of this technology.
FACTORS ASSOCIATED WITH 
READMISSION FOLLOWING COMPLEX 
HEPATO-PANCREATO-BILIARY 
OPERATIONS
J. C. Mansour, O. Jaffer, A. C. Yopp, R. R. Sharma, 
C. McGilvray, G. C. Balch and R. E. Schwarz
University Of Texas Southwestern, Dallas, TX
Objective: To identify factors associated with hospital read-
mission following complex hepato-pancreato-biliary (HPB) 
operations from a prospectively maintained database.
Methods: We identifi ed patients undergoing major resective 
hepatic, pancreatic, or biliary operations between 2008 and 
2011. Patients were reviewed for demographic, tumor-
related, and operative factors and their association with any 
hospital readmission within 30 or 90 days of discharge. 
Patients without 90 days of followup were excluded. Chi-
square (categorical), ANOVA (continuous) and Mann-
Whitney (continuous) statistical analyses were performed.
Results: From 729 major gastrointestinal operations, 246 
patients were identifi ed undergoing major liver (n = 145, 
59%), pancreas (n = 93, 38%) or biliary resections (n = 8, 
3%). Preoperative intent was curative for 238 (97%) patients, 
and postoperative intent was curative for 222 (90%) patients. 
The incidence of Clavien Grade I-V complications was 53%, 
with postoperative mortality 3.7%. The rates of readmission 
within 30 and 90 days were 17% and 24%, respectively. 
Readmission rates were related to preoperative intent (cura-
tive versus non-curative, 23% vs. 66%, p < 0.04), postopera-
tive intent (curative versus non-curative, 22% vs. 50%, 
p < 0.01), the occurrence of a postoperative complication 
(non-complicated versus complicated, 13% vs. 35%, 
p < 0.001), and increased operative time (no readmission 
versus readmission, median: 341 vs. 392 minutes, p < 0.02). 
Factors not associated with readmission included patient age, 
surgeon, pancreatobiliary procedure, length of stay, esti-
mated blood loss, or POSSUM score.
Conclusion: Hospital readmission is a common event fol-
lowing complex HPB operations. Factors associated with 
increased risk of readmission include non-curative operative 
intent, prolonged operative times, and the occurrence of a 
postoperative complication.
INITIAL EXPERIENCE WITH A 
COMPREHENSIVE TISSUE BIOBANKING 
PROGRAM FOCUSING ON COMPLEX 
GASTROINTESTINAL CANCER 
RESECTIONS
J. C. Mansour, C. M. Lewis, G. C. Balch, A. C. Yopp, 
C. McGilvray, R. R. Sharma and R. E. Schwarz
University Of Texas Southwestern, Dallas, TX
Objective: To describe factors associated with consistent 
tissue sampling for gastrointestinal oncology patients during 
the initial phase of a single institution IRB-approved tissue 
biobanking program.
Methods: We identifi ed all patients undergoing operative 
procedures with a hepato-pancreato-biliary (HPB), esopha-
gogastric, or colorectal/anal primary tumor diagnosis during 
the fi rst year of a comprehensive tissue biobanking program 
from prospectively collected clinical and tissue collection 
databases. Operations performed to address hepatic metasta-
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ses were categorized as hepatic operations. Patient-related, 
physician-related, and tumor-related factors were examined 
to identify associations with frequency of tissue sampling.
Results: For a one-year period from 2010 to 2011, 285 cases 
were performed for patients with a HPB, esophagogastric, or 
colorectal/anal diagnosis. Benign or malignant tissue samples 
were collected for 161 (57%) patients. Tumor or blood were 
sampled for 124 (44%) and 166 (58%) patients respectively. 
Patient primary diagnosis was associated with the likelihood 
of tissue sampling (see Table). Operations performed with 
preoperative curative intent were more likely to have tissue 
sampling than non-curative operations (64% versus 33%, 
p < 0.001). Postoperative curative intent had a similar posi-
tive association with tissue, tumor, or blood sampling (63% 
versus 43%, p = 0.002). Other factors associated with fre-
quent sampling included surgeon (p < 0.001) and hospital 
setting (p < 0.001). Length of operation was not associated 
with differences in tissue or blood sampling.
Conclusions: Sample collection for a comprehensive tissue 
biobanking program is associated with preoperative and 
postoperative surgical intent, primary diagnosis, and hospital 
setting. Clearly, the role of the surgeon in the success of a 
comprehensive tissue collection effort is essential.
Primary diagnosis Number 
of cases
Any tissue sampled
(% of total diagnosis)
Tumor sampled
(% of total diagnosis)
Blood sampled
(% of total diagnosis)
Periampullary/pancreas 54 36 (67%) 25 (46%) 38 (70%)
Hepatic 65 42 (65) 41 (63) 43 (66)
Extrahepatic bile duct 26 11 (42) 5 (19) 11 (42)
Esophagogastric 64 43 (67) 33 (52) 44 (69)
Colorectal/anal 76 29 (38) 20 (26) 30 (40)
p-value = 0.001 < 0.001 < 0.001
LYMPHOEPITHELIAL CYSTS OF THE 
PANCREAS: A MANAGEMENT DILEMMA
J. Martin2, J. K. Roberts2, G. Morris-Stiff2, G. A. Falk1, 
D. Joyce1, M. Sheridan3, R. M. Walsh1 and A. M. Smith2
1Department Of General Surgery, Section Of Surgical 
Oncology/HPB, Cleveland, Ohio; 2Department Of 
Pancreatic Surgery, Leeds, West Yorkshire, United 
Kingdom; 3Department Of Radiology, Leeds, West 
Yorkshire, United Kingdom
Background: Pancreatic lymphoepithelial cysts are rare, 
benign lesions and as such they are often an unexpected 
histopathological fi nding following excision of a cystic 
lesion.
Aims: To review the experience in management of lympho-
epithelial cysts in order determine if a specifi c profi le exists 
that may allow their pre-operative diagnosis.
Methods: The histopathology databases of 2 large volume 
pancreatic centers were searched to identify all cases of lym-
phoepithelial cyst undergoing resection. Notes were reviewed 
to determine patient demographic details, mode of presenta-
tion, investigations, treatment and outcome.
Results: Six male patients were identifi ed with a median age 
of 60.5 years. Four were asymptomatic fi ndings, and 2 
reported abdominal pain. All patients underwent CT scans, 
3 of 6 MRI and 5 of 6 EUS. Five patients had lesions in the 
tail and one in the body of the pancreas. 5 of 6 had single 
cysts and 1 had 2 closely approximated cysts. The median 
cyst size was 5 cm. There were no characteristic features 
identifi ed on cross-sectional imaging, EUS or cyst fl uid 
analysis. The pre-operative diagnosis was mucinous cystic 
neoplasm in all cases. All patients were treated by means of 
distal pancreatectomy and splenectomy at which point the 
diagnosis was established.
Conclusions: Pancreatic lymphoepithelial cysts appear to 
be more common in males in the 6th and 7th decades of life, 
are usually large, single and asymptomatic, being located in 
the tail of the pancreas. However, the lack of diagnostic 
radiological features means that they are likely to continue 
to be a histopathological diagnosis.
OBESITY PORTENDS AN INCREASED 
MORBIDITY, ABBREVIATED SURVIVAL 
AND EARLY RECURRENCE FOLLOWING 
OLT FOR HEPATOCELLULAR 
CARCINOMA
A. Mathur1, J. P. Leone1,3, E. S. Franco1,3, 
H. Osman-Mohamed1,3, H. Rojas3, N. Kemmer4, 
G. W. Neff2, A. S. Rosemurgy5 and A. E. Alsina1,3
1Department Of Surgery, University Of South Florida, 
Tampa, FL; 2Department Of Hepatology, Tampa General 
Hospital, Tampa, FL; 3Transplantation And Transplant 
Surgery, Tampa General Hospital, Tampa, FL; 
4Department Of Digestive Disease, University Of 
Cincinnati, Cincinnati, OH; 5Tampa General Hospital, 
Tampa, FL
Introduction: Obesity effects 1.1 billion people worldwide 
estimated. It results in increased morbidity and mortality 
from major abdominal surgeries like pancreatoduodenec-
tomy. Moreover, obesity has been associated with poor 
oncologic outcomes following pancreatoduodenectomy for 
pancreatic cancer. However, there is a paucity of evidence 
evaluating the impact of obesity on post-operative complica-
tions, oncologic outcome and survival for patients with hepa-
tocellular carcinoma (HCC) undergoing orthotopic liver 
transplant (OLT). Therefore, we hypothesize that obesity 
would result in increased complications, and inferior onco-
logic outcomes and survival for patients with HCC undergo-
ing OLT.
Methods: From a database of over 1000 patients who had 
undergone OLT from 1996–2008, 132 patients with a diag-
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nosis of HCC were identifi ed. Age, sex, body mass index 
(BMI), pre-OLT MELD and perioperative parameters includ-
ing ischemia time, length of stay (LOS), complications, 
recurrence, and survival were obtained. Complications were 
grouped according to the Clavien-Dindo grading (I–V). 
Briefl y, Grade III, IV, and V represent serious complications 
requiring surgical, endoscopic or radiologic intervention or 
organ dysfunction or death.
Results: Median age was 54 and the majority of the patients 
(91%) were male and the two groups of patients did not differ 
in this regard.
Conclusions: For patients with HCC undergoing OLT, 
obesity results in an increased risk of life-threatening com-
plications and shorter survival. Moreover, obesity potentiates 
early recurrence of HCC, this represents a novel fi nding not 
previously reported in the literature. Therefore, we conclude 
that BMI is an important prognostic marker that portends 
an abbreviated survival and an inferior oncologic outcome 
following OLT for HCC.
BMI Pre-OLT 
MELD Score
Tumor 
Size(cm)
LOS 
(days)
Complications 
% (Grade III, 
IV, & V)
% Patients with 
Recurrence
Time to 
Recurrence 
(months)
Median Survival 
(months)
< 25
(n = 39)
16 ± 9 3.0 ± 2 11 ± 7 38  8 25 ± 12 64
≥25
(n = 93)
17 ± 7 2.8 ± 1 14 ± 12 58* 15 10 ± 2* 44*
≥30
(n = 47)
18 ± 7 2.7 ± 1 13 ± 8* 70* 15  8 ± 5* 46*
*p < 0.05 vs BMI < 25.
X RESULTS OF SIMULTAENOUS LIVER-
KIDNEY TRANSPLANT: SINGLE CENTER 
REVIEW
E. C. Maynard, W. Chapman, S. Shenoy, N. Vachharajanin, 
M. Henn, J. Lowell, J. Wellen, Y. Lin and M. M. Doyle
Washington University Department Of Abdominal 
Transplantation, St. Louis, MO
Purpose: The aim of this study was to compare simultane-
ous liver-kidney transplantation (SLKT) to liver transplanta-
tion alone (LTA) for dialysis dependent patients.
Methods: A retrospective review of dialysis dependent 
patients undergoing liver transplant between 2000 and 2011 
was performed. Patients receiving SLKT were compared to 
those receiving LTA. Log-rank test was used to compare 
overall graft and patient survival.
Results: Of 823 liver transplants 80 patients were on dialy-
sis pre-transplant; 35 had SLKT vs. 45 LTA. Age, race, BMI, 
and creatinine at time of transplant, were similar between 
groups. LTA patients had a higher mean MELD than SLKT 
(p < 0.0001). Intraoperative blood loss, transfusion require-
ment, hospital and ICU stay, and re-exploration rates, were 
similar among the two groups. Patients undergoing SLKT 
had better graft survival than LTA at 1 and 5 years (91% and 
82% vs 65% and 59% respectively). SLKT also had better 
overall survival at 1 and 5 (94% and 85% versus 68% and 
65% respectively). Five patients who had SLKT required 
dialysis after transplant versus 24 patients receiving LTA 
(p < 0.0004). Eight patients in the LTA group remained dialy-
sis dependent vs 1 in SLKT group.
Conclusion: Patients with ESLD on dialysis who undergo 
liver transplant have better overall and graft survival when 
SLKT is performed compared to LTA. In properly selected 
patients SLKT is an appropriate utilization of a scarce 
resource. Better prognostic indicators to determine which 
patients will benefi t from SLKT are still needed.
POST NECROTIC PANCREATIC 
PSEUDOCYST. LAPAROSCOPIC 
TECHNIQUES
O. Mazza, L. Yazde, R. Sanchez Clariup, J. Salceda and 
J. Pekolj
Hospital Italiano De Buenos Aires, General Surgery 
Service And HPB Surgery Section, Bueno Aires, Argentina
Objective: To show 3 techniques used by laparoscopic 
surgery in acute pancreatic postnecrotic pseudocyst.
Methods: We present a cystojejunostomy, double cystojeju-
nostomy and cystogastrostomy. The choice is based on intra-
operative ultrasound. Complete necrosectomy was achieved. 
Technical procedures are described.
Results: The postoperative period was uneventful. Patients 
were discharged after 3–5 days. No recurrences in follow-up 
(2–8 years).
COMPUTED TOMOGRAPHY 
ENHANCEMENT AND PATIENT 
CHARACTERISTICS AS PREDICTORS OF 
COMPLICATIONS AFTER 
PANCREATICODUODENECTOMY
J. C. McAuliffe, K. A. Parks, S. McNeal, D. E. Morgan 
and J. D. Christein
University Of Alabama At Birmingham, Birmingham, AL
Background: Obesity correlates with morbidity after gas-
trointestinal operations and more specifi cally pancreatico-
duodenectomy (PD). A Hounsfi eld Unit (HU), applied to 
computed tomography (CT), measures tissue density. The 
purpose is to determine whether lower HU score, which 
refers to less dense tissue and a higher degree of steatosis, 
predicts complications.
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Methods: Patients undergoing PD from 2005–2010 were 
analyzed according to NSQIP risk, the Clavien complication, 
and the International Study Group on Pancreatic Fistula (PF) 
classifi cation systems. Noncontrast Computed Tomography 
(CT) Hounsefi eld units (HU) of viscera from a representative 
sample of patients were measured by a blinded assessor. 
Univariate and multivariate analyses were performed.
Results: Three hundred thirty-three patients underwent PD 
for malignant (57%) and benign disease. Mean blood loss 
(EBL) was 340 mL, 19% underwent a transfusion, and 
median stay was 8 days. Overall complication and PF rate 
was 66% and 20%, respectively. Patients with BMI > 25 had 
a higher rate of PF (32%, p < 0.01) as well as any complica-
tion (73%, p < 0.01). Patients were more likely to develop 
any complication as HU decrease for pancreas (p = 0.04), 
muscle (p < 0.01), spleen (p < 0.01), and liver (p < 0.01). 
Multivariate analysis of CT measurements for muscle (p = 
0.02), liver (p = 0.04), and spleen (p < 0.05) remained inde-
pendent predictors of complications when adjusting for BMI, 
age, gender, EBL, and transfusion (Table).
Conclusion: Post-operative complications remain prevalent 
and imaging characteristics are independent predictors of mor-
bidity after PD. A higher degree of steatosis of tissues corre-
lates with complications and surgeons should consider CT 
characteristics as adjunctive predictors along with patient 
factors when discussing morbidity with patients regarding PD.
Fistula Clavien Class
No Yes No Yes
Overall 80% 20% p-value 34% 66% p-value
CT (noncontrast HU mean)
 Pancreas 28.1 29.8 0.58 31.8 26.6 0.04
 Spleen 43.8 40.5 0.12 46.0 41.0 <0.01
 Muscle 41.9 37.5 0.09 45.5 38.0 <0.01
 Liver 50.0 48.5 0.57 53.6 47.0 <0.01
Demographics/Other
 Age ≥ 75 years 80.8% 19.2% 0.40 32.1% 67.9% 0.93
 Female 67.1% 32.9% <0.01 32.9% 67.1% 0.29
 BM I≥ 25 37.6% 32.4% 0.01 26.9% 73.1% 0.01
 EBL ≥ 250 74.3% 25.7% 0.68 26.4% 73.6% <0.01
 Transfusion 85.2% 14.8% 0.29  4% 96.0% <0.001
RIGHT TRISECTIONECTOMY PLUS 
CAUDATE LOBE RESECTION FOR 
HILAR CHOLANGIOCARCINOMA IN A 
PATIENT WITH GBWR < 0.8
L. McCormack, J. Kerman Cabo, A. Sanchez Ruiz, 
P. Mendez and N. Goldaracena
Liver Surgery & Transplantation Unit, Hospital Alem Of 
Buenos Aires, Argentina, Buenos Aires, Argentina
Introduction: The Hilar Cholangiocarcinoma or Klatskin 
tumor is a very rare entity that accounts for 60% of all chol-
angiocarcinomas. To date, the only potentially curative treat-
ment described in literature is the complete surgical resection 
with negative histological margins. This implies the resec-
tion of the supraduodenal extrahepatic bile duct, cholecistec-
tomy, periportal linfadenectomy and, in most cases, partial 
hepatectomy. This is followed by a bilioenteric reconstruc-
tion. The objective of this presentation is to show the surgical 
resolution of a Klatskin Tumor.
Methods: Video presentation of a patient with Hilar 
cholangiocarcinoma.
Results/case description: We present a case of a 56-years-
old male patient. He consulted with a 45-day history of 
obstructive jaundice and imagenological diagnosis of a hilar 
cholangiocarcinoma that compromised the bile duct bifurca-
tion. He was initially treated at another institution with a 
percutaneous biliary drainage. At our centre CT scan showed 
absence of extra-hepatic disease and an estimated Future 
Remnant Liver (FRL) of segments 2 and 3 of only 400 cc 
(Graft to Body Weight Radio (GBWR) = 0.57). Laboratory 
tests showed total bilirrubin = 3 mg/dl and Ca19–9 = 134 UI/
mL (< 35 UI/mL). Portal embolization of the right hemi-liver 
was performed to achieve a hypertrophy of the FRL. Three 
weeks after portal embolization, the FRL increased to 480 cc 
(GBWR = 0.68) and he underwent surgical resection (right 
trisectionectomy + caudate lobe resection + extrahepatic bile 
duct resection).
Conclusion: Even in the presence of reduced FRL, the 
aggressive surgical approach is recommended in selected 
patients with good performance status.
CONCOMITANT DYSREGULATION OF 
MIR-151-3P AND MIR-126 CORRELATES 
WITH IMPROVED SURVIVAL IN 
RESECTED CHOLANGIOCARCINOMA
M. E. McNally, A. Collins, S. Wojcik, J. Liu, J. Henry, 
J. Jiang, T. Schmittgen and M. Bloomston
The Ohio State University Medical Center, Columbus, OH
Background: MicroRNAs (miR) are small non-coding 
genes which become dysregulated in cancer and have been 
shown to predict survival. The role of miRs in outcomes for 
cholangiocarcinoma (CCA) has not been reported.
Methods: RNA was extracted from resected CCA along 
with adjacent uninvolved bile duct epithelium. A miR profi le 
was identifi ed by Nanostring and validated with RT-PCR. 
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Clinicopathologic characteristics and outcomes were cap-
tured and compared. Overall survival curves were created 
using the Kaplan-Meier method and factors compared by 
log-rank, chi-square or Cox regression analyses.
Results: Thirty-two paired CCA and normal samples were 
analyzed. A miR expression profi le identifi ed 41 miRs to be 
signifi cantly dysregulated compared to normal. The absolute 
expression was compared to overall survival after excluding 
patients with perioperative deaths (N = 2). One upregulated 
microRNA (miR-151_3p, p = 0.003) and one downregulated 
microRNA (miR-126, p = 0.023) correlated with survival on 
univariate analysis. Clinical factors along with these miRs 
were compared by multivariate analysis. Dysregulation of 
miRs-151_3p and -126 were the only factors that correlated 
with improved overall survival (12.3 vs 41.5 months, p < 
0.000 and 15.1 vs 21.9 months, p = 0.006, respectively). Eight 
patients had dysregulation of both miR-151_3p and -126 while 
the remainder had dysregulation in only one or none. When 
both miRs were dysregulated (N = 8), there was a stronger 
correlation with survival (58.7 vs 15.1 months; p = 0.000) 
(fi gure); clinicopathologic factors were otherwise similar.
Conclusion: In resected CCA, both miR-151_3p and 
miR-126 were the only factors related to an overall improved 
survival. Further analysis of their targets may yield potential 
therapeutic targets or biomarkers.
SUCCESSFUL SURGICAL MANAGEMENT 
OF SUBACUTE BUDD-CHIARI 
SYNDROME
A. Mejia2, J. Jay1, R. Dickerman1 and P. Mantry2
1Methodist Dallas Medical Center, Dallas, TX; 2The Liver 
Institute At Methodist Dallas, Dallas, TX
Introduction: Budd-Chiari Syndrome (BCS) represents 
one of the most challenging clinical and surgical scenarios 
due to the technical aspects involved and the rapid deteriora-
tion of liver function experienced in an usually younger 
patient population. When the liver is not cirrhotic on biopsy, 
the usual dilema is to decide between liver transplantation 
and a non transplant surgical versus interventional radiology 
approach. In this report we describe the clinical features and 
surgical therapies for 3 cases of subacute BCS.
Methods: 3 cases were identifi ed of subacute BCS managed 
without transplantation. All cases required doppler, venogram 
and liver biopsy for diagnosis confi rmation. All cases were 
evaluated and treated by the liver transplant team. Liver trans-
plant was considered as a back-up plan in 2 of the 3 cases.
Case reports: Clinical variables are described on the Table. 
Discussion: The use of cavo-atrial shunt combined with side 
to side portacaval shunt was very successful in managing 2 
cases of subacute BCS. The use of an IVC stent is an option 
when there is enough room to place the stent and clot has 
not extended into IVC. A stent avoids the use of the cavoatrial 
component but causes occlusion of the hepatic vein outfl ow 
and a porto-systemic shunt becomes mandatory to avoid 
further hepatic decompensation.
Conclusion: In patients with reversible liver damage and 
BCS, a consideration should be given to a non transplant 
therapy. Due to the risks of any surgical approach, transplant 
should be a backup option. As shown in this case series, 
transplant can be avoided with excellent outcomes.
Case 1 Case 2 Case 3
Etiology Anti PhosphoLipid AB MPD- Jak2 mutation Prot C def, Jak2 mutation
Gender/Age F/46 M/33 M/44
Presentation Ascitis, edema, encephalopathy Same Same
Duration of symptoms 2 months 3 weeks 3 months
Surgical therapy IVC stent + Mesocaval shunt CavoAtrial shunt + side to side 
portocaval shunt
Cavoatrial shunt + side to side 
portocaval shunt
Outcome/F/U Alive and well/2 years Alive well/3 years Alive and well/3 years
A SIMPLE ALGORITHM OF EARLY 
DRAIN REMOVAL AFTER 
PANCREATICODUODENECTOMY
V. Menon, A. Annamalai, V. Puri, H. Kotler and N. N. Nissen
Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Routine external drainage after pancreatico-
duodenectomy (PD) continues to be practiced by most sur-
geons, but an optimal drain management strategy remains 
unclear. We report here our efforts to use drain amylase 
monitoring to predict PF and to allow early drain removal.
Methods: 101 consecutive patients undergoing PD by a 
single surgeon were included. In the fi rst 76 patients (Group 
A), drain amylase levels were measured on postoperative 
days 0–5, after which drains were removed if there was no 
evidence of PF by ISGPF criteria. Based on analysis of this 
group, the ensuing 25 patients (Group B) underwent drain 
removal as soon as drain amylase was < 100 U/ml.
54 Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association, HPB, 14 (Suppl. 1), 1–91
Results: In Group A, eight patients (12%) developed PF by 
ISGPF criteria. POD 1 drain amylase of > 5000 U/L had a 
positive predictive value of 1 for PF (3 of 3), while a POD 
1 level of < 100 U/L had a negative predictive value of 0.84 
(1 of 42). Only 2 patients with PF required delayed abdomi-
nal drainage. In Group B, 1 patient (4%) developed PF. 
Drains were removed on average 2.4 days after surgery. No 
patient required delayed drainage or intervention.
Conclusion: Drains can be removed safely after PD when 
the drain amylase level is < 100 U/L without the need for 
resumption of diet or any other milestone. In our entire 
cohort this algorithm would have led to drain removal on 
average on POD 2 with the likelihood of delayed abdominal 
drainage of 2%.
TRANSHEPATIC-TRANSANASTOMOTIC 
STENTS IN BILE DUCT INJURY REPAIR: 
AN ANSWERED DILEMMA
M. Mercado, B. Franssen, C. Chan, R. Aramburo and 
M. Mercado
Department Of Surgery, Instituto Nacional De La Nutricio 
Salvador Zubir, Mexico City, Mexico
Purpose: Provide evidence through the experience of a 
single center that the use of transhepatic-transanasatomotic 
stents (TTS) during bile duct injury (BDI) repair is not neces-
sary and should be limited to very few specifi c scenarios.
Methods: Retrospective analysis of BDI repairs performed 
between 1996–2006. Patients were divided in a stented and 
a non-stented group and compared.
Results: 213 consecutive BDI repairs were divided in Group 
I (GI): 139 patients where TTS were not used and Group II 
(GII): 74 patients where TTS were used. Preoperative vari-
ables including gender, age, open vs laparoscopic cholecystec-
tomy, previous attempts of repair, and type of lesion (Strasberg 
classifi cation) are not signifi cantly different between groups. 
Laboratory tests: abnormal direct billirubin at 3 months (GI: 
15/139, GII: 11/74; NS) and 12 months (GI: 13/139, GII: 
30/74; P < 0.05) Elevated serum Transaminase at 3 and 12 
months postoperatively (3 months GI: 29/139, GII: 34/74 and 
12 months GI: 28/139, GII: 31/74) and Alkaline Phosphatase 
(3 months GI: 49/139, GII: 63/74 and 12 months GI: 35/139, 
GII: 59/74) levels were all signifi cantly different. Complications: 
Cholangitis (GI: 18/139, GII: 9/74; NS), Stenosis (GI: 4/139, 
GII: 16/74; P < 0.05), Abscess (GI: 2/139, GII: 4/74; NS), 
Fistula (GI: 5/139, GII: 1/74; NS), Biloma (GI: 10/139, GII: 
1/74; NS) Only the rate of stenosis is signifi cantly less in the 
non-stented group. Radiologic and surgical reinterventions 
were higher in the stented group (GI: 4% vs GII: 21%). 
Postoperative mortality was present in a single patient in GII.
Conclusions: The rate of stenosis and reinterventions are 
less in the non-stented group, otherwise outcomes are very 
similar in both groups. Most BDI repairs can safely be per-
formed without the use of TTS, buy they remain useful when 
small ducts, a low quality anastomosis or high likelihood of 
future instrumentation are present during surgery.
Group I
Non Stented
Group II
Stented
P
# % # %
Total 139 100 74 100 NS
 Male 33 24 18 24
 Female 106 76 56 76
Age (mean) 40 – 37 – –
Type of Cholecystectomy
 Open 106 76 52 70 NS
 Laparoscopic 33 24 22 30
Previous attempt of repair
 Yes 66 47 28 38 NS
 No 73 53 46 62
Diagnostic
 ERCP 62 45 22 30 0.0397
 Percutaneous Cholangiography 18 13 19 26 0.0234
 Cholangio-MRI 28 20 16 22 NS
 Others (US, Fistulography) 31 22 17 23 NS
Lab Tests
 Bilirrubin Rise (3 months) 15 11 11 15 NS
 Transaminase Rise (3 months) 29 21 34 46 0.0002
 Alkaline Phosphatase Rise (3 months) 49 35 63 85 <0.0001
 Bilirrubin Rise (1 year) 13 9 30 41 <0.0001
 Transaminase Rise (1 year) 28 20 31 42 0.0012
 Alkaline Phosphatase Rise (1 year) 35 25 59 80 <0.0001
Postoperative Complications
 Cholangitis 18 13 9 12 NS
 Stenosis 4 3 16 21 <0.0001
 Abscess 2 1 4 5 NS
 Fistula 5 3 1 1 NS
 Biloma 10 7 1 1 NS
 Reintervention 6 4 16 21 <0.0001
 Operative mortality 0 0 1 1 NS
NS: Not statistically signifi cant.
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PANCREATIC ANASTOMOSIS IN THE 
SOFT PANCREAS AFTER 
PANCREATICODUODENAL RESECTION
W. G. Michael, J. G. Steele and A. M. Cooperman
Pancreas And Biliary Center Of New York At Beth Israel 
Medical Center, New York, NY
There is no sure method to avoid pancreatic fi stula after 
pancreatoduodenectomy, particularly for the soft remnant 
gland. The following method has been utilized in more than 
300 PDR. The undersurface of the distal gland is now of 
nonabsorbable sutures are placed between seromuscular 
jejunum and posterior pancreas. At least 1–1.5 cm of pan-
creas will be imbricated on the jejunum. A duct to mucosa 
anastomosis is made irrespective of duct size with absorbable 
sutures. (stents are used for ducts 5 mm or less). The anterior 
layer of nonabsorbable sutures imbricates the jejunum at 
least 1.5 cm. Drains are utilized. The fi stula rate is 6% for 
soft pancreas anastomosis, all type A.
IS PREOPERATIVE IMAGING 
PREDICTIVE OF OUTCOME IN 
PATIENTS UNDERGOING TOTAL 
PANCREATECTOMY WITH ISLET 
AUTOTRANSPLANTATION FOR 
CHRONIC PANCREATITIS?
K. A. Morgan, J. Romagnuolo, S. M. Owczarski and 
D. B. Adams
Medical University Of South Carolina, Charleston, SC
Background: Total pancreatectomy with islet autotrans-
plantation (TPIAT) is an effective means of pain relief in 
selected patients with chronic pancreatitis. Patient selection, 
however, is challenging. Preoperative pancreatic imaging of 
patients undergoing TPIAT is variable and may be predictive 
of outcome.
Methods: Retrospective review of a prospective database 
was undertaken. Data including demographics, quality of life 
(QOL) measures (SF-12), and pancreas imaging studies 
(ERCP, MRCP, EUS) were evaluated. ERCP and MRCP 
were graded by Cambridge score (Cambr, 0–4) and EUS was 
scored as low, intermediate, or high probability for chronic 
pancreatitis. Success of intervention was defi ned as signifi -
cant improvement in SF-12 Physical Composite Score at 
6 months postoperatively, marked by a score > 40 (one SD 
from norm) or 3 point improvement.
Results: 46 patients (38 women, age 43) were at least 6 
months in follow-up. 31 patients had ERCP preoperatively. 
Patients with Cambr 3–4 were more likely to have signifi cant 
improvement in physical QOL at 6 months than those with 
Cambr 0–2 (86% vs 44%, p = 0.03). Neither MRCP Cambr 
(p = 0.4) nor EUS (p = 0.6) showed signifi cant association 
with outcome. Preoperative oral morphine equivalents (p = 
0.5), duration of disease (p = 0.6), and preoperative mental 
(p = 0.3) and physical (p = 0.1) QOL scores did not predict 
outcome. Multivariate model showed ERCPCambr was asso-
ciated with success (OR 3.1 (95% CI: 1.3–7.3); p = 0.009).
Conclusions: Patient selection for TPIAT in patients with 
chronic pancreatitis remains diffi cult. Preoperative ERCP may 
be predictive of QOL outcomes. Patients with advanced 
disease often do well with TPIAT, despite potential accompa-
nying obstacles of narcotic use and social marginalization.
COLORECTAL METASTASES TO THE 
PANCREAS: A SINGLE INSTITUTION 
EXPERIENCE
L. C. Morley1, J. K. Roberts1, C. S. Verbeke2, 
G. Morris-Stiff1 and A. M. Smith1
1Department Of Pancreatic Surgery, Leeds, West Yorkshire; 
2Department Of Histopathology, Leeds, West Yorkshire, 
United Kingdom
Background: Metastatic spread of colorectal carcinoma to 
the pancreas is a rare event, thus the role of surgical resection 
is unclear.
Aims: To present the outcomes of pancreatic metastasec-
tomy within our pancreatic unit and to compare the results 
to non-operative management.
Methods: 9 cases of colorectal metastasis to the pancreas 
were identifi ed from the histopathology database and were 
retrospectively analyzed. Data was collected in relation to 
presentation and outcome.
Results: Four patients underwent resection and 5 were managed 
with palliative intent. Within the operative group, the median 
interval between diagnosis of colorectal carcinoma and pancre-
atic metastases was 6 years (range 1–7). Pancreatic involvement 
was identifi ed on routine CT surveillance in asymptomatic 
patients. Two patients underwent pylorus preserving pancreato-
duodenectomy and two underwent subtotal pancreatectomy 
with splenectomy. One patients’ recovery was complicated by 
delayed gastric emptying, and another by wound infection and 
incisional hernia. Extra pancreatic metastases occurred in every 
patient prior to the development of pancreatic disease. In the 
surgical cohort, one patient remains disease free 4 years post-
surgery. Of three patients with recurrent disease, one is alive 
with stable disease 4 years post-operatively and two have passed 
away at 1 year 6 months and 5 years following resection. 
Improved outcomes were observed compared to the unresected 
group, where the median survival from diagnosis of pancreatic 
colorectal metastases was 11 months.
Conclusions: Surgical management of colorectal pancreatic 
metastases is infrequent, but in selected cases may be benefi -
cial with minimal complications and prolonged survival 
compared to a cohort of non-operated patients.
ADENOCARCINOMA ARISING IN 
INDRADUCTAL PAPILLARY MUCINOUS 
NEOPLSMS (IPMN): A DIFFERENT 
BIOLOGICAL PROFILE AND CLINICAL 
OUTCOME
G. Morris-Stiff, G. A. Falk, S. Chalikonda and 
R. M. Walsh
Department Of General Surgery, Section Of Surgical 
Oncology/HPB, Cleveland, OH
Background: The rate of malignant transformation in 
patients with IPMN is high, in particular for disease affecting 
the main pancreatic duct.
Aims: To evaluate a subset of patients with pancreatic ade-
nocarcinoma arising in IPMN.
Methods: The pancreatic cyst database was reviewed to 
identify patients with a histopathological diagnosis of 
pancreatic adenocarcinoma arising within an IPMN. Their 
presentation, histopathological characteristics and outcome 
were recorded.
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Results: 30 patients were identifi ed including 14 females 
and 16 males with a median age of 70.0 years. The common-
est modes of presentation included: jaundice (n = 10); pain 
(n = 7); asymptomatic (n = 5); and pancreatitis (n = 4). Only 
1 patient, who presented with pain, had a pre-operative diag-
nosis of carcinoma, the rest being histopathological fi ndings. 
22 patients had main duct IPMN, 5 had side branch IPMN 
and 3 had combined disease. 5 had foci of invasive carci-
noma and the remaining 25 had mass lesions varying from 
1.1 to 12 cm. The stage of disease was: IA (n = 4); IB (n = 
7); IIA (n = 5) and IIB (n = 14). Lymphovascular invasion 
was seen in only 11, and neural invasion identifi ed in 11 
patients. 16 patients have died, 15 of recurrent carcinoma and 
1 of an unrelated cause. The median actuarial survival is 24.9 
months (range: 0.8–84.4 months) and the median time to 
death for those not surviving was 20.8 months (range: 0.8–
65.8 months).
Conclusions: Despite an intensive pre-operative work-up, 
IPMN-related adenocarcinoma is rarely identifi ed pre-oper-
atively. The data would support resection of all symptomatic 
and asymptomatic main duct IPMN and side-branch disease 
being followed very closely.
NATURAL HISTORY OF ASYMPTOMATIC 
PANCREATIC CYSTIC NEOPLASMS
G. Morris-Stiff, G. A. Falk, S. Chalikonda and 
R. M. Walsh
Department Of General Surgery, Section Of Surgical 
Oncology/HPB, Cleveland, OH
Background: Management of asymptomatic pancreatic 
cysts is controversial, with need for excision based on pathol-
ogy and natural history.
Aims: To examine the outcome of asymptomatic lesions 
using our protocol based on size and cyst fl uid analysis.
Methods: A prospective database was queried to identify 
asymptomatic pancreatic cysts. Sequential cross-sectional 
imaging studies were assessed, and for those ≥1.5 cm, results 
of endoscopic ultrasound-guided aspiration were co-ana-
lyzed. Defi nitive histopathology was available for resected 
specimens.
Results: During the period 1998–2008, 338 patients under-
went evaluation (228 females) with a median age of 67 years 
(IQR [Inter-quartile range]: 57–75). 84 cysts were <1.5 cm 
and 254 were ≥1.5 cm in diameter. Median patient follow-up 
was 5.1 years (IQR: 4.1–6.9). In the <1.5 cm group, median 
cyst size at presentation was 1 cm (IQR: 0.6–1.2) increasing 
to 1.2 cm (0.7–1.6) during follow-up. 5 (6.0%) patients 
underwent resection, all within 2 months of presentation, 4 
of these also underwent cyst aspiration which was positive 
for mucin. In the ≥1.5 cm group, the median cyst size at 
presentation was 2.5 cm (IQR: 2.0–3.4) increasing to 2.7 cm 
(IQR: 3.0–4.2). 63 (24.8%) patients underwent resection. 53 
(84.1%) cases were performed within 2 months, 4 (6.3%) 
within 12 months, and 6 (9.6%) >12 months post presenta-
tion. Histopathology of resected specimens revealed 71% 
were malignancies or had malignant potential.
Conclusions: Asymptomatic cysts <1.5 cm can safely be 
followed only by imaging with little change expected. A 
quarter of all asymptomatic cysts ≥1.5 cm are appropriately 
resected based on imaging and cyst fl uid analysis.
PANCREATIC ADENOCARCINOMAS 
ARISING ON THE BACKGROUND OF 
PANCREATIC CYSTIC DISEASE HAVE A 
BETTER OUTCOME THAN POOR 
OUTCOME
G. Morris-Stiff, G. A. Falk, S. Chalikonda and 
R. M. Walsh
Department Of General Surgery, Section Of Surgical 
Oncology/HPB, Cleveland, OH
Background: Pancreatic adenocarcinoma has a poor prog-
nosis with a reported 5-year survival of <5%, however, this 
general fi gure does not differentiate ductal adenocarcinoma 
from adenocarcinomas arising within a background of pan-
creatic cystic disease.
Aims: To report long-term survival rates in patients with 
ductal adenocarcinoma and compare them to carcinomas 
arising in cystic disease and to those originating from the 
endocrine pancreas.
Methods: Frequency and follow-up data was obtained from 
The National Cancer Institute’s Surveillance, Epidemiology, 
End Results (SEER) database for the period 1973–2006. The 
survival of patients with ductal adenocarcinoma (ICD 
[International classifi cation of disease] codes: 8010, 8140–
8147, 8500) were compared to: adenocarcinoma in IPMN 
(ICD: 8453); mucinous cystadenocarcinoma (ICD: 8470–
8471); endocrine/islet cell carcinoma (8240–8249, 8150–
8157); and mucinous adenocarcinoma 8480–8481). 
Carcinomas classifi ed as malignant neoplasms and those of 
other histopathological subtypes were excluded.
Results: During the period February 1998 to December 
2008, 127,295 patients were identifi ed of which 111,714 
were within the remit of the study. Adequate data to perform 
survival analysis was available for 92,911 cases. 5-yr 
Survival for carcinomas arising in IPMN carcinomas (44%) 
and mucinous cystadenocarcinomas (34.1%) were superior 
to that of standard adenocarcinomas (2.3%) or mucinous 
adenocarcinomas (2.8%) [p < 0.001] for each, with survival 
of carcinomas of endocrine origin being similar to that of 
cystic lesion carcinomas (36.7%) [p = 0.38].
Conclusions: It is evident that survival of patients with car-
cinoma arising in this setting is superior and thus all patients 
with a mucinous cystic neoplasm should be referred for a 
surgical opinion.
TEMPORARY PORTO-CAVAL SHUNTING 
IN ORTHOTOPIC LIVER 
TRANSPLANTATION: IS THIS 
TECHNIQUE THE ANSWER TO 
BLEEDING AND EXPOSURE?
S. N. Nadig, P. G. Alluri, D. D. Lee and S. J. Pelletier
University Of Michigan Health System, Ann Arbor, MI
Orthotopic liver transplantation (OLTx) has become the 
treatment of choice for patients with end-stage liver failure. 
Patient’s undergoing OLTx are often coagulopathic and have 
varying degrees of portal hypertension resulting in intrab-
dominal varices. In addition, exposure during the recipient 
hepatectomy can be a challenge. In this abstract, we propose 
revisiting a technique that has allowed for improvement on 
the diffi cult problems of exposure and bleeding in the liver 
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transplant recipient. At the University of Michigan, in the 
past two years we have performed twenty-four temporary 
porto-caval shunts (PCS) prior to explantation of a patient’s 
diseased liver. The construction of a PCS takes approxi-
mately 8 minutes to complete. Overall this maneuver saves 
time and eases the exposure for the hepatectomy. By allow-
ing for an almost immediate decompression of intrabdominal 
varicosities which are prone to torrential bleeding, we can 
eliminate the time consumed by repairing bleeding varicosi-
ties. The use of an end to side PCS, prior to, and during the 
anhepatic phase of transplantation also allows maintenance 
of portal venous return. In addition, the patient maintains 
hemodynamic stability along with a decreased need for blood 
product transfusion. This technique was fi rst described by 
Tzakis and Starzl along with Belghiti in the early and mid-
1990s; however, has been underutilized. This “trick-of-the 
trade” may aid in improvement of patient outcomes after 
OLTx and in the education of transplant trainees.
(2002–2007) was performed. Median follow-up was 35 
months (range 8–80). Associations between clinico-
pathologic factors and survival were evaluated using the 
Cox proportional hazard method.
Results: 320 patients underwent 336 liver resections. The 
majority (n = 181, 57%) had metachronous disease and most 
patients (n = 286, 85%) had a major hepatectomy (>3 seg-
ments). Thirty-six (11%) patients received pre-operative che-
motherapy, predominantly for downstaging unresectable 
disease. Ninety-day mortality was 2.1% and perioperative 
morbidity occurred in 90 (27%) patients. Actual disease 
free survival at 3 and 5 years were 46.2% and 42%, respec-
tively. Actual overall survival at 3 and 5 years were 
63.7% and 55%, respectively. Multivariate analysis 
identifi ed four factors that were independently associated 
with differences in overall survival (HR; 95% confi dence 
interval): size of metastasis >6 cm (2.3; 1.4–3.8), positive 
lymph node status of the primary CRC (N1 (2.0; 1.0–3.8), 
N2 (2.4; 1.2–4.9)), synchronous disease (2.1; 1.2–3.4), and 
treatment with chemotherapy after liver resection (0.42; 
0.23–0.75).
Conclusions: Upfront surgery for patients with resectable 
CRC liver metastases, followed by chemotherapy, can lead 
to favorable overall survival.
A NOVEL TECHNIQUE FOR 
LAPAROSCOPIC 
PANCREATICOJEJUNOSTOMY
B. T. Neichoy, J. G. Trevino, K. E. Behrns and 
S. J. Hughes
University Of Florida – Department Of Surgery, 
Gainesville, FL
Perhaps the greatest barrier to adoption of the laparoscopic 
radical pancreaticoduodenectomy is the technical challenge 
of the pancreaticojejunostomy. We present an intussuscept-
ing technique utilizing a running, single layer of absorbable, 
monofi lament suture (5 min video). After the neck of the 
pancreas is fully mobilized, a 36-cm suture is fashioned by 
tying two 18 cm 4-0 polydioxanone sutures together. The 
sutures are positioned to ultimately produce an intussuscep-
tion of approximately 1 cm. The initial suture is placed tan-
gential to the transected surface of the reconstructive limb 
on the anti-mesenteric border. The suture is then similarly 
passed through the cephalad aspect of the pancreas. The next 
few posterior wall sutures are placed and the suture then 
parachuted to achieve tissue apposition. Anterior tension is 
maintained and exposure facilitated during subsequent 
sutures utilizing a diamond-dust coated instrument. The pos-
terior row is completed at the mesenteric border of the jejunal 
limb and caudad aspect of the pancreas with tension main-
tained by the placement of a Lapra-Ty®. The anterior aspect 
of the anastomosis is completed in an identical fashion. A 
second Lapra-Ty® is applied allowing knot creation without 
the challenge of maintaining appropriate tension. In a con-
secutive series of 18 patients since this technique was 
adopted in March 2011, the leak rate has been 11% (ISGPS 
criteria) with an average time for the anastamosis being 24 
minutes. We conclude that this single-layer, running, intus-
suscepting technique for pancreaticojejunostomy presents 
fewer technical challenges and produces acceptable results 
compared to other techniques.
UP FRONT HEPATIC RESECTION FOR 
METASTATIC COLORECTAL CANCER 
RESULTS IN FAVORABLE LONG-TERM 
SURVIVAL
S. Nanji1, S. Cleary2, P. Ryan3, M. Guindi3, S. Selvarajah2, 
P. Greig2, I. McGilvary2, B. Taylor2, A. Wei2, C. Moulton2 
and S. Gallinger2
1Queen’s University, Department Of Surgery, Kingston, 
Ontario, Canada; 2University Health Network, University 
Of Toronto, Department Of Surgery, Toronto, Ontario, 
Canada; 3University Of Toronto, Department Of Pathology, 
Toronto, Ontario, Canada
Background: Hepatic metastasis from colorectal cancer 
(CRC) is best managed with a multimodality approach; 
however, the timing of liver resection in relation to admin-
istration of perioperative chemotherapy remains unclear. Our 
strategy has been to offer upfront liver resection for patients 
with resectable hepatic metastases, followed by post liver 
resection chemotherapy. We report the outcomes of patients 
based on this approach.
Methods: A retrospective review of all patients undergoing 
liver resection for CRC metastases over a 5-year period 
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PERIPHERAL BLOOD MYELOID CELL 
POPULATIONS EXPAND IN PATIENTS 
WITH HEPATOCELLULAR CARCINOMA 
TREATED WITH RESECTION AND 
ABLATION, BUT NOT WITH 
ENDOLUMINAL THERAPY
P. Newell1,2, B. Cottam2, T. Savage2, C. Hammill1, S. Cho1, 
M. Cassera1, R. Wolf1, T. Thiesing1, M. Gough2 and 
P. Hansen1
1Providence Portland Medical Center, Portland, OR; 
2Earle A. Chiles Research Institute, Portland, OR
Introduction: HCC arises in an environment of chronic injury. 
Genomic analyses have shown the surrounding cirrhotic liver 
is prognostic of survival in HCC, and poor-prognosis gene 
signatures contain gene sets associated with infl ammation. 
Tumor macrophages can drive neoangiogenesis, fi brosis and 
immune suppression as part of a wound healing response. 
Circulating myeloid cells may mirror expanding macrophage 
populations within the HCC environment.
Methods: We measured CD15 and CD14 to identify high 
side scatter granulocytes and intermediate side scatter mono-
cytes in peripheral blood of 18 patients with HCC before and 
3 weeks after treatment with resection, ablation, or endolu-
minal therapy. Tumors were collected to measure macro-
phage infi ltration.
Results: There were no signifi cant differences in myeloid 
counts between patients according to size or number of 
tumors treated, vascular invasion, BCLC or MELD scores, 
or recurrence rates among the 18 patients treated. 8 patients 
progressed or recurred after a mean follow up of 3.6 months. 
There was signifi cantly greater expansion of the granulocyte 
population following resection and ablation than after endo-
luminal treatments (p = 0.028). Childs B and C patients 
tended to have a greater expansion of monocytes following 
treatment (p = 0.066).
Conclusion: We propose that the tumor environment gener-
ated by macrophages is critical to recovery of residual cancer 
cells after therapy. The increase we observe in myeloid cells 
following resection and ablation could refl ect greater wound-
healing response initiated by the more invasive procedures. 
More data is needed to demonstrate whether circulating 
monocytes can predict disease progression and whether 
tumor macrophages could be targeted to enhance response.
VALUE OF INTRA-OPERATIVE 
ULTRASOUND FOR THE 
PERFORMANCE OF PANCREATIC 
SURGERY: A MULTIDISCIPLINARY 
ASSESSMENT
J. Ni Mhuircheartaigh1, M. Sun1, N. Sanchez1, M. Callery1, 
B. Siewert1, C. Vollmer2 and R. Kane1
1Beth Israel Deaconess Medical Center, Boston, MA; 
2Hospital Of The University Of Pennsylvania, 
Philadelphia, PA
Purpose: To evaluate the utility of intra-operative ultra-
sound (IOUS) for pancreatic surgery.
Materials and Methods: All IOUS studies performed in the 
setting of pancreatic surgery performed between January 
2000 and December 2010, were reviewed in concert between 
both the operating pancreatic surgeons and at least two radi-
ologists. A scoring system was developed in consensus with 
a grade of 0–3 assigned on the basis of the utility of the 
IOUS. A score of 0 indicated there was a negative impact on 
the planned surgery. A score of 1 indicated IOUS did not 
contribute to the surgery. A score of 2 indicated IOUS did 
contribute to the surgery but did not alter the operative plan 
and a score of 3 indicated that IOUS had made a signifi cant 
contribution and altered the surgical plan. Data were also 
recorded on the presumptive diagnosis, the surgical proce-
dure performed and the fi nal pathology.
Results: 203 IOUS procedures were performed on 199 patients. 
IOUS value scores were as follows: 0: 3.6%; 1: 11.9%; 2: 
31.1%; 3: 53.4%. Most common contribution resulting in major 
value score was facilitation of technical performance of the 
surgery (n = 59). Major value score was signifi cantly associated 
with performance of pancreatitis-related surgery (p < 0.001). 
The surgical indication most commonly resulting in a score of 
0–1 was staging of pancreatic cancers (100% of negative value 
scores observed in this setting).
Conclusion: IOUS of the pancreas is a useful adjunct in 
many types of pancreatic surgery as we describe in detail.
P53 MUTATIONAL ANALYSIS IS A 
BETTER PREDICTOR OF PROGNOSIS 
THAN HISTOLOGY IN PANCREATIC 
IPMN
J. A. Nicholson1, L. Yan1, R. Sutton1, S. Harrison1, 
F. Campbell2, J. P. Neoptolemos1 and W. Greenhalf1
1NIHR Pancreas Biomedical Research Unit, Liverpool, 
Merseyside, United Kingdom; 2Department Of 
Histopathology, Liverpool, Merseyside, United Kingdom
Background: The role of p53 in the development and pro-
gression of IPMN is unclear. Currently, radiological size and 
location (side branch/main duct) are the most quoted pre-
operative predictors of malignancy in IPMNs.
Aim: To investigate whether p53 mutational status can 
predict malignancy and outcome in IPMNs.
Methods: 29 patients underwent resection for IPMN. p53 
analysis was performed on intra-operatively collected pan-
 Abstracts 59
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association, HPB, 14 (Suppl. 1), 1–91
creatic juice and frozen tissue samples taken from the resec-
tion specimens. p53 results were correlated with histological 
diagnosis and survival data.
Results: Histologically, there were 11 IPMNs, 7 IPMNs 
with invasive adenocarcinoma (IPMCs), 3 conventional 
PDACs and 8 other benign entities. Eight patients died 
(median follow-up: 730 days). Tissue sample p53 status cor-
related with histological malignancy (p = 0.0005). Tissue p53 
predicted survival in IPMN and IPMC (p = 0.0001) and was 
a better predictor of survival than conventional histology (p 
= 0.01). Tissue p53 mutational status matched that in juice 
in all but 2 cases (where mutation site lay within the primers). 
There were no false positive p53 results in pancreatic juice.
Conclusions: p53 mutational status can predict poor outcome 
in IPMNs, regardless of histological grade. Pancreatic juice 
analysis could potentially be used to identify those patients 
with IPMN who should be considered for resection.
MANAGEMENT OF THE DIFFICULT 
PANCREATIC STUMP AFTER 
PANCREATIC RESECTION
N. N. Nissen, V. Menon and A. Annamalai
Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Methods of pancreatic transection in distal 
pancreatectomy include the use of stapling devices, sharp 
division with oversewing of the duct, or oversewing the 
entire distal gland. In patients with a thick pancreas, however, 
all of these techniques are more diffi cult due to staple line 
disruption or suture pull-through along the stump. We report 
here two simple methods used in these settings.
Method 1: Pledgetted closure of the pancreatic stump: In cases 
with a soft pancreas and small pancreatic duct in which there is 
suspicion of staple line disruption, the pancreatic stump is rein-
forced with vicryl pledgets in a horizontal mattress fashion (see 
picture). These are usually placed using an open technique 
through a handport incision but can also be placed laparoscopi-
cally. This technique creates a uniform compression of the pan-
creatic margin with minimal possibility of suture pull-through.
Method 2: Creation of distal pancreaticojejunostomy: In 
cases with a fi rm pancreas, the thickness of which is likely 
to lead to staple line disruption, we perform pancreaticojeju-
nostomy between the distal pancreatic stump and defunction-
alized jejunum. The leak rate in this scenario is very low 
because of the security of the anastomosis to a fi rm pancreas. 
This is especially useful if there is proximal pancreatic duct 
dilatation or other irregularity suggesting compromised 
proximal drainage, which will lead to higher leak rate if an 
attempt to simply close the stump is pursued.
USE OF HD VIDEO MICROSCOPY IN 
THE LOCAL RESECTION OF 
PANCREATIC HEAD AND AMPULLARY 
TUMORS
N. N. Nissen, V. Menon, J. Williams and G. Berci
Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Resection of ampullary and peri-ampullary 
lesions is technically challenging both because of the need 
to avoid injury to the pancreatic duct and bile duct and also 
because of the tight space and awkward angles required to 
successfully access these areas. Various forms of magnifi ca-
tion and illumination are useful in these ventures, with the 
most common form being surgical Loupes and headlights, 
along with as well as overhead lighting. The use of a standard 
operating microscope is intriguing, but this can also be 
cumbersome.
Methods: We have utilized a simple system of video 
microscopy to assist in the resection of lesions in the head 
of the pancreas and peri-ampullary region. This system uses 
the same HD camera utilized in laparoscopic procedures (but 
without the telescope) that is mounted in a mechanical arm 
attached to the operating table (see picture). The image of 
the operative fi eld is then projected to a TV monitor with up 
to 12 × magnifi cation, which provides improved ability to 
resect complex lesions in the head of the pancreas or ampulla 
while avoiding pancreatic or bile duct injury.
Results: Several cases are presented, including resection of 
ampullary masses with re-implantation of the pancreatic duct 
and bile duct and local resection of both solid and cystic 
pancreatic head masses. The improved magnifi cation and 
illlumination offered by this approach is illustrated, as are 
the key components of the video microscopy system, and the 
critical structures of the region which are of vital importance 
to protect.
HEPATIC ARTERIAL CLAMPING ALONE, 
RATHER THAN PORTAL TRIAD 
CLAMPING, CAN BE USED TO REDUCE 
PARENCHYMAL BLEEDING DURING 
LAPAROSCOPIC LIVER RESECTION
N. O’Rourke
Royal Brisbane Hospital, Brisbane, Australia
This report demonstrates a simple, safe, and effective tech-
nique to reduce bleeding during laparoscopic liver resection, 
especially non anatomic or segmental resections, where prior 
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vascular control is not possible before resection. Hogarth 
Pringle described infl ow occlusion in 1908. Often used and 
frequently discussed, the “Pringle Maneuvre” has remained 
a standard procedure for the control of hemorrhage during 
open and laparoscopic liver surgery. However, Portal Triad 
clamping, as it is also called, results in hepatic ischemia and 
venous congestion of the bowel, and may have deleterious 
oncologic effects. Laparoscopic liver surgery is performed 
using intra-abdominal CO2 pressures of 12–16 mm Hg. This 
reduces venous bleeding, overcoming central venous pres-
sure of approximately 5 mm Hg. This CO2 pressure of 
12–16 mm Hg is also greater than portal venous pressure 
(about 10 mm Hg). Logically, there is no need to occlude the 
portal vein during laparoscopic procedures. Clamping the 
hepatic artery alone appears to reduce bleeding, almost as 
much as portal triad clamping. Placing a laparoscopic bulldog 
clamp on the hepatic artery alone, rather than the whole 
portal triad, can reduce bleeding while maintaining portal 
blood fl ow through the liver, and minimize venous conges-
tion of the bowel. Only applicable to laparoscopic liver 
surgery, this “trick” reduces liver ischemia and bleeding, and 
should reduce morbidity from combined synchronous lapa-
roscopic liver and bowel resections, which are rising in 
popularity.
INTERCOSTAL AND TRANS-THORACIC 
TROCARS FACILITATE LAPAROSCOPIC 
RESECTION OF HIGH POSTERIOR 
LESIONS OF THE LIVER
N. O’Rourke
Royal Brisbane Hospital, Brisbane, Australia
This paper demonstrates the technique of laparoscopic resec-
tion of lesions in segment 7 and 8 using accessory trocars 
placed between the ribs. With the patient lying right side up, 
laparoscopy is performed using standard umbilical access 
The liver is inspected and a sling paced around the portal 
infl ow, for later occlusion, if bleeding becomes troublesome. 
Intercostal trocars can be placed under vision by watching 
for initial digital protrusion between the ribs. The diaphragm 
can be pressed against the chest wall using a laparoscopic 
grasper to allow “blind” trocar insertion through the thoracic 
cavity, as previously described. A new alternative is to 
perform thoracoscopy using optical access and a separate 
camera stack. The diaphragm can then be penetrated from 
above under vision with laparoscopic inspection and instru-
ment pressure from below. Kii FIRST ENTRY ports from 
Applied Medical* are preferred because of the infl atable 
internal ballon allowing retraction of the diaphragm, increas-
ing the working space above the liver. On conclusion of the 
procedure, any pneumothorax can be expressed by anesthetic 
hyperinfl ation of the lungs, via a submerged 8 French tube, 
as with standard thoracoscopy. Trans-thoracic diaphragmatic 
port sites are sutured from below. Four lesions (two HCC 
and two mets) have been resected using this technique, all 
with clear margins. This has been a true epiphany for me, as 
it allows much easier access to not only “dome” lesions of 
the liver, but to any high abdominal organ.
SCARLESS HEPATECTOMY – NATURAL 
ORIFICE SPECIMEN EXTRACTION 
AFTER LEFT LATERAL 
SECTIONECTOMY
I. R. Orso1, P. Herman2, H. M. Matsumoto1, 
C. A. Carvalho1, M. W. Bonatto1, T. M. Tanaka1 and 
U. E. Sagae1
1Gastroclca Cascavel, Cascavel, Parana, Brazil; 
2University Of Sao Paulo School Of Medicine, Sao Paulo, 
Brazil
The use of laparoscopy in liver surgery is well established 
and considered as the gold standard for small resections. This 
is due to lower morbidity, better cosmetic results and rapid 
return to activities with oncological results similar to con-
vencional surgery. Current techniques still require an abdom-
inal incision to remove the surgical specimen, that despite 
being smaller than the conventional incision can still cause 
pain and present complications such as hernia, infection, and 
a bad cosmetic result. The possibility of performing a totally 
laparoscopic resection with removal of the specimen trans-
vaginally, without the need for an abdominal incision, can 
further enhance the proven benefi ts of laparoscopic liver 
resections.
Objective: To demonstrate the technique of laparoscopic 
left lateral sectionectomy (segments 2 and 3) with the surgi-
cal specimen removed through the transvaginal route.
Discussion: Several reports of surgical transvaginal extrac-
tion of the specimen in colorectal surgery are available in 
literature. This technique is safe and easily applied, further 
reducing morbidity and improving the cosmetic outcome in 
laparoscopic resection. This benefi t can also be extended to 
selected cases of laparoscopic liver resection in female 
patients. In resections of isolated segments or bi-segmentec-
tomy as left lateral sectionectomy, the specimen can be easily 
removed by this route.
ROBOTIC VERSUS LAPAROSCOPIC 
LEFT LATERAL SECTIONECTOMY: 
COMPARISON OF CLINICAL AND 
ECONOMIC OUTCOMES
V. Packiam1, J. Marsh2, J. Cardinal2, S. Reddy2, M. Saul2, 
D. Geller2, D. Bartlett2 and A. Tsung2
1University Of Pittsburgh School Of Medicine, 
Pittsburgh, PA; 2University Of Pittsburgh Medical 
Center, Pittsburgh, PA
Background: Robotics are emerging as an important tool 
for hepatobiliary surgery due to the inherent limitations of 
laparoscopy. While differences in selection criteria make 
comparing resection techniques diffi cult, the standardization 
of left lateral sectionectomies (LLS) makes them well suited 
for analysis. The purpose of this study was to compare the 
clinical and economic impact of robotic versus laparoscopic 
hepatobiliary surgery.
Methods: A retrospective analysis was performed to 
compare robotic-assisted and total laparoscopic LLS per-
formed at a major hepatobiliary center from 01/2009 to 
07/2011.
Results: A total of 30 patients underwent LLS using either 
a robotic (n = 11) or total laparoscopic (n = 19) approach. 
Demographic, tumor, and operative characteristics of robotic 
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and laparoscopic LLS were similar (Table 1). Patients who 
underwent robotic LLS had a higher rate of minor complica-
tions (Clavien Classifi cation <3) and longer length of stays. 
The total costs of robotic and laparoscopic LLS were not 
signifi cantly different. However, post-operative room costs 
for patients with robotic LLS were 1.74 times more expen-
sive (p < 0.05) due to increased ICU admissions and longer 
total length of stays.
Conclusion: Robotic LLS yields similar clinical outcomes 
compared to the laparoscopic approach. In addition to greater 
post-operative costs due to longer length of stays, robotics 
pose a much higher initial cost of installation, which was not 
captured in this analysis. Future prospective studies are nec-
essary to assess for improvements in clinical outcomes and 
overall cost to determine the indications for robotic-assisted 
hepatobiliary surgery.
Table 1. Robotic and Total Laparoscopic LLS Characteristics
Robotic (n = 11) Total Lap (n = 19) p
Demographic Characteristics
 Age (years) 56.7 ± 16.3 52.5 ± 17.1 0.64
 Gender (M/F) 3/8 5/14 0.95
 BMI (kg/m2) 30.7 ± 7.3 29.7 ± 7.3 0.94
Tumor Characteristics
 Malignant 6 (55%) 9 (47%) 0.71
 Number of resected lesions 1.2 ± 0.6 1.2 ± 0.4 0.57
 Largest tumor size (cm) 5.31 ± 3.61 5.12 ± 3.17 0.99
Operative Characteristics
 EBL (cc) 69 ± 78 82 ± 156 0.56
 OR time (mins) 202 ± 74 186 ± 47 0.19
 Conversion to Open Rate 0 (0%) 0 (0%)
Post-Operative Characteristics
 Post-Op ICU Admission Rate 2 (18.2%) 1 (5.3%) 0.26
 Minor Complication Rate 3 (27%) 0 (0%) 0.04
 Major Complication Rate 0 (0%) 0 (0%)
 Length of Stay (days) 3.9 ± 1.8 2.6 ± 0.9 0.03
 30-Day Mortality 0 (0%) 0 (0%)
IMPACT OF PREOPERATIVE THERAPY 
ON PATTERNS OF RECURRENCE IN 
PANCREATIC CANCER
P. Papavasiliou, J. P. Hoffman, J. C. Watson and 
Y. S. Chun
Fox Chase Cancer Center, Philadelphia, PA
Background: A theoretical advantage of neoadjuvant 
therapy for pancreatic adenocarcinoma is the early treatment 
of micrometastases and reduction in postoperative systemic 
recurrence. However, the impact of preoperative therapy on 
postoperative patterns of recurrence is not well-established.
Methods: Medical records of 309 consecutive patients 
undergoing resection of adenocarcinoma in the head of the 
pancreas were reviewed. Survival was calculated from date 
of surgery using the Kaplan-Meier method. Associations 
between preoperative therapy and patterns of recurrence 
were determined using chi-square analysis.
Results: Among 309 patients undergoing resection of ade-
nocarcinoma in the head of the pancreas, 108 patients 
received preoperative chemoradiation, while 201 patients 
underwent upfront surgery. Neoadjuvant therapy was associ-
ated with a signifi cantly longer median disease-free survival 
of 14 months compared to 12 months with upfront surgery 
(p = 0.025). The rate of local disease as a component of fi rst 
site of recurrence was signifi cantly lower with preoperative 
therapy (12%, preoperative therapy vs. 22%, upfront surgery; 
p = 0.003). Similarly, preoperative therapy was associated 
with a lower rate of hepatic metastases (21%, preoperative 
therapy vs. 37%, upfront surgery; p = 0.006). Preoperative 
therapy did not affect rates of peritoneal (p = 0.24) or pul-
monary metastases (p = 0.57).
Conclusions: Neoadjuvant therapy for pancreatic cancer 
was associated with longer disease-free survival and lower 
rates of local and hepatic recurrences. These data support the 
use of preoperative therapy to reduce not only systemic but 
also local failures after resection.
CHEST CT AND POSITRON EMISSION 
TOMOGRAPHY (PET) IN PATIENTS 
WITH PANCREATIC 
ADENOCARCINOMA: ADDED 
INFORMATION OR JUST ADDED COST?
S. G. Pappas1, K. Chrisitans1, P. Tolat1, A. Lal2, 
L. McElroy1, A. Mautz1, T. C. Gamblin1, K. Turaga1, 
T. Susan1, R. Paul1, B. A. Erickson1, D. Foley1 and 
D. Evans1
1Medical College Of Wisconsin, Milwaukee, WI; 
2Columbia Saint Mary’s Hospital, Milwaukee, WI
Purpose: To determine if routine staging chest CT or PET 
scan alters the clinical management of patients presenting 
with newly diagnosed pancreatic adenocarcinoma.
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Methods: All new pancreas cancer patients seen from June 
1, 2008 through June 30, 2010 were retrospectively reviewed. 
We identifi ed all patients with metastatic disease on chest CT 
or PET that was unsuspected based on initial abdominal 
imaging (pancreas protocol CT).
Results: Histologic confi rmation of pancreatic adenocarci-
noma was present in 247 consecutive patients. Abdominal 
CT demonstrated metastatic disease in 107 (43%) and in 140 
(57%) localized disease in whom chest CT and PET was 
performed. Of these 140 patients, CT imaging suggested 
resectable disease in 54, borderline resectable disease in 60 
and locally advanced disease in 26. Chest CT demonstrated 
an unsuspected mediastinal mass (unrelated to pancreas 
cancer) in one patient with borderline resectable disease and 
PET identifi ed extra-pancreatic disease in two patients with 
locally advanced disease. Chest CT and PET added no new 
information in 137 (98%) of the 140 patients.
Conclusions: The addition of chest CT and PET to high 
quality abdominal CT is of little clinical utility at initial 
staging, and additional sites of metastasis are rarely found. 
However, this data was acquired at an institution that per-
forms very high quality abdominal imaging (to include the 
lower lung fi elds). If the quality of abdominal imaging is less, 
the yield from other imaging modalities may increase. 
Dedicated pancreas-specifi c abdominal CT remains the cor-
nerstone of initial staging for patients with suspected or 
biopsy-proven pancreatic cancer.
CHOLEDOCHODUODENOSTOMY IS AN 
EXCELLENT ALTERNATIVE TO ROUX Y 
CHOLEDOCHOJEJUNOSTOMY
J. G. Peacock1, J. K. Heimbach2, S. L. Nyberg2 and 
C. B. Rosen2
1Mayo Medical School, Rochester, MN; 2Mayo Clinic And 
Mayo Clinic College Of Medicine, Rochester, MN
Choledochoduodenostomy (CDD) is an alternative to Roux 
Y choledochojejunostomy (CDJ) for biliary reconstruction 
during liver transplantation. Potential advantages include 
avoidance of a jejunojejunostomy, decreased operative time, 
and ease of endoscopic intervention after transplantation. 
One of our surgeons adopted CDD as a preferred method of 
biliary reconstruction in 2005, and the others continued to 
perform CDJ. We reviewed our experience with specifi c aims 
to compare safety and postoperative course associated with 
CDD versus CDJ.
Methods: Eighteen CDD biliary reconstructions were per-
formed in patients undergoing whole organ deceased donor 
liver transplantation at our institution between 2005 and 
2011. Forty-fi ve control patients underwent CDJ during the 
same time period. We excluded retransplants and patients 
with cholangiocarcinoma. We reviewed hospitalization dura-
tion, postoperative complications, and survival data. 
Comparisons were made with the Student t-test for binary/
percentage outcomes and with the Mann-Whitney U test for 
non-parametric/median outcomes.
Results: There were no differences in one year patient 
or graft survival between the two groups. There was also 
no difference in median duration of hospitalization. 
Complications requiring intervention were signifi cantly 
more common after CDJ than CDD. Median operative time 
was signifi cantly longer for CDJ than CDD. Absence of 
complications in the CDD group precluded comparison of 
endoscopic intervention.
Conclusion: CDD is an effective and safe technique for 
biliary reconstruction. Safety compares favorably to that of 
CDJ. CDD is associated with shorter operative time and 
fewer complications than CDJ. With additional experience, 
CDD should also prove to be more amenable to endoscopic 
intervention than CDJ.
Results Table:
CDD CDJ p value
Number 18 45
Patient survival (%) 17 (94.4) 40 (88.9) 0.50
Graft survival (%) 17 (94.4) 44 (97.8) 0.49
Hospital stay (days) 
median
10 8 0.27
Leak (%) 0 (0.0) 2 (4.4) 0.37
Stenosis (%) 0 (0.0) 4 (8.9) 0.20
Bowel 
complications 
(%)
0 (0.0) 3 (6.7) 0.26
Total complications 
(%)
0 (0.0) 9 (20.0) 0.04
Median operative 
time (min)
199 275 0.0006
SEQUENTIAL INTRA-ARTERIAL 
THERAPY AND PORTAL VEIN 
EMBOLIZATION IS FEASIBLE AND SAFE 
IN PATIENTS WITH ADVANCED 
PRIMARY AND SECONDARY LIVER 
MALIGNANCIES
P. D. Peng1, C. Pulitano4, F. Shen5, M. Bloomston3, 
E. Dixon2, L. Aldrighetti5, B. Edil1, J. H. Geschwind1, 
K. Hirose1, C. L. Wolfgang1, R. D. Schulick1, M. A. Choti1 
and T. M. Pawlik1
1Johns Hopkins Hospital, Baltimore, MD; 2University Of 
Calgary, Calgary, AB, Canada; 3Ohio State University, 
Columbus, OH; 4Liver Unit, Scientifi c Institute San 
Raffaele, Milan, Italy; 5Eastern Hepatobiliary Surgery 
Hospital, Shanghai, China
Background: Combining portal vein embolization (PVE) 
with intra-arterial therapy (IAT) may increase future liver 
remnant (FLR) hypertrophy, but also may result in more 
morbidity. We sought to investigate the feasibility, safety and 
effi cacy of combined IAT+PVE.
Methods: Between 2000–2011, 81 patients with an 
advanced liver malignancy were identifi ed: 28 (34%) under-
went IAT+PVE, 21 (26%) PVE alone, and 32 (40%) IAT 
alone. Outcomes following combined IAT+PVE were com-
pared to a matched group of patients undergoing either IAT 
or PVE alone.
Results: Most patients had hepatocellular carcinoma (HCC) 
(67%) or colorectal liver metastasis (CRLM) (20%). Median 
tumor size was 6.5 cm (Table). Most patients undergoing 
IAT (n = 60) received transarterial chemoembolization 
(TACE) (52%) or drug-eluting beads (46%). PVE was per-
formed in 49 patients (IAT+PVE, n = 28 vs. PVE alone, n = 
21) mostly using n-butyl cyanoacrylate (49%) or micro-
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spheres (20%). Median time between IAT and PVE was 60 
days. Complete/partial response was 50% in patients treated 
with combined IAT+PVE vs. 44% among patients treated 
with IAT alone (p = 1.0). Mean FLR increase was compa-
rable in IAT+PVE (7.7%) vs. PVE-only (7.7%) groups (p = 
0.76). There were no IAT+PVE associated complications or 
deaths. Among patients treated with IAT+PVE (n = 28), 26 
(93%) underwent subsequent hepatic resection with 96% 
having an R0 margin. Morbidity and mortality were 27% and 
6%, respectively. Among patients with HCC who underwent 
surgery following IAT+PVE, 5-year survival was 55%.
Conclusions: While IAT+PVE was feasible and safe, it did 
not result in additional FLR hypertrophy or better tumor 
response following either PVE or IAT alone. Utilization of 
IAT+PVE prior to resection did lead to long-term survival in 
a subset of patients.
IAT only (n = 32) PVE only (n = 21) IAT+PVE (n = 28) Total (n = 81)
Tumor size, cm 6.2 5.5 10.0* 6.5
Biologic MELD, mean 8.7 7.6 7.6 8.1
EASL complete/partial response 44% 5%* 50% 36%
Change in FLR, mean 0.9%* 7.5% 7.4% 4.7%
Morbidity 6% 9% 0% 5%
*p < 0.05.
HCC: RESECT OR TRANSPLANT
R. PIeretti-Vanmarcke1,2, U. Basit1, M. Ligorio1,2, 
N. Elias1,2, D. L. Berger1,2, K. K. Tanabe1,2 and 
C. R. Ferrone1,2
1Massachusetts General Hospital, Boston, MA; 2Harvard 
Medical School, Boston, MA
Objective: To compare the outcomes of patients with hepa-
tocellular carcinoma (HCC) undergoing either liver trans-
plantation (LT) or resection (LR).
Methods: A single institution retrospective analysis of 268 
HCC patients treated 8/1991–8/2009.
Results: A total of 268 patients with HCC underwent surgi-
cal treatment of whom 79% were male, 21% had hepatitis B 
and 41% hepatitis C. Patients underwent transplantation (n 
= 99) or surgical resection (n = 169). Of the resected patients 
116 did not meet the Milan Criteria (MC) while 53 patients 
were within MC. When comparing resected patients within 
MC to transplanted patients the median tumor diameter was 
3.18 cm and 3.02 cm, respectively. Recurrence rates were 
56.6% for resected patients within MC and 13.13% for LT 
patients (p < 0.0001). The model end-stage liver disease 
(MELD) score median was 5 for resected patients within MC 
and 18.5 for LT patients. The median overall survival (OS) 
was 40 months for both resected and transplanted patients. 
The OS at 1, 3, and 5 years was 47%, 40%, and 23% for 
resected patients within MC and 59%, 49%, and 33% for 
transplanted patients (p = ns). Patients outside of MC who 
were resected had a signifi cantly decreased survival com-
pared to patients within MC and who were transplanted.
Conclusions: For HCC patients within the Milan criteria 
transplantation is associated with a lower recurrence rate, but 
not a signifi cantly improved overall survival. Patients outside 
of Milan criteria had a signifi cantly poorer OS when com-
pared to patients within Milan criteria who were resected or 
transplanted, refl ecting a more aggressive biology of disease.
NATIONAL TRENDS IN 
PANCREATICODUODENAL TRAUMA: 
INTERVENTIONS AND OUTCOMES
E. Ragulin-Coyne, E. R. Witkowski, Z. Chau, S. Ng, 
D. Wemple, S. A. Shah, H. Santry and J. F. Tseng
Surgical Analysis & Outcomes (SOAR), University Of 
Massachusetts, Worcester, MA
Introduction: Pancreaticoduodenal trauma (PDT) has sub-
stantial mortality and morbidity. We analyzed contemporary 
trends using national data.
Methods: The Nationwide Inpatient Sample 1998–2007 
was queried for patients with PDT by ICD-9 and mechanism 
of injury by E-codes. Interventions including any-operation 
and pancreas-specifi c surgery were identifi ed and compared 
over time. We determined trends in treatment and outcomes 
(complication rates, length of stay [LOS], and mortality) for 
surgery vs. non-operative groups. Analyses included Chi2, 
Cochran-Armitage trend, and logistic regression.
Results: 25532 patients (nationally-weighted) had PDT. Of 
those, 14344 injuries were pancreas alone, 9066 duodenal, 
and 2122 combined. Over time, proportion undergoing pan-
creas–specifi c surgery declined (20.4% in 1997 vs. 19.0% in 
2007, p = 0.0004); non-operative management increased 
(57.9% to 58.7%, p = 0.003). For any-operation, mortality 
remained stable (15.5% to 14.5%, p = 0.1); complications 
increased (52.4% to 63.8%, p < 0.0001); LOS increased 
(18.2 to 22.8 days, p = 0.002). For pancreas-operation group, 
mortality remained stable (16.7 vs. 15.1, p = 0.9), complica-
tions increased (47.5% to 63.7%, p < 0.0001), LOS increased 
(18.6 to 22.5, p = 0.03). For non-operative group, mortality 
decreased (9.3% to 8.7%, p < 0.001); complication rate was 
unchanged (38.1 to 40.3%, p = 0.1) and LOS remained stable 
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(11.9 vs. 11.6 days, p = 0.5). For all PDT patients, signifi cant 
independent predictors of mortality were: combined pancre-
aticoduodenal injury, penetrating trauma, age >50. Having 
any surgery was associated with mortality, but pancreatic-
specifi c surgery was not a predictor of death.
Conclusion: The extent of surgery for PDT has declined 
without changing mortality. In the 21st century, a high index 
of suspicion for pancreaticoduodenal injury coupled with an 
evidence-based approach to invasive maneuvers may 
improve outcomes from these morbid and costly injuries.
IS DONATION AFTER CARDIAC DEATH 
DONOR LIVER TRANSPLANTATION 
STILL COST-EFFECTIVE OR JUST A 
MEANS OF SHIFTING WAIT-LIST DEATH 
TO RECIPIENT DEATH?
L. A. Redhage and D. E. Moore
Vanderbilt University Medical Center, Nashville, TN
The aim of this study was to evaluate the cost-effectiveness 
of the continued use of Donation after Cardiac Death (DCD) 
donors compared to the use of Donation after Brain Death 
(DBD) donors alone. A Markov-based decision analytic 
model was created to simulate and compare two wait list 
strategies: 1) a wait list comprised of potential recipients who 
received DBDs only, 2) a wait list comprised of potential 
recipients who received either DBDs or DCDs. Baseline 
values and ranges were determined from the SRTR and an 
extensive literature review. Sensitivity analyses were con-
ducted to test model strength and parameter variability. 
Recipients of organs from DCD donors were modeled to 
have a fi ve year survival of 68% versus 81% for recipients 
of organs from DBD donors. Biliary complications were two 
times more likely in DCD recipients. After transplantation, 
recipients in the DBD only wait list gained 5.5 QALYs 
(Quality Adjusted Life Years) at a cost of $65,000/QALY. 
After transplantation, recipients in the DCD+DBD wait list 
gained 5.8 QALYs at a cost of $57,000/QALY. While the 
overall survival is decreased and biliary complications are 
increased, the extension of life and quality of life provided 
by DCD donors makes their continued use cost-effective.
PATIENT AND COMMUNITY 
CHARACTERISTICS ARE ASSOCIATED 
WITH LONGITUDINAL HEALTH-
RELATED QUALITY OF LIFE IN LIVER 
TRANSPLANT RECIPIENTS
L. Redhage, I. D. Feurer, D. E. Moore, L. Simmons and 
C. W. Pinson
Vanderbilt University Transplant Center, Nashville, TN
The aim of this study was to test whether patient and com-
munity characteristics are associated with longitudinal 
health-related quality of life (HRQOL) in liver transplant 
recipients. HRQOL was measured using the SF-36 physical 
(PCS) and mental (MCS) components, Beck Anxiety 
Inventory (BAI), and CES-D depression scale. Patient char-
acteristics were months post-transplant at each HRQOL 
assessment, whether HCV was the cause of liver failure, age, 
sex, race and type of health insurance (private/public). 
Community characteristics (population, median household 
income, proportion of high school graduates, and urban-rural 
classifi cation) were based on the zip code of permanent resi-
dence using US census and National Center for Health 
Statistics (NCHS) data. Linear mixed models tested the 
effects of patient and community characteristics on longitu-
dinal PCS, MCS, BAI and CES-D scores. Two hundred 
thirty-one adult liver transplant recipients (69% male, 
average follow-up 29 ± 24 months) had one pre- and at least 
one post-transplant HRQOL assessment (>1000 assess-
ments). All four HRQOL outcome measures improved (p < 
0.001) with time after transplantation. Private health insur-
ance was associated with better HRQOL in all models, and 
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increased population was associated with better PCS, MCS, 
and BAI scores (all p < 0.05). HCV infection as the primary 
cause of liver failure was associated with increased symp-
toms of anxiety. Liver transplant recipients with private 
health insurance living in more highly populated areas have 
superior HRQOL, which may be attributed to increased 
access to healthcare resources.
INCIDENCE AND IMPLICATIONS OF 
IMPAIRED GLYCEMIC CONTROL 
FOLLOWING DISTAL 
PANCREATECTOMY
M. Rogers1, G. Morris-Stiff1, G. A. Falk1, S. Chalikonda1, 
L. Yerian2 and R. M. Walsh1
1Department Of General Surgery, Section Of Surgical 
Oncology/HPB, Cleveland, OH; 2Department Of 
Histopathology, Cleveland, OH
Background: The development of diabetes mellitus (DM) is 
an important long-term consequence of distal pancreatectomy.
Aims: To document the prevalence of DM and assess its 
relationship to potential etiological risk factors.
Methods: Patients who had undergone a distal pancreatec-
tomy from 1990 through 2009. Were identifi ed, and demo-
graphic data, medication needed for glycemic control, 
histopathology, and volume resected were collected.
Results: 137 patients underwent resection including 26 
(19.0%) that had DM pre-operatively. New-onset DM was 
identifi ed in 27/111 patients (24.3%) at a mean of 6.4 months 
post-operatively. DM was more common in patients with 
chronic pancreatitis (5/13; 38.5%) and adenocarcinoma 
(7/22, 31.8%), but was not seen in patients undergoing resec-
tion for serous cystadenoma (0/8), or IPMN (0/9). Patients 
developing diabetes were older (63.4 vs. 55.1, p = 0.01) but 
there was no difference in gender or ethnic distributions. DM 
was not linked to the volume of parenchyma resected: lower 
volumes of tissue were resected in those with diabetes 
(119.2 cm3 vs 192.7 cm3; p = 0.314); or related to patient 
body mass index [BMI] (29.3 KgM-2 vs 28.1 KgM-2; p = 
0.51). Of the 26 patients with pre-resection diabetes, 9 were 
taking insulin. In the remaining 17, 8 (47%) deteriorated and 
required insulin postoperatively. The development of post-
operative impaired glycemic control was associated with 
prolonged hospital stay (12.6 days vs. 7.7 days; p = 0.001).
Conclusions: Impaired glycemic control is common follow-
ing distal pancreatectomy, especially in those resected for 
chronic pancreatitis or cancer. In patients requiring distal 
pancreatectomy for chronic pancreatitis, improved outcome 
may include islet replacement.
THE STANDARDIZATION OF LAPARO-
ENDOSCOPIC SINGLE SITE (LESS) 
CHOLECYSTECTOMY
S. B. Ross1, H. Paul2, K. Luberice2, F. Co2, E. Choung2 and 
A. Rosemurgy2
1University Of South Florida, Tampa, FL; 2Tampa General 
Medical Group, Tampa, FL
Many surgeons have found LESS cholecystectomy challeng-
ing. This video is an attempt to promote a standardized 
approach of LESS cholecystectomy in which surgeons with 
laparoscopic skills can safely and effi ciently adopt. This is a 
single incision approach consistent with the 4-incision 
approach of conventional laparoscopic cholecystectomy. After 
administration of general anesthesia, 10 ml of bupivacaine 
was injected at the umbilicus and a 12 mm vertical incision 
was made in the anatomical scar of the umbilicus. A single 
4-trocar port was inserted. A 5 mm defl ectable tip laparoscope 
was placed through the trocar at the 8 o’clock position, a 
bariatric length rigid grasper at the 4 o’clock position (to grasp 
the fundus), a rigid bent grasper at the 2 o’clock position (to 
grasp the infundibulum), and the working port was at the 10 
o’clock position. This arrangement of the instruments and the 
defl ectable tip laparoscope minimizes internal and external 
instrument clashing, and allows retraction of the gallbladder 
in a cephalad and lateral or medial direction. A window was 
developed between the gallbladder and the liver, which pro-
moted the subsequent “critical view” of the cystic duct and 
artery. Before disengaging the gallbladder from the liver bed, 
hemostasis was ensured. The diaphragm was irrigated with 
bupivacaine solution to minimize postoperative pain. The 
umbilical defect was closed with an absorbable suture in a 
fi gure-of-eight fashion, and the skin was approximated.
LONG TERM FOLLOW-UP AFTER 
PRIMARY EXCISION OF DUODENAL 
NEUROENDOCRINE TUMORS, A CASE 
SERIES
J. W. Rostas1 and L. W. Thompson2
1University Of South Alabama College Of Medicine, 
Mobile, AL; 2Cancer Surgery Of Mobile, P.C., Mobile, AL
Background: Although duodenal neuroendocrine tumors 
(NETs) are historically rare, their incidence has increased in 
recent years with an increased utilization of diagnostic upper 
gastro-intestinal endoscopy. Appropriate management of 
small, early NETs is controversial, with most amenable to 
either endoscopic or surgical resection. Surgical resection is 
advocated for tumors with invasion through the submucosa, 
to allow local exploration to minimize missed tumors, and 
due to data demonstrating improved survival rates. Long 
term follow-up data is sparse, and is needed to help elucidate 
the appropriate therapy for this growing problem.
Methods: A single institution retrospective review was con-
ducted from 2002 to 2006, evaluating primary excision of 
small (<2 cm) duodenal NETs. All tumors were identifi ed 
pre-operatively via endoscopy and biopsy. All signifi cant 
complications were included.
Results: Five patients had open resection of a duodenal 
NET; three were males, with an average age of 57.2 years 
(50–73). Three patients had primary closure, and two had 
closure with a Billroth II reconstruction. All tumors were 
well-differentiated NETs resected with clear margins, with 
an average tumor size of 1.4 cm (0.7–1.7). Mean follow-up 
is 6 years (5–7.5). There were no signifi cant complications 
related to the resection of the NETs. One patient, secondary 
to an abscess acquired during endoscopic biopsy, developed 
a chronic right upper quadrant abscess requiring surgical 
debridement and drainage. There have been no tumor related 
deaths or recurrences.
Conclusions: While a small case series, this report demon-
strates the effi cacy of primary resection for duodenal carci-
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noids, as complications were minimal and no patient has 
exhibited recurrence.
SURGICAL TREATMENT FOR PRIMARY 
AND LOCALLY ADVANCED/METASTATIC 
SOFT-TISSUE SARCOMA INVOLVING 
THE PANCREAS AND LIVER
M. Sabbaghian, G. Rosen, H. Pachter and J. Raccuia
New York University School Of Medicine, New York, NY
Purpose: Primary and metastatic sarcoma involving the 
hepatopancreaticobiliary structures is rare. Surgical resection 
is examined for its role in cure or palliation.
Methods: From 1997 to 2011, 151 patients were treated 
surgically for sarcoma involving the retroperitoneum, 
abdomen and pelvis. Sixty-four (42%) had primary or locally 
advanced/metastatic sarcoma involving the pancreas and/or 
liver.
Results: Fifty-two of 64 (81%) patients underwent en bloc 
pancreas and/or liver resection. 34/52 (65%) had recurrent 
disease. Pancreatectomy was performed in 23 (44%), hepa-
tectomy in 17 (33%), and combined resection in 12 (23%). 
The average lesion size was 12.2 ± 8.9 cm. The average 
number of tumors resected at once was 4.8 ± 7.9. 
Intraoperative blood loss averaged 2200 ± 2600 cc with a 
mean number of blood transfusions 3.0 ± 3.3 units. There 
were 4 operative deaths and 18 non-lethal perioperative com-
plications. Pathology included gastrointestinal stromal tumor 
in 18 (34%), leiomyosarcoma in 16 (30%), liposarcoma in 
11 (21%), and various other soft tissue sarcomas in 7 (13%). 
Mean follow-up was 35 ± 41 months. 33/52 patients had 
tumor recurrence at a mean 15 ± 18 months (range 2–71) 
after surgery. Recurrence occurred in the liver (n = 11), ret-
roperitoneum (7), abdomen (6), pancreas (3), lung (3) and 
other multiple sites (3). Sixteen patients remain alive: 5 with 
and 11 without evidence of disease. The median survival has 
been 27 ± 7 months with overall survival at 5 and 10 years 
36% and 19%, respectively.
Conclusions: En bloc pancreas/liver resection for sarcoma 
is feasible, and complete resection seems to provide worth-
while palliation or long-term survival.
SORAFENIB INDUCED VASCULATURE 
CHANGES IMPROVES SURVIVAL WHEN 
COMBINED WITH YTTRIUM-90 RADIO-
EMBOLIZATION FOR THE TREATMENT 
OF ADVANCED HCC
A. Salman, L. Boucher, M. Hassanain, E. Simoneau, 
M. Jamal, M. Al-Jiffry, C. Nudo, P. Chaudhury, 
J. Tchervenkov and P. Metrakos
McGill University Health Centre, Montreal, Quebec, 
Canada
Introduction: Anti-angiogenics can increase radiosensitivity 
by “normalizing tumor vasculature” and increasing O2, pro-
viding rationale for combining Sorafenib (SF) with yttrium-90 
radio-embolization (Y90RE). This study reports median OS 
as related to the effect of SF on HCC vasculature.
Methods: 38 consecutive patients with HCC began SF 
(400 mg po BID) at least 7 weeks prior to Y90RE and con-
tinued thereafter. 8 were withdrawn from the study due to SF 
adverse events. 30 patients received a radionucleotide hepatic 
angiogram to rule out arterial venous shunts. In 19 patients, 
this angiogram was performed as SF was started therefore it 
could be compared with the angiogram at the time of Y90 
RE, 7 or more weeks after start of SF.
Results: Patients were subdivided into 4 groups: well 
defi ned vessels (WDV), less defi ned vessels (LDV), pruning 
(PR), vascular blushes (VB) and no change (NC). Survival 
curves were generated and patients were grouped into two 
groups just by their survival curves; patients with NC/WDV 
(Group A, 13), and into patients with LDV (PR, VB and 
LDV) (Group B, 6). The median OS for all 38 patients was 
12.1 mos. The median OS of the 19 patients with vascular 
assessment was 11.9 mos. Median OS between groups A 
(13.2 mos) and B (7.7 mos) was signifi cantly different (log-
rank, p = 0.0076).
Conclusion: Average OS (12.1. mos) was signifi cantly 
longer then expected with SF alone (SHARP, 10.5 mos). 
When SF improves/maintains the quality of tumor vascula-
ture, there appears to be an improvement of median OS.
MULTICENTER RESULTS OF 
STEREOTACTIC BODY RADIOTHERAPY 
(SBRT) FOR SECONDARY TUMORS OF 
THE LIVER
J. Sanabria1, B. Berber1, M. Yao2, K. Goodman4, 
M. MIlano3, A. Katz3, K. Stephans5, F. Aucejo5 and 
J. Fung5
1Department Of Surgery, University Hospitals Case 
Medical Center, Cleveland, OH; 2Department Of Radiation 
Oncology, University Hospitals Case Medical Center, 
Cleveland, OH; 3Department Of Radiation Oncology, 
University Of Rochester Medical Center, Rochester, NY; 
4Department Of Radiation Oncology, Memorial Sloan-
Kettering Cancer Center, New York, NY; 5Department Of 
Surgery, Cleveland Clinic, Cleveland, OH
More >250,000 patients are diagnosed with liver metastases/
year in USA. < 20% of those lesions are amenable to defi ni-
tive surgical management. Local-regional therapies have 
limited response and no signifi cant impact on patient sur-
vival. SBRT has emerged as an alternative therapy. The aim 
of this study was to determine the response of liver metasta-
ses (LM) to SBRT and if SBRT treatment may confer sur-
vival benefi t to patients with non-resectable liver metastases. 
Patients with LM treated with SBRT from four Academic 
Medical Centers were entered into a common database. 
Descriptive statistics and survival curves were performed 
using SPSS.
Results: 155 patients underwent SBRT for LM. 52% of 
tumors originated in the GI tract while 35% were from the 
thorax including breast. 89% of treated neoplasms responded 
to SBRT at a median dose of 10.5/3 Gy/fractions. A Grade 
III/IV local response was observed in 52% of LM treated 
with a mean decrease in maximum diameter from 4.3 ± 
1.9 cm to 2.5 ± 1.3 cm and a calculated mean total tumor 
volume reduction of 39% (p < 0.01). Recurrences in the 
radiated fi eld were observed in 2% of treated cases. SBRT 
did not conferred a survival advantage in patients with LM 
when compared with matched controls (p > 0.05). Systemic 
recurrences were common. No complications attributable to 
fi ducial placement or SBRT treatment were observed.
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Conclusion: SBRT is a safe and effective treatment modal-
ity for the local control of LM. Further analyses are undergo-
ing to determine response to SBRT according to tumor type.
MASSIVE HEPATOCELLULAR 
CARCINOMA IS ASSOCIATED WITH 
YOUNG, CHRONIC HEPATITIS B 
CARRIERS WITH NON-CIRRHOTIC 
LIVERS
U. Sarpel, D. M. Ayo, I. V. Lobach, R. Xu and E. Newman
New York University Medical Center, New York, NY
Introduction: A subset of patients with hepatocellular car-
cinoma (HCC) present with markedly large tumors. This 
manuscript describes the entity of massive HCC and defi nes 
the related clinical features.
Methods: A retrospective review was performed of all cases 
of HCC at an urban public hospital. Socio-demographic and 
laboratory data were collected. Radiologic images were 
reviewed and maximal tumor diameter on axial imaging was 
recorded. Cirrhosis was defi ned by radiologic and laboratory 
criteria. Univariate analysis with chi-square test and logistic 
regression multivariate analysis were conducted in the tradi-
tional fashion.
Results: 362 cases of HCC were identifi ed over the past 13 
years. Preliminary analysis demonstrated an inverse relation-
ship between size and cirrhosis. A cut-off value to defi ne 
Massive HCC was determined by calculating chi-square 
values of association between cirrhosis and various cut-offs 
of for size, and resulted in a defi nition of Massive HCC as 
≥13 cm. As a result, 58 patients were identifi ed as having 
Massive HCC. Univariate and multivariate analysis demon-
strated signifi cant association of Massive HCC with age <40, 
hepatitis B, Asian ethnicity, and lack of cirrhosis or its sur-
rogates. These tumors were signifi cantly associated with 
gross vascular invasion, and distant metastases.
Conclusion: Massive HCC represents a distinct tumor 
subtype that is associated with young, chronic hepatitis B 
carriers with non-cirrhotic livers. The compliant tissue of the 
non-cirrhotic liver may offer less resistance to expansive 
tumor growth. Treatment options are limited in these patients, 
however the absence of cirrhosis makes them excellent 
resection candidates when metastases or prohibitive vascular 
invasion are not present.
Massive (n = 58) Non-Massive (n = 304) p value
Demographic Features
 Age < 40 20 (35%) 30 (10%) <0.05
 Gender 51 (88%) 250 (82%) NS
 Asian ethnicity 45 (78%) 129 (42%) <0.05
Clinical Features
 Hepatitis B 48 (83%) 140 (46%) <0.05
 Radiologic Cirrhosis 16 (29%) 216 (72%) <0.05
 Platelets <100 4 (7%) 92 (30%) <0.05
 Childs Score = 5 25 (45%) 177 (58%) <0.05
Tumor Features
 Single tumor 29 (51%) 165 (54%) NS
 Vascular Invasion 31 (53%) 58 (19%) <0.05
 Metastases 9 (16%) 16 (5.3%) <0.05
Treatment
 Chemotherapy 16 (29%) 43 (14%)
 Embolization 3 (5.5%) 48 (16%)
 Ablation 0 (0%) 34 (11%)
 Resection or OLT 6 (11%) 70 (23%)
 No treatment 29 (53%) 105 (35%) <0.05
TWO-STAGE LIVER RESECTION IN 
COLORECTAL CANCER (CRC) LIVER 
METASTASIS: SELECTION, 
MICROMETASTASIS AND PROGNOSIS
L. T. Seeberg, G. Wiedswang, K. W. Brudvik, 
B. A. Bjrnbeth, H. Hugenschmidt, K. J. Labori, B. Naume, 
N. E. Klw and A. Waage
Oslo University Hospital, Oslo, Norway
Background: In patients having CRC liver metastasis (LM) 
involving both liver lobes, the volume of the future liver 
remnant (FLR) may limit surgical resections. By performing 
a two-stage procedure combined with portal vein embolization 
(PVE), non-resectable patients might become resectable. This 
study focuses on selection criteria and oncological outcome.
Methods: From June 2008–June 2011 all CRC-LM patients 
scheduled for liver resection were prospectively registered. 
Bone marrow aspiration and blood samples were collected 
intraoperatively and micrometastasis detected by immunocy-
tochemistry. Patients selected for two-stage liver resection 
were included. CT volumetry was performed 4 weeks after 
PVE/fi rst-stage surgery. If suffi cient FLR, right sided hemi-
hepatectomy was scheduled. Prognostic variables and onco-
logical outcome were analyzed.
Results of 133 patients: 19 (14%) were planned for two-
stage resection. 14/19 patients had synchronous disease. FLR 
were suffi cient in all patients. Two patients were non-resect-
able due to progression. Mean follow-up was 15 months 
(range 2–40). All patients received chemotherapy prior to 
surgery. Recurrence was observed in 14/19 patients. Median 
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disease free survival (DFS) was 10 months (range 2–30) 
compared to 18 months in one-stage resected patients. The 
presence of micrometastasis correlates with rapid recurrence 
and reduced survival. Micrometastasis were detected in 5/19, 
and all positive patients relapsed. None of the fi ve disease-
free patients had detectable micrometastasis.
Conclusion: Two-stage liver surgery in combination with 
PVE is an advanced and demanding treatment option. 
Optimizing the selection criteria for resection is crucial. 
Detected micrometastasis predicted impaired survival and was 
a negative prognostic variable in this small cohort of patients.
SURGEON SPECIALIZATION AND 
UTILIZATION AFTER HEPATECTOMY IN 
ACADEMIC MEDICAL CENTERS
J. J. Shaw, C. W. Macomber, H. P. Santry, J. F. Tseng and 
S. A. Shah
University Of Massachusetts Medical School, Worcester, MA
Introduction: Specialized procedures like hepatectomy 
generate high cost and potentially high revenue for hospitals. 
We aimed to determine if variation exists among utilization 
of resources, cost and patient outcomes by specialty for 
hepatectomy.
Methods: We queried all centers (n = 14) in the University 
Health Consortium (UHC) from 2008–2011 for patients who 
underwent hepatectomy in which specialty was designated 
general surgeon (n = 643; 19%) or specialist surgeon, defi ned 
as surgical oncologist (n = 1538; 44%) and transplant surgeon 
(n = 1283; 37%). We then stratifi ed our cohort by severity of 
illness (SOI; quartiles) and primary diagnosis, defi ned as 
primary tumor (n = 1035; 30%), secondary tumor (n = 1502; 
43%) and benign (n = 927; 27%).
Results: Specialist surgeons performed more cases for 
malignancy (primary 89% vs. 11%; secondary 78% vs. 22%) 
and benign disease (79% vs. 21%). There were no statistical 
differences between general and specialist surgeons in in-
hospital mortality (1.9% vs. 2.4%), total length of stay (LOS) 
(7 days vs. 7 days) and 30-day re-admission (12% vs. 8%). 
General surgeons had higher complication rates (6.9%) com-
pared to specialist surgeons (3.5%). When stratifi ed by SOI 
and primary diagnosis specialist surgeons performed hepa-
tectomy with less direct cost for all groups except the highest 
SOI group (see Table 1) and had fewer ICU admissions for 
all groups except the highest SOI group.
Conclusion: Surgical specialization may be an important 
metric for quality and utilization in complex procedures like 
hepatectomy. Further studies are necessary to link direct 
factors related to hospital performance in the changing 
healthcare environment.
COMMON BILE DUCT EXPLORATION 
VIA CYSTIC DUCT WITH A SPECIAL 
REFERENCE TO SEPTUM-LIKE 
STRUCTURE AT THE JUNCTION: A 
SURGICAL PEARL TO AVOID BILE DUCT 
STRICTURE
A. Shimizu, M. Hyodo, Y. Sakuma, T. Fujiwara, 
H. Sasanuma, M. Koizumi, N. Sata and Y. Yasuda
Department Of Surgery, Jichi Medical University, 
Shimotsuke, Tochigi, Japan
Background: Choledochotomy is employed to surgically 
remove choledocal stones. In a case with a non-dilated bile 
duct, however, even if technically feasible, there remains a 
concern about postoperative stricture after primary closure. 
T-tube or C-tube is often used. Still once incised, benign 
biliary stricture could occur as a late complication. Cystic 
duct approach with septum opening has been applied for 
these cases with excellent outcome.
Method: The gallbladder is removed from the hepatic bed 
in a fundus-downward fashion, followed by dissection of the 
cystic duct. Next the lateral side of the cystic duct is incised 
longitudinally up to the junction of the common bile duct to 
identify the opening into the bile duct. A septum-like struc-
ture, a fused abutment of the cystic duct and the common 
hepatic duct is recognized. This is opened without jeopardiz-
ing the free wall of the bile duct. Thereafter lithotomy is 
performed followed by cholangioscopy to ensure no calculus 
left. Then the cystic duct is closed with intermittent 5-0 
absorbable sutures. With this technique, incision to the 
common bile duct can be avoided and therefore theoretically 
stricture will not ensue. This method can also be applied to 
a diffi cult cystic duct cannulation case performing intraop-
erative cholangiography.
Results: During the past three years, fi ve cases with gall-
bladder and/or choledochal stones were treated with this 
technique. No postoperative bile leak, no narrowing of the 
bile duct was noted.
Conclusion: Common bile duct exploration using this 
cystic duct approach is useful to avoid postoperative stricture 
especially in a case with a non-dilated bile duct.
RESECTION VERSUS TRANSPLANT FOR 
SOLITARY HEPATITIS C-ASSOCIATED 
HEPATOCELLULAR CARCINOMA: AN 
INTENTION-TO-TREAT ANALYSIS
B. Shrager
Division Of Surgical Oncology, Department Of Surgery, 
Mount Sinai School Of Medicine, New York, NY
Background: The management of Hepatitis C-virus associ-
ated hepatocellular carcinoma is complex. The aim of this 
study was an intention-to-treat comparison of partial hepa-
tectomy and orthotopic liver transplant, the two established 
curative therapies for this entity.
Methods: We retrospectively reviewed the records of all 
patients at our center treated with partial liver resection or 
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listed for liver transplant for HCV-associated HCC from 
January 2002 through December 2007. Inclusion criteria 
were (1) initial diagnosis of a solitary HCC ≤5 cm and (2) 
Child-Pugh class A or B liver function. Outcomes were ana-
lyzed with the primary endpoint of intention-to-treat survival 
and the secondary endpoints of surgical survival and 
recurrence.
Results: One hundred and thirty-one patients satisfi ed the 
inclusion criteria: 75 patients listed for liver transplant 
(LT-listed group) and 56 patients resected (LR group). 
Intention-to-treat actuarial 5-year survival was superior in 
the LR group as compared to the LT-listed group, but this 
did not reach statistical signifi cance (51.6% vs. 44.1%, p = 
N.S.). Recurrence was observed in 34 (60.7%) of the 56 
resected patients as compared to 12 (21.8%) of the 52 
patients transplanted. For the whole cohort, independent pre-
dictors for impaired survival were albumin ≤3.5 g/dl (hazard 
ratio 2.05, 95% C.I. 1.06–3.96, p = 0.032) and radiographic 
tumor size > 3 cm (hazard ratio 1.95, 95% C.I. 1.18–3.21, 
p = 0.09). Vascular invasion independently predicted recur-
rence (hazard ratio 3.86, 95% C.I. 1.91–7.79, p < 0.001).
Conclusions: With severe limitations on donor organ avail-
ability, partial hepatectomy represents a safe and effi cacious 
primary approach for carefully selected patients with HCV-
associated HCC.
Methods: Retrospective review of patients with symptom-
atic PP and WOPN treated with laparoscopic transgastric 
endolumenal cystogastrostomy (Lap-TEC) and PD was per-
formed (Figure 1).
Results: From October 2006 to April 2011, 10 Lap-TEC and 
PD procedures were performed with 7 being completed lapa-
roscopically. The cohort had a median age of 52 years 
(39–71) and consisted of 50% females. Average BMI was 
30 kg/m2 and 90% had an ASA score ≥3. Gallstones were 
the most common etiology (50%). Half of the PP and WOPN 
were considered to be chronic and median time between 
initial presentation and operation was 65 days (0–360). 
Median operative time and EBL were 178 minutes and 75 cc, 
respectively. Forty percent of patients were admitted to the 
ICU postoperatively. Overall, average length of hospital stay 
was 12 days (4–48). Median follow-up was 3 months with 3 
patients having non-procedural related complications within 
the 30 day postoperative period. There were no reoperations, 
late complications, or mortalities. All patients had resolution 
of their symptoms.
Conclusion: Our technique of internal drainage via 
Lap-TEC and PD has been successful in achieving primary 
drainage and relieving symptoms of PP and WOPN with no 
mortality and minimal morbidity. Strong consideration 
should be given to the utilization of this straightforward and 
successful minimally invasive technique.
ROUTINE AND SEAMLESS 3D LIVER 
LESION TARGETING FOR 
LAPAROSCOPIC ABLATION: ONE STEP 
CLOSER
K. A. Simo1, D. Sindram1, I. H. McKillop1, S. Razzaque2, 
J. B. Martinie1 and D. A. Iannitti1
1Section Of Hepatobiliary And Pancreatic Surgery, Dept. 
General Surgery, Carolinas Medical Center, Charlotte, 
NC; 2InnerOptic Technology, Inc., Hillsborough, NC
Introduction: To overcome challenges of targeting liver 
lesions, a novel 3D image guidance system (3D-IGS) was 
developed by InnerOptic (Hillsborough, NC). The aims of 
this study were to perform an in vivo evaluation of next 
generation magnetic position tracking systems for use with 
microwave antennae and radiofrequency ablation probes 
LAPAROSCOPIC TRANSGASTRIC 
ENDOLUMENAL CYSTGASTROSTOMY 
AND PANCREATIC DEBRIDEMENT
K. A. Simo, R. Z. Swan, D. Sindram, J. B. Martinie and 
D. A. Iannitti
Section Of Hepatobiliary And Pancreatic Surgery, Dept. 
General Surgery, Carolinas Medical Center, Charlotte, NC
Introduction: Cystogastrostomy is commonly performed 
for internal drainage of pancreatic pseudocysts (PP) and con-
comitant pancreatic debridement (PD) for walled-off pancre-
atic necrosis (WOPN). While approaches to cystogastrostomy 
continue to evolve, an optimal minimally invasive technique 
has not yet been well-established.
70 Abstracts
© 2012 The Authors
HPB © 2012 Americas Hepato-Pancreato-Biliary Association, HPB, 14 (Suppl. 1), 1–91
(MWA/RFA) while reviewing system performance under OR 
conditions.
Methods: Tumor mimics were placed intrahepatically in 
swine to compare conventional laparoscopic ultrasound-
guided ablation to 3D-IGS (Figure 1). The 3D-IGS was 
designed with position sensors built into (RF-probe) or 
bonded to (MWA-antenna) laparoscopic instruments in con-
junction with a table top magnetic fi eld generator to track 
positioning. A fl exible laparoscopic ultrasound probe with 
snap-on position sensor was employed to identify tumor 
mimics. After pneumoperitoneum was achieved and ports 
placed, ablations were performed.
Results: Operative workfl ow was not affected by fi eld gen-
erator location, position sensors or presence of a protective 
sleeve. Overall, tracking accuracy remained high with no 
interference detected between this system and essential OR 
instruments/equipment. Minor interference was detected 
with specifi c instruments (notably those with gold-plated 
handles) leading to warnings on the 3D-IGS. Using the 
3D-IGS ablation probe position sensors survived multiple 
stabs/ablations with 8/8 superfi cial targets hit on the fi rst 
attempt (mean = 43.7 seconds; range 24–76 seconds).
Conclusions: The new generation 3D-IGS solved many 
technical issues associated with its predecessor and per-
formed well and with high fi delity in an in vivo model under 
real-time OR conditions. We are proceeding with quantita-
tive validation and human trials.
THE PROGNOSTIC UTILITY OF 
FDG-PET CT IN THE EVALUATION OF 
PATIENTS WITH HEPATOCELLULAR 
CARCINOMA FOR LIVER 
TRANSPLANTATION
E. Simoneau1, M. Jamal1, M. Aljiffry1, A. Salman1, 
J. Kwan1, P. Chaudhury1, J. Tchervenkov1, P. Metrakos1 
and M. Hassanain1,2
1McGill University Health Center, Montreal, QC; 
2King Saud University, Riyadh, Riyadh, Saudi Arabia
Liver transplantation (LT) is an important therapeutic modal-
ity for selected patients with hepatocellular carcinoma 
(HCC). Currently, tumor size and volume are the accepted 
parameters used to decide for transplant eligibility, however, 
there is growing evidence that other parameters could 
increase prognostic precision and should be considered when 
selecting patients for transplantation. It has also been shown 
that positivity of FDG-PET scans could distinguish grades 
of tumors and predicts microvascular invasion. The objec-
tives of our study were to evaluate the prognostic value of 
FDG-PET in patients with HCC undergoing LT and to evalu-
ate the correlation between the standardized uptake values 
(SUV) and survival outcomes.
Methods: Data were collected prospectively for patients 
undergoing LT at our institution from 1991–2011.
Results: 154 patients with HCC underwent LT between 
1991–2011. 58 were outside of Milan criteria and 96 were 
not. 21 patients had PET scans pre-transplantation, 9 were 
PET positive (SUV ≥ 4) and 12 were PET negative (SUV < 
4). The overall 5 year survival of patients within and exceed-
ing Milan criteria was 63% and 48% respectively (p = 0.07). 
Of all PET negative patients, the median survival of patients 
within and exceeding Milan were 6.1 (3.4–6.3) years and 4.4 
(1.7–6.4) years respectively (p = 0.8). However PET positive 
patients within Milan had a median survival of 2.7 years 
(1.7–3.4).
Conclusion: Patients with HCC who have PET negative 
tumors, whether within or beyond Milan criteria, have 
similar survival after LT. However, patients with PET posi-
tive HCC within Milan criteria have decreased survival. The 
potential role of PET to further sub-select HCC patients for 
transplantation requires further validation in a prospective 
study.
IMPROVED SURVIVAL IN 
AFRICAN AMERICAN MALES 
WITH INTRAHEPATIC 
CHOLANGIOCARCINOMA LARGELY 
DUE TO INCREASED OPERATIVE 
TREATMENT
D. Sindram, K. A. Simo, J. B. Martinie and D. A. Iannitti
Section Of Hepatobiliary And Pancreatic Surgery, Dept. 
General Surgery, Carolinas Medical Center, Charlotte, NC
Introduction: African Americans (AA) with intrahepatic 
cholangiocarcinoma (ICCA) have been reported to have 
worse survival than other racial groups. Evaluation of the 
impact of race on treatment and survival in ICCA in the US 
over the past 20 years was undertaken.
Methods: Mortality and survival rates for Whites, AA 
(Blacks), and Hispanics with histologically proven ICCA 
were obtained from the surveillance, epidemiology and end 
results survey (SEER) database. Comparative subgroup 
examination of White vs. Black males was also performed.
Results: 2297 patients (White = 2003, Black = 148, Hispanic 
= 146) had a histologically proven ICCA in the SEER data-
base (1989–1999 = 1206, 1999–2008 = 1091). The % of 
black males with ICCA remained stable between time periods 
(3.2% vs. 3.5%). From 1989–1998, the only statistically sig-
nifi cant difference in Kaplan-Meier survival was found 
between White and Black males (p < 0.005). From 1999–
2008, survival of black males matched that of white males. 
No statistically signifi cant differences in survival for any 
other race or gender from 1999–2008 were found. 
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Comparative examination of White and Black males yielded 
several observations (Table 1). In Blacks, the % undergoing 
surgery is now similar to Whites (16% vs. 18.4%). Substantial 
decreases for Blacks were seen in: (1) not recommending 
surgery (72% to 41%), (2) contraindications to surgery 
(comorbidities) (15.4% to 0%), and (3) refusal of surgery 
(2.6% to 0%). 80% of patients in either group did not receive 
radiation.
Conclusions: The survival of Black males with histologi-
cally proven ICCA, appears to now be equivalent to White 
males in the US and due mainly to increased operative 
treatment.
Table 1. Pathologic Stage and Surgery Rates in the US for White and Black Males 1989–2008
Time Period 1989 to 1998 1999 to 2008
Race White (n = 558) Black (n = 39) White (n = 470) Black (n = 38)
Pathological Grade
 Reported 27.8% 17.9% 31.5% 21%
  Grade 1 5.4% 2.5% 6% 5.2%
  Grade 2 11.5% 15.4% 12.1% 7.9%
  Grade 3 10% NR 11.5% 7.9%
  Grade 4 0.9% NR 1.9% NR
Surgery
 Performed 11.6% 5% 16% 18.4%
  Died before surgery could be performed NA NA 0.002% (n = 1)  5% (n = 2)
  Not recommended 59% 72% 57.5% 41%
  Contraindicated due to comorbidities 5.6% 15.4% 5% 0%
  Refused 1.4% 2.6% 1% 0%
  Unknown 1.6% 2.6% 3.8% 10.5%
VOLUMETRIC ASSESSMENT OF SINGLE 
APPLICATION, SINGLE ANTENNA 
MICROWAVE ABLATION OF LIVER 
LESIONS ON CT IMAGING
D. Sindram, E. M. Hanna, K. A. Simo, J. B. Martinie and 
D. A. Iannitti
Carolinas Medical Center – Dept. Of General Surgery, 
Div. Of Hepatobiliary And Pancreas Surgery, Charlotte, 
NC
Introduction: Computed tomography (CT) volumetrics 
have previously been used in liver surgery for operative 
planning and prediction of postoperative residual liver 
volume. CT volumetrics are used to evaluate the relationship 
of energy applied to volume of ablated liver parenchyma 
achieved.
Methods: Retrospective review was performed of all 
patients undergoing hepatic microwave ablation (MWA) 
from 2007–2011. Two subset groups of single application 
(2.45 GHz generator), single antenna MWA were identifi ed: 
patients with hepatocellular carcinoma (HCC) and known 
cirrhosis and those with other malignancies without cirrho-
sis. One month post ablation triphasic liver CT scans were 
used to calculate volume of liver ablated using Osirix® 
imaging software (Pixmeo, Geneva, Switzerland).
Results: 192 patients underwent 338 different tumor abla-
tions. 16 patients were included with a total of 23 lesions 
which underwent single antenna, single application ablation. 
14 treatments were included in the cirrhotic group, 9 in the 
non-cirrhotic group. Nonlinear regression models were cal-
culated for each subset. Evaluation of the cirrhotic group 
yielded a better fi t model of volume achieved to energy 
applied (R² = 0.78). In the non-cirrhotic group, a predictive 
model could not be calculated (R² = 0.02).
Conclusions: The majority of ablations were achieved with 
multiple applications of MWA or multiple antennas. In single 
antenna ablations, volume ablated to energy applied ratio in 
cirrhotic patients yielded a better model than non-cirrhotic 
patients. We speculate that increased rates of tissue repair 
and regeneration in non-cirrhotics may explain the reduced 
model correlation at one month post ablation. Further study 
is required to more accurately examine this relationship.
MULTIVISCERAL PANCREATIC 
RESECTIONS: ARE THEY WORTH THE 
RISK?
A. Siripong and M. Chung
Grand Rapids Medical Education Partners/Michigan State 
Univ General Surgery Residency Program, Grand Rapids, 
MI
Purpose: As mortality rates associated with pancreatic 
surgery decrease, there has been an increasing drive towards 
extended resections for locally invasive pancreatic disease; 
however, the impact of multivisceral resection on morbidity 
remains inconclusive.
Methods: An IRB-approved retrospective chart review was 
conducted on patients who underwent a pancreatic resection 
by a surgical oncologist at our institution between July 2004 
to July 2011. Patients were grouped into 4 categories based 
on extent of resection: standard pancreaticoduodenectomy 
(SPD), multivisceral pancreaticoduodenectomy (MVPD), 
standard distal pancreatectomy (SDP), and multivisceral 
distal pancreatectomy (MVDP). Variables included demo-
graphics, length of stay, operating room (OR) time, and post-
operative morbidity and mortality.
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Results: 191 patients were included, with 143 undergoing 
standard resection (106 in SPD group; 37 in SDP group) and 
48 having multivisceral resection (23 in MVPD group; 25 in 
MVDP group). No signifi cant difference was seen in demo-
graphics between the standard and multivisceral resection 
groups. MVPD vs. PD was associated with a longer OR time 
(361 vs. 299 min., p < 0.0001) and a higher incidence of 
pancreatic leaks (21% vs. 7.3%, p = 0.04). MVDP vs. DP 
demonstrated a longer length of stay (13 vs. 6 days, p < 
0.0001) and increased abscess formation (24% vs. 6%, p = 
0.03) and gastroparesis (36% vs. 5%, p = 0.002). No differ-
ence in 30-day mortality or incidence of overall minor or 
major complications was seen between standard versus 
multivisceral resection groups.
Conclusion: Our results demonstrate that multivisceral pan-
creatic resections may be performed with acceptable morbid-
ity and mortality in the appropriate patient population with 
locally advanced disease.
A SURGEONS LEARNING EXPERIENCE 
OF PANCREATICODUODENECTOMIES 
(PD): IT CONTINUES DESPITE A 
DECADE LONG EXPERIENCE
V. Siripurapu, E. Liu, A. Khithani, T. Winston and 
D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: Pancreatic surgery outcomes are well docu-
mented to be better at high volume institutions with high 
volume surgeons. We aim to see if a single experienced high 
volume surgeon still improves over the years with this pro-
cedure at the same institution.
Methods: A retrospective database of 245 patients undergo-
ing pancreaticoduodenectomy under a single between 2005–
2011 was interrogated, identifying comorbidities, operative 
parameters, morbidity and mortality to answer whether 
learning continues after substantial experience.
Results: Two years were chosen at random to be fi ve years 
apart from each other, with the fi rst year of analysis to be a 
decade after the designated surgeon started performing pan-
creaticoduodenectomies (PD). A threshold number of 40 PD/
year was chosen. 2006 and 2010 were the years resulting in 
analysis. 41 patients (pts) underwent a PD in 2006, compared 
to 48 pts in 2010. No patients received preoperative therapy, 
with 63% being operated for adenocarcinoma in 2006 versus 
43% in 2010 (p = NS). The patients characteristics, operative 
and pathologic parameters are highlighted in table 1. 
Signifi cance between the years is noted in operative time and 
length of stay (see Table 1). No difference was noted in 
margin status, or morbidity.
Conclusion: With PD performed on similar comorbid 
patients between years investigated, by a single surgeon at 
single institution, we note the operative procedure is per-
formed more effi ciently and with decreased length of stay. 
We believe that an experienced surgeon does continue to 
have a signifi cant learning curve even a decade after practic-
ing the art of pancreaticoduodenectomy.
Table 1. Comparison of Whipples performed by a single 
surgeon over two varying years
2006 (%) 2010 (%) p value 
(2006 vs. 
2010)
Number of 
Patients
41 48 [NS]
Mean Age 
(yrs)
63.9 ± 5.79 63.6 ± 5.26 [NS]
Gender
 Male 16 (39) 24 (50) [NS]
 Female 25 (61) 24 (50) [NS]
Mean Co 
Morb Index
2.24 ± 0.77 2.1 ± 0.70 [NS]
Mean Op 
Time (hrs)
4.12 3.33 P = 0.023
Mean BMI 26.3 26.1 [NS]
Mean Blood 
Loss
542.6 449.3 [NS]
Mean 
Hospital 
LOS (days)
16.2 12.2 P < 0.05
No. of 
Morbidities
27 (13) 38 (15) [NS]
Pathology
No. Negative 
Margins
32 (78) 40 (83) [NS]
Mean Lymph 
Node Ratio
0.092 0.142 [NS]
HOW TO DO A WHIPPLE IN 
APPROXIMATELY THREE HOURS: 
SEPARATION OF THE RIGHT COLON 
MESENTERY TO FIND THE SMV AND 
THE CONCEPT OF THE 
MESOPANCREAS
V. Siripurapu and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Pancreatoduodenectomy is a complex procedure with high 
morbidity and a not insignifi cant mortality. A sequence of 
steps that can help reduce operative and anesthetic time is 
likely to be benefi cial in patient recovery. The authors rou-
tinely perform Whipple surgery in 3.33 hours (Mean value 
of year 2010–11 cases). We intend to illustrate the steps of 
the surgery with video accompaniment as below: 1) Wide 
Kocher 2) Cattell-Brasch maneuver 3) Separate the right 
colon mesentery from pancreas identifying the SMV below 
the try lesser sac 4) Enter the lesser sac between the colon 
and the stomach 5) Find and ligate the right gastroepiploic 
vein at the SMV; trace under the surgical pancreatic neck 6) 
Portal nodal dissection; ligation of right gastric, gastroduo-
denal artery, and bile duct 7) Create tunnel under the neck 
of pancreas 8) Perform antrectomy/duodenectomy 9) 
Transfi xation sutures of pancreatic arcades and transect pan-
creas 10) Divide proximal jejunum 11) Use harmonic scalpel 
to take the proximal jejunum and duodenum 12) Incise the 
“mesopancreas” posteriorly along the SMA 13). Take the 
uncinate off the SMA using harmonic 14) Reconstruct- duct 
to mucosa pancreas 15) Running 5–0 PDS for bile duct 16) 
Stapled gastrojejunostomy 17) G/J tube and one drain.
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Table 1. Operative time for a single surgeon performing whipple procedures
Year 2005–2006 2006–2007 2007–2008 2008–2009 2009–2010 2010–2011
Whipple procedure 
(Average time in minutes)
258 231 233 234 198 165
REFERRAL PATTERNS IN PANCREATIC 
CANCER TO A HIGH VOLUME CENTER; 
THE GASTROENETEROLOGIST 
REMAINS YOUR FRIEND
V. Siripurapu, T. Winston, E. Liu and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Background: Pancreatic cancer referral to surgeons has 
been dominated by gastroenterology through fare. With a 
recent push to perform pancreatic surgery at high volume 
centers, we investigate whether surgeon to surgeon referrals 
has increased over time from a lower volume to a high 
volume institution.
Methods: Retrospective data was collected on patients 
diagnosed with pancreatic cancer who were referred from 
August 2005 through August of 2011, to ascertain the number 
of referrals from gastroenterologists, medical oncologists, 
surgeons, and primary care physicians and notate pattern 
change over the years.
Results: 348 patients were identifi ed in analysis. Nine 
patients were excluded for either emergency room admission 
or direct transfer from outside institution. Patients were 
grouped by referral from gastroenterology, oncology, surgery, 
and primary care physicians. There were two other specialty 
doctors referring patients including two radiologists and one 
gynecologist. The gastroenterologist referred the highest 
number, totaling 221 patients. Over the six year period, the 
percentages of referrals for the gastroenterologists ranged 
from 51% to 73%, oncologists and primary care physicians 
10% to 25%, surgeons 2–8%, with, radiologists and gynecol-
ogy referring 2–4% (see graph).
Conclusion: Although there has been a minimal increase in 
the number of surgeon to surgeon referrals over the last 
several years, the gastroenterologist still dominate as the 
highest referring physician, which may indicate an estab-
lished pattern of referral to a high volume institution.
SUPERIOR MESENTERIC VEIN (SMV) 
MARGIN POSITIVITY IN RESECTABLE 
PANCREATIC CANCER CORRELATES 
WITH HIGH SUEPERIOR MESENTERIC 
ARTERY (SMA) MARGIN POSITIVITY; 
IS VEIN RESECTION ADVISIBLE?
V. Siripurapu, E. Liu, A. Khithani, T. Winston and 
D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: The purpose of this study was to examine the 
hypothesis that patients undergoing pancreaticoduodenec-
tomy (PD) for resectable pancreatic adenocarcinoma with 
positive SMV margin have a high rate of SMA positivity. If 
true, this would question the rationale for clearing the SMV 
margin with vein resection if the SMA margin will remain 
affected.
Methods: A pancreatic cancer database was reviewed to 
identify a single surgeon’s pancreaticoduodenctomies (PD) 
for pancreatic adenocarcinoma that are deemed resectable by 
NCCN guidelines. All patients had pancreatic protocol CT 
scans, Ca 19-9 levels and endoscopic ultrasound as possible. 
The patients characteristics, operative parameters and mor-
bidity/mortality was analyzed. Pathologic inking of PD 
specimen was performed with 4 colors to identify and spe-
cifi cally study the SMV and SMA margins.
Results: 97 patients underwent PD for resectable adenocar-
cinoma. Of the 97 patients, 20 patients had SMV positive 
margins (20.6%). Of these, 9 patients had positive SMA 
margins (45%). Comparing the SMA positive versus SMA 
negative margin groups who had SMV positivity, there was 
signifi cance in operative time suggestive of a more complex 
operation (see Table 1).
Conclusion: In resectable pancreatic cancer, there is still a 
high rate of SMV positivity. In our series this is nearly 20%, 
with 45% of these patients having additional SMA positivity. 
This suggests that vein resection is futile in these cases and 
that preoperative therapy may be necessary for this disease 
despite determined radiological and clinical parameters sug-
gestive of resectability.
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Table 1. Comparison of SMA margin status with SMV/Portal vein positivity
SMA Positive SMA Negative Total
Number of Patients 9 (45) 11 (55) 20
Male 5 (56)  2 (18) [NS]
Female 4 (44)  9 (82) [NS]
Mean Age 66 67 [NS]
Mean LOS (days) 14.8 11.7 [NS]
Mean BMI 27.1 23.8 [NS]
Mean Op Time 4.24 ± 0.70 3.6 ± 0.68 [S] p < 0.05
Mean EBL (mL) 575 440 [NS]
Mean Tumor Size (cm) 3.22 3.51 [NS]
Mean Lymph Nodes examined 13.1 16.5 [NS]
Mean Lymph Nodes Positive 2.38 3.27 [NS]
Mean Co Morb 2.44 1.73 [NS]
Percentages in parentheses.
[NS]: no signifi cant difference.
[S]: signifi cant difference.
TUMOR LOCATION IN PANCREATIC 
CANCER INFLUENCES LYMPH NODE 
POSITIVITY
V. Siripurapu, E. Liu, A. Khithani, A. Mejia, R. Dickerman 
and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: Pancreatic cancer mortality is dependent on 
node positivity, margin status and overall stage of tumor. We 
aim to assess whether equivalent tumor (T) sizes for distal 
pancreatectomy (DP) or pancreaticoduodenectomy (PD) for 
pancreatic cancer have varying nodal positivity ratios related 
to tumor location.
Methods: 622 patients with pancreatic surgery treated in 
2005–2011 under 6 surgeons, inclusive for operative type, 
patient co-morbidities, tumor pathology, nodal status includ-
ing a calculated nodal ratio (node positive/total nodes) were 
analyzed. Patients with T3 tumors were examined to study 
the hypothesis that location affected pattern of nodal 
spread.
Results: 113 patients with PD and 18 patients with DP were 
identifi ed with pathologic T3 pancreatic adenocarcinomas. 
No pre-operative treatment was administered to the groups. 
Mean age for these two groups was 67.8 ± 2.48 yrs (PD) and 
72.4 yrs (DP) (p < 0.05). No signifi cance is noted in co-
morbid index or BMI. Nodal positivity was 77% in PD 
versus 56% in DP group (p < 0.05). Lymphatic invasion was 
signifi cantly higher in the PD group (p < 0.05) as was the 
lymph node ratio (p < 0.05), compared to the DP group. 
Mean number of nodes examined was 16 for PD versus 13 
for DP (p > 0.05) (see Table 1).
Conclusion: With an equivalent T stage between the two 
operative groups, nodal positivity and nodal ratio was higher 
in the PD group compared to the DP group. This suggests 
that tumor location does have a bearing on ease of nodal 
spread despite equivalent tumor size.
Table 1. (2005–2011) Patients Undergoing Pancreaticoduodenectomy and Distal Pancreatectomy
T3
Pancreaticoduodenectomy Distal Pancreatectomy p value
Number of Patients 113 (86) 18 (14)
Mean Age (yrs) 67.8 ± 2.48 72.4 ± 5.80 [NS] p > 0.05
Gender
Male 60 (53) 14 (78)
Female 53 (47) 4 (22)
Mean Co Morb Index 2.59 ± .435 3.05 ± 1.24 [NS] p > 0.05
Mean BMI 25.7 ± 1.17 26.6 ± 3.44 [NS] p > 0.05
Mean Nodes Examined 16 ± 2.01 13.1 ± 5.16 [NS] p > 0.05
Mean Nodes Positive 3 ± 0.762 1.69 ± 1.737 [S] p < 0.05
Lymph Node Ratio 0.21 ± 0.06 0.09 ± 0.08 [S] p < 0.05
Lymph Invasion 56 (50) 5 (28) [S] p < 0.05
Vascular Invasion 32 (28) 4 (22) [NS] p > 0.05
Percentages in parentheses.
[NS]: no signifi cant difference.
[S]: signifi cant difference.
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ROLE OF LYSOPHOSPHATIDIC 
ACID IN THE DEVELOPMENT OF 
HEPATOCELLULAR CARCINOMA
N. J. Skill, J. Wu and M. A. Maluccio
Indiana University, Indianapolis, IN
Previous studies have shown lysophosphatidic acid (LPA) 
reprogramming is commensurate with hepatocellular carci-
noma (HCC). To elucidate the role and mechanism of LPA 
in HCC we examined the effects of LPA and LPA receptor 
(LPAR) antagonism on Hep3B cancer cells and CL48 hepa-
tocyte control cell gene expression. In addition we investi-
gated the potential of LPAR antagonism to abrogate HCC 
development in the MDR2−/− murine model of HCC.
Methods: Hep3B and CL48 cell lines were treated for 24 hr 
with 0–2 μM LPA ± the LPAR antagonist BrP-LPA. LPAR, 
and TNFα gene expression were determined using real-time 
PCR. TNFα biosynthesis was quantifi ed by ELISA. 
MDR2−/− mice were treated with vehicle or 20 μg/g 
BrP-LPA IP weekly from 3–12 m.
Results: In Hep3B cells, LPA induced a signifi cant increase 
in LPAR and TNFα gene expression and TNFα biosynthesis. 
LPA induced TNFα biosynthesis was inhibited by BrP-LPA 
treatment. In contrast, LPAR and TNFα gene expression and 
TNFα biosynthesis was not affected by LPA in CL48 cells. 
At 12 m, 7/7 non-treated versus 3/7 treated mice had devel-
oped macroscopic tumors. The tumor burden in MDR−/− 
mice (7.7 ± 3.5 mm) was signifi cantly greater than in the 
MDR2−/− mice treated with BrP-LPA (1.4 ± 1 mm P = 
0.029).
Conclusion: The role of LPA in HCC is mediated by the 
induction of TNFα via LPAR. LPAR antagonism via LPA 
analogues, such as BrP-LPA, inhibits TNFα biosynthesis 
in-vitro and delays the emergence of HCC in-vivo. This may 
be clinically relevant in humans where TNFα is felt to play 
a role in infl ammation induced HCC.
SURROGATE ONCOLOGIC MARKERS 
FOR LONG TERM SURVIVAL ARE 
IMPROVED WITH THE USE OF 
MINIMAL ACCESS SURGERY FOR 
PANCREATIC CANCER
J. A. Stauffer, A. Rosales-Velderrain, R. F. Goldberg, 
T. Clarke, M. Buchanan, S. P. Bowers and H. J. Asbun
Mayo Clinic Florida, Jacksonville, FL
Introduction: The use of minimal access surgery for pan-
creatic disease is increasing. No long term follow up for 
patients undergoing laparoscopic pancreas surgery is avail-
able due to its recent development. However, several vari-
ables have been shown to improve cancer outcomes for 
gastrointestinal as well as pancreas malignancies in patients 
undergoing open surgery. This study specifi cally looks at 
these parameters as surrogate markers for improved onco-
logic outcomes for those patients undergoing laparoscopic 
pancreatectomy.
Patients and Methods: Our study consisted of a retrospec-
tive review of 5 year time period (July 2006–July 2011) at 
tertiary referral center of open vs. laparoscopic pancreas 
resections. Outcome comparisons were performed for those 
undergoing pancreaticoduodenectomy/total pancreatectomy 
(PD/TP) and distal pancreatectomy (DP) via an open or lapa-
roscopic approach. Standard statistical analysis (t-test & two-
tailed Fisher’s exact test) was performed.
Results: Preoperative characteristics including demograph-
ics, comorbidities, ASA status, and primary pathology were 
similar. Results for open vs. laparoscopic PD/TP & DP are 
given in Table 1. Subgroup analysis on tumor size, margin 
status, lymph node data, and adjuvant chemotherapy for 
those patients undergoing pancreas resection for adenocarci-
noma or neuroendocrine tumors is also given. Statistically 
signifi cant advantages in the laparoscopic group were seen 
for blood loss, transfusion requirements, lymph node harvest, 
and lymph node ratio.
Discussion: Long term survival and oncologic outcomes of 
laparoscopic pancreatic surgery are currently unavailable. 
This limited retrospective study appears to suggest that sur-
rogate oncologic markers may show a benefi t for a minimal 
access approach.
Table 1. Outcomes after Pancreaticoduodenectomy/Total pancreatectomy (PD/TP) and Distal pancreatectomy (DP) after open 
and laparoscopic (Lap) resection
Pancreaticoduodenectomy/Total Pancreatectomy (PD/TP) Distal pancreatectomy (DP)
Open 
(n = 139)
Lap 
(n = 40)
p Open 
(n = 42)
Lap 
(n = 68)
p
Pancreatic fi stula 13% 19.4% 0.3896 (NS) 19.5% 9% 0.1432 (NS)
Reoperation 7.2% 2.5% 0.4600 (NS) 0% 1.5% 1.0 (NS)
Minor complications 41% 25% 0.0943 (NS) 40.5% 17.6% 0.0135
Major complications 20.9% 22.5% 0.8282 (NS) 19% 11.8% 0.4043 (NS)
3 month (90 day) mortality 11.5% 5% 0.3703 (NS) 2.4% 0% 0.3818 (NS)
Mean Estimated blood loss (mL) 1040 200 <0.0001 890 200 <0.0001
Mean pRBC transfusions (Units) 5 0.5 0.0007 2.3 0.4 <0.0001
Mean length of hosp stay (days) 12 8.5 0.0102 8.3 4.4 <0.0001
Mean ICU stay (days) 3.4 0.9 0.0410 0.7 0 <0.0001
*Mean tumor size (cm) 3.2 2.6 0.0568 (NS) 3.5 3.5 1.0 (NS)
*Mean # lymph nodes 14.7 23.8 <0.0001 11.8 26.3 0.0015
*R0 resection 83.9% 93.1% 0.3561 (NS) 94.7% 96% 1.0 (NS)
*node positive (N1) 66.7% 62.1% 0.6601 (NS) 31.6% 28% 1.0 (NS)
*Mean LN ratio (N1 only) 0.256 0.170 0.0435 0.194 0.151 0.6432 (NS)
*Adjuvant chemotherapy given 57.6% 76.2% 0.1961 (NS) 50% 60% 0.6968 (NS)
*Adenocarcinoma & Neuroendocrine tumors only. PD/TP: Open (n = 93 patients); Lap (n = 29 patients); DP: Open (n = 19 patients); Lap (n = 25 patients).
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JAUNDICE, AN IMPORTANT 
UNRECOGNIZED RISK FACTOR FOR 
POOR LONG TERM SURVIVAL IN 
PATIENTS WITH ADENOCARCINOMA 
OF THE HEAD OF THE PANCREAS
S. M. Strasberg, D. C. Linehan, W. G. Hawkins and F. Gao
Washington University In St Louis And Barnes-Jewish 
Hospital, St Louis, MO
Introduction: Jaundice impairs cellular immunity, an 
important defense against the dissemination of cancer (Europ 
J Surg. 168:315,2002). Jaundice is a common mode of pre-
sentation in pancreatic head adenocarcinomas. The infl uence 
of preoperative jaundice on long term survival after resection 
of these cancers was evaluated.
Methods: 30 possible survival risk factors were evaluated 
in a database of over 400 resected patients followed for a 
mean of 4.4 yr years (living patients). Univariate analysis 
was used to determine odds ratio for death and all factors 
with p < 0.30 were entered into a multivariate analysis using 
the Cox model with backward selection.
Results: Presence of preoperative jaundice (J1), age, posi-
tive node status, poor differentiation, and lymphatic invasion 
were signifi cant indicators of poor outcome in multivariate 
analysis. Absence of jaundice (J0) was a highly favorable 
prognostic factor – 5 yr survival in 84 J0 patients was 34.7% 
vs 15.8% in 355 J1 patients (p < 0.03). Jaundice and nodal 
status showed interaction and there was no benefi t of not 
being jaundiced (J0) in N1 patients (see Figure). Strikingly, 
RECOGNITION OF WEAK SIGNALS MAY 
FACILITATE THE DETECTION AND 
PREVENTION OF LAPAROSCOPIC BILE 
DUCT INJURIES. A MULTIVARIATE 
HUMAN FACTORS ANALYSIS
L. Stewart1,2, C. O. Dominguez3, J. G. Hunter4 and 
L. W. Way1
1University Of California, San Francisco, San Francisco, 
CA; 2SF VAMC, San Francisco, CA; 3Klein Associates, 
ARA, Exeter, NH; 4Oregon Health & Science University, 
Portland, OR
Purpose: Many high-risk professions (anti-terrorism, 
police, military) emphasize detection of “weak signals” – 
seemingly inconsequential, normal, or random cues that are 
recognized as signifi cant only when framed differently or 
connected with other cues; these can be indicators of serious 
dysfunction within a system. We analyzed the importance of 
commonly discounted cues (weak signals) reported by sur-
geons during cases with and without associated bile duct 
injury (BDI).
Methods: 431 Lap Cholecystectomies (125 uncomplicated, 
306 BDI) were studied. Operative cues (before BDI search) 
were categorized into: 1) strong (ductal/tubular structure, 
bile), 2) weak (nonspecifi c anatomic abnormalities). We 
compared uncomplicated cases (NoBDI), BDI recognized 
post-op (PopRecBDI), and BDI recognized intra-operatively 
(OpRecBDI). The infl uence of cue type, number, and framing 
by the surgeon was analyzed using bivariate and multivariate 
analysis.
Results: Cue type and number differed signifi cantly among 
the groups (Table, Figures). PopRecBDI cases detected more 
weak cues than NoBDI (P < 0.0001); and fewer strong cues 
than OpRecBDI (P < 0.0001). Multivariate analysis of cases 
without strong cues revealed that recognition of BDI corre-
lated with: number of operative cues [1.7 (+0.26) OpRecBDI 
vs 1.3 (+0.08) PopRecBDI, P = 0.0001], and reframing (BDI 
considered) (67% vs 3%, P = 0.0001).
Conclusions: These fi ndings suggest that weak signals may 
herald impending Lap BDI. Cue categorization infl uenced 
mental processing, and changes in framing amplifi ed the 
cognitive impact of weak cues. The kind and number of cues 
are important. Understanding how the mind processes this 
information and the importance of weak signals provides 
insights for the prevention and early detection of BDI. These 
concepts may also prove fruitful when applied to other 
procedures.
No Abnormal Cues
%
Weak Cues Only
%
Strong Cues
%
P Value
All Comparisons Chi-Squared
NoBDI 73.6% 24% 2.4% <0.0001
PopRecBDI 20.6% 59.4% 20%
OpRecBDI  0% 16% 84%
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ISOLATED TOTAL CAUDATE 
LOBECTOMY UNDER EXTRAHEPATIC 
GLISSONEAN APPROACH
A. Sugioka, Y. Kato, T. Tokoro, Y. Tanahashi, J. Yoshida, 
T. Kagawa and C. Takeura
Department of Surgery, Fujita Health University, Toyoake, 
Aichi, Japan
Introduction: Since the caudate lobe lies deep in the liver 
and has complex structures, isolated total caudate lobectomy 
is one of the most challenging hepatobiliary operations. 
Although several techniques are proposed, we adopt extra-
hepatic glissonean approach, which has never been reported. 
Herein we reported the details of the technique.
Procedures: At fi rst, the gallbaldder concomitant with the 
cystic plate was removed. Then the right anterior and poste-
rior glissonean pedicles were easily secured. The Aranthian 
plate and the left main glissonean pedicle were also secured. 
Afterwards all the glissonean pedicles of the caudate lobe 
including the Spiegel lobe pedicle, the paracaval pedicles, 
and the caudate process pedicle, could be secured and cut. 
The IVC was completely exposed and the common trunk of 
the middle and left hepatic vein as well as the confl uence of 
the right hepatic vein were secured. Liver transection was 
carried out along the discolored area from the left to right 
side exposing the dorsal surface of the middle and right 
hepatic veins. Finally Spiegel lobe was drawn out to the right 
side and the isolated total caudate lobectomy was completed. 
At present we have performed this operation for 3 cases of 
hepatocellular carcinoma with liver cirrhosis.
Conclusion: The extrahepatic glissonean approach makes 
isolated total caudate lobectomy safe and feasible.
in the 123 N0 patients 5 year survival was 66% in 32 patients 
who were J0 vs 20% for 91 patients who were J1 (p < 0.001). 
There were no other differences between these groups e.g., 
in age, tumor size, grade, lymphatic invasion, venous inva-
sion or perineural invasion.
Conclusions: Absence of jaundice is a highly favorable pre-
dictor of outcome in N0 patients. Detailed studies of the 
effect of jaundice on cellular immunity and other factors 
favoring tumor dissemination in this population are 
needed.
MAJOR PANCREATIC RESECTIONS CAN 
SAFELY BE PERFORMED AT A 
COMMUNITY HOSPITAL
P. Suman1,2, J. Rutledge1, S. Rajayer2 and 
A. Yiengpruksawan1
1The Daniel And Gloria Blumenthal Cancer Center, The 
Valley Hospital, Paramus, NJ; 2Department Of Surgery, 
Harlem Hospital Center, New York, NY
This study demonstrates the safety of performing major pan-
creaticoduodenectomies (PD) at a community hospital. We 
conducted a retrospective chart review of 99 PD performed 
by one surgical oncology fellowship-trained surgeon (A. Y.) 
between 2006 and 2010. Data collection and outcome analy-
sis were performed for demographics, clinical presentation, 
perioperative course, histology and survival. Ninety-nine 
patients underwent PD with a median age at presentation of 
69 years. The most common presenting symptom was jaun-
dice (n = 56, 57%). The median operative time was 208 min. 
(range 108–525 min.) with a median blood loss of 200 ml 
(range 50–1500 ml). Pancreaticojejunostomy (n = 68, 69%) 
with pancreatic duct stenting (n = 69, 70%) was the most 
common type of anastomosis performed. The incidence of 
Clavien grade I and II complications was 47% (n = 47), while 
27% (n = 27) of patients developed clinically signifi cant 
Clavien grade III and IV complications with a perioperative 
30-day surgical and in-hospital mortality of 6% (n = 6). 19 
patients (n = 19, 19%) developed clinically signifi cant pan-
creatic fi stulas. The median length of stay was 10 days. 
Malignancy was the most frequent diagnosis (n = 81, 82%) 
with a negative surgical margin of 82% (n = 66). The median 
survival was 18.6 months with one and two year survival 
rates of 57.8% and 42.2% respectively. Major pancreatic 
resections can be safely performed at a community hospital; 
the clinical experience and training of the surgeon may be a 
signifi cant factor that can impact surgical outcomes.
ROBOTIC-ASSISTED DISTAL 
PANCREATECTOMY IS SAFE AND 
FEASIBLE
P. Suman1,2, J. Rutledge1 and A. Yiengpruksawan1
1The Daniel And Gloria Blumenthal Cancer Center, The 
Valley Hospital, Paramus, NJ; 2Department Of Surgery, 
Harlem Hospital Center, New York, NY
In this study we aim to demonstrate the safety and feasibility 
of performing robotic-assisted distal pancreatectomies 
(RADP). We conducted a retrospective chart review of 40 
RADP performed by a single surgeon (A. Y.) between 2006 
and 2010. Data collection and outcome analysis were per-
formed for demographics, clinical presentation, periopera-
tive course, histology and survival. Forty patients with an 
equal gender distribution underwent RADP with a median 
age at presentation of 70 years (range 26–87 y). Distal pan-
createctomy with splenectomy (n = 28, 70%) was the most 
common surgical procedure performed; spleen was pre-
served in 12 surgeries (n = 12, 30%). The mean operative 
time was 203 min. (range 80–365 min.) with an average 
blood loss of 168 ml (range 10–700 ml). The incidence of 
Clavien grade I and II complications was 35% (n = 14), while 
5% (n = 2) of patients developed clinically signifi cant 
Clavien grade III and IV complications. There was no 
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nanopocket crystalline structures. The SCPC was milled to 
250–450 μm particle size, and immersed in CIS (10 mg/ml). 
SCPC-CIS was recovered and compressed to 5 × 2 mm cyl-
inders. In vitro characterization demonstrated reproducible 
CIS release and cytotoxicity in cultured HCC cells. An in 
vivo subcutaneous rat model of HCC was established and 
animals treated with cisplatin (3 mg/Kg/day, ip) or SCPC-
CIS hybrids placed adjacent or within tumors. Tumor growth, 
histology, and toxicity were measured.
Results: Following 5 days of treatment SCPC-CIS hybrids 
signifi cantly reduced tumor growth (0.57 ± 0.23 cm3) versus 
untreated (1.70 ± 0.18 cm3). CIS-i.p. failed to affect tumor 
growth vs untreated. However, CIS-i.p. treatment signifi -
cantly decreased body weight (14.9 ± 0.9%) concomitant 
with increased ALT (168 ± 24 IU), creatinine (2.15 ± 
0.22 mg/dL), and BUN (135 ± 6 mg/dL) (p < 0.01). 
Conversely SCPC-CIS did not signifi cantly affect body 
weight or markers of hepatic/renal function. Histological 
analysis demonstrated signifi cantly increased tumor cell 
death (apoptotic and necrotic) in CIS-SCPC treated vs 
untreated and CIS-i.p treated animals.
Conclusions: SCPC-CIS induces signifi cant HCC cell 
death and inhibits tumor progression in an in vivo model of 
tumor formation in the absence of systemic toxicity. The 
versatility of SCPC to bind a wide range of chemotherapeu-
tics raises the possibility of targeted, “personalized” therapy 
for HCC in the absence of systemic toxicity.
TWO CASES OF SPONTANEOUS 
REGRESSION OF HEPATOCELLULAR 
CARCINOMA WITH EXTRAHEPATIC 
METASTASIS
C. Takeura, T. Tokoro, Y. Tanahashi, J. Yoshida, 
T. Kagawa, Y. Kato and A. Sugioka
Department Of Surgery, Fujita Health University, Toyoake, 
Aichi, Japan
Spontaneous regression of hepatocellular carcinoma (HCC) 
with extrahepatic metastasis is extremely rare. Herein we 
reported 2 cases, one with bone metastasis and another with 
peritoneal dissemination. Case 1: A 69-year-old female was 
referred to our hospital for HCC associated with liver cir-
rhosis due to HCV. Because of poor hepatic functional 
reserve transcatheter hepatic arterial chemoembolization was 
performed twice. However, multiple intrahepatic metastases 
and extrahepatic metastasis to the right iliac bone were 
rapidly developed. Although the treatment with Sorafenib 
was planned, she fell down from the bicycle and suffered 
from bilateral radial bone fractures. After one month intra-
hepatic metastases and bone metastasis were completely 
disappeared. At present she has been doing well without 
recurrence for 10 months. Case 2: An 84-year-old female was 
admitted to our hospital for intrahepatic metastases and peri-
toneal dissemination from HCC after radiofrequent ablation. 
The largest peritoneal dissemination was 6 cm in diameter 
and compressed the ascending colon. Palliative resection was 
scheduled. However, phlegmone of the right lower extremity 
was rapidly developed and the operation was postponed. 
After 4 months, both peritoneal dissemination and intrahe-
patic metastases were completely disappeared. At present she 
has been doing well without recurrence for 1 year and 8 
months. Only 17 cases of spontaneous regression of HCC 
perioperative 30-day surgical or in-hospital mortality. 2 
patients (n = 2, 5%) developed clinically signifi cant pancre-
atic fi stulas. The average length of stay was 5.6 days. Out of 
22 pancreatic cancers (n = 22, 55%), only one had positive 
surgical resection margin (n = 1, 4.5%). The median survival 
was 46 months in patients with pancreatic cancers with one 
and two year survival rates of 77.3% and 64.4% respectively. 
We conclude that robotic-assisted distal pancreatectomy is a 
clinically safe procedure for both benign and malignant pan-
creatic tumors.
NEUTROPHIL TO LYMPHOCYTE RATIO: 
PREDICTOR OF POOR OUTCOME IN 
ACUTE PANCREATITIS
A. Suppiah, D. J. Malde, T. Arab, A. M. Smith and 
G. Morris-Stiff
The HPB Unit, Leeds, Yorshire, United Kingdom
Background: Current scoring systems in acute pancreatitis-
pancreatic (AP) are cumbersome and require multiple inves-
tigations and delay in scoring. Early deterioration in AP is 
associated with marked infl ammatory response.
Method: Neutrophil to lymphocyte ratio (NLR) was calcu-
lated on Day 1, 2 and 3 of admission and correlated with 
outcome. Poor outcome was defi ned as intensive care admis-
sion, need for nutritional support, complications directly 
associated with pancreatitis, pancreatic necrosis or death.
Results: 146 consecutive patients (January–December 
2010) were included with 29 having poor outcome. NLR in 
the poor prognosis group was signifi cantly higher than in the 
favorable prognosis group on all 3 days (Day 1: 17.4 vs. 
13.3; Day 2: 16.2 vs. 10.2; Day 3: 14.6 vs. 7.2). The optimal 
cut-of calculated from a ROC curve was 3.5 giving a sensi-
tivity (Sn) and Specifi city (Sp) of 93% and 15% (Day 1); 
96% (Sn) and 26% (Sp) Day 2; 93% (Sn) and 37% (Sp) Day 
3. The Positive and Negative values of poor outcome were 
28% and 90% on Day 1, 30% and 95% on Day 2 and 30% 
and 94% on Day 3.
Conclusion: Admission and early NLR is signifi cantly 
higher in patients with poor outcome and is an independent 
predictor of poor prognosis.
EVALUATION OF A NOVEL 
BIOCERAMIC DRUG DELIVERY 
SYSTEM FOR TREATING 
HEPATOCELLULAR CARCINOMA (HCC) 
IN VIVO
J. H. Swet1,2, H. G. Pacheco2, A. El-Ghannam2, 
D. Sindram1, J. B. Martinie1, D. A. Iannitti1 and 
I. H. McKillop1
1Carolinas Medical Center, Charlotte, NC; 
2UNC At Charlotte, Charlotte, NC
Aims: This study sought to evaluate a bioceramic silicon-
calcium-phosphate nanocomposite (SCPC) scaffold system 
for intratumoral drug delivery in HCC therapy. For these 
studies cisplatin (CIS) was selected due to well-described 
kinetics and mechanism(s) of action.
Methods: SCPC was formulated to 32.9 mol% silica such 
as to create high surface area-volume microtubule-
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with extrahepatic metastasis were reported. Although the 
mechanism has not been clarifi ed, both cases have distinct 
triggers; bone fractures and phlegmone. These phenomena 
suggest that spontaneous regression of advanced cancer 
could be obtained by appropriate invasive stress.
ADJUVANT ABLATION OF 
NEUROENDOCRINE METASTASES TO 
THE LIVER COMPLEMENTS SURGICAL 
RESECTION
T. Taner, T. D. Atwell, L. Zhang, W. S. Harmsen, 
M. L. Kendrick, D. M. Nagorney and F. G. Que
Mayo Clinic, Rochester, MN
Background: Resection of liver metastases from neuroendo-
crine neoplasms (NEN) prolongs survival and provides 
durable symptom relief. Not all hepatic lesions are amenable 
to resection, particularly when there is multifocal involvement. 
We hypothesized that ablation of concomitant non-resectable 
hepatic NEN metastases is safe and salvages patients who 
would not have been selected for cytoreductive surgery.
Methods: Patients who underwent adjuvant ablation of 
NEN hepatic metastases between 1995–2008 were reviewed. 
NEN were classifi ed by patient and tumor characteristics. 
Regression and Kaplan-Meier models were used to compare 
variables and generate survival curves.
Results: Ninety-four patients (46, carcinoid; 48, pancreatic 
islet cell neoplasms) underwent resection and salvage intraop-
erative ablation. Median number of lesions ablated was 3 
(range 1–19), and size was 1.4 cm (0.3–8 cm). One abscess 
occurred at the ablation site. Local recurrence was detected in 
4 patients (3.8%). Overall survival was 80% and 59% at 5- and 
10-yr. Age, sex, tumor type, grade, primary site, and need for 
repeat ablation had no impact on survival; the rate of apoptosis 
in the tumor was a small but signifi cant risk factor (HR: 1.03, 
P < 0.005). Complete symptom control was achieved in 34% 
at 3-yr and 16% at 5-yr, with no difference between carcinoid 
and islet cell neoplasms. Gastrinomas had the most favorable 
rate of symptoms control (HR: 0.77, P < 0.05).
Conclusion: Ablation of hepatic NEN metastases not ame-
nable to resection is safe and salvages patients for cytoreduc-
tive surgery. Ablation performed intraoperatively and 
repeated postoperatively as needed provides signifi cant 
symptoms control regardless of the tumor grade.
COMBINED 
PANCREATICODUODENECTOMY AND 
COLON RESECTION FOR LOCALLY 
ADVANCED TUMORS OF THE 
PANCREATIC HEAD: ANALYSIS OF 
POST-OPERATIVE MORBIDITY AND 
MORTALITY
S. J. Temple, P. T. Kim, S. P. Cleary, I. D. McGilvray, 
S. Gallinger and A. C. Wei
Department Of Surgery, Toronto, ON
Background: Combined pancreaticoduodenectomy and 
en-bloc colon resection may be necessary to achieve R0 
resection of tumors involving the pancreatic head. This study 
was conducted to examine the morbidity and mortality of this 
procedure.
Methods: A case matched study of patients was performed 
comparing patients who underwent standard pancreaticoduode-
nectomy (S-PD) to PD with en-bloc colon resections (PD-Colon) 
at a single high volume academic institution between 2000–10. 
654 patients underwent PD of which 23 required PD-Colon. The 
PD-Colon group was matched 2:1 for gender, age and primary 
cancer with a control group of (S-PD). Standard nonparametric 
statistical tests were performed using SPSS.
Results: Within the PD-colon group, 22 patients required 
right hemicolectomy, 1 underwent subtotal colectomy. The 
PD-Colon group was more likely to have received pre-opera-
tive chemotherapy and radiotherapy than those with a S-PD 
(3/23, 13% vs. 0, p = 0.01). Higher rate of post-operative 
bleeding was observed in the PD-Colon group (6/23, 26% vs. 
1/46, 2%, p = 0.005). Operative blood loss, complication rate, 
length of stay, and inpatient mortality were similar. Oncologic 
variables including median tumor size and positive–e margin 
rates were not signifi cantly different between the groups.
Conclusion: Our results have demonstrated that PD-colon 
can be performed safely with good oncologic outcomes. 
Although there is an increased risk of post-operative bleed-
ing this did not have an impact on morbidity or mortality of 
the procedure. Thus, PD-Colon is an appropriate approach 
to a locally advanced pancreatic head tumor.
PDColon N = 23
N (%) or Med (range)
StandardPD N = 46
N (%) or Med (range)
P
Male 14 (60.9) 27 (58.7) 0.862
Age (y) 62 (24, 75) 65 (35, 84) 0.268
Pre-op Chemo 3 (13) 0 0.012
Pre-op Radiation 3 (13) 0 0.012
Intra-op EBL (mL) 800 (400, 5000) 650 (200, 2200) 0.234
Complication (CD 2, 3ab, 4ab) 11 (52.4) 14 (31.1) 0.111
Post-operative Death 1 (4.3) 0 0.333
Post-operative Bleed 6 (26.1) 1 (2.2) 0.005
Post-Operative Leak 3 (13.6) 5 (10.9) 0.707
Intra-abdominal Sepsis 7 (30.4) 11 (23.9) 0.573
SSI 5 (21.7) 4 (8.7) 0.148
DGE 3 (13.6) 6 (13) 1
Re-Laparotomy 4 (18.2) 1 (2.2) 0.037
LOS (d) 9 (5, 39) 10 (5, 40) 0.674
Positive Margin 2 (8.7) 2 (4.7) 0.603
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Univariate PNET
Mean PFS (mo)
P NETLM
Mean PFS (mo)
P
Ki ≤ 2 73.1 <0.001 21.3 0.04
Ki 2 – ≤ 20 39.8 23.4
Ki >20 3.3 6
Multivariate HR P HR P
Ki – 67 8.81 0.02 8.64 0.013
Metastatic disease 9.60 0.002
Margin status 5.86 0.015
Tumor size 12.51 <0.001
KI-67 INDEX PREDICTS PROGRESSION 
FREE SURVIVAL IN PRIMARY 
PANCRAETIC NEUROENDOCRINE 
TUMORS AND NEUROENDOCRINE 
LIVER METASTASES
S. J. Temple1, E. Morin2, S. Serra3, P. T. Kim1, A. C. Wei1, 
S. Gallinger1, C. Moulton1, P. D. Greig1, S. Asa3, S. Ezzat2 
and S. P. Cleary1
1Department Of Surgery, Toronto, ON; 2Department Of 
Medicine, Toronto, ON; 3Department Of Pathology, Toronto, 
ON
Background: The purpose of this study was to determine if 
Ki-67 index is a predictor of progression-free survival in 
patients undergoing resection of primary pancreatic neuro-
endocrine tumors (PNET) and neuroendocrine liver metasta-
ses (NETLM).
Methods: A retrospective chart review was performed of all 
patients undergoing resection of a neuroendocrine tumor of 
gastrointestinal origin between 2000 and 2010. From more 
than 700 cases, 114 patients with a primary PNET and 47 
NETLM were identifi ed. Standard nonparametric statistical 
analysis was performed using SPSS.
Results: Ki-67 indices were reported for 71% and 68% of 
pancreatic and liver cases respectively. These values were 
then grouped according to the proposed ENETS grading 
system (≤2, 2 to ≤20, >20). Kaplan-Meier was used to deter-
mine progression free-survival. For patients undergoing pan-
creatic resection and liver resection there was a statistically 
different mean time to disease recurrence or progression for 
higher Ki index (p = 0 for pancreatic resections and 0.040 
for liver resections). In a multivariate analysis for PNET the 
presence of metastatic disease, Ki-67 index, margin status 
and tumor size were independent predictors of progression. 
Ki-67 index was also found to predict progression or recur-
rence in a multivariate analysis of NETLM.
Conclusion: This study supports previously reported results 
showing that Ki-67 index is a prognostic factor in both primary 
pancreatic neuroendocrine tumors and in liver metastases.
107 PANCREATIC RESECTIONS: 
FACTORS AFFECTING MORTALITY AND 
MORBIDITY
V. M. Thumma, N. Bheerappa and R. A. Sastry
NIzam’s Institiute Of Medical Sciences, Hyderabad, AP, 
India
Background: Studies analyzing risk factors related to spe-
cifi c and overall complications are scant.
Aim: To identify risk factors for morbidity after all pancre-
atic surgeries and after pancreaticoduodenectomy (PD). To 
identify predictive value of Possum & P-Possum scores in 
assessing mortality and morbidity after pancreatic surgery.
Methods: All patients who underwent major pancreatic 
resection for benign and malignant conditions in the Dept of 
SGE, NIMS Hyderabad from 2007 to 2009 is presented. 
Complications were graded and were analyzed for risk 
factors which included patient, disease, operative and post-
operative factors.
Results: 107 pancreatic operations were done of which 64 
were PD. Mortality after pancreatic surgery was 2.8%. 
Complications occurred in 54.2%. Major morbidity (Clavien 
GR 3 >) was seen in 26/107 (24.2%) of patients. Signifi cant 
risk factors for morbidity after pancreatic surgery were soft 
pancreas, SGPT >73 U/L and absence of chronic pancreati-
tis. Soft pancreas (OR: 5.864, CI 1.11–30.95, p = 0.37) for 
pancreatic fi stula, Intra abdominal Complications (OR: 6.5, 
CI 1.424–14.95, p = 0.011) and Diabetes (OR: 3.5, CI 0.926–
27.04, p = 0.06) for DGE, Liver disease (OR: 26.76, CI 
1.72–415.29, p = 0.01) and PF grade B and C (OR: 7.52, CI 
0.96–58.98, p = 0.05) for PPH were signifi cant risk factors 
after PD. The Observed to predicted mortality ratio was 
0.42:1 and 1.5:1 using POSSUM & P-POSSUM and that of 
morbidity is 0.72:1.
Conclusion: Soft pancreas, age >50 yrs, SGPT >73 U/L 
and absence of chronic pancreatitis are independent factors 
predicting morbidity after pancreatic surgery. POSSUM and 
P-POSSUM prediction of morbidity and mortality was poor.
RISK FACTORS FOR DELAYED GASTRIC 
EMPTYING AFTER 
PANCREATICODUODENECTOMY
V. M. Thumma, N. Bheerappa and R. A. Sastry
NIzam’s Institiute Of Medical Sciences, Hyderabad, AP, 
India
Background: Although DGE is known to be associated 
with other intra-abdominal complications, factors responsi-
ble for DGE in patients without intra-abdominal complica-
tions are poorly understood.
Aim: The aim of the present study is to analyze factors 
causing delayed gastric emptying.
Material and Methods: Between 2007 and 2009, 64 
patients underwent Whipple’s procedure. Delayed gastric 
emptying occurred in 29 of these patients (45.3%) according 
to ISGPS criteria (Grade A-14; Grade B-8; Grade C-7). DGE 
without intra-abdominal complication was seen in 12 patients 
(18.7%). The risk factors studied were Patient factors, 
Disease factors (liver function tests, cholangitis, preoperative 
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pancreatitis, site of tumor, histopathology), Operative factors 
(preoperative biliary drainage, total operative time, blood 
loss), Technical factors (pylorus preserving or classical, pan-
creaticogastrostomy vs. pancreaticojejunostomy, antecolic 
vs. retrocolic gastrojejunostomy) and Postoperative factors. 
Risk factors were analyzed for DGE and DGE without 
intraabdominal complications.
Results: Signifi cant risk factors on univariate analysis for DGE 
were diabetes (p = 0.11), BMI (p = 0.05), preoperative biliary 
drainage (p = 0.12) and intraabdominal complication (p = 
0.005). Signifi cant factors independently predicting DGE were 
Intraabdominal complication (OR 6.5, CI 1.424–14.95, p = 
0.011) and Diabetes (OR 3.5, CI 0.926–27.04, p = 0.06). On the 
other hand, risk factors for DGE without intraabdominal com-
plications were age and retrocolic duodenojejunostomy on uni-
variate analysis. The factor independently predicting DGE 
without intraabdominal complication was retrocolic duodenoje-
junostomy (OR 3.99, CI 1.037–42.664, p = 0.04).
Conclusion: Retrocolic duodenojejunostomy was an inde-
pendent risk factor for DGE in patients without intrabdomi-
nal complication.
RADIOFREQUENCY ABLATION VS. 
RESECTION FOR EARLY STAGE 
HEPATOCELLULAR CANCER: 
OUTCOMES FROM A WESTERN CENTER
S. Tohme1, J. Cardinal2, R. Srinevas2, J. Steel2,3, 
J. W. Marsh2, D. A. Geller2 and A. Tsung2
1University Of Pittsburgh, Department Of Surgery, 
Pittsburgh, PA; 2Division Of Hepatobiliary And Pancreatic 
Surgery, Department Of Surgery, University Of Pittsburg, 
Pittsburgh, PA; 3Department Of Psychiatry, University Of 
Pittsburgh Medical Center, Pittsburgh, PA
Background: Survival outcomes after hepatic resection 
(HR) and radiofrequency ablation (RFA) for early stage 
hepatocellular carcinoma (HCC) at a western hepatobiliary 
center were compared.
Methods: Demographic, clinicopathologic tumor character-
istic, and survival outcomes among patients undergoing HR 
and RFA for early stage HCC were reviewed.
Results: Between 2001–2011, 111 patients with stage 1 or 2 
HCC underwent either HR (n = 50) or RFA (n = 61). Etiology 
of cirrhosis and MELD score were similar between the two 
groups (Table). Patients who underwent HR had larger tumors, 
longer length of stay, and higher post-operative complications 
(Table). After a median follow-up of 29 months after treat-
ment, there were no signifi cant differences in one, three, and 
fi ve-year overall (RFA: 62%, 38%, 29% vs. HR: 65%, 52%, 
33%, p = 0.55) or disease-free (RFA: 51%, 38%, 25% vs. HR: 
53%, 33%, 33%, p = 0.82) survival. 58 patients in the RFA 
group demonstrated complete radiological response on the 3 
month follow up CT scan. Of these, 96.5% had a sustained 
complete local response over the entire follow up period. 
There was no signifi cant difference in the location of disease 
recurrence between both treatment groups. In subgroup analy-
sis including only tumors ≥2 cm, there were no differences in 
OS or DFS after HR compared to RFA.
Conclusions: RFA is equally as effective as HR in prolong-
ing survival among patients with early stage HCC, including 
those with larger tumors (2–5 cm). These data indicate that 
RFA can be considered as an excellent option for patients 
with early HCC even when HR is possible.
Age (yrs ± SD) RFA
65.6 ± 12
HR
66.3 ± 1
p = 0.723
Etiology of 
Cirrhosis
p = 0.853
 Hepatitis B 
 only
 5.2%  6.4%
 Hepatitis C 
 only
48.3% 38.7%
 Hepatitis 
 B & C
12.1% 12.9%
 Non-Viral 34.4% 41.9%
MELD score in 
Cirrhotic
8.05 ± 2.4 8 ± 3.1 p = 0.929
Tumor Size (cm) 2.36 ± 0.94 3.07 ± 1.17 p = 0.001
Length of 
hospital stay 
(days)
2.2 ± 1.85 5.36 ± 2.9 p < 0.01
Postoperative 
Complications
9 (14.7%) 15 (30%) p = 0.04
30-day Mortality 2 (4%) 0 (0%)
Median OS* 
(months)
31 49 p = 0.554
Median DFR* 
(months)
27 28 P = 0.8
*OS: overall survival, DFR: disease-free survival.
INHIBITOR OF DIFFERENTIATION-1 
(ID1) EXPRESSION CORRELATES WITH 
SRC ACTIVATION AND TUMOR 
DIFFERENTIATION IN HUMAN 
PANCREATIC CANCER SPECIMENS
J. G. Trevino1, B. A. Centeno2, S. N. Hochwald1, 
S. J. Hughes1, K. E. Behrns1 and S. P. Chellappan2
1University of Florida-Gainesville, Gainesville, FL; 
2H. Lee Moffi tt Cancer Center & Research Institute, 
Tampa, FL
Introduction: We previously reported our discovery from an 
in vitro and vivo model of pancreatic cancer demonstrating that 
inhibitor of differentiation-1 (Id1) overexpression contributes to 
tumor progression through a Src-dependent signaling axis. To 
determine the clinical signifi cance of this fi nding, we tested the 
hypothesis that Id1 expression in human tissue specimens of 
pancreatic cancer would correlate with Src phosphorylation, 
worsening grade/differentiation, and clinical outcome.
Methods: Tissue microarrays (TMAs) constructed from 100 
samples of resected pancreatic ductal adenocarcinoma were 
stained for Id1, phospho-Src (activated form), and total Src 
using standard immunohistochemistry techniques and also 
by H&E. Scores based on intensity and percent of positive 
cells and a pathological grade (1–4) were assigned to each 
malignant core.
Results: There was a statistically signifi cant correlation 
between Id1 and tumor grade/differentiation (p = 0.0368). 
Additionally, the correlation of protein levels of Id1 and 
phospho-Src was also statistically signifi cant (p = 0.0024); 
no signifi cant correlation between total Src and Id1 expres-
sion was observed (p = 0.1516). Analysis of overall survival 
and tumor grade was also signifi cant (p = 0.05); the correla-
tion between overall survival and Id1 expression trended 
toward statistical signifi cance (p = 0.06).
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coagulant effects of hepatectomy. To test these hypotheses, this 
project was designed to evaluate relationships between extent 
of hepatectomy, postoperative VTE, and bleeding events.
Methods: 5651 elective hepatectomies were identifi ed in 
the recently released 2005–09 ACS-NSQIP participant use 
fi le. Factors associated with 30-day rates of VTE, postopera-
tive transfusion, and return to operating room (ROR), were 
analyzed.
Results: There were 3376 (59.7%) partial; 585 (10.4%) left; 
1134 (20.1%) right; and 556 (9.8%) extended hepatectomies. 
Overall event rates included: deep venous thrombosis (1.93%), 
pulmonary embolus (1.31%), VTE (2.88%), postoperative 
transfusion (0.76%), ROR with transfusion (0.44%). VTE was 
associated with magnitude of hepatectomy (partial-2.13%, 
left-2.05%, right-4.15%, extended-5.76%, p < 0.001, Figure) 
and was more frequent than postoperative transfusion and/or 
ROR with transfusion (3.8–6.5 times, p < 0.001). Other factors 
independently associated with VTE were preoperative AST 
≥27 (odds ratio [OR]-1.41, p = 0.022), ASA class ≥3 (OR-
1.90, p < 0.001), operating time >222 min (OR-1.37, p = 
0.043), postoperative organ space infection (OR-10.64, p < 
0.001), and length of stay ≥7 days (OR-1.58, p = 0.004). 
Patients with VTE experienced a 30-day mortality rate of 7.4% 
compared to 2.3% in non-VTE patients (p = 0.001).
Conclusions: In contrast to the common belief that transient 
postoperative liver insuffi ciency protects against VTE, these 
data confi rm that VTE risk actually increases with extent of 
resection. VTE incidence far exceeds major bleeding events and 
is strongly associated with postoperative mortality. Combined, 
these results support the recommendation for routine postopera-
tive VTE chemoprophylaxis in hepatectomy patients.
Conclusions: Id1 expression in human pancreatic cancer 
correlates with phospho-Src expression levels and tumor dif-
ferentiation. These results support the clinical assessment of 
Id1 expression as a biomarker of prognosis and support 
further studies to assess the potential effi cacy of targeted 
therapy against Id1 expression in pancreatic cancer patients.
COMPARISON OF STANDARD DISTAL 
PANCREATECTOMY AND 
SPLENECTOMY TO RADICAL 
ANTEGRADE MODULAR 
PANCREATOSPLENECTOMY
P. Trottman, K. Swett and P. Shen
Wake Forest University School Of Medicine, Department 
Of General Surgery, Winston Salem, NC
Background: Radical antegrade modular pancreatosplenec-
tomy (RAMPS) has been reported to provide improved margin 
resection and lymph node retrieval for tumors of the body and 
tail of the pancreas compared to standard resection. We exam-
ined our experience with RAMPS and standard resection to 
determine differences in clinic-pathologic outcomes.
Methods: A comparison of RAMPS procedures was made 
to standard distal pancreatectomy and splenectomy examin-
ing various clinic-pathologic variables through retrospective 
chart review.
Results: Twenty-fi ve patients underwent distal pancreatec-
tomy with or without splenectomy between November 2004 
and June 2011. Nineteen patients underwent standard resec-
tion for the following histologies: 1 adenocarcinoma, 5 muci-
nous cystic neoplasms, 8 neuroendocrine tumors, 1 serous 
cystadenoma, 3 pseudocysts, and 1 solid pseudopapillary 
neoplasm. Six patients underwent RAMPS procedures with 
the following histologies: 3 adenocarcinoma, 1 neurodendo-
crine tumor, 1 mucinous cystadenoma, and 1 serous cystad-
enoma. Due to the heterogeneity of diseases margin status 
could not be assessed. Fisher exact and wilcoxon rank sum 
tests showed no difference in operating time, estimated blood 
loss, length of hospital stay, or complications; but did dem-
onstrate a signifi cant difference in number of lymph nodes 
removed with mean of 4.3 and 11.2 lymph nodes obtained 
for standard resection and RAMPS, respectively (p = 0.03).
Conclusion: Though margin status could not be assessed in 
this diverse pancreatic resection cohort, the RAMPS procedure 
for lesions of the body and tail of the pancreas retrieved signifi -
cantly more lymph nodes than standard distal pancreatectomy 
and splenectomy. It should be the preferred surgical approach 
when lymph node count is important for tumor staging.
RISK OF VENOUS THROMBOEMBOLISM 
OUTWEIGHS POST-HEPATECTOMY 
BLEEDING COMPLICATIONS: ANALYSIS 
OF 5651 NSQIP PATIENTS
C. D. Tzeng, M. H. Katz, J. B. Fleming, P. W. Pisters, 
J. E. Lee, E. K. Abdalla, S. A. Curley, J. N. Vauthey and 
T. A. Aloia
The University Of Texas MD Anderson Cancer Center, 
Houston, TX
Background: Historically, liver surgeons have withheld 
venous thromboembolism (VTE) chemoprophylaxis due to per-
ceived postoperative bleeding risk and theorized protective anti-
YIELD OF CLINICAL AND 
RADIOGRAPHIC SURVEILLANCE IN 
PATIENTS WITH RESECTED 
PANCREATIC ADENOCARCINOMA 
FOLLOWING MULTIMODALITY 
THERAPY
C. D. Tzeng, J. B. Fleming, J. E. Lee, X. Wang, 
P. W. Pisters, J. N. Vauthey, G. Varadhachary, R. A. Wolff, 
C. H. Crane and M. H. Katz
The University Of Texas MD Anderson Cancer Center, 
Houston, TX
Background: The National Comprehensive Cancer 
Network recommends serial evaluation of patients with pan-
creatic adenocarcinoma (PDAC) to assess for symptoms and 
the treatment of patients with detected recurrence. We 
hypothesized that clinical and radiographic surveillance 
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would detect recurrence when it would be most amenable to 
treatment. We sought to evaluate the diagnostic yield of an 
intensive surveillance strategy.
Methods: We identifi ed all patients who underwent poten-
tially curative pancreaticoduodenectomy at our institution 
from 1998–2008. We compared clinical factors between 
patients with symptomatic recurrence and asymptomatic 
recurrence. Factors associated with post-recurrence overall 
survival (PROS) were evaluated with multivariate models.
Results: Follow-up was complete for 327/356 (92%) eligi-
ble patients; 216 (66%) developed recurrence. Recurrence 
was symptomatic in 98 (45%) patients and asymptomatic in 
118 (55%). The median duration between surveillance CT 
scans did not differ between groups (p = 0.33). Symptomatic 
recurrence was characterized by multifocal disease or carci-
nomatosis, poor performance status (PS), and low rate of 
subsequent therapy. The median time to recurrence did not 
differ between groups (p = 0.38), minimizing lead-time bias, 
but symptomatic patients had a shorter PROS (5.1 vs. 13.0 
months, p < 0.001). At recurrence, preserved PS, administra-
tion of therapy, low CA 19-9, and isolated local or distant 
(vs. regional or multiple-site) recurrence were independent 
predictors of longer PROS (p < 0.001).
Conclusions: Symptomatic recurrence is associated with 
poor PS, signifi cant disease burden, and rapid clinical decline 
which may preclude further treatment. Intensive surveillance 
strategies may be useful for detecting patients with preserved 
PS at recurrence who can tolerate and potentially benefi t 
from further therapy.
years, the most important complication of hepatic surgery is 
the postoperative liver failure. In order to prevent the growth 
of the secondary tumor in the remnant liver, PPVE is not 
indicated in patients with bilobar liver metastases (LM). The 
therapeutic strategy for these patients is: 1) To resect the 
remnant liver metastatic lesion. 2) To perform the portal vein 
ligation or a percutaneous portal embolization of the meta-
static lobe and 3) The subsequent resection of the affected 
lobe. In the absence of postoperative complications, this 
strategy requires a period of approximately two months. 
During this time the patient is not receiving chemotherapy. 
We introduce a new surgical strategy for patients with bilobar 
LM (multiple liver metastases en segments IV, V, VI, VII and 
VIII and 2 cm liver metastases in segment II): 1) First stage. 
Local resection in LM located in segment II. Right hepatic 
artery, right portal vein, right biliary duct and right hepatic 
vein dissection. In situ split procedure and right portal vein 
ligation. 2) Second stage: Remnant liver volume measure-
ment for two weeks and 3) To complete the extended right 
resection. The advantages of this therapeutic strategy are: 1) 
Perform two surgical procedures with less impact to the 
patient, 2) To short the postoperatiove period and facilitate 
the initiation of adjuvant chemotherapy and 3) Increased 
resectability of patients with multiple bilobar liver 
metastases.
SURGERY FOR LIVER MALIGNANCIES 
WITH TUMOR THROMBUS EXTENDING 
INTO THE SUPRA-DIAPHRAGMATIC 
INFERIOR VENA CAVA AND RIGHT 
ATRIUM WITHOUT THE USE OF 
CARDIOPULMONARY BYPASS
E. Vicente, Y. Quijano, H. Duran, E. Diaz, I. Fabra and 
R. Puga
Madrid Sanchinarro University Hospital, “Clara Campal” 
Oncological Center, San Pablo University, Madrid, Spain
Liver tumors and retroperitoneal malignancies, such as renal 
cell carcinoma and adrenocortical carcinoma can extend into 
the inferior vena cava (IVC) and right atrium (RA). Poor 
results of non-operative treatment have prompted to attempt 
radical operations. A complete removal of the tumor and 
thrombus probably provides the only chance of cure. Patients 
with extension of the thrombus into the right atrium represent 
a greatest surgical challenge. The traditional approach to 
cavo-atrial thrombus excision has been with the use of car-
diopulmonary bypass (CPB) and deep hypothermic circula-
tory arrest. Although this approach provides adequate 
visualization for the thrombus excision, it is associated with 
signifi cant morbidity and mortality. We introduce a technique 
of intrapericardial IVC and cavo-atrial junction isolation 
through the abdominal cavity and “transdiaphragmatic peri-
cardial windows”. This technique can achieve gross tumor 
en-bloc resection and avoid the need of sternotomy, thora-
cotomy and CPB. Intraoperative transesophageal echocar-
diography was performed for monitoring pulmonary 
embolism during surgery. Surgical removal of hepatic tumors 
and IVC and RA thrombus (cephalic extension of the throm-
bus into RA: 2.5 cm) through a transabdominal approach 
with complete liver mobilization technique and total vascular 
exclusion avoids the potential added risk of morbidity of 
CPB, shortening the operative time.
EXTENDED RIGHT 
HEMIHEPATECTOMY AND LEFT 
METASTASECTOMY AFTER IN SITU 
SPLIT. A NEW SURGICAL STRATEGY 
PERFORMED IN TWO STAGES TO 
ACHIEVE RESECTABILITY OF BILOBAR 
LIVER METASTASES
E. Vicente, Y. Quijano, H. Duran, E. Diaz, I. Fabra and 
R. Puga
Madrid Sanchinarro University Hospital, “Clara Campal” 
Oncological Center, San Pablo University, Madrid, 
Madrid, Spain
In spite of advances in surgical technique, resecability rates 
for colorrectal liver metastases remain around 40%. In recent 
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(n = 50). Academic centers were identifi ed by affi liation 
to a medical school (n = 8). Patterns of adherence to stage-
specifi c NCCN guidelines (surgery, chemotherapy, and 
radiation) and mortality were evaluated. Risk adjusted 
multivariable models estimated the likelihood of guideline 
compliance. Cox models estimated mortality.
Results: 17,970 patients were treated for PC in California’s 
large hospitals during the study period. Overall compliance 
with NCCN guidelines was only 34.5% (Fig. 1). Patients were 
less likely to get recommended therapy with advanced age and 
low SES. Academic centers were not signifi cantly more com-
pliant than non-academic centers (OR = 1.16 (0.99–1.36), p = 
0.06). On multilevel analysis, controlling for patient factors 
(incl. demographics, comorbidities), hospital factors (e.g., 
size, academic affi liation, volume), and receipt of individual 
therapies, compliance with NCCN guidelines was associated 
with reduced risk of mortality (Hazard Ratio for death 0.68 
(0.59–0.77, p < 0.00005)) (Kaplan-Meier in Fig. 2).
FAILURE TO COMPLY WITH NCCN 
GUIDELINES FOR MANAGEMENT OF 
PANCREATIC CANCER COMPROMISES 
OUTCOMES
B. C. Visser1,2, Y. Ma2, Y. Zak1 and K. Rhoads1,2
1Stanford University Department Of Surgery, Stanford, CA; 
2Stanford Cancer Institute, Stanford, CA
Introduction: There is little data regarding compliance with 
the National Comprehensive Cancer Network (NCCN) 
guidelines. We investigated variation in the management of 
pancreatic cancer (PC) among large hospitals in California, 
specifi cally to evaluate whether compliance with NCCN 
guidelines correlates with outcomes.
Methods: The California Cancer Registry was used to iden-
tify patients treated for PC from 2001–2006. Only hospitals 
with ≥400 beds were included to limit evaluation to centers 
likely possessing resources to provide multimodality care 
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Conclusions: There is a poor overall compliance rate with 
the NCCN PC guidelines in California’s large hospitals. 
Higher compliance rates are correlated with improved sur-
vival. Efforts must be made to improve adherence to NCCN 
guidelines.
LAPAROSCOPIC MICROWAVE 
ABLATION OF HEPATOCELLULAR 
CARCINOMA IN PATIENTS WITH 
PORTAL HYPERTENSION; TECHNICAL 
TIPS FOR A SAFE PROCEDURE
M. Vivanco, E. Feinberg and J. Chapochnick Friedmann
Montefi ore Medical Center/Albert Einstein College Of 
Medicine, Bronx, NY
Background: Cirrhosis and portal hypertension historically 
has been considered a contraindication for surgery. With 
improved surgical techniques and newer technology surgical 
ablations can be accomplished in a safe way in this high risk 
group of patients. Our own group has previously presented 
good outcomes with surgical microwave ablation of hepato-
cellular Carcinomas (HCC) in cirrhotic patients with portal 
hypertension and we aim in this abstract to share what we 
consider to be the key steps to obtain good oncological out-
comes and low morbidity.
Description of technique: Step 1: Minimally invasive 
approach; usually two ports is enough. Step 2: Periumbilical 
port (10 mm Hassan) placement. Location based on umbili-
cal vein situation. Step 3: Position of second (5 mm) port 
based on tumor location and presence of abdominal wall 
varices. Step 3: Diagnostic laparoscopy and tumor identifi ca-
tion. Step 4: Division of falciform with Ligasure or vascular 
endo GIA staplers. Argon beam could be helpful. Division 
of other suspensory ligaments as necessary. Step 5: 
Intraoperative ultrasound and doppler. Step 6: Placement of 
microwave antennas under intraoperative ultrasound guid-
ance. Step 7: Tumor ablation and retrieval of antennas. Step 
8: Hemostasia and post ablation ultrasound and Doppler. 
Step 9: Retrieval of ports and closure.
Conclusion: Laparoscopic microwave ablation of HCC in cir-
rhotic patients with portal hypertension can be accomplished 
with good oncological outcomes and minimal morbidity.
THE SIX-DAY WHIPPLE PATHWAY
D. M. Walters, A. L. Strong, E. W. Good, R. B. Adams and 
T. W. Bauer
The University Of Virginia, Department Of Surgery, 
Charlottesville, VA
Background: Utilization of postoperative clinical pathways 
leads to shorter hospital stays and decreased healthcare costs. 
The purpose of this study was to evaluate patient outcomes 
after implementation of a six-day discharge pathway follow-
ing pancreaticoduodenectomy.
Methods: A postoperative clinical pathway was developed 
and implemented for patients undergoing pancreaticoduode-
nectomy at our institution. Patients received preoperative 
teaching of the pathway, which briefl y consisted of nasogas-
tric tube (NGT) removal on postoperative day three, clear 
liquid diet on day four, solid diet on day fi ve, and discharge 
on day six. Patient charts were retrospectively reviewed to 
determine rates of adherence to the pathway at each step, 
readmission, and postoperative complications.
Results: 113 patients underwent pancreaticoduodenectomy, 
receiving postoperative care under the clinical pathway guide-
lines and 30-day follow-up was available for 98.2% of patients. 
Average blood loss was 267 cc. The median length of stay was 
7 days (mode 6 days); 42% of patients were discharged by 
postoperative day six, 63% by day seven, and 80% by day 
eight. 93% of patients underwent NGT removal on day three. 
83% and 64% tolerated liquids and solids, respectively, on the 
targeted days. 16% of patients required readmission within 30 
days of discharge, 18% of patients had delayed gastric empty-
ing (DGE), and there were no deaths within 30 days.
Conclusions: Clinical pathway utilization following pan-
creaticoduodenectomy allows a high percentage of patients 
to be discharged within a week and is associated with a low 
rate of DGE and readmission. Clinical pathway implementa-
tion allows for safe and effi cient patient care.
THE KIND AND INFLUENCE OF THE 
DRAIN INFECTION UPON THE 
SEVERITY OF POST OPERATIVE 
PANCREATIC FISTULA
K. Watanabe, M. Taniguchi, T. Einama, K. Imai, 
H. Karasaki, T. Kono and H. Furukawa
Division Of Gastroenterological And General Surgery, 
Asahikawa Medical University, Asahikawa City, Hokkaido, 
Japan
Background and Aim: Postoperative pancreatic fi stula 
(POPF) is a most striking complication after pancreaticoduo-
denectomy (PD). The objective of this study is to reveal the 
infl uence of the drain infection around the pancreaticojeju-
nostomy (PJ) upon the severity of POPF.
Methods: PD was performed for 76 patients between 01/06 
and 04/11, and the bacteriological examination of the drain-
age fl uid around the PJ was achieved on day 3, 5, 7.
Results: POPF was found in 48 (63.1%) patients; grade A 
group (GrA) by international defi nition in 27 (35.5%), grade 
B and C group (GrBC) in 21 (27.6%). The number of the 
infection by intestinal bacterium on day 3 in GrBC; 9/21 
(42.9%) was signifi cantly higher than in non pancreatic 
fi stula group (no PF); 2/28 (7.1%) and in GrA; 2/27 (7.4%): 
(P < 0.01). The number of the infection by non-intestinal 
bacterium in no PF and GrA were increased from day 3; 0/28 
(0%), 5/27 (19%) to day 7; 10/21 (48%), 7/21 (33%), respec-
tively, however, in GrBC remained unchanged from day 3; 
1/12 (5%) to day 7; 0/18 (0%), (P < 0.01).
Conclusion: Endogenous infection around the PJ on day 3 
was a risk factor for grade B or C POPF after pancreatico-
duodenectomy. However retrograde infection was not sig-
nifi cantly associated with grade B or C POPF. Early 
prophylaxis against endogenous infection around the PJ 
might be advantageous for the reduction of severe POPF.
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SKELTONIZATION NOT RESECTION OF 
THE SUPERIOR MESENTERIC VEIN IN 
PDR
M. G. Wayne, J. G. Steele and A. M. Cooperman
Pancreas And Biliary Center Of New York At Beth Israel 
Medical Center, New York, NY
Involvement of the SMV by extrinsic compression rather 
than direct invasion is far more common when the SMV is 
narrowed in cancer of the pancreas. If the computed tomog-
raphy angiogram (CTA) shows a free anterior interface 
between the neck of the pancreas and the SMV the gland is 
divided. A freer vascular dissector is utilized to separate 
tumor fi brosis from the SMV and SMA. In 99% of cases 
selected this clears tumor from the major vessels. The deci-
sion to utilize radiation is based on the fi nal pathology. We 
have utilized this method for more than 20 years in PDR. It 
avoids SMV-SMA resection, limits blood transfusions, short-
ens PDR time and does not adversely affect survival.
RESECTION OF MULTI-SITE 
METASTASES FROM COLORECTAL 
CANCER: FEASIBILITY AND INTERIM 
RESULTS OF A MULTI-CENTRE 
PROSPECTIVE PHASE II STUDY
A. C. Wei1, N. G. Coburn2, C. Moulton1, S. P. Cleary1, 
C. Law2, P. D. Greig1 and S. Gallinger1
1Toronto General Hospital, University Health 
Network, Toronto, ON; 2Odette Cancer Center Sunnybrook 
Hospital, Toronto, ON, Canada
Background: Resection of intra-hepatic metastases (IHM) 
from colorectal cancer (CRC) is associated with an excellent 
5-year survival of up to 60%. But as many as 80% of patients 
are ineligible for liver resection – many due to the presence 
of extra-hepatic metastases (EHM). The objective of this 
study was to evaluate the results of metastasectomy for 
patients with multi-site CRC metastases.
Methods: A phase II study of metastasectomy for IHM and 
EHM from CRC was conducted at 2 high-volume HPB 
centers. Eligible patients with IHM and ≤3 foci of EHM, 
resectable with R0 intent were identifi ed prospectively and 
offered metastasectomy. Clinical and survival data were col-
lected and analyzed using standard statistical methods.
Results: 23 patients were enrolled with a median age of 56 
(32–84) years. Most patients presented with synchronous 
disease (12/23, 52%). The median numbers of IHM, EHM 
and combined sites were 2, 1 and 3, respectively. The lung 
was the most common EHM (12/23, 52%). Prior to enroll-
ment, 21/23 (91%) received chemotherapy. Protocol surgery 
was completed in 18/23 (74%) cases including 12/23 (52%) 
planned sequential resections. Perioperative morbidity and 
mortality was 9/23 (40%) and 1 (4%) respectively. At last 
follow up, 19/23 (83%) had developed recurrent disease with 
a median DFS of 4 months.
Conclusion: Complete metastasectomy of multisite CRC is 
feasible and safe. But the vast majority of patients will recur 
quickly. Thus metastasectomy for multi-site CRC metastases 
should still be considered experimental and these procedures 
should be performed in the context of a clinical trial.
COMPREHENSIVE DNA METHYLATION 
ANALYSIS OF HEPATOCELLULAR 
CARCINOMA
D. J. Weisenberger, T. Hinoue, L. Petrovic, C. Romero and 
L. S. Sher
University Of Southern California, Los Angeles, CA
Introduction: Hepatocellular Carcinoma (HCC) is a global 
health concern, representing nearly 2.5% of all deaths world-
wide. Surgical extirpation may provide a cure, but the tumor 
is often too large for surgical extirpation. Therefore there 
is a need to identify biomarkers for sensitive detection of 
early stage HCC. DNA methylation markers are stable and 
robust biomarkers. Human cancers are characterized by 
regional CpG island DNA hypermethylation and global 
hypomethylation.
Objective: The goal was to identify aberrantly methylated 
loci in HCC for use in diagnosis, surveillance and 
monitoring.
Methods: Paired HCC tissue and adjacent non-malignant 
tissues were obtained from 10 patients who had undergone 
surgical excision. A DNA methylation analysis was per-
formed using the Illumina Infi nium450 DNA methylation 
assay, which surveys over 450,000 CpG dinucelotides 
(CpGs) in the human genome.
Results: Over 3700 hypermethylated CpGs were identifi ed 
in HCC, mostly located in CpG islands and CpG island 
shores. DNA hypomethylation was a dominant signature of 
the sample set, with over 17,000 CpGs displaying DNA 
hypomethylation in HCC, the majority located in CpG island 
shelves and non-CpG islands. Interestingly, nearly 25% of 
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aberrantly methylated loci were in enhancer regions of the 
genome.
Conclusion: This study represents a comprehensive view of 
the HCC methylome and highlights the widespread epigen-
etic dysregulation in HCC. Identifying specifi c epigenetic 
biomarkers will be effective for use in future diagnostic and 
sensitive detection experiments.
THE PREVALENCE AND SIGNIFICANCE 
OF EXTRAPANCREATIC CYSTS IN 
PATIENTS WITH PANCREATIC CYSTIC 
LESIONS
M. J. Weiss, S. Gaujoux, E. C. Zabor, M. Gonen, 
M. Schattner, M. I. D’Angelica, Y. Fong, T. P. Kingham, 
R. P. DeMatteo, W. R. Jarnagin and P. J. Allen
Memorial Sloan-Kettering Cancer Center, New York, NY
Background and Aim: With greater use of diagnostic 
imaging, incidental pancreatic (PCs) and extrapancreatic 
cysts (EPCs) are frequently encountered in clinical practice. 
This study analyzes the prevalence of EPCs in patients with 
PCs and seeks to identify potential associations with clinical 
behavior, treatment recommendations or pathology.
Methods: We performed a retrospective review of all 
patients evaluated for PCs at our institution from 1995–2010. 
Clinical, radiological and available pathological data was 
analyzed.
Results: This study included 1424 patients. Seventy-three 
percent of patients with PCs also had EPCs (n = 1035). The 
location of EPs included: 398 kidney (28%), 233 liver (16%), 
388 kidney and liver (27%), and 16 other (2%). EPCs were 
associated with older age (p < 0.001), smaller PCs (median 
1.9 cm versus 2.1 cm, p = 0.002), lack of symptoms (p < 
0.001), absence of solid components in PCs (p = 0.003) and 
non-surgical management (p = 0.006). Combined renal and 
hepatic cysts were associated with older age (p < 0.001), 
smaller PCs (median 1.6 cm versus 2.0 cm, p < 0.001), pan-
creatic head location of PCs (p = 0.016), lack of symptoms 
(p < 0.001) and non-surgical management (p = 0.006). In the 
selected subgroup of patients who underwent surgical resec-
tion (n = 469), the presence of EPCs was not associated with 
pathological diagnoses (p = 0.169).
Conclusions: Extrapancreatic cysts are highly prevalent in 
patients with pancreatic cysts. The presence of EPCs cysts 
correlated with older age, smaller PCs, absence of a solid 
component in the PC, and a lower likelihood of undergoing 
resection; however, there was no obvious correlation with 
fi nal histologic diagnosis. Further investigation into whether 
PC patients may represent a polycystic syndrome is 
warranted.
RENAL CELL CARCINOMA 
METASTASES TO THE PANCREAS: A 
WORTHWHILE INDICATION FOR 
RESESCTION
K. E. Westesson, G. A. Falk, G. Morris-Stiff, 
C. H. Simpfendorfer, S. Chalikonda, M. C. Gong, 
S. C. Cambpell and R. M. Walsh
Cleveland Clinic Foundation, Cleveland, OH
Background: Metastatic lesions are an uncommon but 
growing indication for pancreatic resection. Renal cell car-
cinoma (RCC) is the most common primary pathology, 
however the majority of the published literature reports small 
series and case reports.
Aims: To review the institutional experience of the manage-
ment and outcome of resectable RCC metastases to the pan-
creas in a large tertiary referral centre.
Methods: The institutional RCC database was reviewed to 
identify all patients who developed pancreatic metastases 
and subsequently underwent resection of these lesions. Data 
was recorded in relation to patient demographics, the histo-
logical features of the primary lesion, and those of the pan-
creatic metastases. Outcome data were also recorded.
Results: 27 patients were identifi ed consisting of 20 males 
and 7 females with a median age of 63 years (range: 34–81 
years). One resection was synchronous and the remaining 
were metachronous with a median interval between nephrec-
tomy and pancreatic resection of 82.6 months (range: 
1–278.4 months). 18 patients underwent distal pancreatec-
tomy and the remaining 9 pancreatoduodenectomy. All 
lesions were solitary with a median size of 2.2 cm (range: 
1.6–5.5 cm). The median follow-up was 88.1 months after 
resection (range: 14.2–238.0 months). Eleven patients had 
died with a median interval from pancreatic resection of 
100.8 months (range: 16.3–150.4 months).
Conclusions: Pancreatic resection for selected patients with 
RCC metastases may provide a signifi cant chance of cure in 
select patients with metastatic RCC.
TRANSECTION OF LEFT SEGMENTAL 
HEPATIC DUCTS DURING 
LAPAROSCOPIC CHOLECYSTECTOMY
A. M. Williams, R. Gedaly, M. F. Daily, M. B. Shah, 
A. Dawkins and J. C. Hundley
University Of Kentucky, Lexington, KY
Background: Despite many advantages, laparoscopic cho-
lecystectomy (LC) has been associated with a higher inci-
dence of iatrogenic bile duct injuries when compared to 
traditional open cholecystectomy. To our knowledge, tran-
section of left segmental hepatic ducts have never been 
described in the literature.
Methods/Results: We report three patients who were 
referred to our institution after sustaining transection of left 
segmental hepatic ducts during LC. Patient 1 presented with 
transection of the right hepatic duct, the bile duct from 
segment I, the bile duct from segments II, III, and IV, and 
the right hepatic artery. Patient 2 presented with transection 
of the right hepatic duct, the bile duct from segments II and 
III, and the bile duct from segment IV. Patient 3 presented 
with transection of the right hepatic duct, three small 
bile ducts from segment I, the bile duct from segments II 
and III, and the bile duct from segment IV. Roux-en-Y 
hepaticojejunostomy was performed in each case. Patients 2 
and 3 both had late gastrointestinal bleeding thought to be 
due to arteriobiliary fi stulae. Patient 2 died from this 
complication.
Conclusion: To our knowledge, these are the fi rst reports of 
injury to left segmental hepatic ducts during LC. All patients 
also sustained right hepatic duct transections. Late arterio-
biliary fi stulae were seen in two of three patients. We were 
unable to identify any risk factors that predisposed these 
patients to left sided biliary injuries.
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ENDEMIC GALLBLADDER CANCER: IS 
THERE A ROLE FOR PROPHYLACTIC 
CHOLECYSTECTOMY?
E. R. Witkowski, E. Ragulin-Coyne, T. P. McDade, 
L. W. Chen, S. A. Shah and J. F. Tseng
Surgical Outcomes Analysis & Research (SOAR), 
University Of Massachusetts Medical School, Worcester, 
MA
Background: Gallbladder cancer (GBC) is an often lethal 
malignancy with variable distribution. Incidence in the 
United States is low. However, in areas of Central/South 
America, Central Europe, Japan, and the Indian subconti-
nent, GBC is a major cause of cancer death. Cholecystectomy 
is safe and commonly performed worldwide. Thus, prophy-
lactic cholecystectomy (PCCY) has been proposed in regions 
with endemic GBC. We developed a simple decision model 
to assist caregivers in determining the optimal strategy for 
managing GBC based on local incidence and technological 
capabilities.
Methods: Rates of disease and outcomes were derived from 
a review of the literature. Using TreeAge-Pro software, a 
decision model was created to simulate expected health out-
comes for populations with high GBC incidence, following 
3 treatment strategies: no early intervention, one-time screen-
ing ultrasound (US), or PCCY. Lifetime cancer-specifi c sur-
vival was the outcome of interest. Sensitivity analyses were 
performed to determine threshold values.
Results: Based on our model, populations where lifetime 
risk of GBC exceeds 0.4% may benefi t from early interven-
tion by US or PCCY. Two-way sensitivity analysis shows 
that over a relatively narrow range of disease incidence, US 
may be favored if sensitivity exceeds 50%. In many cases 
where lifetime risk exceeds 1%, PCCY may improve 
survival.
Conclusions: GBC varies in incidence, but affects many 
individuals in some populations in the Americas. The lethal-
ity of GBC may justify aggressive public health intervention 
including screening or prophylactic cholecystectomy. 
Decision analysis models using best-available evidence may 
help determine the optimal treatment of individuals at risk 
for GBC.
CASE SERIES AND LITERATURE 
REVIEW OF PANCREATIC ACINAR CELL 
CYSTADENOMA
A. M. Wolf1, C. J. Yeo1, J. Winter1, A. J. Prestipino2 and 
H. Lavu1
1Department Of Surgery, Thomas Jefferson University, 
Philadelphia, PA; 2Department Of Pathology, Thomas 
Jefferson University, Philadelphia, PA
Cystic lesions are among the most common abnormalities 
found in the pancreas, and the incidence has risen with the 
increasing use and sensitivity of modern imaging techniques. 
The most common cysts are pseudocysts, with the remaining 
cystic lesions subdivided by their cell of origin, fl uid content, 
and malignant potential. Within the past decade a new entity, 
acinar cell cystadenoma, has been described as a non-malig-
nant lesion with distinct pathologic features. Thus far, only 
15 cases have been reported in the literature. We have 
recently resected two additional cases of acinar cell cystad-
enoma at our institution and now report the aggregate experi-
ence with this rare pancreatic neoplasm (Table). There is a 
slight female preponderance among the 17 cases (58.8%), 
with a mean age at diagnosis of 45 years. Although many 
patients presented with pain, over half of the tumors (52.9%) 
were found incidentally. Patients who presented with pain 
were more likely to have larger cysts, although three patients 
had incidentally discovered tumors larger than 5 cm. Average 
tumor diameter was 4.64 cm yet some were multiloculated, 
containing multiple sub-centimeter cysts. Out of eight 
patients who were followed for more than 2 years, no recur-
rences have been identifi ed even if complete resection was 
not attained (n = 2, no growth at 4 and 2.5 years follow-up). 
These fi ndings suggest that acinar cell cystadenoma (as his-
tologic fi ndings indicate) is a benign dilation of the acini, yet 
we recommend complete resection to confi rm diagnosis and 
prevent local extension or malignant transformation into 
cystadenocarcinoma.
Table. Acinar Cell Cystadenoma Cases
Case # Age 
(years)
Sex Size 
(cm)
Location in Pancreas Abdominal 
Pain
 1∧ 33 F 10 Uncinate Present
 2+∧ 46 F 4, 10 Head and tail, 
two cysts
Present
 3+∧ 16 F 7.5 Head Present
 4∧ 44 F 0.1–1.5 Entire gland, 
multiple cysts
Absent
 5 47 F 0.5–2.5 Head and tail, 
two cysts
Present
 6 39 F 4 Uncinate Present
 7∧ 49 F 0.5 Tail Absent
 8∧ 57 M 0.5 Tail Absent
 9∧ 66 M 0.2 Uncinate Absent
10 61 M 0.2 Head Absent
11 52 M 5 Uncinate, head, 
and body
Absent
12+ 9 M 11 Entire gland Absent
13∧ 55 F 10 Retroperitoneum 
near tail
Present
14 52 M 5 Body Present
15 58 F 9 Body and tail Absent
16* 54 F 1.5 Proximal tail Absent
17* 25 M 6 Head Present
Complete resection was not attained in cases denoted “+”. Cases denoted “∧” 
were followed for more than 2 years. Reported for the fi rst time here is our 
experience with two cases, denoted “*”.
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THE UTILITY OF POSITRON EMISSION 
TOMOGRAPHY IN HEPATOCELLULAR 
CARCINOMA
S. M. Wong, M. H. Jamal, P. Chaudhury, T. T. Tran, 
E. Simoneau, S. Jabbour, Y. Yousef, Y. Jozaghi, 
S. Al-Abbad, M. Al-Jiffry, J. Kwan, G. Arena, P. Metrakos 
and M. Hassanian
McGill University Health Centre, Montreal, QC, Canada
Background: Positron emission tomography (PET) using 
18F-fl uorodeoxyglucose (FDG) is being increasingly used in 
the fi eld of oncology. For hepatocellular carcinoma (HCC), 
it has been suggested that it may be an important predictor 
of outcomes for patients undergoing resection or transplanta-
tion. However in the management of locally advanced HCC, 
the prognostic utility of FDG-PET is still undefi ned.
Methods: From 2007 to 2010, 79 patients with locally 
advanced HCC who had PET scans were identifi ed. A retro-
spective chart review was performed and complete follow up 
with dates of death were obtained until September 2011 from 
the Government of Quebec populational database.
Results: At time of follow up 60% of patients were alive. 
Twenty seven patients were PET positive (SUV >4) and fi fty 
two were PET negative (SUV ≤ 4). At univariate analysis, 
age, number of lesions, negative PET and size of liver lesion 
were associated with survival. However, at multivariate 
analysis only a negative PET scan was associated with favor-
able survival at 1 year [OR 4.64 (95% CI 1.1–20.7)].
Conclusion: PET scan use can be of value in early prog-
nostigation of patients with HCC.
PREOPERATIVE IMAGING FINDINGS 
CONCERNING FOR GALLBLADDER 
MALIGNANCY: IS INITIAL 
LAPAROSCOPIC APPROACH TO 
RESECTION REASONABLE?
G. Wright1, A. Siripong1, M. D. Winton3, E. J. Mitchell1 
and M. H. Chung1,2
1Grand Rapids Medical Education Partners/Michigan State 
Univ General Surgery Residency Program, Grand Rapids, 
MI; 2Spectrum Health Medical Group, Grand Rapids, MI; 
3Michigan State University College Of Human Medicine, 
Grand Rapids, MI
Purpose: We examined patients with abnormal preoperative 
imaging concerning for gallbladder malignancy to determine 
the incidence of pathology-confi rmed malignancy in this 
population and to discover factors that may be used to 
determine which patients may be initially managed 
laparoscopically.
Methods: All patients referred to a hepatobiliary focused 
surgical oncologist with preoperative imaging concerning for 
gallbladder malignancy from 2005 to 2011 were reviewed. 
Retrospective chart review was used to record variables 
including demographic data, imaging, operative fi ndings, 
and fi nal pathology.
Results: A total of 4474 patients were evaluated for gall-
bladder pathology during the study period. Twenty-nine 
patients met criteria for study, including 15 females and 14 
males with a median age of 70 (23–90). Preoperative imaging 
included computed tomography, ultrasound, and magnetic 
resonance imaging in 25, 11, and 9 patients respectively. 
Twelve patients had multiple imaging studies. Eight patients 
(27.6%) were initially managed laparoscopically with 3 con-
versions to an open procedure. A total of 14 patients (48.3%) 
had pathology-confi rmed maglinancy. Malignant fi ndings 
included adenocarcinoma (37.9%), neuroendocrine carci-
noma (6.9%) and malignant melanoma (3.4%). Benign 
fi ndings included chronic cholecystitis (34.5%), adenomy-
oma (10.3%), and gallbladder diverticulum (6.9%). Age, sex, 
BMI, and performance of MRI were not statistically signifi -
cant predictors of pathology-confi rmed malignancy.
Conclusion: Our results demonstrate that over one half of 
patients with preoperative imaging fi ndings concerning for 
gallbladder malignancy had benign pathology following sur-
gical resection. These fi ndings suggest that initial laparo-
scopic approach in selected patients may be appropriate.
VASCULAR RESECTION AND 
RECONSTRUCTION FOR A REPLACED 
RIGHT HEPATIC ARTERY CAN BE 
AVOIDED DURING A 
PANCREATICODUODENECTOMY 
PROCEDURE
J. M. Zakhary, H. Shokouh-Amiri, G. Zibari, 
H. D’Agostino and Q. D. Chu
Lousiana State University Health Science Center 
Shreveport, Shreveport, LA
Objectives: There is a paucity of literature on the manage-
ment of a replaced right hepatic artery (RRHA) during a 
pancreaticoduodenectomy. It is believed that up to 9% of 
patients with RRHA will require a vascular resection/recon-
struction. Whether this is avoidable has not been well 
described. Except for an artery that has penetrated through 
the tumor, we believe that, with careful identifi cation and 
meticulous dissection of this variant, a pancreaticoduodenec-
tomy can safely be performed without a vascular resection/
reconstruction.
Methods: From 2008 to 2011, a retrospective review of 100 
consecutive patients who underwent a pancreaticoduodenec-
tomy was performed. Patients demographics, fi nal pathology, 
size of tumor, and the presence or absence of a RRHA were 
recorded. A preoperative evaluation included an endoscopic 
ultrasound, MRI, and/or CT scans.
Results: There were 13 patients (13%) who had an intraop-
eratively identifi ed RRHA. Seventy-seven percent of patients 
had a malignancy. The average tumor size was 2.4 cm (range, 
1.0 to 4.5 cm) and all had a negative resection margin. None 
of the variants penetrated the tumor and therefore, none of 
the 13 patients required a vascular resection/reconstruction.
Conclusions: A preoperative CT/MRI can help identify a 
replaced right hepatic artery in patients undergoing a pancre-
aticoduodenectomy. Surgeons should be cognizant of such 
an anomaly during the dissection. The presence of a RRHA 
that does not penetrate the tumor does not necessitate a vas-
cular resection/reconstruction as long as a meticulous dissec-
tion is performed.
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EXPERIENCE WITH SELECTIVE 
TRANSARTERIAL EMBOLIZATION AS A 
THERAPEUTIC OPTION FOR FOCAL 
NODULAR HYPERPLASIA: A CASE 
SERIES
M. Zanini, A. Abou Abbass, M. Kazimi, A. Yoshida and 
M. Abouljoud
Henry Ford Hospital Division Of Transplant & 
Hepatobiliary Surgery, Detroit, MI
Background: Resection is frequently considered for enlarg-
ing/symptomatic focal nodular hyperplasia (FNH). 
Transarterial embolization (TAE) may be considered as an 
alternative. We present a case series of FNH treated with 
TAE that was met with favorable outcomes.
Methods: Review of prospectively collected dataset on 
patients with symptomatic FNH. Management offered 
included resection versus embolization. Clinical outcomes 
and follow up CT scans are described.
Results: From May 2005 through May 2011, seven women, 
ages 22 to 49 years, diagnosed with FNH presented with 
symptoms such as pain and/or enlargement of tumor. All 
underwent super selective bland TAE. On follow up CT scan 
at 6 to 8 weeks post procedure, four patients had radiologic 
response described as a moderate loss of vascularity with 
decrease in tumor size. Two patients required resection due 
to poor response with embolization including continued pain 
(1), and persistent large, residual size with additional lesions 
(1). One patient had laparoscopic biopsy with radiofrequency 
ablation (RFA) due to history of colon cancer with atypical 
appearance of the lesion on PET/CT. All patients had symp-
tomatic resolution with no major complications long term.
Conclusion: In our series, TAE was found to be a safe and 
effective alternative to surgical resection in a select group of 
patients. TAE should be considered as an appropriate option 
in the armamentarium of therapy for FNH.
DONOR-DERIVED METASTATIC 
PARAGANGLIOMA IN A LIVER 
TRANSPLANT RECIPIENT: DIAGNOSIS 
AND TREATMENT
A. Zarrinpar, J. R. Hiatt and R. W. Busuttil
The Dumont-UCLA Transplant Center, Los Angeles, CA
Introduction: The transmission of donor-derived tumors by 
organ transplantation is uncommon but devastating. As the 
donor pool ages, the risk will increase. Paragangliomas are 
rare catecholamine-releasing neuroendocrine tumors with a 
rate of malignancy approaching 50%. We report a case of an 
organ recipient with transmitted paraganglioma.
Methods and results: A liver graft became available from 
a deceased donor with no history of cancer for a seventy-one 
year old recipient with cryptogenic cirrhosis. After discus-
sion with the family, the transplantation was performed 
despite a mass at the donor’s aortic bifurcation consistent 
with leiomyoma on frozen section. Final pathology showed 
paraganglioma. Six years later the patient presented with 
three intrahepatic paragangliomas. Multiple radio-frequency 
ablations and a resection of the largest tumor were per-
formed, but the tumor recurred. Because of the patient’s 
decreasing tolerance of further ablations, she returned to the 
operating room for a left hepatic lobectomy. She is currently 
doing well with much improved symptoms. A review of the 
literature, as well the over 5000 liver transplants at our insti-
tution, has revealed no other episodes of donor-derived para-
gangliomas. There are no reported cases of donor derived 
malignancies successfully treated by locoregional therapy 
and resection.
Conclusion: While graft removal of non-life-sustaining 
organs and discontinuation of immunosuppressive medica-
tion would theoretically result in tumor rejection, this is not 
an option in liver transplantation. Retransplantation of the 
liver in a recipient of advanced age and multiple medical 
co-morbidities with a slow-growing tumor is also not accept-
able. Minimizing immunosuppression in combination with 
locoregional therapy and resection serves as the best option.
THE USE OF HYDROGEN PEROXIDE TO 
IDENTIFY SMALL BILE LEAKS DURING 
LIVER RESECTION
A. Zarrinpar, M. Rajan, F. M. Kaldas and R. W. Busuttil
Dumont-UCLA Transplant Center, Los Angeles, CA
Background: Bile leakage is a common complication 
occurring in up to 30% of liver resections. It is associated 
with an increased peritonitis, sepsis, and death. While there 
are no standard preventive methods, many have tried tech-
niques as complex as intraductal or intravenous injection of 
high pressure saline, methylene blue, indocyanine green, or 
diluted fat emulsion, among others. We aim to demonstrate 
the application of topical hydrogen peroxide as an easy and 
inexpensive means of identifying small cut surface bile leaks 
after hepatectomy.
Methods: During hepatic resection without biliary recon-
struction, all patients undergo an intraoperative leak test with 
topical application of 1.5% hydrogen peroxide. The peroxide 
decomposes into water and oxygen, bleaching the blood and 
creating a vigorous white froth against which the yellow 
color of the bile highlights the location of any bile leaks. This 
will then allow the surgeon to close the bile ducts with suture 
ligation. The peroxide can be easily washed out with saline 
irrigation thus allowing for multiple applications without any 
interference from previous tests.
Results: Among the 82 patients who underwent liver resec-
tion without biliary reconstruction by the senior author over 
the last 12 months, there were no postoperative bile leaks.
Conclusion: Topical application of hydrogen peroxide can 
detect insuffi ciently closed bile ducts that are not identifi able 
by standard means. The routine use of this method may prove 
invaluable for the prevention of bile leakage after hepatic 
resection.
ROLE OF OPERATIVE THERAPY IN 
TREATMENT OF INTRA AND 
EXTRAHEPATIC METASTATIC 
HEPATOCELLULAR CARCINOMA IN 
PATIENTS WITHOUT CIRRHOSIS
V. Zaydfudim, R. L. Smoot, M. L. Kendrick, F. G. Que, 
M. B. Farnell and D. M. Nagorney
Mayo Clinic, Rochester, MN
Introduction: We investigated the role of operative therapy 
in patients with metastatic HCC.
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Methods: This retrospective cohort study included consecu-
tive patients with metastatic HCC and without cirrhosis 
between 1990 and 2009. Patients were stratifi ed by operative 
therapy (resection; ablation; transcatheter therapy). Kaplan-
Meier analyses with log-rank comparisons tested effects of 
operative therapy on survival.
Results: Of 195 patients treated for HCC during the study 
period, 98 (age 60 ± 15 years, 55% male) developed meta-
static HCC (74 liver, 24 lung, 9 bone, 9 peritoneum, 8 lymph 
node, 2 brain, 2 adrenal, 1 omentum, 1 skin). Half of these 
patients (n = 50) underwent operative treatment of metasta-
ses. Median time to development of metastases after the 
index operation was 16 months (IQR: 6–23 months); median 
number of treated metastases was 2 (IQR: 1–3). Twenty 
patients (40%) underwent metastasectomy (10 liver, 3 lung, 
7 other); 18 (36%) ablation (13 radiofrequency, 1 cryoabla-
tion, 4 alcohol), and 12 (24%) transcatheter therapy 
(6 chemoembolization, 1 bland embolization, 5 internal 
radiotherapy). Operative therapy was associated with 
improved one- and fi ve-year disease-specifi c survival com-
pared to systemic therapy alone (88% and 51% vs. 34% and 
0%, p < 0.001). One- and fi ve-year disease-specifi c survival 
did not differ between patients treated with resection or abla-
tion (95% and 50% vs. 94% and 49%, p = 0.888), however 
both were better than transcatheter therapy (67% and 0%, 
both p < 0.001). Nine patients (7 resection, 2 ablation) are 
disease-free at a median 50 month (range 7–180 months) 
follow-up.
Conclusions: Resection or ablation provide long-term dis-
ease-free survival and should be considered in selected 
patients with metastatic HCC.
INHIBITION OF CASPASES 3/7 ENZYME 
ACTIVITY WITH AN INFUSION OF 
TIMP-3 MINIMIZES APOPTOSIS IN 
NORMAL LIVERS DURING SUB-LETHAL 
TOTAL HEPATIC ISCHEMIA IN RATS
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The infl ammatory response to ischemia/reperfusion injury 
involves the critical mediator TNF-alpha which is converted 
to an active form by the enzyme TACE/ADAM-17. TNF-
alpha regulates both positive (e.g. proliferation) and negative 
(e.g. apoptosis) events in the liver. Published data suggest 
that treatment with TIMP-3, an endogenous inhibitor of 
TACE/ADAM-17, improves liver health in animals. The 
purpose of this study is to investigate whether TIMP-3, an 
endogenous inhibitor of TACE/ADAM-17, has an effect on 
apoptosis during ischemia/reperfusion injury. Forty-eight 
male Wistar rats (n = 4 per group at time points 6, 24, 48 
hours or 7 days) underwent our established total warm isch-
emia model for 30 minutes. One hour after ischemia, all 
animals were cannulated for one hour with either 0.9% NaCl 
solution (control) or TIMP-3 at 1000 ng/kg of body weight 
(treatment). Blood and liver tissue samples were collected 
after time points. Caspases-3/7 activity was quantifi ed. For 
our results, all animals survived sub-lethal hepatic ischemia. 
In control livers at 6 hours, histological evaluation reveals 
notable early ischemic changes and apoptosis. Treated 
samples have intact cytoarchitecture. With a continuous 
TIMP-3 infusion, caspases-3/7 activity was decreased sig-
nifi cantly at all time points when comparing control with 
treatment. In conclusion, a continuous infusion of TIMP-3 
minimizes apoptosis as shown by a decrease in hepatic cas-
pases-3/7 activity. This study augments the existing evidence 
that TIMP-3, administered as an infusion after I/R injury, 
could be applied clinically to save injured livers in humans.
Table 1. Signifi cant Inhibition of Caspases-3/7 Enzyme Activity by TIMP-3
6 hours 24 hours 48 hours 7 days
Caspases-3/7 244 C 223 C 137 C 30.1 C
 60.7 T**  74.7 T*  19.9 T** 12.6 T
Units – Relative Luminescence Units (RLUs)
C = saline-treated control |*p < 0.05
T = TIMP-3-treated |**p < 0.01.
